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Abstract
Estimating causal effects in clinical trials is often complicated by treatment
noncompliance and missing outcomes. In time-to-event studies, estimation
is further complicated by censoring. Censoring is a type of missing outcome,
the mechanism of which may be non-ignorable. While new estimates have
recently been proposed to account for noncompliance and missing outcomes,
few studies have specifically considered time-to-event outcomes, where even
the intention-to-treat (ITT) estimator is potentially biased for estimating
causal effects of assigned treatment. In this thesis, we develop a series of
parametric potential-outcome (PPO) survival models, for the analysis of
randomised controlled trials (RCT) with time-to-event outcomes and non-
compliance. Both ignorable and non-ignorable censoring mechanisms are
considered. We approach model-fitting from a likelihood-based perspective,
using the EM algorithm to locate maximum likelihood estimators. We are not
aware of any previous work that addresses these complications jointly. In ad-
dition, we give new formulations for the average causal effect (ACE) and the
complier average causal effect (CACE) to suit survival analysis. To illustrate
the likelihood-based method proposed in this thesis, the HIP breast cancer
trial data (Baker, 1998; Shapiro et al., 1988) were re-analysed using spe-
cific PPO-survival models, the Weibull and log-normal based PPO-survival
models, which assume that the failure time and censored time distributions
both follow Weibull or log-normal distributions. Furthermore, an extended
PPO-survival model is also derived in this thesis, which permits investigation
into the impact of causal effect after accommodating certain pre-treatment
covariates. This is an important contribution to the potential outcomes, sur-
vival and RCT literature. For comparison, the Frangakis-Rubin (F-R) model
(Frangakis & Rubin, 1999) is also applied to the HIP breast cancer trial data.
To date, the F-R model has not yet been applied to any time-to-event data
in the literature.
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Chapter 1
Introduction
1.1 A case-study in medical research: HIP breast cancer study
In medical research, investigators often need to determine whether a medical
treatment or a detection procedure is effective. The following questions often
pertain: “What is the efficacy of a certain drug in a given population?” or
“What fraction of deaths from a given disease could have been avoided by a
given treatment or policy or intervention?”
For convenience, we start from a real case-study of a randomised breast
cancer clinical trial, known as the Health Insurance Plan (HIP) trial, which
was undertaken in Greater New York (Shapiro, 1977; Shapiro et al., 1982,
1988; Baker, 1998).
1.1.1 The HIP breast cancer study
In the early 1960s, the mammography technique was developed to detect
breast cancer through screening procedures. At the time of its release, it
was not certain if screening indeed reduced the mortality rate (i.e. death
from breast cancer). To investigate this question, the Health Insurance Plan
(HIP) of Greater New York, USA, conducted a Screening Examination Trial
commencing in 1963 (Shapiro, 1977; Shapiro et al., 1982, 1988; Baker, 1998).
In the HIP breast cancer trial, participants were women who had enrolled as
members of the Health and Insurance Plan (HIP) of Greater New York for one
or more years1. The trial continued from 1963 to 1986. All participants were
over the age of 40 at entry into the trial and had no breast cancer symptoms
when they enrolled. All participants in the HIP trial were followed up in the
1From the date the programme started in 1963.
1
long term, up to 18 years from their date of entry.
In the HIP trial, a total of 60,696 women were eligible. Of these,30,131
were randomly assigned to the screening group and 30,565 were assigned
to the control group. Women in the screening group were offered free an-
nual breast examinations four times. These examinations consisted of film
mammography (cephalocaudal and later views of each breast), a clinical ex-
amination of the breast by a physician (usually a surgeon), an interview for
demographic and other background information; and a health history, while
the women in the control group only received their usual health care.
For simplicity, we introduce some notation (Table 1.1) to illustrate the
HIP trial. Let N denote the sample size and Nz (for z = 1 and 0) denote
the number of individuals in the relevant treatment group. Here Zi = z
is the randomised assigned treatment (1 for the screening group, and 0 for
the control group). We then have N = 60, 696; while N1 = 30, 131 and
N0 = 30, 565 for the HIP trial.
For the 9,984 women in the screening group who refused to take the
screening examination, it is considered that these women switched off their
assigned treatment directly. Let Di(Zi) denote the actual received treatment
when the individual is assigned to the treatment group Zi = z (for z = 1 and
0); we can then write Zi = 1 and Di(1) = 0 for these women. This implies
that the HIP trial falls into the so-called randomised controlled trial (RCT)
with all-or-none compliance (Section 1.2) scenario (Baker, 1997).
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During the HIP trial observation period (1963-1986), a total of 2,325
women were diagnosed with breast cancer (BC) (1171 in the screening group
and 1154 in the control group); the 786 who died due to breast cancer are
denoted by (Ri = 1). Of these, 372 were in the screening group and 474 were
in the control group. In addition, in the HIP trial, the date of enrolment for
all women was recorded, as well as their date of death (if an individual died
from breast cancer) or their date of the last follow-up (if an individual did
not die from breast cancer). The length of time, from the date of enrolment
till the date of death from breast cancer (if an individual died from breast
cancer) was then observed and known as the so-called event time or failure
time, denoted by Ti. In general, when the outcome of interest is event time,
then the data are called time-to-event data and the pertinent analysis is
termed time-to-event analysis (Section 1.3).
Note that individuals who did not die from breast cancer had dates of
death from breast cancer as unknown. Therefore their event time or fail-
ure times Ti were not available in the HIP trial. This situation is termed
censoring (Section 1.3), and these individuals are known as the censored
individuals. For censored individuals, we note that, instead of their failure
time, it is their censoring times, denoted by Ci, that are observed, namely
the length of time from the date of enrolment till the date of last follow-up.
Hence, no matter whether an individual in the HIP trial died from breast
cancer or not, at least one of either the failure time or censoring time is
observed. This is the so-called observed time Yi(z) and it can be written as
Yi(z) = min(Ti(z), Ci(z)), where z denotes the assigned treatment, that is
Zi = z.
In the HIP trial, the mean of the observed time, Y¯ =
∑N
i Yi(z)/N (for
all individuals, including both z = 1 and z = 0), is Y¯ = 14.051; whereas
for the screening group (Zi = 1) ( or the control group (Zi = 0)), the
mean values of observed time are Y¯ (1) =
∑N
i∈{i:Zi=1} Yi(1)/N1 = 14.1578 (or
Y¯ (0) =
∑N
i∈{i:Zi=0} Yi(0)/N0 = 13.9457). The mortality of breast cancer in
the screening group was 0.0123/18 = 6.83E − 4 (per year); whereas it was
0.0135/18 = 7.5E − 4 (per year) for the control group. Basic statistics on
the HIP data are given in Table 1.1. For convenience, all notation used in
this thesis is given in Table 1.2.
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The main task of the HIP trial was to determine to what degree mam-
mography was effective in reducing breast cancer mortality. However, this
question is not easily answered. This thesis aims to find an appropriate way
to answer this question rigorously, using the concepts of non-compliance and
of all-or-none compliance, defined in Section 1.2 via established literature.
Section 1.3 addresses a special type of data: the so-called time-to-event data
and their unique features. Causal inference is introduced briefly in Section
1.4; some common methods used in causal inference for noncompliance anal-
ysis are addressed in Sections 1.6 and 1.7.1. The most important covariate in
noncompliance analysis, the so-called compliance type Ui, is defined in Sec-
tion 1.7.2. The aim of this thesis is outlined in Section 1.8, and an overview
of the thesis is given in Section 1.9.
1.2 All-or-none compliance
About one-third of participants in the screening group of the HIP trial refused
the examination, which indicates that not all participants in the treatment
group had taken up the offer of a screening examination. This phenomenon is
termed treatment switching from an assigned treatment, that is, participants
involved in a trial do not follow their assigned treatment properly. This is
also referred to as noncompliance in the literature (Dunn & Goetghebeur,
2005a; White, 2005; Dunn et al., 2005b; Baker & Kramer, 2005).
When treatment switching occurs immediately after randomisation, this
is known as all-or-none compliance, a special type of noncompliance, in which
it is supposed that every patient either does or does not comply with their
assigned treatment completely, and no partial compliance exists. The HIP
breast cancer trial falls into the all-or-none compliance category (Baker,
1997). All-or-none compliance studies have received much attention over the
last decade (Imbens & Rubin, 1997; Baker, 1998; Frangakis & Rubin, 1999;
Hirano & Imbens, 2000; Jo, 2002a,b; Loeys & Goetghebeur, 2003; Levy et al.,
2004; Peng et al., 2004; O’Malley & Normand, 2005; White, 2005; Gong et al.,
2005).
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1.3 Time-to-event data
In medical research, the outcome of interest is often related to time; such as
the time of death due to a given disease, the time to relapse, or the time to
a specific symptom appearing. Time-to-event data refers to the case where
the outcome of interest is the time at which individuals experienced a pre-
specified event (such as death, relapse or failure status).
As noted earlier, in the HIP breast cancer trial, the pre-specified event is
death from breast cancer, and the outcome of interest is the time when an
individual dies from breast cancer, which is the event time (or failure time).
This is also called survival time, because the event time in the HIP trial
implies that a given individual has survived until the event (death) occurs
(given breast cancer death eventuates).
When an individual’s failure time cannot be observed because the indi-
vidual did not experience the event of interest (during the observation time),
we say her/his failure time is censored, and call such individuals censored
individuals. In time-to-event studies, it would not be realistic to expect that
all individuals involved in the trial have an available failure time, since it
is likely that some may not experience the pre-specified event in the given
observation time frame or follow-up time. Hence, censoring is the primary
concept that has to be accommodated for in time-to-event studies. Since,
for censored individuals, their real failure time would not be observed, this
can be treated as a non-response. On the other hand, their censoring time
is observed. In this case, we still can gather information on them via their
observed censoring time. For example, if an individual in the HIP trial did
not die from breast cancer by the date that follow-up ended, their actual
survival time cannot be observed. However, we know that this individual
has a survival time at least after that day. Let Ci = t denote the censoring
time, i.e. the last follow-up recorded time. Then this individual’s survival
time T would be greater than t, which implies that Ti > t holds. Because of
this feature, time-to-event data is at least partially observable.
7
1.4 Causal inference
1.4.1 Causal inference in general
Causal inference, roughly speaking, seeks to infer the causation of interest
through observations (Pearl, 2000; Graham, 2000; Geng & Jing, 2002). For
example, Bradford Hill’s criteria (Graham, 2000) is a well-known approach of
causal inference in epidemiology. In this approach, Hill gave nine causal crite-
ria for judging if there is evidence for causation. The nine causal criteria are:
strength of association, consistency, specificity of association, temporality,
biological gradient, plausibility, coherence, experiment and analogy. These
criteria typically determine whether the associations between the exposures
and outcomes represent a causal effect (as judged by investigators) (Graham,
2000). Causal inference generally focuses on learning the causal relationships
from raw data, whereby statistical inference is often employed (Pearl, 2000).
Statistical inference is usually concerned with associational inference (Hol-
land, 1986), as its purpose is mainly to discover how the response variables
(outcomes) are associated with other covariate variables (exposures) for each
subject in a population. As in Hill’s criteria-based approach, statistical meth-
ods are used only for finding associations between exposures and outcomes
(statistical inference), and are not used for inferring causation from obser-
vations (causal inference). Therefore, statistical inference is not the same as
causal inference, even though there is certainly a parallel in their inferential
process.
Causal inference involves the extraction of information about compar-
isons, such as decisions in economic, educational and medical research, and
also in public health or social policy. This is dependent on the appropriate
evaluation of competing treatments or policies (Holland, 1986; Frangakis &
Rubin, 2002).
Statistical studies of causal inference have progressed rapidly during the
last two decades (details given later in this section ). An increasing num-
ber of researchers accept the idea that causality should play a significant
role in scientific work (Pearl, 2000) and the growing emphasis, over recent
time, on evidence-based practice (Loeys & Goetghebeur, 2003; Mealli et al.,
2004; Baker, 1998) has led to an increased commitment to studies of clinical
8
effectiveness on the part of clinicians, researchers and policy makers. It is
noteworthy that the rapid development of computational techniques makes
complicated computations involved in causal inference more tractable (Pearl,
2000).
Causal inference is a large topic and encompasses many methodologies
applied to many applications. This thesis focuses on a specific methodology of
causal inference which is based on the potential outcomes framework (Dawid,
2000; Hirano & Imbens, 2000; Hogan & Daniels, 2002; Barnard et al., 2003;
Greenland, 2004).
1.4.2 Potential outcomes framework
A milestone in causal inference is the emergence of the potential outcomes
framework, in which all possible outcomes, including those that are ob-
servable and unobservable (counterfactuals), are considered simultaneously.
Causal inference has a history that goes back to the early work of Neyman in
the 1920s. He first used the potential outcomes framework in his Ph.D. thesis
in 1923 (Rubin, 2005). However the potential outcomes framework had not
attracted much attention in statistical area until Rubin’s work (Rubin, 1974,
1978). During the last few decades, more and more researchers have consid-
ered the potential outcomes framework, including frequentists (Frangakis &
Rubin, 1999; Little & Rubin, 2000; Joffe, 2001; Joffe et al., 2003; Loeys &
Goetghebeur, 2003; Barnard et al., 2003; Peng et al., 2004a; O’Malley & Nor-
mand, 2005) and Bayesians (Imbens & Rubin, 1997; Graham, 2000; Hirano
& Imbens, 2000; Hamilton, 2001; Chib & Hamilton, 2002; Hogan & Daniels,
2002; Gong et al., 2005).
In brief, the potential outcomes framework can be described as a frame-
work in which the outcome of interest appears as a vector, which is the so-
called potential outcomes vector (Imbens & Rubin, 1997; Greenland, 2004).
Potential outcomes vector
The potential outcomes vector, as its name suggests, is a vector corresponding
to all possible responses from all exposure or treatment levels, regardless of
whether the individual is exposed or not in practice. This concept can be
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described precisely via mathematical notation, as follows.
Suppose there are p potential exposure or treatment levels in a RCT. In
general, we useYi to denote the potential outcomes vector for the ith individ-
ual, where Yi = [Yi(0), Yi(1), . . . , Yi(p − 1)]. For convenience and without
loss of generality, let us address the simplest case with p = 2 (when p > 2, it
is straightforward to extend the arguments we used from the simplest case).
Then the potential outcomes vector Yi has two components [Yi(0), Yi(1)],
where Yi(0) denotes the outcome of the ith individual if assigned to the con-
trol group and Yi(1) represents the outcome of the ith individual if assigned
to the treatment group. In our study, the possible treatments (in a RCT)
are only the so-called treatment and control. Note that for each individual,
only one of the outcome components of Yi(0) and Yi(1) is observed.
1.4.3 Causal inference in the potential outcomes framework
During the last decade, a methodology based on the potential outcomes
framework (Dawid, 2000; Hirano & Imbens, 2000; Hogan & Daniels, 2002;
Barnard et al., 2003; Greenland, 2004) in causal inference attracted much
more attention (Section 1.4.2). Apart from its application to epidemiol-
ogy and medical research (Shrout, 1998; Schuck & Widom, 2001; Waitzkin
et al., 2001; Holman et al., 2001; Iribarren et al., 2001; Kaufman & Cooper,
2001; Schochat & Seidel, 2001; Aiello & Larson, 2002; Little & Rubin, 2002;
Suter et al., 2002; Weed, 2002; Acquavella et al., 2003; Breslow, 2003; Joffe
& Brensinger, 2003b; Li & Sung, 2003; Terracini & Zanetti, 2003; Hernan
et al., 2005), this methodology has also been applied to economics (Dehejia
& Wahba, 2002; Persson & Tabellini, 2002), education (Barnard et al., 2003;
Jo, 2002a), psychology (White, 2001; Cobos et al., 2002; Jo, 2002; Hassin
et al., 2002); and social science (Draper, 1995; Yau & Little, 2001).
In brief, this methodology regards the outcome of interest as a vector
that corresponds to each potential treatment level (Greenland, 2004) rather
than a scalar, and defines the causal effect as a quantity which contrasts the
components of the potential outcomes vector (Rubin, 1978; Holland, 1986;
Graham, 2000), thereby describing the effect caused by a certain intervention.
Its formal definition is given in Chapter 2.
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Causal effects may vary in different applications: for example, the effect of
education on employment and earnings, the effect of an employment training
programme on subsequent labour market histories, and the effect of a job
training intervention for preventing deterioration in an individual’s mental
health as a result of job loss. In the field of medicine and health sciences,
the usual effect of interest is that of a given drug or therapy for a specific
disease, such as the effect of the drug 6-mercaptopurine (6-MP) for children
with acute leukaemia (Klein, 1997) or the effect of treatment via resection
and chemotherapy for liver metastases due to colorectal cancer (Loeys &
Goetghebeur, 2003). In the HIP breast cancer trial, the causal effect of
interest is the effect of the breast screening examination in reducing breast
cancer mortality.
1.4.4 Fundamental problem of causal inference
In practice, however, with respect to the potential outcomes vector Yi, only
one of its components is observable. This is because an individual only
receives one possible treatment in a RCT. This problem is defined as the
fundamental problem of causal inference (Holland, 1986). Consequently, the
causal effect is defined as a contrast of two potential outcomes for each indi-
vidual. It is also unobservable. To deal with this problem, the most plausible
approach proposed to date is to use randomisation (Holland, 1986; Imbens
& Rubin, 1997).
1.5 Randomisation
The randomisation technique was introduced by Sir RA Fisher in the 1920s,
and this procedure creates a fair balance between the randomly assigned
groups, including those with unknown confounders.
The key point of randomisation is that no-one can determine which treat-
ment group an individual should be in unless we obtain a randomised assign-
ment (Zi) by a randomly drawn given distribution (such as the bernoulli,
binomial or uniform distributions). This is similar to the procedure of toss-
ing a coin at only two treatment levels, e.g. treatment (Zi = 1) and control
(Zi = 0). The important role of randomisation is to yield comparable treat-
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ment groups without bias. Therefore the treatment and control groups in
a RCT can be viewed as drawn randomly from the same population. This
property of randomisation is useful in solving the fundamental problem of
causal inference. Further discussion is given in Chapter 2.
Despite randomisation being a useful tool for solving the fundamental
problem of causal inference, it requires that no noncompliance exists in RCTs.
One simplest solution is to ignore all noncompliance issues in a RCT, though
this is not a highly plausible approach.
1.6 Intention-to-treat (ITT) analysis
In the early causal inference literature, the issue of imperfect compliance
(noncompliance) was ignored. This means that all individuals involved in a
randomised controlled trial (RCT) were supposed to be intent on following
their randomised assignment treatment properly. The noncompliance issues
were not considered. This scenario is the well known intention-to-treat (ITT)
scenario (Angrist et al., 1996; Imbens & Rubin, 1997; Frangakis & Rubin,
1999; Heitjan, 1999; White, 2005).
White (2005) described the typical intention-to-treat (ITT) analysis as
the situation that compares outcomes between the groups as randomized,
ignoring the actual treatment(s) received.
Sommer & Zeger (1991) defined biologic efficacy as the effect of treatment
for all individuals who receive the treatment to which they were assigned.
This implies that all individuals in the RCT comply well with their ran-
domised assigned treatment. Biologic efficacy then measures the biologic
action of treatment among so-called compliant individuals or compliers (Sec-
tion 1.7.2).
Intention-to-treat comparisons estimate the programmatic effectiveness
or short effectiveness of a treatment rather than its biologic efficacy (Som-
mer & Zeger, 1991; Loeys & Goetghebeur, 2003). This is true especially in
imperfect RCTs, where some participants do not properly comply with their
randomised assigned treatment .
Only in perfect RCTs, wherein all participants ideally follow their ran-
domised assignment exactly and where no treatment switch occurs, does the
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intention-to-treat (ITT) approach provide an estimator of biologic efficacy
and effectiveness of treatment without bias (Loeys & Goetghebeur, 2003;
O’Malley & Normand, 2005; Frangakis & Rubin, 1999). Otherwise, ITT
analysis may provide biased estimators of biologic efficacy in the analysis of
data from non-perfect RCTs. This is because the ITT approach ignores the
noncompliance issue and estimates the causal effect of assigned treatment
rather than the causal effect of actually received treatment. This is inher-
ently a mixture of the effect of the received treatment and of the absence of
the treatment (Loeys & Goetghebeur, 2003; Frangakis & Rubin, 2002).
1.7 Noncompliance studies
1.7.1 Instrumental variables
A RCT where there is a high proportion of individuals who do not com-
ply with their assigned treatment is likely to be viewed as a RCT with
non-ignorable noncompliance. Such is the case in the HIP breast cancer
trial, where up to one third of participants were non-compliant (Baker, 1998;
Shapiro et al., 1988). For these type of RCTs, the ITT approach may provide
a biased estimator of the effect of treatment.
In the literature for noncompliance (Angrist et al., 1996; Imbens & Ru-
bin, 1997; Frangakis & Rubin, 1999; Hogan & Daniels, 2002; O’Malley &
Normand, 2005; Gong et al., 2005), there is a so-called instrumental variable
(IV) approach, which is widely used in economics and was first introduced
to statisticians by Angrist et al. (1996). This IV approach has been accepted
by many statisticians. Instrumental variables (IVs) are such variables that
are only included in some equations (as they are explicitly excluded from
others), and are correlated with some outcomes only through their effect on
these subset of variables (Angrist et al., 1996).
In brief, the assigned treatment, Zi = z (z = 1 for the treated group
and z = 0 for the control group), can be viewed as an instrumental variable
(IV); Di = [Di(1), Di(0)] is used to denote the potential received treatment,
where Di(1) = 1 (or Di(1) = 0) indicates that an individual i assigned to the
treated group Zi = 1 would (or would not) actually receive the treatment. In
contrast, Di(0) = 1 (or Di(0) = 0) represents that an individual i, assigned to
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the control group Zi = 0 would (or would not) actually receive the treatment.
Hence in a two-arm RCT, only Di(1) or Di(0), one of the components of Di
denote by Dobsi = Di(Zi) is observable. The unobservable component of Di
can then be written as Dmissi = Di(1− Zi) because Zi is a binary. The miss
symbol indicates that when an individual is assigned to the treated group
(Zi = 1), we would never be able to know his/her actual received treatment
which corresponds to the control group (1 − Zi = 0). Here Di(1 − Zi) is
a counterfactual variable and can never be observed in practice (Imbens &
Rubin, 1997).
In the case of a perfect compliance trial, the received treatment, Di(z), for
each individual would equal Zi = z; either 1 or 0 in the two arms of a RCT.
For example, if the HIP breast cancer trial were a perfect compliance trial,
there would be no participants who were assigned to the screening group and
who then refused the preferred screening examination. This is equivalent to
the condition that each participant would take the screening examination
(Di(1) = 1) if she was assigned to the screening group (Zi = 1), or would
just receive normal health care (Di(0) = 0) if she was assigned to the control
group (Zi = 0). In this case, there is little advantage of the instrumental
variable (IV) approach, since Di(z) = z (where Zi = z and for z = 1, or 0.).
In the imperfect compliance trial, Di(z) can differ from Zi = z for var-
ious reasons. These may include cases where some participants refuse to
receive the offered treatment, e.g. the screening examination in the HIP
trial, (Shapiro et al., 1988; Baker, 1998); or, for example, in the ECOG trial
E9288 (Loeys & Goetghebeur, 2003), where some patients with liver metas-
tases (from colorectal cancer), assigned to the treatment group (implantation
of an arterial device) had not been implanted (in the ECOG trial E9288) for
reasons related to survival . In these kinds of RCTs, the assigned treatment
Zi, does not indicate whether the individual receives the treatment or not,
but Di(z) does. In other words, the assigned treatment Zi = z only works
through Di(z); hence Zi is regarded as an instrumental variable (IV) (Angrist
et al., 1996).
Similarly, the potential outcomes vector Yi can also be expressed via the
instrumental variable (IV) (Zi = z); thereby Yi = [Y (1, Di(1)), Y (0, Di(0))].
It is not difficult to understand that the effect of assigned treatment, Zi = z
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onYi, happens only through the effect of the treatment receivedDi(z) onYi,
(Imbens & Rubin, 1997; O’Malley & Normand, 2005; Graham, 2000; Gong
et al., 2005) since the outcome Yi(z,Di(z)) can only be affected by Di(z),
which is the actual received treatment. This implies that for an individual,
no matter what the value of her assigned treatment Zi = z (for z = 1, or 0)
is, as long as her observed and unobserved received treatments have the same
value (i.e. Di(1) = Di(0)) then the components of her potential outcomes
vector should be the same. That is:
Yi(1, Di(1)) = Yi(0, Di(0)) if Di(1) = Di(0). (1.7.1)
Equation (1.7.1) is equivalent to the assumption of exclusion estriction
(Angrist et al., 1996; Imbens & Rubin, 1997; Frangakis & Rubin, 1999), its
definition is given in Section 5.2. Since in practice only one of Yi(1, Di(1))
and Yi(0, Di(0)) is observable, we can then write it as Y
obs
i = Yi(Zi, D
obs
i ) =
Yi(Zi, Di(Zi)). The unobservable component of the potential outcomes vector
Yi can thus be treated as missing and we write it as Y
mis
i = Yi(1−Zi, Dmisi ) =
Yi(1− Zi, Di(1− Zi)).
1.7.2 Compliance types
For noncompliance analysis, individuals’ compliance behaviour in RCTs is a
very important issue. In the literature, a variable defined to describe such
behaviour is commonly known as the compliance type (Imbens & Rubin,
1997), compliance state (O’Malley & Normand, 2005), or principle strata
(Frangakis & Rubin, 2002; White, 2005). In this thesis, we follow the work
of Imbens & Rubin (1997) and refer to this new variable as the compliance
type and denote it by U.
The definition of compliance type given by Imbens & Rubin (1997) is as
follows:
1. Compliers (c) are those individuals who receive the treatment when
they are assigned to the treated group. They would not receive any
treatment when assigned to the control group. That is, compliers al-
ways comply with their assigned treatment Zi.
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2. Always-takers (a) are those individuals who always receive the treat-
ment regardless which groups they are assigned to. That is, always-
takers only comply with their assigned treatment when Zi = 1.
3. Never-takers (n) are individuals who would never receive the treatment
regardless which group they are assigned to. That is, never-takers only
comply with their assigned treatment when Zi = 0;
4. Defiers (d) are individuals who receive the treatment when they are
assigned to the control group and would not receive the treatment
when they are assigned to the treatment group. That is, defiers never
comply with their assigned treatment Zi = z no matter whatever value
Zi has.
Using the symbol of potential received treatment Di = [Di(1), Di(0)],
these four compliance types can be written mathematically as follows,
Ui =

c, (i.e. subject i is a complier) if Di(1) = 1 and Di(0) = 0;
n, (i.e. subject i is a never-taker) if Di(1) = 0 and Di(0) = 0;
a, (i.e. subject i is an always-taker) if Di(1) = 1 and Di(0) = 1;
d, (i.e. subject i is a defier) if Di(1) = 0 and Di(0) = 1.
(1.7.2)
This compliance type variable, Ui, allows us to classify a population into
four subpopulations by the four categories of individuals’ compliance be-
haviour, that is compliers (Ui = c), always-takers (Ui = a), never-takers
(Ui = n) and defiers (Ui = d).
In the literature, the fourth compliance type, defier (Ui = d), is often
omitted, since there is no reason to suppose that individuals who agree to
participate in a trial will necessarily always counter their experimenters. To
avoid this extreme situation, a very common assumption named Monotonic-
ity (Angrist et al., 1996; Imbens & Rubin, 1997; Frangakis & Rubin, 1999)
is given, which supposes that the component of the received treatment Di
is a monotone function with respect to Zi, that is Di(1) and Di(0) have a
relationship as follows,
Di(1) ≥ Di(0). (1.7.3)
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Instead of using the terminology of Monotonicity, some authors directly
assume, however, that there are strictly no defiers in the study (Baker, 1998;
Baker & Kramer, 2005).
1.8 Aim of this research
The purpose of this research is to develop a new approach for causal infer-
ence in survival analysis, that is based on the Frangakis-Rubin (F-R) method
(Frangakis & Rubin, 1999). Our approach considers noncompliance and miss-
ing outcomes (censoring) together, which is unlike previous research. Our fo-
cus is the analysis of time-to-event data, rather than binary or dichotomous
outcomes or normal distributed data, as in the literature of this area to date
(Mealli et al., 2004; Peng et al., 2004; O’Malley & Normand, 2005). This is
the first study to develop a likelihood-based (EM) approach for survival data
for RCT’s which accommodates both missing outcomes and noncompliance
simultaneously.
The research of this thesis constructs survival modelling within the po-
tential outcomes approach (Greenland, 2004) for causal inference, ultimately
constructing a class of causal survival models which appropriately model the
time dynamic nature of causal processes, whether in medicine or in other
RCT survival analytic scenarios.
In this thesis, a class of extended parametric survival models will be es-
tablished by following assumptions given in Frangakis & Rubin (1999). These
can be applied to the analysis of the efficacy of a treatment in RCTs with
noncompliance and allows also for an ignorable or non-ignorable censoring
mechanism.
1.8.1 Main problems
To achieve the goals stated above, we address the following issues; namely
that of
1. not fully observable potential-outcome vectors;
2. unobservable compliance type; and
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3. an ignorable or non-ignorable censoring mechanism.
These three issues are discussed in brief below.
Not fully observable potential-outcome vectors
For the potential outcomes vector Yi = [Yi(0), Yi(1)], either Yi(0) or Yi(1) is
observed. In practice, each individual would only be assigned to one of the
treatment groups and receive one treatment only in a RCT. This means that
in a RCT, each individual’s potential outcomes vector is not fully observ-
able; instead, only one component would be observed if the individual is not
censored. Using the notation given in Section 1.7.1, the potential outcomes
vector Yi can then be written as Yi = [Y
obs
i , Y
mis
i ].
Unobservable compliance type
By the definition of compliance type (Section 1.7.2), we require knowledge
of the full vector Di = [Di(1), Di(0)] to determine individual i ’s compliance
type Ui = u. However, Di is not fully observable as stated in Section 1.7.1.
Therefore, compliance type (Ui) is an unobserved variable. This is a common
challenge in noncompliance analysis (Imbens & Rubin, 1997; Frangakis &
Rubin, 1999; Yau & Little, 2001; Peng et al., 2004; O’Malley & Normand,
2005).
Non-ignorable censoring mechanism
Apart from the two problems stated above (Section 1.8.1), which accompany
the fundamental problem in causal inference (Section 1.4.4), that only one
of the potential outcomes is observed in a RCT (Holland, 1986)), another
challenge arises in time-to-event study due to censoring. Because of the
presence of noncompliance, we have to consider the impact of both noncom-
pliance and censoring together. This implies that the traditional assumption
in survival analysis, which requires an independent censoring or ignorable
censoring mechanism, may not hold (Baker, 1994). Instead, the assumption
of latent ignorability (Frangakis & Rubin, 1999) has to be assumed. How-
ever, the latter needs to be specified in a form to suit time-to-event studies,
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as censoring is slightly different to the usual case of non-response. In fact,
censoring can be viewed as a special form of missing data. This feature leads
to more complexities in the estimation of the causal effect in time-to-event
RCTs.
In this thesis, we commence with the original potential outcomes frame-
work and combine it with features of RCTs for time-to-event studies, such
as censoring and noncompliance. Thereby we create a class of paramet-
ric potential-outcome survival models (PPO-survival models), pertinent to
standard intention-to-treat (ITT) analyses. Recall that the ITT approach
traditionally only provides an estimator of the efficacy of assigned treat-
ment, rather than of the efficacy of the actual received treatment. As men-
tioned in Section 1.6, when noncompliance occurs, it is well known the ITT
(Intention-to-treat) is biased estimator of effect of received treatment. Fur-
thermore, when non-ignorable non-response occurs, e.g. non-ignorable cen-
soring in time-to-event studies, the ITT may also be biased for effect of
assigned treatment (Frangakis & Rubin, 1999).
Because of the presence of censoring, which is the major feature in time-
to-event data, the new definitions of the Average of Causal Effect (ACE)
and the Complier Average of Causal Effect (CACE) are given in the context
of this thesis (Section 3.3). This, as derived, is based on the survival func-
tion, a traditional and well-used quantity in survival analysis; ours is a novel
approach to causal effect estimation.
1.9 Overview of the thesis
This thesis has a structure as follows: Basic concepts from several topics, in-
cluding causal inference, time-to-event studies, randomised RCTs and non-
compliance are introduced in Chapter 1. Chapter 2 concentrates on a lit-
erature review for potential-outcome models. Chapter 3 describes the dis-
tinctions of time-to-event analysis from general data analysis, where the two
important quantities for causal inference, in terms of Average Causal Effect
(ACE) and Complier Average Causal Effect (CACE), have been redefined to
accommodate for survival outcomes. Chapter 4 addresses different types of
censoring mechanisms with their related likelihood function structures.
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Theoretical parametric potential-outcome survival models, (PPO-survival
models for short), are given in Chapter 5. The PPO survival models (I) are
established for causal inference on time-to-event data, which are associated
with the case where noncompliance is non-ignorable and the censoring mech-
anism is ignorable or non-ignorable. All the theoretical models established
in Chapter 5 are illustrated in Chapter 6 via their specified forms on the
HIP data (Baker, 1998; Shapiro et al., 1988), where Weibull or log-normal
distributions are assumed for both the failure and censoring time distribu-
tions. The PPO-survival models (II), which extend the PPO-survival models
(I) to incorporate pre-treatment covariates, are derived theoretically and il-
lustrated briefly in Chapter 7. The discussion and conclusions are given in
Chapter 8.
Overall, the first two chapters are background material related to the
main topic addressed in this thesis. Chapters 3 and 4 provide new ideas:
the foundational concepts for establishing our PPO-survival models (I) and
(II). Chapter 5 and Chapter 7 are the main parts of this thesis, original
contributions to the potential outcomes, survival analysis and potential out-
come literature; where we address the creation of our PPO-survival by way
of models (I) and (II). Chapter 6 pertains to the application of our new PPO-
survival models (I). This is the first time PPO-survival models (I) have been
applied. In addition, Section 6.4 provides the application of the Frangakis-
Rubin model (Frangakis & Rubin, 1999) on the HIP data, which is also
an original work as we are not aware of any relevant previous work in the
literature.
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Chapter 2
Potential-outcome models
Having given basic concepts which relate to the topics of causal inference
or time-to-event studies in Chapter 1, this chapter concentrates on defining
the causal effect in the potential-outcomes framework (Section 2.1) and also
reviews potential-outcome models in the current literature (Section 2.3). In
addition, further discussion about potential-outcome models is given in Sec-
tions 2.4 and 2.5, which include the limitations of potential-outcome models
and the current state of development of them in the literature. The last
section of this chapter gives the summary.
2.1 Definition of causal effects
In Section 1.4.3, the causal effect, a quantity for measuring causal influence,
was roughly described as a contrast between potential outcomes (Rubin,
1974, 1978). In fact, this contrast can be obtained in two ways: one is a
difference and the other is a ratio. In other words, the causal effect measure
has more than one form. The one based on the ratio is termed the relative
causal effect. This is distinct from causal effect, which is obtained via the
difference of two potential outcomes. Furthermore, the causal effect can also
be defined at both an individual and a population level. In this section,
we give the definitions of causal effect and relative causal effect for both
individual (Section 2.1.1) and population (Section 2.1.2) levels. Recall that
in the potential outcomes framework, the outcome of interest in a two-arm
RCT can be written as a vector, that is Yi = [Yi(0), Yi(1)]. Here Yi(0) and
Yi(1) denote the outcome of interest corresponding to the two different levels
of assigned treatment, i.e. Yi(0) is for the control (untreated), and Yi(1) is
for the assigned treatment.
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2.1.1 Individual level causal effects
At the individual level, the causal effect is called the individual causal effect,
which is the difference between two potential outcomes of an individual and
is denoted by ICEi.
Given the potential outcomes vector Yi = [Yi(0), Yi(1)] for individual i,
ICEi can then be expressed as follows:
ICEi = Yi(1)− Yi(0). (2.1.1)
Similarly, the relative causal effect at an individual level, namely the
individual relative causal effect, denoted by IREi, is the ratio between the
two potential outcomes (if they all are positive). IREi can be expressed as
follows:
IREi =
Yi(1)
Yi(0)
for Yi(0) > 0 and Yi(1) > 0. (2.1.2)
Note that in equation (2.1.2) above IREi is undefined when Yi(0) = 0.
2.1.2 Population level causal effects
At the population level, there are two forms of so-called Averaged Causal
Effects (ACE): one from the individual causal effects, which is based on
ICEi (denoted by ACE), and the other from the individual relative causal
effects, based on IREi (denoted by RCE). These can be written as
ACE = E(Yi(1))− E(Yi(0)), (2.1.3)
and
RCE =
E(Yi(1))
E(Yi(0))
, (2.1.4)
where E() denotes an expectation over all the population of treated or control
individuals.
By following the property of expectation, the following equality always
holds:
E(Yi(1))− E(Yi(0)) = E(Yi(1)− (Yi(0)). (2.1.5)
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Hence the ACE can be re-expressed as follows:
ACE = E(ICEi). (2.1.6)
The relationship given in equation (2.1.6) implies that a potential-outcome
model for estimating the ACE (Average Causal Effect) is often related to the
ICE (Individual Causal Effect), we name this type of model as ICE based
potential-outcome model, which can be seen in the literature on causal in-
ference. In fact, ACE has attracted much attention in the last decades for
general data (Angrist et al., 1996; Imbens & Rubin, 1997; Yau & Little,
2001; Peng et al., 2004; O’Malley & Normand, 2005), whereas the RCE is
less tractable for time-to-event data because E(Yi(1))
E(Yi(0))
6= E(Yi(1)
Yi(0)
), which implies
RCE 6= E(IREi).
2.2 Role of randomisation
In Section 1.5, we stated that the treatment and control groups in a RCT are
able to be comparable because they can be viewed as two samples, which are
drawn randomly and independently from the same population. This implies
that the outcome variable Yi = [Yi(1), Yi(0)] is independent of the assigned
treatment Zi. That is [Yi(1), Yi(0)]⊥Zi. So the conditional distributions of
the potential outcomes Yi(1) or Yi(0), given the assigned treatment Zi = z
(for z = 1 or 0), can be regarded as the same. That is:
Pr(Yi(1)|Zi = 1) = Pr(Yi(1)|Zi = 0) = Pr(Yi(1)),
P r(Yi(0)|Zi = 1) = Pr(Yi(0)|Zi = 0) = Pr(Yi(0)),
(2.2.1)
where Pr() denotes the probability distribution. This leads to the following
equalities hold:
E(Yi(1)|Zi = 1) = E(Yi(1)|Zi = 0) = E(Yi(1)),
E(Yi(0)|Zi = 1) = E(Yi(0)|Zi = 0) = E(Yi(0)),
(2.2.2)
where E() denotes the expectation that takes over all the population of
treated or control individuals.
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Therefore equation (2.1.3) can be replaced by the following:
ACE = E(Yi(1)|Zi = 1)− E(Yi(0)|Zi = 0). (2.2.3)
If we write µ1 = E(Yi(1)) and µ0 = E(Yi(0)), then via equation (2.2.2),
randomisation implies µ1 = E(Yi(1)|Zi = 1) and µ0 = E(Yi(0)|Zi = 0),
which can be estimated in randomised trials, via
µˆ1 =
∑N1
i∈{i:Zi=1} Yi(1)
N1
;
and
µˆ0 =
∑N0
i∈{i:Zi=0} Yi(0)
N0
,
(2.2.4)
where N1 and N0 denote the number of subjects in the treatment group and
control group respectively. The ACE, average causal effect, can then be
estimated straightforwardly as follows
ÂCE = µˆ1 − µˆ0. (2.2.5)
Similarly, the RCE can be estimated by
R̂CE =
µˆ1
µˆ0
if µˆ0 6= 0. (2.2.6)
Equations (2.2.5) and (2.2.6) thus provide a possible way to solve the fun-
damental problem in casual inference (Section 1.4.4), where randomisation
plays an important role.
2.3 Potential-outcome models
Since Neyman in 1923 first proposed the concept of the potential outcomes
framework, which in itself is the first example of a potential-outcome model
(Greenland, 2004), potential-outcome models have been attractive, especially
over the last decade (Angrist et al., 1996; Imbens & Rubin, 1997; Frangakis
& Rubin, 1999; Hirano & Imbens, 2000; Graham, 2000; Barnard et al., 2003;
Rubin, 2004; O’Malley & Normand, 2005).
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Neyman’s model is a classic and formal statistical model for causal infer-
ence (Greenland, 2004) and is also called the Rubin Causal Model (RCM) in
the literature (Holland, 1986; Rubin, 2004; Angrist et al., 1996; Frangakis &
Rubin, 1999; Hirano & Imbens, 2000; Graham, 2000; Barnard et al., 2003;
Rubin, 2004; O’Malley & Normand, 2005), even though the RCM refers to
the Neyman model which was proposed earlier. However, apart from the
RCM model, in the literature there are still some other potential-outcome
models such as the structural nested failure time model (SNFTM) (Robins
(1998), Robins (1998a)); the marginal structural model (MSM) (Robins
(1999), Robins (1999a), Robins et al. (1999b), Hernan et al. (2000, 2001)),
the component equations in structural-equation model (SEM) (Pearl, 1995,
2000; Jeffrey, 2007) and the causal diagrams model (Pearl, 1995).
In this thesis, we class potential-outcome models into two types by their
applied data type; one is for general data causal inference models that are
based on Average Causal Effect (ACE) or Complier Average Causal Effect
(CACE) analysis, and the other is for time-to-event data causal inference
models which are mostly derived from a semi-parametric survival model but
have not been related to ACE estimating yet. We review the former class of
potential-outcome models in Section 2.3.1, where they are referred as ACE
or ICE based potential-outcome model. Another class of potential-outcome
models, which we called the semi-parametric potential-outcome models, are
reviewed in Section 2.3.2.
2.3.1 For general data analysis
According to the current literature, the potential-outcome models for esti-
mating ACE or CACE, which are the ICE based potential-outcome models,
have been applied only on the general data (Angrist et al., 1996; Imbens &
Rubin, 1997; Hirano & Imbens, 2000; Graham, 2000; Barnard et al., 2003;
Rubin, 2004; O’Malley & Normand, 2005). Most of these models proposed
in the papers mentioned above are under the assumption of the stable unit
treatment value (SUTVA), which was first given by Rubin (1986) and as-
sumed that individuals’ potential outcomes are unrelated to the treatment
status of other individuals (Graham, 2001; Peng et al., 2004; Mattei & Mealli,
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2007); where the definition of causal effect at the individual level (ICE) was
given exactly by equation (2.1.1) (Holland, 1986) but not equation (2.1.2),
as general data may have zero or negative values.
Under randomisation, especially in intention-to-treat analysis (Section
1.6), the causal effect at the population level (ACE) can be specified by
equation (2.2.3), and the ACE, can easily be estimated by equation (2.2.5)
(Holland, 1986).
After adoption of an instrumental variable technique and via two asso-
ciated assumptions, the exclusion restriction (equation (1.7.1)) and mono-
tonicity (equation (1.7.3)), Angrist et al. (1996) extended these ACE based
models to deal with the critical problem of evaluating the treatment effect in
a randomised trial when noncompliance occurred, but without consideration
of non-responses.
Imbens & Rubin (1997) then used the compliance type covariate, whereby
the ACE (equation (2.2.3) ) can further be written as the difference between
the potential outcomes of compliers, namely complier average causal effect
(CACE) in a noncompliance scenario, that is
CACE = E(Yi(1)|Zi = 1, Ui = c)− E(Yi(0)|Zi = 0, Ui = c). (2.3.1)
Furthermore, given the exclusion restriction assumption (Imbens & Ru-
bin, 1997)(equation (1.7.1)), it leads to the following equations:
E(Yi(1)|Zi = 1, Ui = a) = E(Yi(0)|Zi = 0, Ui = a);
E(Yi(1)|Zi = 1, Ui = n) = E(Yi(0)|Zi = 0, Ui = n).
(2.3.2)
The average causal effect (ACE) can be expressed as:
ACE = picCACE (2.3.3)
where pic is the probability of compliers (Ui = c), i.e. pic = Pr(Ui = c)
(Imbens & Rubin, 1997).
Recall that because of randomisation, the covariate of compliance type is
independent of the assigned treatment Zi, that is Ui⊥Zi. Hence the following
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equation holds,
Pr(Ui = c|Zi = 1) = Pr(Ui = c|Zi = 0) = Pr(Ui = c). (2.3.4)
Hence pic = Pr(Ui = c|Zi = 1) can be estimated by pˆic = N11N1 , where
N1 denotes the number of individuals in the treated group and N11 is the
number of individuals who do actually receive the treatment in the treated
group (Imbens & Rubin, 1997; Baker, 1998; O’Malley & Normand, 2005).
By adding in the latent ignorability assumption, which assumes that the
potential outcomes and associated potential non-response indicator are in-
dependent (for each level of the latent compliance types), Frangakis & Ru-
bin (1999) developed the extended potential-outcome model to estimate the
causal effect of treatment, which accommodated both noncompliance and
non-response mechanisms. As such, they introduced a more plausible ex-
tended potential-outcome model which appeared in the literature as the so-
called Frangakis-Rubin model (F-R model) (Mealli et al., 2004).
Amongst the extensive body of literature on noncompliance, most papers
address noncompliance as missing covariates. This is because the compliance
type Ui = u is considered to be an unobservable variable, at least for those
individuals in the control group. Hence the compliance type is often regarded
as a missing covariate (O’Malley & Normand, 2005; Frangakis & Rubin,
1999; Baker, 1998). Some recently published papers, however, do consider
noncompliance and subsequent non-response together (Frangakis & Rubin,
1999; Baker, 1998; Hirano & Imbens, 2000; Barnard et al., 2003; Peng et al.,
2004; Mealli et al., 2004; O’Malley & Normand, 2005). This is partially
relevant for time-to-event studies, which often involve censoring and hence
missing outcomes (of kinds).
The Frangakis-Rubin (F-R) model (Frangakis & Rubin, 1999; Mealli
et al., 2004) is the first potential outcomes model to consider both noncom-
pliance and non-response mechanisms together. For intention-to-treat (ITT)
analysis, a standard approach can be biased, in some settings, because of
the need to omit subjects with missing outcomes and ignore an individual’s
compliance information. Frangakis & Rubin (1999) constructed a new es-
timation procedure which was designed to address all-or-none compliance
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and allows for missing outcomes. In this way, the ITT effect could main-
tain good randomisation-based properties under more plausible conditions,
namely that of non-ignorable noncompliance and of non-ignorable missing
outcomes. Frangakis & Rubin (1999) also allow for the compound exclusion
restriction to hold on the effect of assignment and for latent ignorability to
be valid for the missing data mechanism. The Frangakis-Rubin (F-R) model
supposed that individuals who were assigned to the control group did not
have any chance to receive the intervention treatment. This assumption
implies that no always-takers exist in the randomised trial. In this case,
compliance types are thus reduced and can be indicated by a binary vari-
able. The two key concepts of compound exclusion and latent ignorability
are also relevant in even more complicated settings, such as right censoring
of a time-to-event outcome (Frangakis & Rubin, 1999; Klein, 1997).
For the analysis of data from an extended framework experiment with
the complexities of a large amounts of noncompliance, a binary treatment
regime, binary encouragement and background covariates, Hirano & Imbens
(2000) adopted a Bayesian approach for inference and sensitivity analysis.
They adopted an instrumental variable (IV) approach to link intention-to-
treat effects with the treatment effects.
Follmann (2000) proposed two methods: a propensity score (PS) ap-
proach and a counterfactual (CF) approach (which is specific to the Weibull
distribution). Follmann (2000) examined how the effect of treatment varies
with compliance to treatment via a pseudo-likelihood method to derive the
maximum likelihood estimators (MLEs).
Based on the maximum likelihood (ML) approach and Bayesian infer-
ential methods for CACE, a model for inference was developed by Yau &
Little (2001), which allowed for the inclusion of baseline covariates and han-
dled missing data in repeated measures. Yau and Little’s model (Yau &
Little, 2001) was applied to a randomised trial of job training intervention
for unemployed workers. The results show that job training intervention
significantly reduced depression for high-risk compliers (up to six months
post-intervention) but not for low-risk compliers (Yau & Little, 2001).
In a two-armed randomised trial to compare the efficacy of two antipsy-
chotics for adults with refractory schizophrenia, which also assumed all-or-
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none compliance and allowed for subsequent non-response, O’Malley & Nor-
mand (2005) proposed a maximum likelihood estimator (MLE) of the causal
effect of assigned treatment, which was based on a latent compliance type
covariate. The latter described the behavior of a subject under all possible
assigned treatments. This characterized the missing data mechanism as in
the Frangakis-Rubin (F-R) model (Frangakis & Rubin, 1999) and used the
EM algorithm for parameter estimation. The authors claimed that simulated
results showed that the MLE (for normal outcomes) compares favourably to
other methods such as the standard intention-to-treat (ITT) estimator, the
method-of-moments (MOM) estimator (under both normal and non-normal
data), and accommodated for departures from the latent ignorability and
compound exclusion restriction assumption (O’Malley & Normand, 2005).
Research on the efficacy of the school choice scholarship foundation pro-
gramme in New York (Barnard et al., 2003) revealed threats to valid esti-
mates of experimental effects that exist in the presence of noncompliance
and missing data. This occurred even when the goal was to estimate sim-
ple intention-to-treat (ITT) effects. A model with covariates was developed
by Barnard et al. (2003) which accommodated for these complications and
was based on the general framework of principal stratification. Barnard et al.
(2003) created a better solution to allow for both noncompliance and missing
data. Principal stratification is an approach proposed by Frangakis & Rubin
(2002). In brief, the principal stratification, with respect to a post-treatment
variable, is a cross-classification of individuals defined by the joint poten-
tial values of the given post-treatment variable under each of the treatments
being compared (Frangakis & Rubin, 2002).
In a study of job search intervention for unemployed workers, Peng et al.
(2004) proposed an extended general location model to estimate the CACE
from data with both noncompliance and missing data in the outcome of inter-
est and also in baseline covariates. Models for both continuous and categor-
ical outcomes, and ignorable and latent ignorable missing data mechanisms
were developed by Peng et al. (2004). Inference for these models was based
on the EM algorithm and on Bayesian MCMC methods. Simulation results
were used to investigate sensitivity to model assumptions and to assess the
influence of the missing data mechanism (Peng et al., 2004).
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Later, Mealli et al. (2004) proposed a new missing data model that, like
the Frangakis-Rubin model, is specially suited for models with instrumen-
tal variables, but under different substantive assumptions. The new model
has been applied on analysis data from a randomised trial of breast self-
examination (BSE). Mealli et al. (2004) also claimed that their new model
appears to be the most plausible of the three models, the standard model
for missing data (missing at random), the Frangakis-Rubin (F-R) model and
the author’s model, where the model of missing at random appears to be the
least plausible.
We now summarize the main assumptions involved in the above ap-
proaches:
1. The stable unit treatment value assumption (SUTVA) (Imbens & Ru-
bin, 1997; Peng et al., 2004; Mattei & Mealli, 2007): the potential
outcomes of each individual are unrelated to the treatment status of
other individuals.
2. Random assignment: each individual has been assigned randomly to
treatment group.
3. Exclusion restriction: the assigned treatment has an effect on the out-
come only through its effect on the received treatment.
4. Monotonicity: the actual received treatmentDi(Zi) is a monotone func-
tion with respect to the potential treatment levels (1 for being treated
and 0 for being in the control), that is Di(1) ≥ Di(0).
5. Latent ignorability: the potential outcomes and associated potential
non-response indicator are independent for each level of the latent com-
pliance types.
In general, most of methods developed from the ACE or CACE based
potential-outcome models listed above, such as those proposed by Angrist
et al. (1996); Imbens & Rubin (1997); Yau & Little (2001); Barnard et al.
(2003); Mealli et al. (2004); Peng et al. (2004) and O’Malley & Normand
(2005), do not deal directly with time-to-event data. Some studies pertain
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to binary outcomes (Imbens & Rubin, 1997; Yau & Little, 2001; Barnard
et al., 2003; Mealli et al., 2004) and others to general data that are assumed
to follow a normal distribution (Peng et al., 2004; O’Malley & Normand,
2005).
All these approaches may be viewed as potential-outcome models for gen-
eral data in noncompliance studies, where the focus is the complier average
causal effect (CACE). The CACE has attracted much attention in the last
decade (Rubin, 1998; Yau & Little, 2001; Jo, 2002a,b; Dunn et al., 2003;
Mealli et al., 2004; Peng et al., 2004). However, to date, CACE analysis has
not been developed for time-to-event studies. This is one of the aims of this
thesis.
2.3.2 For time-to-event data analysis
In time-to-event studies, as noted in Chapter 1, the outcome of interest is
defined as the event time, which usually takes positive values and does not
follow a normal distribution. As the event time is the outcome of inter-
est, it is also highly related to the occurrence of censoring. Hence most
of the potential-outcome models described in Section 2.3.1 are not suitable
to time-event-study scenarios as they are mainly applicable only to general
data. This thesis will develop potential-outcome models which are based
on the RCM, and also consider noncompliance and subsequent non-response
together. These new potential-outcome models for causal inference are ap-
plicable to RCTs with noncompliance and time-to-event studies. (Details are
given Chapter 5 and Chapter 7).
Before addressing our potential-outcome models, we will review some
potential-outcome models that were recently proposed for time-to-event stud-
ies.
Amongst the extensive body of literature on potential-outcome models
for time-to-event data analysis, the following models could plausibly be used:
the structural nested failure time model (SNFTM) (Robins & Tsiatis, 1991;
Robins, 1998,a; Vandebosch et al., 2005; Hernan et al., 2005), the marginal
structural Cox Proportional Hazards model (Hernan et al., 2000a; Loeys &
Goetghebeur, 2003; Gong et al., 2005) and the method of inverse probability
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of censoring weighted log-rank tests (Robins & Finkelstein, 2000).
The common approach underlying these models is the accelerated failure
time (AFT) model (p.46, Klein (1997), or p.64, Cox & Oakes (1984)), where
the potential outcomes, if contrary to the fact (unobservable), can be ex-
pressed as a product of the observable time Ti(Zi) and the accelerated factor
exp(−βZi), that is
Ti(0) = exp(−β)Ti(1), (2.3.5)
when the individual i is assigned to the treated group (Zi = 1) in a two-arm
RCT. Note that here, Ti(0), the survival time corresponding to the control
group is contrary to the fact and can not be observed in practice.
Following the definition of causal effect for positive outcomes, namely
the individual relative causal effect (given in equation (2.1.2)), the IRE for
the survival time, the outcome of interest in time-to-event studies, has the
following form:
IREi =
Ti(1)
Ti(0)
=
Ti(1)
exp(−β)Ti(1) = exp(β). (2.3.6)
Therefore, the accelerated parameter β can be interpreted as the param-
eter of causal effect as equation (2.3.6) has shown that exp(β) is the causal
effect for time-to-event outcomes.
Robins & Tsiatis (1991) is the earliest paper on noncompliance analysis
for survival outcomes with a view to estimating the treatment effect. In
Robins & Tsiatis (1991), a class of models called rank-preserving structural
failure time models (RPSFTM) were introduced with a latent failure time
variable, called the treatment-free time, denoted by T 0i (even if the treatment-
free time may not be observable). Then T 0i is the failure time of the ith
individual who never received the treatment. By following the development
of usual time-dependent accelerated models (p.66-67, Cox & Oakes (1984)),
the latent failure time variable can then be related to the observable random
variables as follows:
T 0i =
∫ Ti
0
exp(−β0Di(t))dt. (2.3.7)
where Di(t) refers to a time-dependent treatment indicator, ( Di(t) = 1 for
the ith individual receiving the treatment at time t and Di(t) = 0 otherwise);
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β0 is the unknown parameter with a causal interpretation. The treatment-
free time, T 0i , can be viewed as the lifetime of the ith individual if he/she
does not received the treatment of interest in the trial. Under the assumption
of that the baseline lifetime T 0i is independent of the assigned treatment
indicator Zi, (T⊥Zi), the survival function of the baseline life time is the
same in the treated and the control group. That is:
Pr(T 0i ≥ t|Zi) = S0(t) for Zi ∈ (0, 1). (2.3.8)
This implies that all individuals will have a T 0i = T
0, whether or not the
actually receive the treatment.
Standard nonparametric methods can be applied to test the null hypoth-
esis β0 = 0. Robins & Tsiatis (1991) assumed that no censoring prior to
the end of follow-up exists, which means that this model is covered by the
assumption of noninformative censoring. We can make this assumption be-
cause no censoring prior to the end of follow-up implies that censoring time is
a constant rather than a random variable; no censoring mechanism needs to
be considered. Robins & Tsiatis (1991) also supposed that they had a rank-
preserving model, which means that individuals keep their order of failure
time when they receive the same treatment. For instance, suppose that any
two individuals, i and j, both received a particular treatment. If individual
i fails before individual j, then for any other treatment they both receive,
individual i would fail before individual j (Robins & Tsiatis, 1991).
Mark & Robins (1993) proposed an approach to analyzing randomised
trials without ignoring information on postrandomization compliance, which
uses Robins and Tsiatis’ method and takes advantage of postrandomization
smoking history without requiring untenable assumptions about the compa-
rability of compliers and noncompliers in the data from the Multiple Risk
Factor Intervention Trial (MRFIT).
More generally, the model is also known as the so-called the structural
nested failure time model (SNFTM) (Robins, 1998,a; Vandebosch et al., 2005;
Hernan et al., 2005), a generalization of the strong accelerated failure time
(AFT) model (p.46, Klein (1997), or p.64, Cox & Oakes (1984)), in which
it is supposed that the assigned treatment (Zi) may vary and the actual
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survival time interval, LS = [0, Ti(z)], (0 denotes the start point and Ti(z)
represents the point of time when individual i in the Zi = z treatment group
experienced the event of interest) is divided into K successive intervals of
length 4t1, . . . ,4tK . The potential survival time, Ti(0), corresponding to
the control group, can then be written as follows:
Ti(0) =
∑
k
exp(−βzk)4tk; (2.3.9)
when the treatment history is continuous, z(t) in, equation (2.3.9) can then
be replaced by the following equation:
Ti(0) =
∫
LS
exp(−βz(t))dt. (2.3.10)
In the marginal structural Cox proportional hazards (PH) model (Hernan
et al., 2000; Loeys & Goetghebeur, 2003; Gong et al., 2005), the Cox propor-
tional hazards model (p. 230, Klein (1997), or p.70, Cox & Oakes (1984)),
which is a standard semi-parametric method, was adopted rather than the
accelerated failure time model (p.46, Klein (1997) or p.64, Cox & Oakes
(1984)). The subject of interest in the marginal structural Cox proportional
hazard (PH) model is the hazards rate function (Section 3.1.2) rather than
survival time itself. Here the hazard rate functions, corresponding to the ob-
served treatment level Zi = 1 and Di(1) = 1 and the unobservable potential
treatment level, Zi = 0 and Di(0) = 1 (counterfactual), are denoted by λ11(t)
and λ10(t) respectively.
By following Cox’s proportional hazards model (p.230, Klein (1997) or
p.70, Cox & Oakes (1984)), the two hazard rate functions have a relationship
as follows:
λ11(t) = λ10(t) exp(ψ), (2.3.11)
where exp(ψ) denotes the causal proportional hazards effect within the treat-
able subpopulation (Loeys & Goetghebeur, 2003).
Korhonen & Laird (1999) discussed different methods, which include the
intention-to-treat approach, the as-treated approach and the g-estimation
approach, for estimating the effect of treatment actually received in a lon-
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gitudinal placebo-controlled trial with noncompliance. All these models are
based on the Cox proportional hazard model (p.230, Klein (1997), or p.70,
Cox & Oakes (1984)), where noncompliance is treated as non-ignorable and
the censoring mechanism has been ignored.
Korhonen (2000) addressed several accelerated failure time models for
dealing with the noncompliance issue in randomised clinical trials. Even
though the author did not claim that the mechanism of censoring was ignor-
able, at least they are not under the latent ignorability assumption (Frangakis
& Rubin, 1999).
Robins & Finkelstein (2000) proposed a new method: the so-called Inverse
Probability of Censoring Weighted (IPCW) log-rank test for estimating the
effect of treatment with noncompliance and a non-ignorable censoring mech-
anism. Here a fundamental assumption is assumed, namely no unmeasured
confounders of censoring (Robins, 1997) or, equivalently, the assumption of
sequential ignorability of censoring (Robins & Finkelstein, 2000). It is ex-
pressed in equation (2.3.12), which means that conditional on the assigned
treatment Zi and recorded history Hi(t) of all associated time-dependent co-
variates Xi(t), where Hi(t) = {Xi(u); 0 ≤ u ≤ t}, the cause-specific hazard
rate of censoring λC(t) (at time t, Ci = t ) does not further depend on the
possibly unobserved failure time Ti, i.e.
λC(t|H(t), Z, T, T > t) = λC(t|H(t), Z, T > t). (2.3.12)
The usual assumption of independent censoring is that, given the treat-
ment group Zi = z, the cause-specific hazard of failure time Ti = t (for
individuals at risk) denoted by λT (t|Z,C ≥ t) is the marginal hazard of fail-
ure time Ti = t, λT (t|Z) (Robins & Finkelstein, 2000). This can be expressed
as:
λT (t|Z,C ≥ t) = λT (t|Z). (2.3.13)
With respect to the study of causal inference for survival data obtained
from cluster randomised trials, Loeys et al. (2001) proposed that structural
models can be employed to account for post-randomisation exposures, but
that structural models should not ignore clustering. This was illustrated
using a Vitamin A trial for the prevention of infant mortality in the rural
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plains of Nepal (Loeys et al., 2001). Marginal modelling and random effects
models were used to adapt structural estimators to account for clustering
(Loeys et al., 2001).
In survival analysis of standard proportional hazards (PH) models that
traditionally follow the intention-to-treat (ITT) principle, Loeys & Goetghe-
beur (2003) derived an estimating equation for the Compliers PROPortional
Hazards Effect of Treatment (C-PROPHET) in an analysis of data from a
clinical trial of cancer patients with liver metastases. The jackknife method
was used for bias correction and variance estimation, while potential treat-
ment compliance was considered as unobserved in the control arm. Loeys &
Goetghebeur (2003) clearly claimed that their proposed C-PROPHET model
was under the noninformative censoring assumption.
More recently, Hernan et al. (2005) used a nested structural accelerated
failure time model to estimate the total causal effect of a highly active an-
tiretroviral therapy (HAART) on the time to AIDS (or death) among human
immunodeficiency virus (HIV) infected participants. This was a part of the
Multicenter AIDS Cohort and Women’s Interagency HIV Studies (Hernan
et al., 2005).
In the analysis of causal effects of observed exposures in randomised trials,
structural accelerated failure time models may thus be seen to be selective i.e.
reliant on unmeasured prognostic factors, when the actual exposure levels are
not completely controlled for the effect of such exposures (on a right censored
survival outcome). Note also that Vandebosch et al. (2005) derived consistent
randomisation-based estimators to allow estimation of the structural effect
of an experiment.
Note that almost all the potential-outcome models listed above are based
on estimating the hazard rate. It is noteworthy that the structural acceler-
ated failure time models (Robins & Tsiatis, 1991; Vandebosch et al., 2005;
Hernan et al., 2005) provide consistent estimates of causal effects when un-
measured confounding and model misspecification are absent, thereby giving
bias in the standard time-dependent accelerated failure time (AFT) model
(p.66, Cox & Oakes (1984)).
The approaches mentioned above, for noncompliance analysis and for
survival outcomes in imperfect randomised trials, are mostly based on semi-
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parametric (Korhonen & Laird, 1999; Korhonen, 2000; Robins & Finkelstein,
2000; Loeys & Goetghebeur, 2003) or non-parametric (Robins & Tsiatis,
1991) methods in survival analysis. They all depend on certain specific as-
sumptions for the underlying censoring mechanism.
2.4 Limitation of current potential-outcome models
In this chapter, potential-outcome models have been categorized by the type
of outcome of interest: either 1) general data, or 2) time-to-event data. The
first type (general data) is related to estimation of the causal effect for non-
time-to-event data, where the definition of casual effect follows the concept
of average causal effect (ACE). ACE is defined as the difference between
the components’ mean of the potential outcomes vector (equation (2.1.3)),
its related model approaches include both parametric and non-parametric
models. The second type (time-to-event data) is based primarily on semi-
parametric methods and focuses on survival outcomes. Here, the definition
of casual effect follows the concept of relative causal effect (Graham, 2001).
Among the approaches reviewed in Section 2.3.1, some are primarily based on
the ICE at the individual level and aim at estimating average causal effect
(ACE) or complier average causal effect (CACE) for the population level
estimate.
In addition, most studies focus on outcomes which are binary (Sommer
& Zeger, 1991; Barnard et al., 2003; Mealli et al., 2004; Robins & Rotnitzky,
2004) or normally distributed (Yau & Little, 2001; O’Malley & Normand,
2005; Peng et al., 2004), or alternatively, approach inference from a non-
parametric perspective (Frangakis & Rubin, 1999). Only the approaches,
proposed by Frangakis & Rubin (1999) and by Baker (1998) respectively,
have concerned to survival outcomes with the noncompliance and with an
assumed non-ignorable censoring mechanism. The former is based on the
Kaplan-Meier estimator (Section 3.2.1), considered to be the standard non-
parametric estimator in survival analysis; the latter is based on cause-specific
hazard and provides a likelihood form to estimate the cost-effectiveness of a
cancer screening programme (Baker, 1998). Both of these approaches (Fran-
gakis & Rubin (1999) and Baker (1998)) assume no defiers (monotonicity)
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and exclusion restriction, but only Frangakis & Rubin (1999) assume latent
ignorability, which can viewed as a special case of informative censoring for
survival outcomes. The method used in Robins & Finkelstein (2000) con-
siders both noncompliance and informative censoring, but it is based on the
semi-parametric model rather than the parametric model.
All the potential-outcome models for time-to-event data (Section 2.3.2)
are based on the hazard rate and use semi-parametric methods. To the best
of the author’s knowledge, no survival model which considers noncompli-
ance behaviours and censoring mechanism together, are to be found in the
literature to date. Instead of this simultaneous consideration, Robins & Tsi-
atis (1991) and Korhonen (2000) proposed accelerated failure time models
which accommodate the non-ignorable noncompliance issue; alternatively,
Rotnitzky et al. (1997) proposed an approach which accommodates for non-
response. In other words, among all the potential-outcome models discussed
in Section 2.3, we have not found any parametric potential model that can
be used to deal with problems arising from the case such as the HIP breast
cancer study, which involves the following: noncompliance behaviour, non-
response (censoring) and survival outcomes. This is the motivation of this
research.
2.5 Direction of developing potential-outcome models
According to the literature reviewed above, most work (Robins & Tsiatis,
1991; Korhonen & Laird, 1999; Loeys & Goetghebeur, 2003; Gong et al.,
2005) on potential-outcome models for time-to-event data are based on the
assumption of non-informative censoring. This is equivalent to assuming
independent censoring. In some trials, however, it is hard to claim that
failure and censored time are independent. Note the case that has been
addressed in Frangakis & Rubin (1999), where the failure and censoring time
may be independent conditional on some other unobservable covariates, e.g.
compliance type, for the scenario where noncompliance is an issue of concern.
In the HIP breast cancer trial, with its high proportion of non-compliers,
noncompliance is not ignorable. Therefore, we cannot simply assume inde-
pendent censoring. Following the assumption of latent ignorability (Fran-
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gakis & Rubin, 1999), we consider an independent censoring mechanism con-
ditional on compliance types (Baker, 1998; Frangakis & Rubin, 1999). In
other words, censoring is likely to be informative in this situation. Frangakis
& Rubin (1999) thus proposed their methodology for survival data via a
nonparametric survival method which was based on the usual Kaplan-Meier
estimator (Section 3.2.1) rather than one based on parametric models (Sec-
tion 3.2.3).
However, with the rapid development of computer techniques, many com-
putational methods are now available, such as the Expectation Maximiza-
tion (EM) algorithm (Dempster et al., 1977), and Markov-chain Monte Carlo
(MCMC) methods, which can be adopted for parametric studies with miss-
ing data. Therefore, all models can be applied to parametric survival studies
with noncompliance.
The EM algorithm supplements the maximum likelihood-based method
proposed by Dempster et al. (1977), and has been further developed by Louis
(1982) and Meng & Rubin (1993). The EM algorithm is now widely adopted
when dealing with missing data, particularly in handling unobservable vari-
ables such as compliance type variables in noncompliance studies (Peng et al.,
2004; O’Malley & Normand, 2005). The approach proposed in this thesis
adapts the EM algorithm as necessary for time-to-event data.
2.6 Summary
This chapter reviews the potential-outcome models for two types of data:
general data and time-to-event data. These methods can be viewed as the
models developed from Neyman’s potential-outcome model or the RCM but
which follow the different definitions of causal effect. For general data, it is
based on the individual causal effect and for time-to-event data, it can be
regarded from relative causal effect perspective.
After reviewing the current literature on potential-outcome models, we
observe that, to date, no parametric potential-outcome model can be used
to estimate causal effect for time-to-event data from RCTs with all-or-none
compliance, as the case for the HIP breast cancer trial. This is precisely the
motivation for doing this project.
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Chapter 3
Causal effect for time-to-event data
As mentioned in Chapter 1, time-to-event data is a special type of data
where censoring is often present and event time of the outcome of interest
never follows a normal distribution. In this chapter, more details about
time-to-event data are addressed. The features of time-to-event data are
addressed in Section 3.1, some conventional statistical methods for survival
analysis are introduced briefly in Section 3.2 and a new definition of causal
effect for time-to-event data is given in Section 3.3.
3.1 Features of time-to-event data
In time-to-event studies, it would be impossible to expect that all individu-
als involved in the trial have available failure time, as some are likely not to
experience the pre-specified event of interest during the observation period.
This is a common feature of time-to-event data and is known as censoring
(p.55, Klein (1997)). For censored individuals, their real failure time is not
known; only their censoring time is observed. In the case of missed fail-
ure time, we can still gather some information about censored individuals
via their observed censoring time. We need, however, knowledge about the
underlying censoring mechanism involved in the given RCT.
3.1.1 Censoring types
In general, three censoring types exist: right censoring, left censoring and
interval censoring. Right censoring is the case where an individual may
experience the event of interest after the given time t; we know only that the
individual is alive (not failed) up to the given time (p.56, Klein (1997). Left
censoring is where an individual has experienced the event of interest prior
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to the start of the study (p.62, Klein (1997)). Interval censoring is where the
only information is that the event occurs within some interval of time (p.63,
Klein (1997)).
Let T and C represent the failure and censoring time respectively. Then
the three types of censoring can be expressed mathematically as the following:
Right censoring : T ∈ (Cr, ∞) and it is known only that the failure time
T is greater than the observed censoring time Cr, but exact value of
failure time is unobservable.
Left censoring : T ∈ (0, Cl) and it is known only that the failure time
T is less than the observed censoring time Cl, but its exact value is
unobservable.
Interval censoring : T ∈ (Cl, Cr) and it is known only that the failure
time T is less than the observed right censoring time Cr and greater
than the observed left censoring Cl, but its exact value is unobservable.
For example, if individuals are right censored at time Ci = t, we know
that their failure time would be at least greater than t, that is T > t (Klein,
1997; Cox & Oakes, 1984).
Besides censoring, there is another feature, the so-called truncation issue,
which may also be present in some time-to-event studies. We do not con-
sider this concept in this thesis, as our causal effect and potential-outcome
approach does not consider truncated data. In fact, the approach proposed
in this thesis is based only on right censoring. It may will be possible to
develop our methods later for other types of censoring, such as interval cen-
soring. In the remainder of the thesis, when censoring appears, it always
means right censoring unless otherwise specified.
For analysing time-to-event data, two quantities are possibly of greater
interest than failure time itself. They are known as the survival function and
the hazard (rate) function with respect to failure time t.
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3.1.2 Survival function and Hazards function
The survival function S(t) is the probability of a subject surviving after a
given time point t, i.e.:
S(t) = Pr(Ti > t) =
∫ ∞
t
f(u)du, (3.1.1)
where Pr() denotes the probability function, Ti is the failure time of the
individual i and f() represents the probability density function (p.d.f.).
The hazard (rate) function h(t) is the instantaneous rate of failure at
given time t and can be written as:
h(t) = lim
∆t→0
P (t ≤ Ti ≤ t+∆t|Ti ≥ t)
∆t
=
f(t)
S(t)
, (3.1.2)
where S(t) is the survival function at time t, defined in equation (3.1.1)
(Klein, 1997; Cox & Oakes, 1984; Kalbfleisch & Prentice, 2002); and f(t) is
the same as in equation (3.1.1).
3.1.3 Censoring mechanisms
There are several types of censoring schemes which lead to different likelihood
functions for inference. These are delineated below.
Type I censoring
For Type I censoring, the event is observed only if it occurs prior to some
pre-specified time. Censoring time may vary from individual to individual.
Owing to cost or time considerations, the investigators may terminate the
study or report the results before all subjects realise their events. If no
accidental loses or subject withdrawals, censored observations have times
equal to the length of study time period; the censored time for each individual
is the same and can be treated as a fixed time for a certain trial (Klein, 1997;
Cox & Oakes, 1984; Kalbfleisch & Prentice, 2002).
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Type II censoring
For Type II censoring, the study continues until r individuals experience the
pre-specified event of interest. This number r may be some predetermined
integer. Experiments for testing equipment failure time often involve this
type of censoring. In this case, the censored time for each individual may
be different and can be treated as a random variable. However, Type II
censoring rarely occurs in clinical trials involving human subjects (Klein,
1997; Cox & Oakes, 1984; Kalbfleisch & Prentice, 2002).
Random censoring
Random censoring involves the so-called competing risks scenario. In this,
individuals experience other competing events which may cause them to be
removed from the study, and the primary event of interest is then not ob-
served (p.61,Klein (1997)). For individuals in the HIP trial analysed in this
thesis the underlying censoring mechanism maybe viewed as this type of
random censoring.
3.1.4 Non-informative censoring
In general in survival analysis, it is often assumed that failure and censored
times are independent. Hence we can assume that knowledge of a censoring
time for an individual does not contribute further information about that
individual’s likelihood of survival at a future time. In other words, we can
say that the distribution of censoring times contains no information about
the distribution of the individual’s failure time. Then the likelihood function
with respect to failure time would not include any distribution for censoring
time.
In other words, we have:
L(θ|T ) ∝
n∏
i=1
f(ti|θT )RiS(ti|θT )1−Ri (3.1.3)
where L(θ|T ) denotes the likelihood function for survival time and f(ti|θT )
refers to the probability density function at failure time t, while its associ-
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ated survival function is denoted by S(ti|θT ), and θT represents the param-
eter associated with the failure time distribution. The likelihood form given
in (3.1.3) highlights that the contribution from censored individuals is only
through the survival function of failure time S(ti|θT ). This is because an
individual being censored at time t, Ci = t, is equivalent to that same indi-
vidual surviving after time t (Ti > t). This is also known as non-informative
censoring as no function of censoring time is involved in the likelihood struc-
ture with respect to failure time (equation (3.1.3)) (Klein, 1997; Kalbfleisch
& Prentice, 2002).
3.1.5 Informative censoring
However, the estimation of the failure time distribution, such as S(t) the
survival function, may be influenced by the distribution of the censoring
time. For instance, some individuals withdraw from a clinical trial because
of the high risk of negative effects of receiving their treatment. Such cases
are not treated as censored at random and censoring time distributions will
influence the estimations of failure time distribution (Klein, 1997; Kalbfleisch
& Prentice, 2002). Therefore, the distribution of censoring time needs to be
included in the likelihood function.
Note that (Yi = t, Ri = 1) and (Ti = t, Ci > t) (where Yi and Ri de-
note the observed time and censoring indicator) indicate the same event,
which is that individual i failed (experienced the event of interest) at time
t. Consequently, the probability of occurrence of this event can be written
as Pr(Yi = t, Ri = 1) and also Pr(Ti = t, Ci > t). Both must be identical.
Then for the ith individual experiencing the event of interest at time t, we
have the following equation:
Pr(Yi = t, Ri = 1; |X,θ) = Pr(Ti = t, Ci > t|X;θ) (3.1.4)
where X denotes covariates vector and θ is the parameter associated with
the joint distribution of failure and censoring time.
Similarly, for the ith individual censored at time t, we have the equation
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as follows:
Pr(Yi = t, Ri = 0|X;θ) = Pr(Ti > t,Ci = t|X;θ) (3.1.5)
where X is covariates vector and θ represents the parameter associated with
the joint distribution of failure and censoring time.
In general, we need additional assumptions to construct the likelihood
function associated with the scenario of informative censoring as the like-
lihood form given in (3.1.3) is invalid for this situation. For the simplest
case, when failure and censoring time are independent conditional on the
covariates X, the likelihood function can be expressed as:
L(θ|T,C) ∝
n∏
i=1
[f(ti|θT )G(ti|θC)]Ri [S(ti|θT )e(ti|θC)]1−Ri , (3.1.6)
where L(θ|T,C) is the likelihood function for survival outcomes including
both failure time and censoring time; f(ti|θT ) and S(ti|θT ) are same as
defined in equation (3.1.3); e(t) and G(t) denote the probability density and
probability functions at censoring time t.
Under the assumption of informative censoring, which is equivalent to
that the failure and censoring times are independent, conditional on X, the
joint probability of failure and censoring times given covariatesX, Pr(Ti, Ci; |X,θ)
can then be replaced by the product of the conditional probabilities of failure
and censoring time, that is
Pr(Ti = t, Ci > t|X;θ) = Pr(Ti = t|X;θT )Pr(Ci > t|X;θC) for the event,
P r(Ti > t,Ci = t|X;θ) = Pr(Ti > t|X;θT )Pr(Ci = t|X;θC) for censoring.
(3.1.7)
In other words, standard likelihood structure formulating with respect to the
failure time would not be suitable in such cases, because failure and censoring time
are not independent exactly. Hence the parameter corresponding to failure time
may also be determined by the censored time distribution.
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3.2 Conventional Methodologies
Since the 1950s, many approaches, including the non-parametric, semi-parametric
and parametric methods, have been developed for time-to-event studies. Most
of the methods are based on the non-informative censoring assumption (Loeys &
Goetghebeur, 2003; Robins & Tsiatis, 1991). In fact, to date, only a few papers
exist on failure time analysis under the assumption of informative censoring, es-
pecially for latent ignorability (Frangakis & Rubin, 1999; Baker, 1998; Scharfstein
et al., 2001) for censoring. The primary objective of many clinical trials is to pro-
vide a reliable comparison of the efficacy and safety of two interventions, where
efficacy is often assessed in terms of a time-to-event outcome measure, such as the
survival function or hazard function (Section 3.1.2).
3.2.1 Non-parametric methods
Non-parametric methods are one of the conventional statistical approaches for
which there is no need to assume any distribution for the underlying data. These
are also called parameter-free methods or distribution-free methods, which were
developed to be used in cases where the researcher knows nothing about the pa-
rameters of the variable of interest. (Fraser, 1957; Kraft & Eeden, 1968; Casella
& Berger, 2002).
In survival analysis, the most plausible non-parametric estimator of the survival
function is the Kaplan-Meier (1958) or the Nelson-Aalen (1972,1978) estimator
of S(t) (Klein, 1997; Cox & Oakes, 1984; Kalbfleisch & Prentice, 2002; Ibrahim
et al., 2001). Both of these are calculated under the assumption of non-informative
censoring. Let t1 represent the trial start time and di denotes the number of deaths
in the ith time interval; the number of subjects under risk in the associated time
interval is denoted by Yi. Then the Kaplan-Meier estimator (p.84, Klein (1997))
of the survival function is formulated as:
Sˆ(t) =
1 if t < t1,∏
ti≤t(1− diYi ) if t1 < t .
(3.2.1)
Nelson in 1972 proposed an alternative estimator of the cumulative hazard rate
function in a reliability context; Aalen (1978) rediscovered the estimator by using
modern counting process methodology (Aalen, 1975), so therefore, this estimator
is also commonly known as the Nelson-Aalen estimator of the cumulative hazard
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(Klein, 1997).
Let Hˆ(t) denote the estimated Nelson-Aalen estimator of the cumulative haz-
ard function. It can then be written as follows:
Hˆ(t) =
0 if t < t1,∑
ti≤t
di
Yi
if t1 < t.
(3.2.2)
For the relationship between the survival function and the cumulative hazard func-
tion, it is straightforward to obtain the estimator of survival function based on the
Nelson-Aalen estimator which then has a form as follows:
S˜(t) = exp
(
−Hˆ(t)
)
. (3.2.3)
Hypothesis test methods would also be an integral part of non-parametric
methods for clinical scenarios. Of these, the most plausible and most popular test
method is the so-called log-rank test method (p.193, Klein (1997)). Alternative test
methods could be used, such as the Peto-Peto-Wilcoxon test (p.194, Klein (1997))
and the Fleming-Harrington test (p.194, Klein (1997)). We omit the context of
these test methods as the non-parametric method is not the focus of the thesis.
3.2.2 Semi-parametric methods
In time-to-event studies, we often need to link the outcome of interest with so-called
associated explanatory variables X. This is out of the scope of the non-parametric
method. Cox (1972), however, proposed a proportional hazards model, which has
the following formulation:
h(t|X) = h0(t)ψ(βTX); (3.2.4)
where h0(t) is an arbitrary baseline hazard rate which is treated nonparametrically
(p.230, Klein (1997)), ψ(βTX) represents a known function, and β is a parameter
vector associate with X, and T denotes transpose.
This model is known a semi-parametric model. Since h(t|X) must be positive,
a common form for ψ is the exponential function, ψ(βTX) = exp(βTX). This
model is also called the proportional hazard model because the hazard ratio is a
constant for time-independent covariates X. That is:
h(t|X1)
h(t|X2) =
h0(t)exp(βTX1)
h0(t)exp(βTX2)
= exp(βT (X1 −X2); (3.2.5)
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where the model parameter β can be estimated by maximizing the related partial
likelihood function.
Let R(ti) be the set of all individuals who are still under study at a time just
prior to ti. Here ti represents the ith ordered failure time (t1 < t2 · · · < tI). Then
the partial likelihood function, assuming no ties in the event time data, has a form
as follows:
L(β) =
I∏
i=1
exp(βTXi)∑
j∈R(ti) exp(β
TXj)
. (3.2.6)
In the presence of ties among the event times, several suggestions for constructing
the partial likelihood times have been given by Breslow (1974) and Efron (1977)
(p.239, Klein (1997)).
3.2.3 Parametric methods
Parametric methods are based on the assumption that the outcome of interest fol-
lows some specific distribution. In survival analysis, failure time distributions have
been considered for a so-called homogeneous population. In general, distributions
such as the exponential, Weibull, log-normal, Gamma, and log-logistic distribu-
tions have been used throughout the failure time literature. The exponential and
Weibull distributions have a closed-form expression for tail area probabilities, and
also have simple formulas for the survival and hazards functions. Log-normal and
Gamma distributions are also used frequently despite being generally less conve-
nient for computation (Klein, 1997; Cox & Oakes, 1984; Kalbfleisch & Prentice,
2002).
It is common to estimate the parameters involved in the given distribution
by a conventional statistical method, such as the maximum likelihood method
(Casella & Berger, 2002). The estimated values of hazard function and survival
function can then be easily obtained (Klein, 1997; Cox & Oakes, 1984; Kalbfleisch
& Prentice, 2002).
3.3 Inference for causal effects for time-to-event data
As a very special variable, time has its own features, especially for time-to-event
outcomes. For instance, a failure time has rarely a negative value and it never de-
creases. Therefore, distributions commonly used for general outcome or response
variables, such as a normal distribution (in which negative values are often in-
cluded) or a Bernoulli distribution (which is only suitable for binary variables)
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do not suit specific data collected in time-to-event studies, where the outcome of
interest is event time. Because event time is very unlikely to follow these previ-
ously mentioned distributions, the outcome of interest in the time-to-event studies
should be distinguished from the general data scenario. This means that the
event times should have their own distributions rather than conform to normal or
Bernoulli distributions. In fact, many distributions are suitable for non-negative
variables, such as the Weibull, log-normal, Gamma, etc. distributions. However,
as noted in Chapter 2, potential-outcome models based on the individual causal
effect (ICE) mostly focus on estimating the average causal effect (ACE) or com-
plier average causal effect (CACE) for noncompliance for general data rather than
time-to-event data. Our approach extends the ICE based model, as found in the
study of O’Malley & Normand (2005) and Peng et al. (2004), for causal inference
on survival data. Since in time-to-event studies, as discussed in Section 3.1.2,
specific functions of failure time, e.g. the Survival function and the hazard rate
function, are more interesting than failure time itself, it would be good progress if
the causal effect on the time-to-event data can be expressed as a function of failure
time. To reach this goal, we first need to define a new form of outcome of interest
for time-to-event data.
3.3.1 A new outcome of interest
Let us consider the indicator function I{}, which has a value of 1 when the con-
dition given in {} holds and 0 otherwise. We then use v to denote the potential
treatment level and denote Oiv(t) = I{Ti(v) > t} as the outcome of interest, which
is the indicator of individual i experiencing treatment level v and surviving after
time t if assigned to treatment level v. Note that the new outcome Oiv(t) is a
function of time and also a new outcome variable.
3.3.2 Causal effect for time-to-event data
By following the general definition of Individual Causal Effect, ICE corresponding
to the new outcome Oiv(t) has the form as follows:
ICEi(t) = Oi1(t)−Oi0(t) = I{Ti(1) > t} − I{Ti(0) > t}, (3.3.1)
which is a function of failure time t.
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3.3.3 Average causal effect (ACE) for time-to-event data
We can then define a time variant of ACE as follows:
ACE(t) = E(Oi1(t)−Oi0(t)) = E(Oi1(t))− E(Oi0(t))
=
∑N
i=1 I{Ti(1) > t}
N
−
∑N
i=1 I{Ti(0) > t}
N
,
(3.3.2)
where N denotes the population size.
Let Γv(t) denote the term
∑N
i=1 I{Ti(v)>t}
N in equation (3.3.2), which is the pro-
portion of individuals who would survive beyond time t if assigned to treatment
level v. Then equation (3.3.2) can be expressed as
ACE(t) = Γ1(t)− Γ0(t). (3.3.3)
Can we link the new function of time, ACE(t), to the survival function ?
Recall that v represents the potential treatment level, the numerator of Γv(t) is∑N
i=1 I{Ti(v) > t}, which gives the number of individuals in the study if assigned
to treatment level v who survive after time t; while the denominator N is the total
number of individuals in the population. Γv(t) is then the survival proportion
of individuals if assigned to treatment level v who survive beyond time t in the
population. Now the probability of an event can be expressed as a proportion of
the number of events and the total number of cases (population), that is:
Probability of an event =
Number of occurrence of event
Population
. (3.3.4)
Thereby, the fraction Γv(t) can be written as:
Γv(t) =
Number of event {Ti(v) > t}
Population
. (3.3.5)
The numerator of Γv(t) is the total number of occurrences of events of interest
(survival after time t), and its denominator is the total number of individuals
involved (the population).
Therefore, as stated before, the fraction Γv(t) can be viewed as the probability
of an individual surviving after time t with the potential treatment level v. Recall
that the survival function S(t) = Pr(Ti > t) is the probability of an individual
surviving beyond time t. Here the probability notation Pr() can be interpreted
as the population proportion or as a relative frequency under repeated sampling
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from the population. For the potential treatment level v, Sv(t) can be written
as Sv(t) = Pr(T (v) > t). Hence the two quantities Γv(t) and Sv(t) describe the
same object, the survival probability of individuals exposed to potential level v.
Therefore we have Γv(t) ≡ Sv(t). After replacing Γv(t) with Sv(t) (for v = 1 or
0) in equation (3.3.3), we have obtained a relationship between ACE(t) and Sv(t)
(for v = 1 0r 0), i.e.:
ACE(t) = S1(t)− S0(t). (3.3.6)
Equation (3.3.6) successfully extends the potential outcomes model for the
general data (which are based on the individual causal effect rather than the
related causal effect) to the time-to-event scenario, the new form of outcome
Oiv(t) = I{Ti(v) > t} provides a useful bridge to achieve this. A more important
point is that Oiv(t) has linked our new quantity of ACE(t) in causal inference
with the conventional quantity, Sv(t), in time-to-event studies. It would be conve-
nient to adopt traditional methods for evaluating the survival function in order to
estimate the average causal effect. In addition, if we regard the survival function,
Sv(t), as special in time-to-event data analysis, as is the mean value µv in general
data analysis, it should be straightforward to employ the conventional methods
developed in the literature on ACE to the ACE(t) extension.
The fundamental problem described and defined in Section 1.4.4 still exists,
however, because for each individual i, only one of its outcomes of interest, Oi1(t) or
Oi0(t), is observable, and likewise for their survival functions. Nevertheless, as we
noted in the previous chapter, randomisation may serve as a powerful tool to handle
this problem. Consider this conceptual link between ACE(t) and Zi = 0 or 1 for
RCT settings. In RCTs, the survival function Sv(t) for each possible treatment
group is often estimated via those observations involved in the relevant treatment
group. For instance, all individuals assigned to the treated group (Zi = 1) would
be a source of information to estimate S1(t), that is Sˆ1(t)=SZ=1(t). Similarly, for
the control group, we have Sˆ0(t)=SZ=0(t). Consequently, the estimated average
causal effect ÂCE(t) can be obtained as follows:
ÂCE(t) = Sˆ1(t)− Sˆ0(t). (3.3.7)
3.3.4 Complier average causal effect (CACE) for time-to-event data
The Complier Average Causal Effect (CACE) for time-to-event data is also a
function of failure time, which we create via CACE(t). Let Oi,uz(t) = I{Ti(z) >
51
t|Ui = u} denote the outcome of interest, where Ui = u is the compliance type
introduced in Chapter 1. We then have
̂CACE(t) = Sˆc1(t)− Sˆc0(t), (3.3.8)
where Sˆcz(t) represents the estimated survival function at time t corresponds to
the subgroups where all individuals have compliance type Ui = c and have been
assigned to the treated group Z = 1 or to the control group Z = 0. That is:
Sˆcz(t) =
∑Nz
i=1 I{Ti(z) > t|Ui = c}
Nz
, for z = 0 or 1 (3.3.9)
3.4 Summary
This chapter provides the new definitions of Average Causal Effect (ACE) and
Compliers Average Causal Effect (CACE) for time to-event data, which allow us
to extend those potential-outcome models based on the ICE (Individual Causal
Effect) for general data to be suitable for time-to-event data in a straightforward
manner. Note that, unlike general data, time-to-event data has its special features,
among them censoring is a primary issue that needs to be considered carefully,
which can be viewed as a special case of non-response.
In Section 3.3, we developed the ICE based potential-outcome model for time-
to-event data through an indicator function I{Ti(v) > t} and the newly defined
variable Oiv(t) = I{Ti(v) > t}. The advantage of this extension is that it success-
fully links quantities of the causal effect, say ACE and CACE, with the associ-
ated survival function of failure time. These functions of time, namely ACE(t)
and CACE(t), will reflect more features of the failure time distributions and also
avoid effects from censoring on failure time. In addition, it is convenient to adopt
conventional methods for evaluating survival function to estimate the ACE(t) and
the CACE(t) by following our new definitions. As a consequence, more informa-
tion can be obtained via our new ACE(t) or CACE(t) than from the conventional
ACE or CACE, as the latter are not functions of failure time.
Furthermore, it would also be convenient to employ those methods that de-
veloped for causal inference on general data through estimating the ACE and the
CACE in time-to-event studies. For instance, the method of Peng et al. (2004)
which considered covariates in regression models could also be adopt for time-to-
event data.
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Chapter 4
The ignorable and non-ignorable censoring mechanisms
As stated in previous chapters (Chapter 1 and Chapter 3), censoring is the
primary feature of time-to-event data (Sections 1.3 and 3.1). When censoring
occurs, an individual’s event time, the outcome of interest, cannot be observed.
This is a special case of non-response or of a so-called missing outcome. This
chapter is based on the theory of missing data (Little & Rubin, 2002) and defines
three censoring mechanisms, which include censoring at the end of the follow-
up (Section 4.3.1); censoring at random conditional on observed covariates only
(Section 4.3.2); and censoring at random conditional on observed and unobservable
covariates (Section 4.3.3). In addition, three likelihood forms corresponding to
these three censoring mechanisms are constructed. Consequently, the ignorability
of these three censoring mechanisms can be shown, which can be viewed as the
foundation for creating our potential-outcome models. These models are given in
subsequent chapters of this thesis. However, in order to simplify the presentation,
in this chapter we consider only single outcome variables rather than potential-
outcome vectors.
4.1 Missing data mechanisms
Little & Rubin (2002) pointed out that missing data mechanisms per se are crucial,
as missing data methods strongly depend on the nature of the dependencies in the
missing mechanism. However, in the analysis of data with missing values, the
important role of the missing mechanism has been largely ignored. This continued
until Rubin (1976) addressed the concept of missing data theoretically through
missing data indicators. Rubin’s missing data theory, in brief, claimed that the
missing mechanism can be ignored only when it is missing completely at random
(MCAR) or missing at random (MAR) (Little & Rubin, 2002).
For convenience, we use the same notation as in Little & Rubin (2002). Let
Y = (yij) denote the complete data, an (n×K) rectangular dataset with missing
53
values, with ith row yi = (yi1, yi2, . . . yiK), where yij is the value of the jth
variable Yj for the ith subject. The missing data indicator matrix is denoted by
M = (mij), i.e. mij = 1 if yij is missing and mij = 0 if yij is observed. Then
the missing data mechanism is characterized by the conditional distribution of M
given Y, say f(M |Y, φ), where φ is a set of unknown parameters.
4.1.1 Missing completely at random (MCAR)
For the case of data missing completely at random (MCAR), it is assumed that
the “missingness” does not depend on the value of the data Y = (Yobs,Ymis),
including the missing outcomes Ymis or of the observed Yobs. This can be expressed
as follows:
f(M |Y, φ) = f(M |φ) for all Y and φ. (4.1.1)
4.1.2 Missing at random (MAR)
For the case of data missing at random (MAR), it is supposed that missingness
only depends on the observed value of the data Yobs, instead of the missing value
of the data Ymis, such that:
f(M |Y, φ) = f(M |Yobs, φ) for all Ymis and φ. (4.1.2)
4.1.3 Not missing at random (NMAR)
If the distribution of M depends on the missing values in the data matrix Y, the
mechanism is called not missing at random (NMAR) (Little & Rubin, 2002). We
then have:
f(M |Y, φ) = f(M |Yobs,Ymis, φ) for φ. (4.1.3)
4.2 Censoring mechanisms
It is necessary to consider the underlying potential censoring mechanism carefully
in time-to-event studies, especially when formulating the likelihood structure, (as
censoring can be viewed as a special type of missing data). In survival analysis,
we often denote time-to-event data as a pair of (Yi, Ri). Here the censoring indi-
cator R (1 for the event occurring (observed), 0 for censoring (missing)) indicates
the situation of observed or missing failure time. However, it is noteworthy that
censoring time does provide information beyond the censoring indicator itself. For
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instance, in the case of right censoring time Ci = t, we know that Ti > t must
hold, even though observing Ci precludes full observation of Ti.
To discuss the incomplete data issue in time-to-event studies, it is of value to
consider instead the distribution of (Ti, Ci) (the failure time Ti and the censor-
ing time Ci) rather than the observed time and its censoring indicator (Yi, Ri).
This is so, even despite the predominance in terms of the (Yi, Ri) formulation in
conventional survival analysis.
Since censoring causes a special case of missing outcome where failure time is
missing, it is important to ensure which type of censoring mechanism has occurred,
because the likelihood construct may vary according to the censoring mechanism.
In the following subsections, three types of mechanism for censoring are defined,
which derive from three types of missingness as defined in Section 4.1.
4.2.1 Censoring completely at random
In time-to-event studies, MCAR is analogous to censoring completely at random.
In this case, the censoring time distribution does not depend on any observed or
missing data. Thereby, we can write:
Pr(C|T,D,Z,U,X,θC) = Pr(C|θC) for all T,D,Z,U,X and θC . (4.2.1)
Recall that in this chapter we only focus on single variable rather than potential
outcomes vector, which means that T and C are observable failure and censoring
time; Z and D denote the randomised assigned and actually received treatment;
U is unobservable compliance type, and X is covariate vector.
4.2.2 Censoring at random
In time-to-event studies, MAR is analogous to censoring at random, which means
that the censoring time distribution depends only on the observed covariates. They
are, in the case of a RCT with noncompliance, the assigned treatment Zi = z, the
actual received treatment Di = Dobsi and other pretreatment covariates X. In this
case, we suppose that the censoring mechanism depends only on these observable
covariates Z, D(Z) and X, we can then write:
Pr(C|T,D,Z,U,X,θC) = Pr(C|D,Z,X,θC) for all T, U and θC . (4.2.2)
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4.2.3 Censoring not at random
Censoring not at random implies that the censoring time distribution may not
only depend on observed data, but also on the missing data. For RCTs with
noncompliance, we suppose that the censoring time distribution depends on the
observable covariates, (Di, Zi and Xi), and also on the unobservable covariate Ui.
This assumption can be expressed as follows:
Pr(C|T,D,Z,U,X,θC) = Pr(C|D,U,Z,X, θC) for all T and θC . (4.2.3)
Specifically in this thesis, we focus on studying a special case, in which the
censoring time (C) and failure time (T) are conditionally independent given the
unobservable covariates (U). This may be viewed as the assumption of latent
ignorability for time-to-event data (Frangakis & Rubin, 1999). In brief, it can be
expressed as:
Pr(T,C|U,X,Z) = Pr(T|U,X,Z)Pr(C|U,X,Z) (4.2.4)
(Frangakis & Rubin, 1999; Mealli et al., 2004).
4.3 Likelihood structures
Having defined the three censoring mechanisms, we can then establish the rele-
vant likelihood structure. At first, we consider the joint distribution of all related
variables, including failure (Ti) and censoring (Ci) times, assigned treatment (Zi),
received treatment (Di(Zi)), compliance type (Ui) and other pre-treatment covari-
ates (Xi). Note that in this chapter, each outcome variable is viewed as a single
outcome rather than a potential outcomes vector. So the failure (Ti) and censoring
(Ci) time indicate single outcomes only, which correspond to the treatment levels
Zi = z, i.e. Ti = Ti(z) and Ci = Ci(z). For the received treatment (Di), only the
observed Di = Di(z) is considered.
Suppose N individuals are included in the RCT. Then the assigned treatment
is a vector of length N, Z = (Z1, . . . , ZN )T . Consequently, the single outcomes can
also be viewed as a set of vectors of length N, where each component is a scalar.
We have:
D = (D1, . . . , DN )T : the actually received treatment corresponding to treat-
ment group Zi = z;
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T = (T1, . . . , TN )T : the failure time associated with the given treatment
Zi = z; and
C = (C1, . . . , CN )T : the censoring time associated with the given treatment
Zi = z.
Similarly, covariate variables can still be written in vector forms of length N,
as follows: U = (U1, . . . , UN )T and X = (X1, . . . , XN )T . Of the vector variables
for the N individuals given above, only the component of pre-treatment Xi is
allowed to be a vector when the number of pre-treatment covariates (denoted by
J) involved in the RCT is more than one (J > 1), that is Xi = (Xi1, . . . , XiJ).
By the latent ignorability assumption (Frangakis & Rubin, 1999), the joint dis-
tribution of failure (T) and censoring (C) times that are conditional on all observ-
able (Z,D,X) and on unobservable covariates (U) is denoted by Pr(T,C|D,Z,X;θ),
and can be written as:
Pr(T,C|D,Z,X,U;θ) = Pr(T|D,Z, X,U,θT )Pr(C|D,Z,X,U;θC), (4.3.1)
where θT and θC denote the parameters corresponding to the conditional proba-
bilities of failure time and censoring time, respectively. In fact, equation (4.3.1)
can be simplified further when the censoring mechanism is specified as one of the
three censoring mechanisms discussed in Section 4.2.
4.3.1 Censoring at the end of follow-up
In this situation, the censored individuals, namely subjects who did not experience
the event of interest (during the observation period), are all censored at the same
time (on the same day) when the trial ends, given that they all enrolled into the
trial at the same time (on the same day), or given that they have been followed
up for the same time duration. Therefore their censoring times are the same; i.e.
the censoring time Ci (for i ∈ {1, 2, . . . NC}; where NC is the number of censored
individuals in the RCT) is considered to be as a constant, Ci = Cr, rather than
a random variable. Therefore, in this case, no censoring distribution or censoring
mechanism exists. This implies that a probabilistic model for censoring time is
not required.
Consequently, in such a case, instead of the joint distribution of failure and
censoring time, Pr(T,C|D,Z,X,U;θ), only the conditional distribution of failure
time T (given those observable and unobservable covariates) is involved. Therefore
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equation (4.3.1) is simplified as follows:
Pr(T|D,Z,X,U;θ) = Pr(T|D,Z,X,U;θT ), (4.3.2)
where the censoring mechanism is ignored because the so-called censoring time Ci
is a constant Ci = Cr (for i ∈ {1, 2, . . . NC}).
Therefore, the parameter θ associated with the joint distribution of failure and
censoring time is only associated with the parametric of the failure time distribu-
tion, θT . To estimate the parameter θT , we need only to construct the likelihood
function with respect to the parameter θT , which then only relates to the distri-
bution of failure time t, Pr(T|D,Z,X,U;θT ).
Consider the joint distribution of failure time T and all the covariates (includ-
ing the observable D, Z, X and unobservable U). By following the relationship
between the outcome and covariates, for the ith individual, this joint distribution
can be written as the product of the conditional distribution of the outcome of
interest (failure time Ti) and the joint distribution of all related covariates, namely
the assigned treatment Zi, the received treatment Di = Di(Zi), and the observed
covariates Xi. In other words:
Pr(Ti, Di, Zi, Xi, Ui;Ψ) = Pr(Ti|Di, Zi, Xi, Ui;θ)Pr(Di, Ui, Zi, Xi; Υ), (4.3.3)
where Ψ denotes the parameter associated with the joint distribution, which has
been divided into two parts: Ψ = (θ,Υ). One is the parameter θ that corresponds
to the conditional probability of the outcome variable (failure time Ti), given
all related covariate variables (including the unobservable covariates Ui), and on
all those observed covariates (the assigned treatment Zi, the received treatment
Di = Di(Zi) and the observed covariates Xi). The other parameter Υ corresponds
to the joint distribution of all the covariate variables.
In addition, by following the property of probability, the second term on the
right-hand side of equation (4.3.3), Pr(Di, Ui, Zi, Xi|Υ), can be broken down fur-
ther as follows:
Pr(Di, Ui, Zi, Xi; Υ) = Pr(Ui|Di, Zi, Xi;pi)Pr(Di, Zi, Xi;λ). (4.3.4)
where Pr(Ui|Di, Zi, Xi;pi) (the right-hand side of equation (4.3.4)) denotes the
conditional distribution of compliance type Ui = u, given all observed covariates
Di, Zi, Xi, and pi represents its associated parameter. Pr(Di, Zi, Xi;λ) is the joint
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distribution of all observed covariatesDi, Zi, Xi, and λ is its associated parameter.
Equation (4.3.3) can then be re-written as:
Pr(Ti, Di, Zi, Xi, Ui;Ψ)
= Pr(Ti|Ui, Di, Zi, Xi;θ)Pr(Ui|Di, Zi, Xi;pi)Pr(Di, Zi, Xi;λ).
(4.3.5)
In general, the likelihood function needs to be determined by the probability
density function (p.d.f.) or cumulative probability function (c.d.f.) of the related
outcome variable (given all observed data). For the parameter θ, given that Ui
is theoretically unobservable, the likelihood function cannot be obtained directly
from Pr(Ti|Ui, Di, Zi, Xi;θ), the so-called conditional distribution of failure time
(Ti), given all covariates.
We then consider the joint distribution of failure time and all related covari-
ates Pr(Ti, Di, Zi, Xi, Ui;Ψ) . By taking the integral of Pr(Ti, Di, Zi, Xi, Ui;Ψ)
with respect to Umisi = Ui, the joint distribution of failure time and all observed
covariates Pr(Ti, Di, Zi, Xi;Ψ) is obtained, that is:
Pr(Ti,Di, Zi, Xi;Ψ) =∫
Pr(Ti|Di, Zi, Xi, Ui;θ)Pr(Di, Zi, Xi;λ)Pr(Ui|Di, Zi, Xi;pi)dUi.
(4.3.6)
Because of the assumption of independent and identically distributed (i.i.d.)
observations (for all individuals), the joint distribution of failure time and covari-
ates for all individuals, Pr(T,D,Z,X,U;Ψ), equals the multiple of the same joint
distribution in each individual Pr(Ti, Di, Zi, Xi;Ψ), that is:
Pr(T,D,Z,X,U;Ψ) =
N∏
i=1
Pr(Ti, Di, Zi, Xi;Ψ). (4.3.7)
After substituting equation (4.3.6) into equation (4.3.7), we then have the form
as follows:
Pr(T,D,Z,X,U;Ψ)
=
N∏
i=1
∫
Pr(Ti|Di, Zi, Xi, Ui;θ)Pr(Di, Zi, Xi;λ)Pr(Ui|Di, Zi, Xi;pi)dUi
=
N∏
i=1
Pr(Di, Zi, Xi;λ)
∫
Pr(Ti|Di, Zi, Xi, Ui;θ)Pr(Ui|Di, Zi, Xi;pi)dUi,
(4.3.8)
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where the second equation holds because Pr(Di, Zi, Xi;λ) can be regarded as a
constant with respect to Ui, as the variable of integration Ui is not involved in
Pr(Di, Zi, Xi;λ). Now Pr(Ti|Di, Zi, Xi, Ui;θ) can be specified by the event of
interest or by censoring, that is:
Pr(Ti|Di, Zi, Xi, Ui;θ) =Pr(Ti = t|Di, Zi, Xi, Ui;θ) = f(t|Di, Zi, Xi, Ui;θ) Ri = 1, Ti = t,Pr(Ti > Cr|Di, Zi, Xi, Ui;θ) = S(Cr|Di, Zi, Xi, Ui;θ) Ri = 0,Ci = Cr ,
(4.3.9)
where Ri = 1 represents the event occurring, (0 for censoring); f() and S() denote
the probability density function (p.d.f.) and the survival function, respectively.
The contribution to the likelihood for an individual dying before the end of
follow-up at time t is then :
Pr(Ti = t|Di, Zi, Xi, Ui;θT ), (4.3.10)
and the contribution to the likelihood of an individual censored at time t = Cr is:
Pr(Ti > Cr|Di, Zi, Xi;θT ). (4.3.11)
Note that Cr is a constant and denotes the censoring time for all censored indi-
viduals.
The likelihood function with respect to the parameter θ, which is associated
with the conditional distribution of failure time Ti given Di, Zi, Xi, Ui, needs to
also relate to the parameter pi that corresponds to the conditional probability
of compliance type Ui given Di, Zi, Xi. We denote the likelihood function as
L1(θ,pi), where
L1(θ,pi) =
∫
Pr(Ti|Di, Zi, Xi, Ui;θ)Pr(Ui|Di, Zi, Xi;pi)dUi. (4.3.12)
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Equation (4.3.12) can then be re-written as follows:
L1(θ,pi)
=
∫ 
Pr(Ti = t|Di, Zi, Xi, Ui;θ)Ri
×Pr(Ti > Cr|Di, Zi, Xi, Ui;θ)1−Ri
×Pr(Ui|Di, Zi, Xi;pi)
 dUi;
=
∫ 
f(t|Di, Zi, Xi, Ui;θ)Ri
×S(Cr|Di, Zi, Xi, Ui;θ)1−Ri
×Pr(Ui|Di, Zi, Xi;pi)
 dUi.
(4.3.13)
Equation (4.3.13) then provides the required likelihood structure for the special
case of RCTs with noncompliance, where all censoring occurs at the end of follow-
up t = Cr.
4.3.2 Censoring at random conditional on observed variables only
In practice, it is not common to have a constant censoring time for each censored
individual, especially in the medical area. In this section, we discuss the more
usual case, where censoring time is treated as a random variable rather than a
constant.
We assume that the censoring time distribution is dependent only on observable
covariates, its related formulation is given in equation (4.2.2). Then the joint
distribution can be decomposed further, such that
Pr(Ti, Ci, Di, Zi, Xi;θ, λ)
= Pr(Ti|Di, Zi, Xi;θT )Pr(Ci|Di, Zi, Xi;θC)Pr(Di, Zi, Xi;λ).
(4.3.14)
Note that in this case, compliance type Ui is not involved in equation (4.3.14)
as it is not an observed covariate. Censoring time distribution is included, and
the parameter θ associated with the joint distribution of the failure and censoring
time can then be broken down into two parts, θ = (θT ,θC), where θT and θC
are the parameters corresponding to the conditional distribution of the failure and
censoring time, respectively.
Focussing on the likelihood structure of L(θ), we note that the censoring dis-
tribution has to be included, as θ = (θT ,θC). Under this conditional random
censoring model, the joint distribution of failure and censoring time can thus be
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broken down as follows:
Pr(Ti, Ci|Di, Zi, Xi;θ) = Pr(Ti|Di, Zi, Xi;θT )Pr(Ci|Di, Zi, Xi;θC). (4.3.15)
According to the definition of likelihood function, the likelihood function, de-
noted here by L2(θ), should be a function of the parameter θ and also be propor-
tional to Pr(Ti, Ci|Di, Zi, Xi;θ). The latter is the joint distribution of failure and
censoring time, which is conditional on the observed covariates Di, Zi, Xi. The
contribution to the likelihood of an individual dying before the end of follow-up
at time t, is then:
Pr(Yi = t, Ri = 1|Di, Zi, Xi;θ)
= Pr(Ti = t|Di, Zi, Xi;θT )Pr(Ci > t|Di, Zi, Xi;θC).
(4.3.16)
On the other hand, the contribution to the likelihood of an individual censored at
time t, is:
Pr(Yi = t, Ri = 0|Di, Zi, Xi;θ) = Pr(Ti > t|Di, Zi, Xi;θT )Pr(Ci = t|Di, Zi, Xi;θC).
(4.3.17)
Equations (4.3.16) and (4.3.17) are based on the fact that (Yi = t, Ri = 1)
and (Ti = t, Ci > t) represent the same scenario, i.e. individual i experienced
the event of interest at time t. Therefore Pr(Yi = t, Ri = 1|Di, Zi, Xi;θ) and
Pr(Ti = t, Ci > t|Di, Zi, Xi;θ) both represent the conditional probability that
individual i failed at time t.
In this case, the likelihood function of θ can be represented as
L2(θ) =
∏
i
[
(Pr(Ti = t|Di, Zi, Xi;θT )Pr(Ci > t|Di, Zi, Xi;θC))Ri ×
(Pr(Ti > t|Di, Zi, Xi;θT )Pr(Ci = t|Di, Zi, Xi;θC))1−Ri
]
=
∏
i
[
Pr(Ti = t|Di, Zi, Xi;θT )RiPr(Ci > t|Di, Zi, Xi;θC)Ri×
Pr(Ti > t|Di, Zi, Xi;θT )1−RiPr(Ci = t|Di, Zi, Xi;θC)1−Ri
]
=
[ ∏
i Pr(Ti = t|Di, Zi, Xi;θT )RiPr(Ti > t|Di, Zi, Xi;θT )1−Ri×∏
i Pr(Ci > t|Di, Zi, Xi;θC)RiPr(Ci = t|Di, Zi, Xi;θC)1−Ri}
]
= L2(θT )L2(θC).
(4.3.18)
Essentially, the equivalence L2(θ) = L2(θT )L2(θC) allows us to ignore the
distribution of θC . This is true if we are interested only on θT , which parameterizes
survival time. Therefore, the likelihood function associated with the failure time
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parameter θT would have a form as follows:
L2(θT ) =
∏
i
Pr(Ti = t|Di, Zi, Xi;θT )RiPr(Ti > t|Di, Zi, Xi;θT )1−Ri . (4.3.19)
Using the same notation as given in the previous section (Section 4.3.1), L2(θT )
can be expressed as the following:
L2(θT ) =
N∏
i=1
f(t|Di, Zi, Xi;θT )RiS(t|Di, Zi, Xi;θT )1−Ri . (4.3.20)
This demonstrates that when the censoring mechanism is at random only con-
ditional on the observed covariates (MAR), the parameter θC associated with the
censoring time distribution is ignorable.
4.3.3 Censoring at random conditional on observed and unobserved vari-
ables
When censoring at random is conditional on unobserved variables, the process
governing censoring is not considered independent of the process that governs sur-
vival. This holds even after conditioning on all observed covariates. However, the
remaining dependency between censoring and survival is assumed to be accounted
for by an unobserved covariate, U , the compliance type, (see definition given in
equation (1.7.2) Section 1.7.2). Here, the censoring mechanism is considered to
be at random, and conditional on either the observed covariates (Di, Zi, Xi) and
on the unobserved covariate Ui. We then have the NMAR case where the cen-
soring mechanism is not at random. Then equation (4.2.3) holds and the joint
distribution can be written as follows:
Pr(Ti, Ci, Di, Zi, Ui, Xi;Ψ)
=
{
Pr(Ti|Di, Zi, Ui, Xi;θT )Pr(Ci|Di, Zi, Ui, Xi;θC)
×Pr(Ui|Di, Zi, Xi;pi)Pr(Di, Zi, Xi;λ)
}
(4.3.21)
Recall that compliance type Ui is considered as an unobservable covariate.
Then the joint distribution of all observed variables can then be obtained by in-
tegrating Pr(Ti, Ci, Di, Zi, Ui, Xi;ψ) with respect to Ui, which has the form as
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follows:
Pr(Ti, Ci, Di, Zi, Xi;ψ)
=
∫ {
Pr(Ti|Di, Zi, Ui, Xi;θT )Pr(Ci|Di, Zi, Ui, Xi;θC)
×Pr(Ui|Di, Zi, Xi;pi)Pr(Di, Zi, Xi;λ)
}
dUi.
(4.3.22)
Under random censoring that is conditional on unobservable covariate Ui, the
joint distribution of failure and censoring times can be broken down as follows:
Pr(Ti, Ci|Di, Zi, Xi;θ,pi)
=
∫
Pr(Ti|Di, Zi, Ui, Xi;θT )Pr(Ci|Di, Zi, Ui, Xi;θC)Pr(Ui|Di, Zi, Xi;pi)dUi.
(4.3.23)
Now the contribution to the likelihood of an individual dying before the end
of follow-up at time t is given by:
Pr(Yi = t, Ri = 1|Di, Zi, Xi;θ)
=
∫ 
Pr(Ti = t|Di, Ui, Zi, Xi;θT )
×Pr(Ci > t|Di, Ui, Zi, Xi;θC)
×Pr(Ui|Di, Zi, Xi;pi)
 dUi.
(4.3.24)
Meanwhile, the contribution to the likelihood of an individual censored at time
t is as follows:
Pr(Yi = t, Ri = 0|Di, Zi, Xi;θ)
=
∫ 
Pr(Ti > t|Di, Ui, Zi, Xi;θT )
×Pr(Ci = t|Di, Ui, Zi, Xi;θC)
×Pr(Ui|Di, Zi, Xi;pi)
 dUi.
(4.3.25)
As noted earlier, the parameter pi, which is associated with the conditional dis-
tribution of compliance type Ui, has to be involved in the joint distribution. In
this case, the two parameters, say θ = (θT ,θC) and pi, have to be included in the
given likelihood function. This is the case, even though we are only interested in
the parameter associated with the failure time distribution, namely θT .
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We denote the likelihood function for this case as L3(θ,pi), which has the form
given in equation (4.3.26). Because both distributions of θT and θC are related to
the parameter pi, which corresponds to the distribution of Ui (the unobservable co-
variate). This censoring case, unlike the case considered previously (Section 4.3.2),
the likelihood function therefore cannot be broken down as L3(θ) 6= L3(θT )L3(θC).
In this case, the censoring mechanism is considered to be non-ignorable. We must
then construct the likelihood function of θ rather than of θT itself.
Equation (4.3.26) can then be expressed as follows
L3(θ,pi) =
=
∏
i
∫ [
f(t|Di, Zi, Xi;θT )RiS(t|Di, Zi, Xi;θT )1−Ri×
g(t|Di, Zi, Xi;θC)1−RiG(t|Di, Zi, Xi;θC)Ri
]
pr(Ui|Di, Zi, Xi;pi)dUi.
(4.3.27)
where f() and S() denote the probability density and survival function of the failure
time; meanwhile, g() and G() denote these same name functions for censoring time.
4.4 Summary
We addressed three types of censoring mechanisms (Section 4.2). The first two
can be treated as ignorable censoring mechanisms, whereas the last can be treated
as a non-ignorable censoring mechanism.
Because of the presence of unobservable covariates, (i.e. compliance type) the
likelihood function is much more complicated than in the case of an ignorable cen-
soring mechanism. For situation, we provide two likelihood structures, equations
(4.3.6) and (4.3.22) for time-to-event studies with noncompliance. Equation (4.3.6)
can be viewed as a parametric survival model allowing noncompliance with an ig-
norable censoring mechanism; it is comparable to the approach proposed by Loeys
& Goetghebeur (2003). Their approach is based on the semi-parametric method:
the Cox proportional hazard model. Equation (4.3.22) can be regarded as a para-
metric survival model allowing both noncompliance and a non-ignorable censoring
mechanism. This is comparable to the Frangakis-Rubin method (Frangakis & Ru-
bin, 1999), a non-parametric method, which accommodates noncompliance and a
non-ignorable censoring mechanism. It is noteworthy that the latent ignorability
assumption is required in both of these two models, equation (4.3.22) and the
Frangakis-Rubin model (Frangakis & Rubin, 1999).
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Chapter 5
Parametric potential-outcome survival models
5.1 Motivation
Estimating the causal effect of interventions is often required when undertaking
empirical studies in medicine. Randomisation is generally the only accepted ap-
proach for causal inference, but randomised controlled trials (RCTs) often suffer
from noncompliance (Mealli et al., 2004), because not all participants follow their
assigned treatment (Zi) properly in practice. As stated in Section 1.7.2, compliance
type Ui is often used to describe this situation. By its definition, compliance type
Ui is determined by the potential received treatmentDi = [Di(1), Di(0)] (equation
(1.7.2)). Since only one of Di(1) or Di(0) is observed in a RCT, compliance type
Ui is an unobservable variable.
Many RCTs in medical field involve time-to-event outcome(s) of interest; often,
it is the time to a predefined event. Censoring is also a primary feature of time-
to-event data (Chapter 3). The type of censoring mechanism is important, in that
it will determine the structure of the likelihood function (Chapter 4).
More specifically, in Section 4.2, we have argued that if compliance type Ui, an
unobservable variable, is involved in a time-to-event study (such as in a RCT with
noncompliance), in general, the censoring mechanism should be treated as non-
ignorable. This is true unless the case of no loss to follow-up or the assumption of
noninformative censoring is given as in Loeys & Goetghebeur (2003). When the
censoring mechanism is not ignorable, extra assumptions are required. These are
detailed in Section 4.3.3 of Chapter 4.
In Chapter 2, we reviewed current potential-outcome models that are pertinent
to general data (Section 2.3.1) or to time-to-event data (Section 2.3.2). It was
shown that among the current potential-outcome models for time-to-event data
(Section 2.3.2), few consider noncompliance and non-response (censoring mecha-
nism) simultaneously. It is noteworthy that except for Frangakis & Rubin (1999),
few models for time-to-event data have been derived. On the other hand, for
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the few models that do consider noncompliance and non-response simultaneously,
whilst they follow the assumption of latent ignorability, they focus only on gen-
eral data (Yau & Little, 2001; Mealli et al., 2004; Peng et al., 2004; O’Malley &
Normand, 2005), and do not consider time-to-event data.
In this chapter, we follow the assumptions (Section 5.2) as given in Frangakis &
Rubin (1999) and aim to establish a parametric potential-outcome (PPO) survival
model for RCTs with all-or-none compliance for the case where censoring is al-
lowed, namely a non-ignorable censoring mechanism parametric potential-outcome
(PPO) survival model, or the non-ignorable PPO-survival model for short (Section
5.3 - Section 5.9). Furthermore, the ignorable censoring mechanism parametric
potential-outcome (PPO) survival model or an ignorable PPO-survival model for
short, is addressed in Section 5.10. For the ignorable PPO-survival model, an extra
assumption is required (Section 5.10.1). To the best of the author’s knowledge,
there has not been any work to date that addresses both treatment noncompliance
and non-response (missing) simultaneously in a time-to-event scenario.
The remains of this chapter follows this outline: Section 5.2 defines all assump-
tions required for creating the PPO-survival models. The compliance type variable
and its distribution is then discussed in Section 5.3. Section 5.4 structures the joint
distribution of all potential observable variables. The likelihood function of the
PPO-survival model is given in Section 5.5, and they are specified to Weibull and
log-normal distributions for failure and censoring time in Section 5.6. Section 5.7
addresses the AFT model and its property in Weibull or log-normal distribution.
Section 5.8 appoints the interest parameters for specific PPO-survival models. The
issues surrounding the model computation are given in Section 5.9. The special
case of the PPO-survival model, the so-called ignorable PPO-survival model, is
disccused in Section 5.10. The summary of this chapter is given in Section 5.11.
5.2 Assumptions
Recall the assumptions given in Frangakis & Rubin (1999). They are as follows:
1. The stable unit treatment value assumption (SUTVA) (Rubin, 1986; Imbens
& Rubin, 1997; Peng et al., 2004): this assumes that the potential outcomes
of each individual are unrelated to the treatment status of other individuals.
2. Random assignment: this assumes that each individual has been assigned
randomly to a treatment group.
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3. Exclusion restriction: this assumes that the assigned treatment has an effect
on the outcome only through its effect on the received treatment.
4. Monotonicity: the actual received treatment Di(z) is a monotone function
with respect to the potential treatment levels, 1 for being in the treatment
group and 0 for being in the control group.
5. Latent ignorability: this assumes that the potential outcomes (of failure
time) and the associated potential non-responses (censoring time) are inde-
pendent at each level of the latent compliance types.
In the literature, the latent ignorability assumption for general data from RCTs
has been expressed as follows:
Pr(Yi,Ri|Ui, Zi) = Pr(Yi|Ui, Zi)Pr(Ri|Ui, Zi); (5.2.1)
where Yi and Ri represent the potential-outcome variable and the response indi-
cator for the ith individual, respectively. The notation we used here, Ui and Zi
are the same as in Frangakis & Rubin (1999), Mealli et al. (2004) and O’Malley
& Normand (2005). That is, Ui denotes the compliance type, and Zi indicates the
assigned treatment.
The analogous assumption for time-to-event data is:
Pr(Ti,Ci|Ui, Zi) = Pr(Ti|Ui, Zi)Pr(Ci|Ui, Zi), (5.2.2)
where Ti and Ci denote the potential outcomes vector for failure time and cen-
soring time respectively. This assumes that in RCTs with time-to-event outcomes,
the potential failure and censoring times are independent conditional on the latent
compliance type. We regard equation (5.2.2) as the time-to-event version of the la-
tent ignorabilty assumption given by Frangakis & Rubin (1999). Note that in this
chapter, we use the bold symbols, such as Ti and Ci, to denote potential-outcome
vectors.
5.3 Compliance type and its distribution
Noncompliance is the main issue we have to consider in our PPO-survival approach
and it is often described by compliance type variable, which is defined by the vector
of potential received treatment Di = [Di(1), Di(0)]. As discussed in Section 1.7.2,
compliers are defined by Di(1) = 1 and Di(0) = 0; alawys-takers are defined
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by Di(1) = 1 and Di(0) = 1; and never-takers are defined by Di(1) = 0 and
Di(0) = 0. By following the property of conditional probability, Pr(Di|Zi, ε), the
conditional distribution of vector Di given the assigned treatment Zi, (where ε is
the associated parameter for this distribution) is broken down in equation (5.3.1).
This is because Di can also be expressed as [Dmisi , D
obs
i ]. Recall that in Section
1.7.1, we have defined Dmisi = Di(1 − Zi) and Dobsi = Di(Zi), which denote the
unobservable and observable components of potential received treatment vector
Di.
Pr(Di|Zi; ε) = Pr(Dmisi , Dobsi |Zi; ε)
= Pr(Dmisi |Dobsi , Zi; εzd)Pr(Dobsi |Zi; εz),
(5.3.1)
where εzd and εz represent the parameters associated with these two conditional
distributions of Dmisi and D
obs
i respectively.
On the other hand, by the definition of compliance type Ui, given the actual
received treatment Dobsi = Di(Zi), learning the value of D
mis
i is equivalent to
learning the value of Ui. This implies that the conditional probability distribution
of the compliance type Ui given Dobsi = Di(Zi) and Zi, Pr(Ui|Di(Zi), Zi, ;pi), can
be obtained from Pr(Dmisi |Dobsi , Zi; ε), the conditional probability distribution of
Dmisi , the unobservable component of the potential received treatment vector Di,
given the actual received treatment Dobsi and assigned treatment Zi. In other
words:
Pr(Ui|Dobsi , Zi;pi)⇐d⇒ Pr(Dmisi |Dobsi , Zi; εzd); (5.3.2)
where ⇐d⇒ indicates distributional equivalence: any probability on one side of
the equation can be obtained from the distribution on the other side. For example,
Pr(Ui = c|Dobsi = 1, Zi = 1,pi) = Pr(Dmisi = 0|Dobsi = 1, Zi = 1, εzd).
After substituting equation (5.3.2) into the second line in equation (5.3.1), we
have:
Pr(Di|Zi, ε)⇐d⇒ Pr(Ui|Dobsi , Zi;pi)Pr(Dobsi |Zi; εz), (5.3.3)
where pi denotes the parameter corresponding to the distribution of Ui condi-
tional on the actual received treatment Dobsi and assigned treatment Zi, and εz
is the parameter associated with the distribution of Dobsi given Zi. This implies
that Pr(Di|Zi, ε) can be obtained from the product of Pr(Ui|Dobsi , Zi;pi) and
Pr(Dobsi |Zi; εz). In other words, Pr(Di|Zi, ε), the conditional distribution of Di
(the potential received treatment vector) given assigned treatment Zi, can also be
obtained from the product of two conditional distributions, Pr(Ui|Dobsi , Zi;pi) and
Pr(Dobsi |Zi; εz), the former is the conditional distribution of Ui given the actual re-
70
ceived treatment Dobsi and assigned treatment Zi, and the latter is the conditional
distribution of Dobsi given Zi (equation (5.3.3)).
5.4 The structure of the joint distribution
5.4.1 The joint distribution of T, C, D and Z
Suppose a RCT includes N individuals, each component of the potential outcomes
vector, including failure time Ti = [Ti(1), Ti(0)], censoring time Ci = [Ci(1), Ci(0)]
and the potential received treatment Di = [Di(1), Di(0)], can then be written as
a vector of length N, as follows:
T(1) = [T1(1), . . . , TN (1)] , the failure time if assigned to the treatment group;
T(0) = [T1(0), . . . , TN (0)], the failure time if assigned to the control group;
C(1) = [C1(1), . . . , CN (1)], the censoring time if assigned to the treatment group;
C(0) = [C1(0), . . . , CN (0)], the censoring time if assigned to the control group;
D(1) = [D1(1), . . . , DN (1)], the received treatment if assigned to the treatment
group;
D(0) = [D1(0), . . . , DN (0)], the received treatment if assigned to the control
group;
We also assume that all related variables are independent and identically dis-
tributed (i.i.d.) random variables, which include failure time T, censoring time
C, potential received treatment D and assigned treatment Z. Their joint distri-
bution can then be expressed as a product of the joint distribution for N single
observations, that is:
Pr(T(1),T(0),C(1),C(0),D(1),D(0),Z;Ψ)
=
∏
i
Pr(Ti(1), Ti(0), Ci(1), Ci(0), Di(1), Di(0), Zi;Ψ),
(5.4.1)
where Ψ denotes the model parameter vector.
We suppose that the model parameter Ψ can be broken down into three parts,
namely Ψ = (θ, ε, χ), where θ is the parameter associated with the joint dis-
tribution of failure and censoring times (outcomes), ε is the parameter for the
distribution of the vector of potential received treatment Di (post-treatment co-
variates), and χ is the parameter corresponding to the distribution of assigned
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treatment Zi (pre-treatment covariates). According to the rule of conditional dis-
tribution, the joint probability of all the aforementioned variables, corresponding
to the ith individual, Pr(Ti(1), Ti(0), Ci(1), Ci(0), Di(1), Di(0), Zi;Ψ), can thus
be expressed as a product of three distributions:
• The joint distribution of failure time Ti = [Ti(1), Ti(0)] and censoring time
Ci = [Ci(1), Ci(0)] given potential received treatment Di = [Di(1), Di(0)]
and assigned treatment Zi, Pr(Ti(1), Ti(0), Ci(1), Ci(0)|Di(1), Di(0), Zi;θ).
• The distribution of potential received treatment Di = [Di(1), Di(0)] given
assigned treatment Zi, Pr(Di(1), Di(0)|Zi; ε).
• The distribution of assigned treatment Zi, Pr(Zi, χ).
Note that θ, ε and χ denote the parameters associated with these above three
distributions, respectively. We then have:
Pr(Ti(1), Ti(0), Ci(1), Ci(0), Di(1), Di(0), Zi;Ψ) =
Pr(Ti(1), Ti(0), Ci(1), Ci(0)|Di(1), Di(0), Zi;θ)Pr(Di(1), Di(0)|Zi; ε)Pr(Zi;χ).
(5.4.2)
Using the notation of potential-outcome vectors, equation (5.4.2) can thus be ex-
pressed as follows:
Pr(Ti,Ci,Di, Zi;Ψ) =
Pr(Ti,Ci|Di, Zi;θ)Pr(Di|Zi; ε)Pr(Zi;χ);
(5.4.3)
for Ψ = (θ, ε, χ), the model parameter vector defined earlier.
In Section 5.3, we derived equation (5.3.2), which allows us to replace Pr(Di|Zi; ε)
with Pr(Ui|Dobsi , Zi;pi)Pr(Dobsi |Zi; εz). The joint distribution of all the aforemen-
tioned variables given in equation (5.4.1) can now be rewritten as follows:
Pr(Ti,Ci,Di, Zi; Ψ)⇐d⇒
Pr(Ti,Ci|Zi,Di;θ)Pr(Ui|Zi, Dobsi ;pi)Pr(Dobsi |Zi; εz)Pr(Zi;χ),
= Pr(Ti,Ci|Zi,Di;θ)Pr(Ui|Zi, Dobsi ;pi)Pr(Dobsi , Zi;λ);
(5.4.4)
where ⇐d⇒ indicates equivalence in distribution.
The last equality holds in equation (5.4.4) is because
Pr(Dobsi , Zi;λ) = Pr(D
obs
i |Zi, εz)Pr(Zi;χ). (5.4.5)
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Therefore, these two parameters εz and χ, have been replaced with the parameter
of λ. The advantage of using λ to replace εz and χ is that it simplifies notation of
the parameters involved in the model. Recall that the main parameter of interest
in our approach is θ, the parameter associated with the joint distribution of failure
time and censoring time (survival outcomes).
In addition, the vector of received treatment Di can be viewed as being equiv-
alent to compliance type Ui. This is because, on one hand, Ui = u (for u ∈
{c, a, n, d}) is determined by Di = [Di(1) = d1, Di(0) = d0] (for d0, d1 ∈ {0, 1})
(equation (1.7.2)), and, on the other hand, if we know the compliance type Ui = u,
the values of vector Di = [Di(1), Di(0)] are then also known. So we write (Ui =
u)⇔ (Di = [Di(1), Di(0)] = [d1, d0]) where ⇔ denotes equivalence.
Let Ui replace Di. We have:
Pr(Ti,Ci,Di, Zi; Ψ)⇐d⇒ Pr(Ti,Ci, Ui, Zi; Ψ); (5.4.6)
then equation (5.4.4) is equivalent to
Pr(Ti,Ci, Ui, Zi; Ψ)
⇐d⇒Pr(Ti,Ci|Zi, Ui;θ)Pr(Ui|Zi, Dobsi ;pi)Pr(Dobsi , Zi;λ).
(5.4.7)
Furthermore, it is useful to impose some additional structure on the model.
This is achieved by partitioning the parameter vector as θ = (θT ,θC , θTC)T , where
T denotes transpose. We also require that the marginal bivariate failure time
distribution depends only on θT and that the marginal bivariate censoring time
distribution depends only on θC . Hence the θTC parameters act as association
parameters. This latter condition is only required to complete the parametrisation
of the joint distribution of the potential failure and censoring times.
By following the assumption of latent ignorability, equation (5.2.2), which gives
the joint distribution of failure and censoring times conditional on Ui and Zi,
denoted by Pr(Ti,Ci|Zi, Ui;θ), can be separated as a product of two distributions
of the failure time and the censoring time (conditional on compliance type Ui only
because of randomisation). Specifically:
Pr(Ti,Ci|Ui, Zi;θ) = Pr(Ti|Ui, Zi;θT )Pr(Ci|Ui, Zi;θC), (5.4.8)
This means we can break down θ into θ = (θT ,θC)T . In other words, under the
latent ignorability assumption, the third part of θ, namely θTC , has been omitted.
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Consequently, the model parameter Ψ can then be broken down as Ψ =
{θT ,θC ,pi, λ}, where the subcomponent parameters of Ψ are detailed below:
θT corresponds to the parametrisation of the distribution of failure time,
θC corresponds to the parametrisation of the distribution of censoring time,
pi corresponds to the parametrisation of the conditional distribution of compliance
type Ui, and
λ corresponds to the parametrisation of the joint distribution of (Dobsi , Zi).
Equation (5.4.8) can also be expressed as the following equivalence relation-
ships:
Pr(Ti(1), Ci(1)|Ui, Zi = 1;θ) =Pr(Ti(1)|Ui, Zi = 1; θT1)Pr(Ci(1)|Ui, Zi = 1; θC1)
Pr(Ti(0), Ci(0)|Ui, Zi = 0;θ) =Pr(Ti(0)|Ui, Zi = 0; θT0)Pr(Ci(0)|Ui, Zi = 0; θC0).
(5.4.9)
We propose a similar structuring of the marginal bivariate failure and cen-
soring time models by assuming θT = (θT1, θT0, θT10) and θC = (θC1, θC0, θC10)
respectively. We then have:
Pr(Ti(0)|Ui;θT ) = Pr(Ti(0)|Ui; θT0) (5.4.10)
Pr(Ti(1)|Ui;θT ) = Pr(Ti(1)|Ui; θT1). (5.4.11)
Pr(Ci(0)|Ui;θC) = Pr(Ci(0)|Ui; θC0) (5.4.12)
Pr(Ci(1)|Ui; θC) = Pr(Ci(1)|Ui; θC1). (5.4.13)
Note that the third components of θT and θC , denoted by θT10 and θC10, were
not involved. This can be interpreted as that an individual in a RCT can only be
assigned into one of treatment groups (Zi = 1 or 0). No one can be assigned into
both two treatment groups (Zi = 1 and 0). In other words, in practice no such a
situation exists which need parameter θT10 or θC10 to describe. So we simplify θT
and θC as θT = (θT1, θT0) and θC = (θC1, θC0).
Under randomisation, the assigned treatment Z is independent of all other
variables. This is denoted as Z⊥(T,C,D, U), where ⊥ means independent. It
therefore follows that:
Pr(Ti,Ci|Zi, Ui;θ) = Pr(Ti,Ci|Ui;θ). (5.4.14)
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Equation (5.4.14) represents a major simplification because it means that the
dependency of the potential survival (and censoring) times on assigned treatment
(Zi) does not have to be explicitly modelled. In non-randomised studies, this
dependency normally has to be modelled. Without additional assumptions, this
generally leads to problems with identifiability (Rubin, 1978; Graham, 2000).
The joint distribution of all potential entities for the ith observation can then
be expressed as follows:
Pr(Ti,Ci,Di, Zi; Ψ)
⇐d⇒ Pr(Ti|Ui;θT )Pr(Ci|, Ui;θC)Pr(Ui|Dobsi ;pi)pr(Dobsi , Zi;λ);
(5.4.15)
where the model parameter Ψ is Ψ = {θT ,θC ,pi, λ}.
Our primary focus is on θT . In particular, we wish to focus on (θT1, θT0),
the parameters of the marginal failure time distributions. Given estimates of
these parameters and given our specific distributional assumptions, the estimated
potential survivor functions (under the alternative assigned treatment) and the
estimators of ACE(t) and CACE(t) can then be obtained. Here ACE(t) and
CACE(t) are the forms of average causal effect (ACE) and complier average causal
effect (CACE) (Angrist et al., 1996; Imbens & Rubin, 1997; Yau & Little, 2001;
Peng et al., 2004; Mattei & Mealli, 2007), respectively, for time-to-event studies.
Note that they both are functions of time t.
5.4.2 The joint distribution of the observable variables
For deriving the formulation of the likelihood function, we need to address the
construct of the joint distribution of observed variables first, as it is well known
that the likelihood function of the model parameter Ψ, denoted by LF (Ψ), is a
function of Ψ, for fixed observed variables, and the function is proportional to the
joint distribution of all observed variables.
In time-to-event studies, however, failure time Ti and censoring time Ci cannot
be fully observed jointly. It is convenient to present a construct of the joint distri-
bution of all observable variables (denoted by Pr(T obs, Cobs, Dobs, Z; Ψ)), rather
than the joint distribution of all observed variables, as the former can be ob-
tained directly by integrating Pr(Ti,Ci,Di, Zi; Ψ)) with respect to the unobserv-
able/missing variables, which are Tmisi = Ti(1 − Zi), Cmisi = Ci(1 − Zi) and
Dmisi = Di(1− Zi) when Zi is a binary. Therefore:
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Pr(T obsi , C
obs
i , D
obs
i , Zi; Ψ)
=
∫ ∫ ∫
Pr(Ti,Ci,Di, Zi; Ψ)dDmisi dC
mis
i dT
mis
i ,
(5.4.16)
where Pr(Ti,Ci,Di, Zi; Ψ) is given in equation (5.4.15).
Because of equation (5.4.15), equation (5.4.16) can then be expressed as follows
Pr(T obsi , C
obs
i , D
obs
i , Zi; Ψ)⇐d⇒∫ ∫ ∫
Pr(Ti|Ui;θT )Pr(Ci|Ui;θC)Pr(Ui|Dobsi ;pi)Pr(Dobsi , Zi;λ)dUidCmisi dTmisi ,
(5.4.17)
where dDmisi is replaced by dUi because, given D
obs
i and Zi, we have D
mis
i ⇔ Ui.
Recall that Dobsi = Di(Zi), this implies that for the ith individual, his/her assigned
treatment Zi and actual received treatment Dobsi are always observed.
Table 5.1: Compliance types Ui = u given observed values of Zi and Di(Zi).
Zi Di(Zi) Possible Ui
1 1 a or c
1 0 n
0 1 a
0 0 n or c
Under the assumptions of exclusion restriction and monotonicity, compliance
type Ui has up to three categories, which are compliers (Ui = c), never-takers
(Ui = n) and always-takers (Ui = a) and shown in Table 5.1. Then integration in
equation (5.4.17), with respect to Ui (compliance type), can be further replaced
by its summation. We then write:
Pr(T obsi , C
obs
i , D
obs
i , Zi; Ψ)⇐d⇒∫ ∫ ∑
Ui∈{c,n,a}
Pr(Ti|Ui;θT )Pr(Ci|Ui;θC)Pr(Ui|Dobsi ;pi)Pr(Dobsi , Zi;λ)dCmisi dTmisi ,
= Pr(Dobsi , Zi;λ)
∑
Ui∈{c,n,a}
Pr(Ui|Dobsi ;pi)
∫
Pr(Ti|Ui;θT )dTmisi
∫
Pr(Ci|Ui;θC)dCmisi ,
= Pr(Dobsi , Zi;λ)
∑
Ui∈{c,n,a}
Pr(T obsi |Ui;θT )Pr(Cobsi |Ui;θC)Pr(Ui|Dobsi ;pi).
(5.4.18)
76
where ⇐d⇒ denotes distributional equivalence.
5.5 The likelihood function
As stated in Section 5.4.2, the likelihood function with respect to the model pa-
rameter Ψ can be a function that is proportional to the joint distribution of all
observed variables (p9, Tanner (1993)). However, because in time-to-event studies
for the ith individual, either failure time (T obsi ) or censoring time (C
obs
i ) can be
observed, but not both. This implies that Pr(T obsi , C
obs
i , D
obs
i , Zi;Ψ) can only be
viewed as the joint distribution for the observable variables (equation (5.4.18))
rather than the joint distribution for the observed variables.
Hence, instead of the likelihood function, we formulate a function of the model
parameter Ψ that is proportional to the joint distribution of all observable vari-
ables, the so-called the idealised likelihood function with respect to the model
parameter Ψ denoted by IDL(Ψ).
5.5.1 The idealised likelihood function
Given the joint distribution of the observable variables, Pr(T obsi , C
obs
i , D
obs
i , Zi|Ψ),
in equation (5.4.18), for the ith observation, the idealised likelihood function with
respect to the model parameter Ψ, denoted by IDLi(Ψ), has the following form:
IDLi(Ψ) ∝ Pr(T obsi , Cobsi , Dobsi , Zi; Ψ). (5.5.1)
On the other hand, by following equation (5.4.18), the product of four distribu-
tions, Pr(T obsi |Ui, Zi;θT ),Pr(Cobsi |Ui, Zi;θC), Pr(Ui|Dobsi , Zi;pi) and Pr(Dobsi , Zi;λ)
can be viewed as a function of the model parameter Ψ = (θT , θC , pi, λ), and
it is proportional to the joint distribution of the idealised observed variables,
Pr(T obsi , C
obs
i , D
obs
i , Zi; Ψ).
The idealised likelihood function with respect to the model parameter Ψ,
(IDLi(Ψ)), can then be obtained from the right hand side of equation (5.4.18), so
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it has the formulation as follows:
IDLi(Ψ)
=
∑
Ui∈{c,n,a}
Pr(T obsi |Ui, Zi;θT )Pr(Cobsi |Ui, Zi;θC)Pr(Ui|Dobsi , Zi;pi)Pr(Dobsi , Zi;λ)
=Pr(Dobsi , Zi;λ)
∑
Ui∈{c,n,a}
Pr(T obsi |Ui, Zi;θT )Pr(Cobsi |Ui, Zi;θC)Pr(Ui|Dobsi , Zi;pi),
(5.5.2)
where the second equation holds because the term Pr(Dobsi , Zi;λ) is not
related to the compliance covariate Ui involved in the summation (equation
(5.5.2)).
Note that in equation (5.5.2), assigned treatment Zi is involved in each
term of conditional distribution on the right-hand side. This is true because
the observable variables, namely T obsi , C
obs
i and D
obs
i , all rely on the given
value of Zi.
Recall that in our approach, the main parameter of interest is θT , the
parameter associated with the distribution of failure time Ti. However, from
equation (5.5.2), we can see that because the three parameters, θT , θC and
pi, are all involved in the summation over compliance type Ui, the likelihood
for these parameters does not separate into distinct components which can
be maximised separately. This implies that estimation of θT cannot pro-
ceed independently. So we write these three parameters as a row vector,
β = (θT , θC ,pi), which are associated with the distributions of failure time,
censoring time and compliance type, respectively. We then focus on deriv-
ing the idealised likelihood function for β, denoted by IDLi(β) rather than
IDLi(Ψ). Then IDLi(β) can be expressed as follows:
IDLi(β)
=
∑
Ui∈{c,n,a}
Pr(T obsi |Ui, Zi;θT )Pr(Cobsi |Ui, Zi;θC)Pr(Ui|Dobsi , Zi;pi).
(5.5.3)
5.5.2 Likelihood function for complete data
In Section 4.2, the censoring indicator Ri was introduced to indicate the sit-
uation of observed failure time or censoring time, (1 for the event occurring
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(observed failure time), 0 for censoring (observed censoring time)). There-
fore, once given the censoring indicator Ri for the ith individual, the idealised
likelihood function IDLi(β) can be specified to the likelihood function Li(β),
which can be written as the following equation:
Li(β)
=

∑
Ui∈{c,n,a}

pr(T obsi = t|Ui, Zi;θT )
×Pr(Cobsi > t|Ui, Zi;θC)
×Pr(Ui|Dobsi , Zi;pi)
 for Ri = 1, Ti(z) = t,
∑
Ui∈{c,n,a}

Pr(T obsi > t|Ui, Zi;θT )
×pr(Cobsi = t|Ui, Zi;θC)
×Pr(Ui|Dobsi , Zi;pi)
 for Ri = 0, Ci(z) = t.
(5.5.4)
where Pr() and pr() denote the probability function and the probability
density function, respectively. However, in practice, the compliance type
Ui cannot be observed fully. Hence the parameter β cannot be estimated
through the form of Li(β) given in equation (5.5.4). Dempster et al. (1977)
proposed an approach for MLE of incomplete data, named the EM-algorithm,
which can be employed in our case as Ui is considered unknown and can be
treated as incomplete data.
Briefly, the EM algorithm involves two steps: the E-step and the M-step,
which denote the expectation and maximisation steps, respectively (Demp-
ster et al., 1977). The E-step aims to obtain the conditional expectation of the
log-likelihood function for complete data log(LF (β)), denoted by Q(β,βk),
given the observed data T (z), C(z), D(z) and Z = z, and given the current
parameter values βk. More details for the EM algorithm is given in Section
5.5.5.
In the EM-algorithm, the first step requires the explication of the like-
lihood form for complete data denoted by LF (β). This depends on the as-
sumption that all compliance covariates are known. We then find the related
likelihood form for the ith observation, which can be written as follows (for
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known compliance covariates Ui = u):
LF i(β) = Li(β, u)
=


pr(T obsi = t|Ui, Zi; θT )
×Pr(Cobsi > t|Ui, Zi; θC)
×Pr(Ui|Dobsi , Zi; pi)
 for Ri = 1, Ti(z) = t,
Pr(T obsi > t|Ui, Zi; θT )
×pr(Cobsi = t|Ui, Zi; θC)
×Pr(Ui|Dobsi , Zi; pi)
 for Ri = 0, Ci(z) = t.
(5.5.5)
Compliance type Ui = u is used to describe an individual’s compliance be-
haviour. Therefore, we have redefined the parameter of interest, θT1 = (θT,u1)
and θT0 = (θT,u0) (for u ∈ {c, a, n}). Recall that θT = (θT1, θT0). More
specifically, the parameter of interest associated with the failure time distri-
bution, θT , is redefined as θT = (θT,c1, θT,n1, θT,a1, θT,c0, θT,n0, θT,a0). This
is equivalent to θT = (θT,uz) (for u ∈ {a, c, n} and z ∈ {0, 1}). Here the
subscripts indicate failure time (T ) with U = u for u ∈ {a, c, n} and assigned
treatment Z = z for z ∈ {0, 1}.
Similarly, we use θC,uz for u ∈ {a, c, n}, and z ∈ {0, 1} to denote the
components of θC , the parameter associated with the censoring time distri-
bution. In other words, we have θC = (θC,c1, θC,n1, θC,a1, θC,c0, θC,n0, θC,a0).
Hence, for the specific assigned treatment Zi = z (with known Ui = u),
equation (5.5.5) can be simplified as follows:
Li(β, u)
=


pr(T (z)i = t|Ui, Zi; θT,uz)
×Pr(C(z)i > t|Ui, Zi; θC,uz)
×Pr(Ui|Di(z), Zi;piu,zd)
 for Ri = 1, Ti(z) = t,
Pr(T (z)i > t|Ui, Zi; θT,uz)
×pr(C(z)i = t|Ui, Zi; θC,uz)
×Pr(Ui|Di(z), Zi;piu,zd)
 for Ri = 0, Ci(z) = t.
(5.5.6)
where Ri is the observed indicator of censoring, which is 1 for the event
of interest and 0 for censoring. The parameter piu,zd is associated with the
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conditional probability of compliance, given Zi = z and Di(z) = d, and is
defined by piu,zd = Pr(Ui = u|Zi = z,Di(z) = d) for u = (a, c, n) and z, d =
0, 1. Details about the estimation of the parameter piu,zd will be discussed in
Section 5.9.
According to equation (5.5.6), an individual randomised to treatment
Zi = 1 who dies or is censored at (observed) time t has a contribution to the
likelihood β as follows:
Li∈{i:Zi=1}(β, u)
=


pr(T (1)i = t|Ui = u, Zi = 1; θT,u1)
×Pr(C(1)i > t|Ui = u, Zi = 1; θC,u1)
×Pr(Ui|Di(1), Zi = 1; piu,1d)
 for Ri = 1, T (1)i = t,
Pr(T (1)i > t|Ui = u, Zi = 1; θT,u1)
×pr(C(1)i = t|Ui = u, Zi = 1; θC,u1)
×Pr(Ui|Di(1), Zi = 1; piu,1d)
 for Ri = 0, C(1)i = t.
(5.5.7)
for d = 0 or 1 and u ∈ {c, a, n} .
Similarly, an individual randomised to treatment Zi = 0 who dies or is
censored at (observed) time t has a contribution to the likelihood for β as
follows:
Li∈{i:Zi=0}(β, u)
=


pr(T (0)i = t|Ui = u, Zi = 0; θT,u0)
×Pr(C(0)i > t|Ui = u, Zi = 0; θC,u0)
×Pr(Ui|Di(0), Zi = 0; piu,0d)
 for Ri = 1, T (0)i = t,
Pr(T (0)i > t|Ui = u, Zi = 0; θT,u0)
×pr(C(0)i = t|Ui = u, Zi = 0; θC,u1)
×Pr(Ui|Di(0), Zi = 0; piu,0d)
 for Ri = 0, C(0)i = t.
(5.5.8)
for d = 0 or 1 and u ∈ {c, n, a} .
Recall from Table 5.1 that knowing the values of Zi = z and Di(z) = d
means that compliance type Ui = u can be determined for up to two types.
Hence, given the value of z and d, equations (5.5.7) and (5.5.8) can then be
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expressed as the following form:
Li∈{i:Zi=z,Di(z)=d}(β;u)
=


pr(T (z)i = t|Ui = u, Zi = z; θT,uz)
×Pr(C(z)i > t|Ui = u, Zi = z; θC,uz)
×Pr(Ui|Di(z), Zi = z;piu,zd)
 for Ri = 1, T (z)i = t,
Pr(T (z)i > t|Ui = u, Zi = z; θT,uz)
×pr(C(z)i = t|Ui = u, Zi = z; θC,uz)
×Pr(Ui|Di(z), Zi = z;piu,zd)
 for Ri = 0, C(z)i = t.
(5.5.9)
for z and d = 0 or 1 and u ∈ {c, a, n} .Note that equation (5.5.9) given above
is a likelihood function of our non-ignorable PPO-survival model which is
analogous to the one given in O’Malley & Normand (2005) model that is for
normally distributed outcomes.
For notational convenience, we introduce the following conventions:
f iu(v, t; θT,uv) = pr(Ti(v) = t|Ui = u, θT,uv) for v = 0or 1,
Siu(v, t; θT,uv) = Pr(Ti(v) > t|Ui = u, θT,uv) for v = 0or 1,
eiu(v, t; θC,uv) = pr(Ci(v) = t|Ui = u, θC,uv) for v = 0or 1,
Giu(v, t; θC,uv) = Pr(Ci(v) > t|Ui = u, θC,uv) for v = 0or 1.
(5.5.10)
As mentioned before, Pr() and pr() denote the probability and probabil-
ity density function, respectively and v indicates potential treatment levels.
Equation (5.5.9) can then be rewritten as:
Li∈{i:Zi=z,Di(z)=d}(β;u)
=
[
f iu(z, t; θT,uz)G
i
u(z, t; θC,uz)
]Ri [Siu(z, t; θT,uz)eiu(z, t; θC,uz)]1−Ri piu,zd.
(5.5.11)
Furthermore, we write:
F iu,zd(θT,uz, θC,uz)
=
[
f iu(z, t; θT,uz)G
i
u(z, t; θC,uz)
]Ri [Siu(z, t; θT,uz)eiu(z, t; θC,uz)]1−Ri .
(5.5.12)
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Equation (5.5.9) can then be expressed more simply as:
Li∈{i:Zi=z,Di(z)=d}(β;u) = F
i
u,zd(θT,uz, θC,uz)piu,zd = l
i
θ(θ;u)l
i
pi(pi; u) (5.5.13)
Because of the independent and identically distributed (i.i.d.) assumption
for all observable variables (conditional on model parameters), the likelihood
function for complete data denoted by LF (β) = L(β, u) can be expressed by
the product of the fully likelihood function associated with each individual.
In other words, we have:
LF (β) =
∏
i=1
Li(β, u) =
∏
i=1
F iu,zd(θT,uz, θC,uz)piu,zd =
∏
i=1
liθ(θ; u)l
i
pi(pi;u).
(5.5.14)
Given observed Zi = z and Di(z) = d, the likelihood form of θ for com-
plete data, in which compliance type Ui (for each individual) is presumed to
be known, can then be expressed as:
LF (β) = L(β, u) =
∏
i
Li(β, u)
=

∏
i∈{i:Ui=c,Zi=1,Di(1)=1} F
i
c,11(θT,c1, θC,c1)pic,11∏
i∈{i:Ui=a,Zi=1,Di(1)=1} F
i
a,11(θT,a1, θC,a)pia,11∏
i∈{i:Ui=c,Zi=0,D(0)=0} F
i
c,00(θT,c0, θC,c0)pic,00∏
i∈{i:Ui=n,Zi=0,Di(0)=0} F
i
n,00(θT,n0, θC,n0)pin,00∏
i∈{i:Ui=n,Zi=1,D(0)=0} F
i
n,10(θT,n0, θC,n0)pin,10∏
i∈{i:Ui=a,Zi=0,D(0)=1} F
i
a,01(θT,a1, θC,a1)pia,01.
(5.5.15)
5.5.3 The likelihood form for incomplete data
Since compliance type Ui is unobservable, Ui needs to be treated as a variable
with missing data. Hence, data associated with the case where noncompli-
ance occurs have to be viewed as incomplete data.
Let A(z, d) denote the subset of subjects with specified values of Z andD;
more specifically, A(z, d) = {i : Zi = z, and Di = d}. The likelihood form
for incomplete data for the non-ignorable PPO-survival models can then be
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written as shown below:
L(β) =
∑
u∈{c,n,a}
L(β, u) =
∑
u∈{c,n,a}
∏
i
Li(β, u)
=

∏
i∈A(1,1)
{(
F ic,11(θT,c1, θC,c1)pic,11
)
+
(
F ia,11(θT,a1, θC,a1)pia,11
)}∏
i∈A(0,0)
{(
F ic,00(θT,c0, θC,c0)pic,00
)
+
(
F in,00(θT,n0, θC,n0)pin,00
)}∏
i∈A(1,0)
(
F in,10(θT,n0, θC,n0)pin,10
)∏
i∈A(0,1)
(
F ia,01(θT,a1, θC,a1)pia,01
)
.
(5.5.16)
The likelihood function of β for incomplete data, given in equation (5.5.16),
does not appear to be readily broken down into products of functions involv-
ing only θT and θC , respectively. That is L(β) 6= L(θT )L(θC). That is the
case where censoring is not ignorable (Baker, 1997).
5.5.4 Simplification of model parameter β
In equation (5.5.15), we observe that the parameter β has the form β =
(θT,uz,θC,uz,piu,zd) for u = (a, c, n) and z, d = (0, 1). However, the number
of model parameters can be further reduced by following the assumption
of compound exclusion restriction (Angrist et al., 1996; Frangakis & Rubin,
1999).
The compound exclusion restriction assumes that all potential-outcome
vectors can be affected by the received treatment Di(Z), rather than by
the assigned treatment Zi. This implies that the outcome of interest for an
individual, as long as his/her received treatment has the same value, will
have the same value when he/she is assigned into either treatment group (if
possible in practice). For convenience to express the assumption of exclusion
restriction mathematically, we use the notation Ti(Zi = z,Di(z) = d) and
Ci(Zi = z,Di(z) = d) to denote the ith individual’s failure and censoring time
where his/her assigned treatment Zi and actual received treatment Di(Zi)
are given by Zi = z and Di(z) = d, respectively. Recall that in a two-arm
RCT, we have z and d ∈ {1, 0}. Hence the exclusion restriction assumption
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can be expressed as follows:
Ti(Zi = 1, Di(1) = d) = Ti(Zi = 0, Di(0) = d) for failure time,
Ci(Zi = 1, Di(1) = d) = Ci(Zi = 0, Di(0) = d) for censoring time.
(5.5.17)
This also implies that individuals who are never-takers or always-takers
would have the same failure and censoring times probability distributions,
whether they are in the treated group or in the control group. In other words:
Pr(Ti(Zi, Di(Zi))|Zi = 0, Ui = u)
= Pr(Ti(Zi, Di(Zi))|Zi = 1, Ui = u) for u = a or n;
Pr(Ci(Zi, Di(Zi))|Zi = 0, Ui = u)
= Pr(Ci(Zi, Di(Zi))|Zi = 1, Ui = u) foru = a or n.
(5.5.18)
For convenience, in the remainder of this thesis, we use Ti(Zi) and Ci(Zi)
to denote the failure and censoring times corresponding to the assigned treat-
ment for the ith individual, whose assigned treatment is Zi = z and whose
actual received treatment is Di(z) = d. Equation (5.5.18) can then be re-
written as:
Pr(Ti(0)|Zi = 0, Ui = u)
= Pr(Ti(1)|Zi = 1, Ui = u) for u = a or n;
Pr(Ci(0)|Zi = 0, Ui = u)
= Pr(Ci(1)|Zi = 1, Ui = u) foru = a or n.
(5.5.19)
Consequently, the parameters associated with the outcome distributions
(failure and censoring), which correspond to the subgroup with Ui = n and
Zi = 1 or 0, and to subgroup with Ui = a and Zi = 1 or 0, are equivalent.
Hence, we have the following relationships:
θT,n1 = θT,n0 θT,a1 = θT,a0
θC,n1 = θC,n0 θC,a1 = θT,a0.
(5.5.20)
Therefore we can use θT,n to represent both θT,n1 and θT,n0, as they are
identical under the assumption of exclusion restriction. Similarly, the two
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parameters θT,a1 and θT,a0 are identical under the same assumption. So we
can use θT,a to denote both θT,a1 and θT,a0. By following the same logic, we
write θC,n = θC,n1 = θC,n0 and θC,a = θC,a1 = θC,a0.
Equation (5.5.20) implies that the parameters θT,uz and θC,uz, which are
associated with the failure and censoring times for the subgroup with Ui = u
and assigned treatment Zi = z, include the following components:
θT,uz = (θT,c1, θT,c0, θT,n, θT,a)
θC,uz = (θC,c1, θC,c0, θC,n, θC,a).
(5.5.21)
Note that no parameter for the subgroup with Ui = d and Zi = 1 or 0 exists,
because under the assumption of Monotonicity, no defiers exist.
Thereby, because we have assumed monotonicity, up to two categories
exist for compliance type Ui = u (knowing the value of Zi and Di(Zi))
(Table 5.1). The parameter piu,zd = Pr(Ui = u|Zi = z,Di(z) = d), which
is defined as the conditional probability of compliance type Ui given the
assigned treatment Zi = z and actual received treatment D
obs = d, can now
satisfy the following equations:
pic,11 + pia,11 = 1 for u ∈ {c, a} when Zi = 1 and Di(1) = 1,
pic,00 + pin,00 = 1 for u ∈ {c, n} when Zi = 0 and Di(0) = 0,
pin,10 = 1 for u ∈ {n} when Zi = 1 and Di(1) = 0,
pia,01 = 1, for u ∈ {a} when Zi = 0 and Di(0) = 1.
(5.5.22)
The other piu,zd for u ∈ {c, n, a} and z, d = 1 or 0 have zero values.
Now the model parameters of interest β can then be specified as β =
(θ,pi), where
θ = (θT,c1,θT,c0,θT,n,θT,a,θC,c1,θC,c0,θC,n,θC,a),
pi = (pic,11, pic,00).
(5.5.23)
In addition, using piu to denote the probability of compliance type Ui = u,
i.e. piu = Pr(Ui = u), and by following the theorem of total probability, we
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have:
Pr(Ui = u) =
∑
d∈{1,0}
∑
z∈{1,0}
Pr(Ui = u,Di(z) = d, Zi = z)
=
∑
d∈{1,0}
∑
v∈{1,0}
Pr(Ui = u|Di(z) = d, Zi = z)Pr(Di(z) = d, Zi = z).
(5.5.24)
Recall that piu,zd = Pr(Ui = u|Di(z) = d, Zi = z). Denote λzd = Pr(Di(z) =
d, Zi = z) to correspond to the probability of individuals with values (Zi =
z, Di(z) = d)) in the population. Then equation (5.5.24) can be re-written
as:
piu =
∑
d∈{1,0}
∑
z∈{1,0}
piu,zdλzd. (5.5.25)
By following this definition, λzd can then be estimated by λ̂zd =
Nzd
N
. Here
Nzd is the size of the subgroup in a trial where all individuals have Zi = z
and Di(z) = d, and N is the total number of individuals involved in the
study trial. Furthermore, we have Pr(Ui = u|Zi = 1) = Pr(Ui = u|Zi = 0)
as randomisation guarantees a balance between the treated (Zi = 1) and the
control (Zi = 0) groups. Therefore we can write piu = Pr(Ui = u|Zi = 1) =
Pr(Ui = u|Zi = 0).
Since the number of subjects who do or do not actually receive the treat-
ment in the treatment group (Zi = 1) are observable (denoted by N11 and
N10 respectively), we can then estimate pin by pin =
N10
N1
. If always-takers exist
in a trial, then the number of subjects N01 in the control group who receive
the treatment is known. Then we have pia =
N01
N0
. Also pic + pia + pin = 1
because no defiers exist. Then the probability of compliers can be estimated
by pic = 1 − pia − pin (O’Malley & Normand, 2005). These can be expressed
as:
pin =
N10
N1
;
pia =
N01
N0
;
pic = 1− pia − pin.
(5.5.26)
Recall that individuals from the subgroup with Zi = 1 and Di(1) = 1 can
be written as i ∈ A(1, 1). Their compliance type can be compliers, Ui = c, or
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always-takers, Ui = a. Similarly, individuals from the subgroup with Zi = 0
and Di(0) = 0, denoted by i ∈ A(0, 0), may either be compliers, Ui = c, or
never-takers, Ui = n. Then, following the definition of piu,zd and by Table
5.1, we have:
pic,11 =
pic
pic + pia
,
pic,00 =
pic
pic + pin
.
(5.5.27)
By following equation (5.5.14) and considering the relationships given in
equation (5.5.27), the likelihood function LF (β) with respect to β, can be
replaced by a product of lF (θ) and lF (pi). That is:
LF (β) = lF (θ)lF (pi), (5.5.28)
where
lF (θ) =
∏
i=1
F iu,zd(θT,uz, θC,uz),
lF (pi) =
∏
i=1
piu,zd.
(5.5.29)
Therefore, to maximise LF (β) is equivalent to maximise lF (θ) and lF (pi),
separately.
Because of the relationships given equation (5.5.27), which implies that
pic,11 and pic,00 can be calculated directly through the value of piu for u ∈
{c, n, a}, we then write:
pi∗ = (pic, pin, pia). (5.5.30)
Therefore, to estimate parameter β = (θ,pi) is equivalent to estimating
(θ,pi∗). As we stated before, the MLE of pi∗ can be estimated by equation
(5.5.26). Hence we need only to maximise lF (θ) for obtaining the MLE of
θ. The EM algorithm is employed here because an unobservable variable,
compliance type Ui, is involved in the likelihood function l
F (θ).
In other words, there is only the first part of parameter β, denoted by θ
need to be further estimated through the EM algorithm. That is:
θ = (θT,uzθC,uz);
= (θT,c1,θT,c0,θT,n,θT,a,θC,c1,θC,c0,θC,n,θC,a).
(5.5.31)
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The rest part of β, the parameter pi∗ can be regarded as a known param-
eter when we estimate the parameter θ. As a consequence, the parameter pi
is also known because of equation (5.5.27). For simplification of notation, in
the remains of this chapter we still use pi rather than pi∗ to refer to the rest
part of β.
5.5.5 EM algorithm
The EM algorithm is a generally applicable algorithm that provides an it-
erative procedure for computing MLEs in such situations. Indeed, the EM
algorithm is a commonly used method of maximum likelihood to deal with
incomplete data (Laird & Louis, 1982; Baker, 1992; Meng & Rubin, 1991,
1993; Imbens & Rubin, 1997; O’Malley & Normand, 2005; Peng et al., 2004).
In general, the likelihood method requires the score equation to be solved.
Unfortunately, the likelihood function of β for incomplete data, as given in
equation (5.5.16), cannot be formulated. This is because, at least for those
individuals assigned to the control group, their compliance type, Ui, will
never be observed. The EM algorithm approaches this problem (of solving
the incomplete data likelihood score function) indirectly by proceeding iter-
atively in terms of the complete data log likelihood function of β, denoted
by log(LF (β)) (equation (5.5.28)).
The expectation step
According to Dempster et al. (1977), as introduced in Section 5.5.2, the
first step in the EM algorithm is to obtain the conditional expectation of
log(LF (β)), the Q-function Q(β,βk). Now it is replaced by the conditional
expectation of log(lF (θ)), the Q-function Q(θ,θk). In other words:
Q(θ,θk) = Eu{log(lF (θ)|(Ti, Ci)obs, Zi = z, Di(z) = d), Ui = u, ;θk},
(5.5.32)
where u ∈ {c, n, a} and lF (θ) denotes the likelihood function with respect
to parameter θ for the complete data that is given in equation (5.5.29).
(Ti, Ci)
obs indicates the observable part of survival outcomes (Ti, Ci), which
is (T obsi = t, C
obs
i > t) if the ith individual experienced the event at time t;
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or (T obsi > t, C
obs
i = t) if the ith individual is censored at time t.
Note that equations (5.5.27) and (5.5.26) have shown that pi is only de-
termined by the observed values of subgroup sizes, which are denoted by N1,
N10, N0, and N01. This implies that for a certain dataset, L
F (pi) would be
a constant because in the dataset N1, N10, N0, and N01 are fixed. Hence, to
maximise lF (θ) is equivalent to maximise LF (β|pi) = lF (θ)lF (pi) = KlF (θ)
when pi is known. (K refers to any constant here). So we give the likeli-
hood function with respect to parameter θ as lF (θ) = LF (β|pi), which has
the same structure as LF (β), the likelihood function of β given in equation
(5.5.15), but pi is viewed as a known vector. The advantage of using this form
of the likelihood function lF (θ) = LF (β|pi) will be seen in Chapter 7 when
we create an extended PPO-survival model for a more complicated situation
in time-to-event study.
As compliance type, Ui, can be treated as a discrete random variable
with c, a, n (three states), then, by the definition of expectation of discrete
random variables, equation (5.5.32) can be expressed as follows:
Qi(θ,θk)
=
∑
u∈{c,n,a}
{
Pr(Ui = u|(Ti, Ci)obs, Zi = z, Di(z) = d; θk)
{log(l(θ, u)}
}
(5.5.33)
where l(θ, u) is another form of lF (θ), the likelihood function with respect
to θ for complete data, we give its form as follows:
lF (θ) = L(β, u|pi), (5.5.34)
because LF (β) = L(β, u).
In addition, we can further assume that compliance type, Ui, follows
the Bernoulli distribution, given observed data Ti(z), Ci(z), Di(z). This
is true because of the assumptions of compound exclusion restriction and
monotonicity, given (Zi = z, Di(z) = d). Recall that compliance type has
up to two compliance categories for this development (refer to Table 5.1).
More details about the structure of the Q-function Q(θ,θk), the expectation
function, are given Section 5.9.2.
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The maximisation step
After obtaining the formulation of Q-function Q(θ,θk) given the current
parameter values θk, the second step of the EM algorithm is to find a new
estimate, θk+1, which maximizes the Q-function Q(θ,θk). This implies that
the following inequality is always satisfied:
Q(θk+1,θk) ≥ Q(θ,θk) for all θ ∈ Ωθ, (5.5.35)
where Ωθ is the parameter space of θ.
Further information on the process of maximisation for the non-ignorable
PPO-survival model is given in Section 5.9.3.
5.6 Model specifications
For the purpose of showing how our non-ignorable models work, we focus
mainly on the Weibull model as the survival distribution. This is due to
its special features. Firstly, the Weibull distribution is flexible for many dif-
ferent patterns of data. This can be seen from its varying types of hazard
curve (Klein, 1997; Cox & Oakes, 1984). Secondly, the Weibull distribution
is associated with relatively simple survival, hazards and probability density
functions (equations (5.6.1), (5.6.2) and (5.6.3)). This makes the Weibull a
very popular parametric model in conventional survival analysis. Further-
more, the Weibull distribution is the only distribution which satisfies both the
accelerated failure time (AFT) and the Cox proportional hazard (PH) models
(Cox & Oakes, 1984). The log-normal model is another plausible paramet-
ric distribution used in conventional survival analysis. We also specify the
log-normal distribution for the non-ignorable PPO-survival model (Section
5.6.3). In this thesis, our parametric potential-outcome (PPO) models are
specified in terms of the Weibull and the log-normal distributions. Other
distributions are the topic of future research.
5.6.1 Weibull distribution
Following standard survival analytic procedures, we suppose that the time-
to-event of interest (or failure time) has a Weibull distribution (Klein, 1997;
91
Cox & Oakes, 1984; Kalbfleisch & Prentice, 2002). The Weibull distribution,
which has a variable shape parameter, can be conveniently used to describe
many different patterns of survival data. It is well known that the hazard
function in a Weibull model varies according to the value of its shape pa-
rameter. It may be increasing, decreasing, constant, or possess some other
characteristics which describe the failure mechanism (Klein, 1997; Cox &
Oakes, 1984; Kalbfleisch & Prentice, 2002).
The Weibull failure time distribution (T) is parameterized by (ρ, α),
where ρ and α represent scale and shape parameters, respectively. So the
density function and survival function corresponding to a Weibull distribu-
tion can be expressed as follows:
fw(t) = αρ(ρt)
(α−1) exp(−(ρt)α), (5.6.1)
Sw(t) = exp(−(ρt)α); (5.6.2)
and the hazard rate function can be written as:
hw(t) = αρ(ρt)
(α−1), (5.6.3)
(p. 19, Cox & Oakes (1984)).
5.6.2 Log-normal distribution
Since in time-to-event studies, the outcome of interest, T (the event time), is
almost certainly a positive value (T > 0), the most common way of realising
the relevant data transformation is to take the natural logarithm of event
time, log(T ). If the transformed data log(T ) follow a normal distribution,
by definition, the event time T will possess a log-normal distribution. Like
the normal distribution, the log-normal distribution is completely specified
by two parameters, µ and σ, the mean and variance of log(T ), respectively.
Its density function is expressed as follows:
fl(t) =
exp[−1
2
( log[t]−µ
σ
)2]
t(2pi)1/2σ
= φ(
log[t]− µ
σ
)/t, (5.6.4)
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where φ() represents the standard normal probability density function, which
can be written as φ(x) = 1√
2pi
exp(−x2
2
) (p. 39, Klein (1997)).
By following the definition of the survival function, it is straightforward
to obtain its form for the log-normal model, namely:
Sl(t) = 1− Φ(log[t]− µ
σ
), (5.6.5)
where Φ() is the cumulative distribution function of a standard normal vari-
able, which can be expressed as Φ(x) =
∫ x
−∞ φ(u)du (p. 39, Klein (1997)).
The hazard function in the log-normal model can be expressed as a function
of its density and survival function, namely:
hl(t) =
fl(t)
Sl(t)
, (5.6.6)
(p. 37, Klein (1997)).
The hazard function of the log-normal is hump-shaped. Specifically, its
value at t = 0 is zero, hl(0) = 0, and it increases to a maximum and then
decreases to zero when the time variable t approaches infinity (t → ∞).
Note that the hazard function decreases for large values of t, which seems
implausible in many time-to-event studies. This is precisely why the log-
normal model has been criticised when chosen as a lifetime distribution. The
log-normal distribution may fit certain cases, however, where large values of
t are not of interest (Klein, 1997).
5.6.3 Specific non-ignorable PPO-survival models
When accounting for a censoring time distribution, the non-ignorable sur-
vival model can be specified in more than two forms. This is true, even
when the Weibull and the log-normal are the only pre-specified distribu-
tions. Note that failure and censoring times may follow different types of
distribution. For instance, suppose that the failure time follows a Weibull
distribution and its associated censoring time has an underlying log-normal
distribution. In this case, the non-ignorable survival model has to be specified
as a NIGN-WL model; namely a non-ignorable survival Weibull log-normal
model. However, when failure and censoring times follow the log-normal and
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the Weibull distribution, respectively, we have the NIGN-LW model. In this
thesis, we focus, however, on specific non-ignorable survival models with the
same distributions for both the failure and censoring times. These are clearly
denoted as the NIGN-WW model and the NIGN-LL model. Table 5.2 gives
the nomenclature for the non-ignorable survival model specifications.
Table 5.2: Specification of the non-ignorable PPO-survival models.
Distribution non-ignorable survival model
Weibull NIGN-WW model
log-normal NIGN-LL model
5.7 The AFT model
To simplify the model structure, especially to simplify model parameter β,
we adopt an accelerated failure time (AFT) model approach (Cox & Oakes,
1984; Klein, 1997). In this section, we first prove a useful property of AFT
for the Weibull or log-normal distribution (Section 5.7.1), then focus on the
formulation and application for the simplest case, where no pre-treatment
covariate is involved (Section 5.7.2 and Section 5.7.3). The complicated form
for incorporating pretreatment covariates is, however, given in Section 7.4.
5.7.1 An AFT property with its proof
Theorem 1. Suppose a failure time variable T satisfies an accelerated fail-
ure time (AFT) model T = T0 exp(β
′X), where T0 represents the failure time
corresponding to the baseline; X and β denote covariate vector and its asso-
ciated regression coefficients, both of them are column vectors with the same
length p.
1. If T0 = t0 ∼ Weib(ρ0, α0), t0 follows a Weibull distribution with scale
parameter ρ0 and shape parameter α0, the new variable T = t then
follows a Weibull distribution with ρ = ρ0 exp(−β′X) and α = α0,
namely t ∼Weib(ρ, α).
94
2. If T0 = t0 ∼ Logn(µ0, σ0), t0 follows a log-normal distribution with
two parameters, µ0 and σ0, the mean and variance of log(T0), the new
variable T = t then follows a log-normal distribution with µ = µ0+βX
′
and σ = σ0, i.e. T = t ∼ Logn(µ, σ).
Proof. By following the definition of the survival function with respect to the
failure time T , the survival function can be expressed as follows:
S(t) = Pr(T > t) = Pr(T0 exp(β
′X) > t); ∵ T = T0 exp(β′X);
= Pr(T0 > t exp(−β′X)); ∵ exp(β′X) > 0;
= S0(t exp(−β′X)); by the definition of S0(t). (5.7.1)
In addition, by the definition of a probability density function (p.d.f.), we
have the following:
f(t) = −dS(t)
dt
; (by definition);
=
dS0(t0)
dt0
dt0
dt
; for t0 = t exp(−β′X)
= f0(t0) exp(−β′X). (5.7.2)
1) ∵ T0 = t0 ∼Weib(ρ0, α0), we have
fw0(t) = α0ρ0(ρ0t)
(α0−1) exp(−(ρ0t)α0), (5.7.3)
Sw0(t) = exp(−(ρ0t)α0). (5.7.4)
where fw0(t) and Sw0(t) denote the probability density (p.d.f.) and survival
functions (S) with respect to T0.
By following equations (5.7.1) and (5.7.2), the survival function and the
probability density function (p.d.f.), fw(t), with respect to the failure time
T in a Weibull model, can be expressed as:
Sw(t) = Pr(T > t) = Sw0(t exp(−β′X));
= exp(−[ρ0t exp(−β′X)]α0), (5.7.5)
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and the probability density function (p.d.f.), fw(t) as:
fw(t) = fw0(t exp(−β′X)) exp(−β′X);
= α0ρ0(ρ0t exp(−β′X))(α0−1) exp(−[ρ0t exp(−β′X)]α0) exp(−β′X);
= α0ρ0 exp(−β′X)(ρ0t exp(−β′X))(α0−1) exp(−[ρ0t exp(−β′X)]α0).
(5.7.6)
Let ρ = ρ0 exp(−β′X) and α = α0. Equations (5.7.7) and (5.7.7) can
then be re-written as:
Sw(t) = Pr(T > t) = exp(−[ρ0t exp(−β′X)]α0)
= exp(−(ρt)α), (5.7.7)
and
fw(t) = = α0ρ0 exp(−β′X)(ρ0 exp(−β′X)t)(α0−1) exp(−[ρ0 exp(−β′X)t]α0);
= αρ(ρt)(α−1) exp(−(ρt)α). (5.7.8)
Because equations (5.7.7) or (5.7.8) hold, we have T = t ∼ Weib(ρ, α)
where ρ = ρ0 exp(−β′X) and α = α0.
2) ∵ T0 = t0 ∼ Logn(µo, σ0), we can write:
fl0(t0) =
exp[−1
2
( log[t0]−µ0
σ0
)2]
t0(2pi)1/2σ0
= φ(
log[t0]− µ
σ
)/t0; (5.7.9)
where φ() represents the standard normal probability density function, which
can be written as φ(x) = 1√
2pi
exp(−x2
2
); and
Sl0(t) = 1− Φ(log[t]− µ0
σ0
); (5.7.10)
where Φ() is the cumulative distribution function of a standard normal vari-
able, which has the general form Φ(x) =
∫ x
−∞ φ(u)du. By following equations
(5.7.1) and (5.7.2), the survival function and the probability density function
(p.d.f.) fl(t) with respect the failure time T in a log-normal model can be
expressed as follows:
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Sl(t) = Pr(T > t) = Sl0(t exp(−β′X));
= 1− Φ(log[t exp(−β
′X)]− µ0
σ0
);
1− Φ(log[t]− β
′X − µ0
σ0
); (5.7.11)
and
fl(t) = fl0(t exp(−β′X)) exp(−β′X);
=
exp[−1
2
( log[t exp(−β
′X)]−µ0
σ0
)2]
t exp(−β′X)(2pi)1/2σ0 exp(−β
′X);
=
exp[−1
2
( log[t]−β
′X−µ0
σ0
)2]
t exp(−β′X)(2pi)1/2σ0 exp(−β
′X);
=
exp[−1
2
( log[t]−(β
′X+µ0)
σ0
)2]
t(2pi)1/2σ0
. (5.7.12)
Using µ = µ0 + β
′X and σ = σ0, equations (5.7.11) and (5.7.12) can be
re-written as follows:
Sl(t) = 1− Φ(log[t]− µ
σ
), (5.7.13)
and
fl(t) =
exp[−1
2
( log[t]−µ
σ
)2]
t(2pi)1/2σ
. (5.7.14)
Therefore, T = T0 exp(β
′X) follows a log-normal distribution with the
parameters µ and σ. Explicitly, T = t ∼ Logn(µ, σ) where µ = µ0 + β′X
and σ = σ0.
5.7.2 The AFT model for failure time
In general, the simplest form of the AFT model can be written as Ti(1) =
Ti(0)/ψ, where ψ is often given as an exponential function ψ = exp(β
TZ)
where Z denotes covariates and β is a vector parameter that is associated
with those related covariates variables (p.64, Cox & Oakes (1984)) and is the
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so-called accelerated factor(p.47, Klein (1997)).
Being based on the potential outcome framework, the AFT model can
be constructed in two parts, the first modelling the relationship between
potential outcomes (the causal model) and the second modelling differences
between compliance types (selection model). Thus we first assume the sim-
plest form as the following, where compliance type is presumed to have only
two categories:
Ti(1) = Ti(0) exp(ζ + ζUUi);
Ti(0) = T0i exp(φUUi);
T0i ∼ D(θ(1)T , θ(2)T ),
(5.7.15)
where T0i denotes failure time of baseline and D(θ
(1)
T , θ
(2)
T ) represents a stan-
dard distribution, such as the Weibull distribution, and (θ
(1)
T , θ
(2)
T ) denotes its
associated parameters. For example, if the standard distribution is given by
a Weibull distribution, then θ
(1)
T = ρ
0
T and θ
(2)
T = α
0
T . In this case, we have
D(θ
(1)
T , θ
(2)
T ) ' W (ρ0T , ρ0T ).
However, the ith individual’s compliance type, Ui = u, can possibly fall
into one of three categories: complier, always-taker and never-taker (u ∈
{c, a, n}). So we can use two dummy variables, i.e. U (c)i and U (a)i , to denote
Ui, that is Ui = (U
(c)
i , U
(a)
i )
T . More specifically, (U
(c)
i , U
(a)
i )
T = (1, 0)T is
equivalent to Ui = c, which indicates a complier ; (U
(c)
i , U
(a)
i )
T = (0, 1)T is
equivalent to Ui = a, which indicates an always-taker, and (U
(c)
i , U
(a)
i )
T =
(0, 0)T is equivalent to Ui = n, which indicates a never-taker. Table 5.3
gives the relationship between dummy variables and the categorical variable
for compliance type.
Table 5.3: Dummy variables for compliance type Ui.
Ui = u (U
(c)
i U
(a)
i )
c (1 0)
a (0 1)
n (0 0)
Let ζU = (ζ
(c), ζ(a)), and φU = (φ
(c), φ(a)), then equation (5.7.15) can be
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re-written as follows:
Ti(1) = Ti(0) exp(ζ + ζ
(c)U
(c)
i + ζ
(a)U
(a)
i );
Ti(0) = T0i exp(φ
(c)U
(c)
i + φ
(a)U
(a)
i );
T0i ∼ D(θ(1)T , θ(2)T ).
(5.7.16)
The first equality in equation (5.7.16) is a model for the relationship
between the two potential outcomes. This model represents the effect of
assigned treatment, which is assumed to multiply the failure time that would
be observable if not assigned to treatment (Ti(0)) by exp(ζ) for never-takers
((U
(a)
i , U
(c)
i ) = (0, 0)), by exp(ζ + ζ
(a)) for always-takers ((U
(a)
i , U
(c)
i ) = (1, 0)
) or by exp(ζ+ζ(c)) for compliers ((U
(a)
i , U
(c)
i ) = (0, 1)). These can be written
as:
Ti(1) =

Ti(0) exp(ζ + ζ
(c)) for Ui = c;
Ti(0) exp(ζ + ζ
(a)) for Ui = a;
Ti(0) exp(ζ) for Ui = n.
(5.7.17)
In other words, the effect of assigned treatment is allowed to vary with
compliance type. However, by following the exclusion restriction assumption,
which implies that Ti(1) = Ti(0) for Ui = u and u ∈ {a, n}, we have the
following equations:
exp(ζ) = 1;
exp(ζ + ζ(a)) = 1;
(5.7.18)
which are equivalent to the following constraints:
ζ = 0;
ζ(a) = 0;
(5.7.19)
This means that under the exclusion restriction assumption, these constraints,
ζ = ζ(a) = 0, should be imposed because under this restriction, it is quite
reasonable to assume that, since assigned treatment does not change the
treatment received for always-takers and never-takers, there is no causal ef-
fect of assigned treatment for these groups.
The second equality in equation (5.7.16) models the effect of compliance
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type, if not assigned to treatment. Under this model, the failure time, if not
assigned to the treatment, is T0i for never-takers, T0i exp(φ
(a)) for always-
takers and T0i exp(φ
(c)) for compliers. In other words, we have:
Ti(0) =

T0i exp(φ
(c)) for Ui = c,
T0i exp(φ
(a)) for Ui = a,
T0i for Ui = n.
(5.7.20)
The two expressions given in equation (5.7.16) imply that the model for
the potential outcome corresponding to being assigned to treatment Zi = 1,
Ti(1) can be written as follows:
Ti(1) = T0i exp(ζ + (ζ
(c) + φ(c))U
(c)
i + (ζ
(a) + φ(a))U
(a)
i ); (5.7.21)
which is reduced as
Ti(1) = T0i exp((ζ
(c) + φ(c))U
(c)
i + φ
(a)U
(a)
i ); (5.7.22)
under the exclusion restriction ζ = ζ(a) = 0.
Note that the AFT model makes quite strong assumptions: it effec-
tively models individual-level causal effects. For example, the model assumes
Ti(1)/Ti(0) = ζ
(c) for all compliers.
The relationships between the categorial variable Ui and the dummy vari-
ables (U
(c)
i , U
(a)
i ), which were given in Table 5.3, have been used in equations
(5.7.17) and (5.7.20). Given the values of the vector (U
(c)
i , U
(a)
i ) which corre-
sponds to the three different compliance type Ui (Table 5.3), equation (5.7.16)
can then be re-written:
Ti(1) =

T0i exp(ζ
(c) + φ(c)) for Ui = c;
T0i exp(φ
(a)) for Ui = a;
T0i for Ui = n;
(5.7.23)
and
Ti(0) =

T0i exp(φ
(c)) for Ui = c,
T0i exp(φ
(a)) for Ui = a,
T0i for Ui = n;
(5.7.24)
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where T0i ∼ D(θ(1)T , θ(2)T ).
5.7.3 The AFT model for censoring time
Similarly, for censoring time, the AFT model based on the potential outcomes
framework can be expressed as follows:
Ci(1) = Ci(0) exp(ξ + ξUUi),
Ci(0) = C0i exp(ϕUUi),
C0i ∼ D(θ(1)C , θ(2)C );
(5.7.25)
where C0i denotes censoring time of baseline, and D(θ
(1)
C , θ
(2)
C ) represents a
standard distribution, and θ
(1)
C , θ
(2)
C denote its associated parameters. For
example, if the standard distribution is given as a Weibull distribution, then
θ
(1)
C = ρ
0
C and θ
(2)
C = α
0
C .
By following the logic used in Section 5.7.2, we have the simplified AFT
model for censoring time, that is:
Ci(1) = C0i exp((ξ
(c) + ϕ(c))U
(c)
i + ϕ
(a)U
(a)
i ); (5.7.26)
under the exclusion restriction ξ = ξ(a) = 0.
Now equation (5.7.25) is equivalent to:
Ci(1) =

C0i exp(ξ
(c) + ϕ(c)) for Ui = c,
C0i exp(ϕ
(a)) for Ui = a,
C0i for Ui = n;
(5.7.27)
and
Ci(0) =

C0i exp(ϕ
(c)) for Ui = c,
C0i exp(ϕ
(a)) for Ui = a,
C0i for Ui = n;
(5.7.28)
where C0i ∼ D(θ(1)C , θ(2)C ).
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5.8 Parameter of interest θ in the specific models
The parameter θ = (θT,uz,θC,uz) is associated with failure and censoring
time distributions, respectively, corresponding to four subgroups each. In
total, θ includes 8× 2 = 16 components. This is true, as both a Weibull and
a log-normal distribution include two model parameters: the scale parameter
ρ and the shape parameter α for the Weibull; the mean µ and the variance
σ of the logarithms of survival outcome for the log-normal.
5.8.1 Parameter θ in the NIGN-WW model
Suppose failure time T0i, corresponding to the baseline, follows a Weibull
distribution with parameter ρ0T and α
0
T . By following Theorem 1 (proved
in Section 5.7.1), the parameter of most interest, θT = θT,uz, which is as-
sociated with the distributions of failure time and is specified in equation
(5.5.31) (the first four parameters corresponding to 4 possible subgroups),
has the following relationships with the parameters associated with the stan-
dard distribution for the baseline failure time, ρ0T and α
0
T , and the regression
coefficients in AFT model, which are:
θT,c1 = (ρT,c1, αT,c1); where ρT,c1 = ρ
0
T exp(ζ
(c) + φ(c)) and αT,c1 = α
0
T ,
θT,c0 = (ρT,c0, αT,c0); where ρT,c0 = ρ
0
T exp(φ
(c)) and αT,c0 = α
0
T ,
θT,n = (ρT,n, αT,n); where ρT,n = ρ
0
T and αT,n = α
0
T ,
θT,a = (ρT,a, αT,a); where ρT,a = ρ
0
T exp(φ
(a)) and αT,c0 = α
0
T .
(5.8.1)
Similarly, we suppose that the censoring time C0, corresponding to the
baseline, also follows a Weibull distribution with parameters ρ0C and α
0
C . In
this case, θC = θC,uz) can be specified as follows:
θC,c1 = (ρC,c1, αC,c1); where ρC,c1 = ρ
0
C exp(ξ
(c) + ϕ(c)) and αC,c1 = α
0
C ,
θC,c0 = (ρC,c0, αC,c0); where ρC,c0 = ρ
0
C exp(ϕ
(c)) and αC,c0 = α
0
C ,
θC,n = (ρC,n, αC,n); where ρC,n = ρ
0
C and αC,n = α
0
C ,
θC,a = (ρc,a, αC,a); where ρC,a = ρ
0
C exp(ϕ
(a)) and αC,c0 = α
0
C .
(5.8.2)
Consequently, the parameter θ given in equations (5.5.31) for the NIGN-
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WW model can be written as follows:
θ = (θT,uz,θC,uz),
= (ρT,c1, ρT,c0, ρT,n, ρT,a, αT , ρC,c1, ρC,c0, ρC,n, ρC,a, αC).
(5.8.3)
Here αT = α
0
T and αC = α
0
C denote the shape parameters of the Weibull
models associated with the failure and censoring times (which correspond
to the baseline), respectively. The number of components involved in θ
is now reduced from 16 to 10. Note that equations (5.8.1) and (5.8.2)
show that these scale parameters (corresponding to the four subgroups),
namely ρT,c1, ρT,c0, ρT,n, ρT,a, have been linked to ρ
0
T ( the scale parameter
in the Weibull distribution, associated with the failure time for the baseline),
through ζ(c), φ(c), φ(a), the regression coefficients in the AFT model. How-
ever, we use the scale parameters associated with the four subgroups, rather
than the AFT regression coefficients because at this stage, the former clearly
describe model parameters in which each subgroup (either for failure time
or censoring time) has its own scale parameter and these subgroups share
the same shape parameter. Recall that these four subgroups are as follows:
Subgroup 1 and Subgroup 2 consist of compliers who are all assigned to the
treated group (Ui = c and Zi = 1) or the control group (Ui = c and Zi = 0),
respectively; Subgroup 3 includes never-takers (Ui = a) only; and Subgroup
4 includes always-takers (Ui = a).
5.8.2 Parameter θ in the NIGN-LL model
As in the NIGN-WW model, the parameter θ given in equation (5.5.31) for
the NIGN-LL model can then be specified as follows:
θ = (θT,uz,θC,uz),
= (µT,c1, µT,c0, µT,n, µT,a, σT , µC,c1, µC,c0, µC,n, µC,a, σC).
(5.8.4)
The parameters σT and σC , given in equations (5.8.4), denote the vari-
ance parameters of the logarithm of the failure time log(T0i) (θ
(2)
T ) and the
logarithm of the censoring times log(C0i) (θ
(2)
C ) associated with the baseline
σT = σ
0
T and σC = σ
0
C (which were given in equations (5.7.16) and (5.7.25)).
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By following Theorem 1, given in Section 5.7.1, the parameters associated
with the failure time distribution satisfy the following equations:
θT,c1 = (µT,c1, σT,c1) where µT,c1 = µ
0
T + ζ
(c) + φ(c) and σT,c1 = σ
0
T ,
θT,c0 = (µT,c0, σT,c0) where µT,c0 = µ
0
T + φ
(c) and σT,c0 = σ
0
T ,
θT,n = (µT,n, σT,n) where µT,n = ρ
0
T and σT,n = σ
0
T ,
θT,a = (µT,a, σT,a) where µT,a = ρ
0
T + φ
(a) and σT,c0 = σ
0
T .
(5.8.5)
Parameters associated with the censoring time distribution have the fol-
lowing relationships:
θC,c1 = (µC,c1, σC,c1) where µC,c1 = µ
C
0 + ξ
(c) + ϕ(c) and σC,c1 = σ
0
C ,
θC,c0 = (µC,c0, σC,c0) where ρC,c0 = µ
C
0 + ϕ
(c) and σC,c0 = σ
0
C ,
θC,n = (µv,n, σC,n) where ρC,n = ρ
0
C and σC,n = σ
0
C ,
θC,a = (µC,a, σC,a) where ρC,a = ρ
0
C + ϕ
(a) and σC,c0 = σ
0
C .
(5.8.6)
Table 5.4 shows the parameters involved in the NIGN-WW and the
NIGN-LL models.
Table 5.4: Non-ignorable PPO-survival model parameter vectors.
Model name model parameter vector
NIGN-WW ρT,c1, ρT,c0, ρT,n, ρT,a, αT , ρC,c1, ρC,c0, ρC,n, ρC,a, αC
NIGN-LL µT,c1, µT,c0, µT,n, µT,a, σT , µC,c1, µC,c0, µC,n, µC,a, σC
5.9 Computational issues
Since the compliance type variable, Ui = u, is unobservable, those general
MLE methods are not easily implemented for the PPO-survival model. Alter-
natively, as mentioned before (Section 5.5.5), the EM algorithm (Dempster
et al., 1977) can be employed for our developments. Since the posterior prob-
abilities of compliance type Ui, Pr(Ui = u|(Ti, Ci)obs, Zi = z, Di(z) = d; θk),
have been involved in the Q-function, Q(θ,θk), (equation (5.5.33)), we need
to formulate it first before giving the specified Q-function Q(θ,θk).
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5.9.1 Posterior probabilities of compliance type Ui
For convenience of expression, we use P iac, P
i
nc, P
i
n and P
i
a to denote the
related posterior probabilities for non-censored Ri = 1 associated with the
following cases: (1) Zi = 1, Di(1) = 1; (2) Zi = 0, Di(0) = 0; (3) Zi = 1,
Di(1) = 0; and (4) Zi = 0, Di(0) = 1. Note that in the first two cases
given above, compliance type Ui can possible be two categories, say compliers
(Ui = c) or always-takers (Ui = a) for case (1) and compliers (Ui = c) or
never-takers (Ui = n) for case (2); while in case (3), compliance type Ui can
only be never-takers (Ui = n); and in case (4), compliance type Ui can only
be always-takers (Ui = a) (Table 5.1). This is because of the monotonicity
assumption, which excludes defiers.
So we define P iac, P
i
nc, P
i
n and P
i
a as follows:
P iac = Pr(Ui = c|(Ti(1), Ci(1))obs, Zi = 1, Di(1) = 1; θk) for Ri = 1 ,
P inc = Pr(Ui = c|(Ti(0), Ci(0))obs, Zi = 0, Di(0) = 0; θk) for Ri = 1 ,
P in = Pr(Ui = n|(Ti(1), Ci(1))obs, Zi = 1, Di(1) = 0; θk) for Ri = 1 ,
P ia = Pr(Ui = a|(Ti(0), Ci(0))obs, Zi = 0, Di(0) = 1; θk) for Ri = 1 .
(5.9.1)
Similarly, we use Qiac, Q
i
nc, Q
i
n and Q
i
a to denote the related posterior prob-
abilities for censored Ri = 0 associated with the aforementioned four cases,
they are defined as the following:
Qiac = Pr(Ui = c|(Ti(1), Ci(1))obs, Zi = 1, Di(1) = 1; θk) for Ri = 0 ,
Qinc = Pr(Ui = c|(Ti(0), Ci(0))obs, Zi = 0, Di(0) = 0; θk) for Ri = 0,
Qin = Pr(Ui = n|(Ti(1), Ci(1))obs, Zi = 1, Di(1) = 0; θk) for Ri = 0,
Qia = Pr(Ui = a|(Ti(0), Ci(0))obs, Zi = 0, Di(0) = 1; θk) for Ri = 0 .
(5.9.2)
Note that when the event occurs (non-censored and denoted by Ri = 1), the
observed data includes: failure time Ti(z), censoring time (Ci(z) > Ti(z)),
assigned treatment Zi = z and actual received treatment Di(z), and when
an individual is censored (denoted by Ri = 0), the observed data includes:
censoring time Ci(z), censored failure time Ti(z) > Ci(z), assigned treatment
Zi and actual received treatment Di(z).
The formulations for the posterior probabilities corresponding to the last
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two cases, namely Zi = 1, Di(1) = 0 ; and Zi = 0, Di(0) = 1, are as follows:
Pr(Ui = n |(Ti(1), Ci(1))obs, Zi = 1, Di = 0; θk) = 1; for Ri = 1;
Pr(Ui = a |(Ti(0), Ci(0))obs, Zi = 0, Di = 1; θk) = 1; for Ri = 1;
Pr(Ui = n |(Ti(1), Ci(1))obs, Zi = 1, Di = 0; θk) = 1; for Ri = 0;
Pr(Ui = a |(Ti(0), Ci(0))obs, Zi = 0, Di = 1; θk) = 1; for Ri = 0.
(5.9.3)
This is true, because no defiers exist and by the definition of compliance
type Ui, we know that an individual is a never-taker if he/she is assigned to
the treatment group Zi = 1 but does not receive the treatment Di(1) = 0 or
is an always-taker if the individual is assigned to the control group Zi = 0
but for some reason does receive the treatment.
Equation (5.9.3) gives the following equivalences:
P in = 1 for i ∈ C(1, 0, 1),
Qin = 1 for i ∈ C(1, 0, 0),
P ia = 1 for i ∈ C(0, 1, 1),
Qia = 1 for i ∈ C(0, 1, 0).
(5.9.4)
where C(z, d, r) denotes the subset of individuals, which is defined by the
following: C(z, d, r) = {i : Zi = z, Di = d, Ri = r} for all z, d, r ∈ {1, 0}.
Now, we formulate the posterior probability of compliance type Ui for the first
two cases, i.e. Zi = 1 and Di(1) = 1, and Zi = 0 and Di(0) = 0. Since both
failure and censoring times are involved in the non-ignorable PPO-survival
model, so too are their posterior probabilities. As per Bayes’ theorem, these
can be written as the formulae given in equations (5.9.5) and (5.9.6) (see
next page). For the non-ignorable PPO-survival model, P iac, P
i
nc, Q
i
ac and
Qinc can then be written as the equivalences shown in equation (5.9.7) on
page 108.
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For convenience, we use Wi(u,θ
k) to denote the posterior probability
of compliance type Pr(Ui = u|(Ti, Ci)obs, Zi = z,Di(z) = d,θk) given the
observed data (and parameter values) for the non-ignorable PPO-survival
model. That is:
Wi(u,θ
k) = Pr(Ui = u|(Ti, Ci)obs, Zi = z,Di(z) = d;θk), (5.9.8)
where (Ti, Ci)
obs is same as given in equation (5.5.32), and indicates the
observable part of survival outcomes (Ti, Ci). (Ti, Ci)
obs is equivalent to
T obsi = Ti(z) given Zi = z, when Ri = 1; (Ti, Ci)
obs is equivalent to Cobsi =
Ci(z) given Zi = z, when Ri = 0; and θ
k represents the given value of the
relevant model parameters, the components of which are:
(ρT,c1, ρT,c0, ρT,n, ρT,a, α, ρC,c1, ρC,c0, ρC,n, ρC,a, αC) (5.9.9)
for the NIGN-WW model and
(µT,c1, µT,c0, µT,n, µT,a, σ, µC,c1, µC,c0, µC,n, µC,a, σc) (5.9.10)
for the NIGN-LL model.
The posterior probabilityWi(u, θ
k) of the ith individual can then be writ-
ten as follows:
Wi(u,θ
k) =

(P iac)
I{Ui=c}(1− P iac);I{Ui=a} for i ∈ C(1, 1, 1),
(P inc)
I{Ui=c}(1− P inc);I{Ui=n} for i ∈ C(0, 0, 1),
(Qiac)
I{Ui=c}(1−Qiac);I{Ui=a} for i ∈ C(1, 1, 0),
(Qinc)
I{Ui=c}(1−Qinc);I{Ui=n} for i ∈ C(0, 0, 0),
P in = 1; for i ∈ C(1, 0, 1),
Qin = 1; for i ∈ C(1, 0, 0),
P ia = 1; for i ∈ C(0, 1, 1),
Qia = 1; for i ∈ C(0, 1, 0);
(5.9.11)
where I{} is an indicator function, and P iac, P inc, Qiac and Qinc denote the
posterior probabilities for the specific cases, given by equation (5.9.7) for the
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non-ignorable PPO-survival model. Recall that C(z, d, r) denotes the subset
of individuals C(z, d, r) = {i : Zi = z, Di = d, Ri = r} for all z, d, r ∈ {1, 0}.
5.9.2 Structures of the expectation function Q(θ,θk)
After defining the posterior probability, Wi(u,θ
k), which is given in equation
(5.9.11), the expectation equation, Q-function Q(θ,θk) specified in equation
(5.5.33) can then be re-written as:
Qi(θ,θk) =
∑
u∈{c,n,a}
Wi(u,θ
k){log(lF (θ)}
=
∑
u∈{c,n,a}
Wi(u,θ
k){log(l(θ, u)},
(5.9.12)
where lF (θ) is given in equation (5.5.15).
After substituting equations (5.9.7), (5.9.11) and (5.5.15) into equation
(5.9.12), Q(θ,θk) can be specified as in equation (5.9.13) overleaf.
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5.9.3 Maximization of the expectation function Q(θ,θk)
As stated in Section 5.5.5, the M-step aims to maximise the expectation
function given in equation (5.9.13). To realise this goal, the score equation
(McLachlan & Krishnan, 1997; Casella & Berger, 2002) is often used in the
M-step. Specifically, for the ith individual, we take the first partial derivative
of Qi(θ, θk), with respect to the parameter θ in equation (5.9.13) for the non-
ignorable PPO model. Then the ith score equation is:
Sobsi (θ) =
∂
∂θ
Qi(θ,θk) =
∑
u∈{c,n,a}
Wi(u,θ
k)
∂
∂θ
logli(θ, u). (5.9.14)
As before, let Si,θ(u,θ) denote
∂
∂θ
logli(θ, u). Then the score equation for
the ith individual can be expressed as:
Sobsi (θ) =
∑
u
Wi(u, θ
k)Si,θ(u,θ). (5.9.15)
All parameters can then be estimated simultaneously by solving:
n∑
i
Sobsi (θ) = 0. (5.9.16)
Let θ(k+1) denote the solution of equation (5.9.16). We then substitute
θ(k) in Q(θ, θ(k)) with θ(k+1) and repeat the M-step until convergence.
The models proposed in this thesis use a built-in function in MATLAB
(7.4.0, R2007a) (Higham & Higham, 2000). This function, fminsearch,
is based on the Nelder-Mead method (Lagarias et al., 1998) for multidi-
mensional unconstrained minimisation. We use it to minimise the negative
expectation function −Q(θ, θ(k)), which is equivalent to maximising the
expectation function Q(θ, θ(k)).
5.9.4 Estimation of the standard errors
The standard error for the estimated model parameter
The EM algorithm relies only on the convergence of iterative procedures, in
which no gradient matrices are derived. As such, the EM algorithm does
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not provide the information matrix required for traditional calculation of the
asymptotic variance-covariance matrix of the MLEs, from either the expected
information matrix or the observed information matrix (OIM). Consequently,
no standard errors of the MLEs can be obtained, even after possible adapta-
tion of the EM algorithm.
Louis (1982), however, proposed an approach for calculating the observed
information matrix (OIM) when the EM algorithm is used to find MLEs for
so-called incomplete data problems. Louis’s approach (Louis, 1982) only
requires computation of the complete-data gradient vector or computation
of the second derivative matrix, (which is not associated with the incomplete-
data likelihood function). After obtaining the OIM, the covariance matrix
can then be calculated easily. Only the inverse of the OIM is then required.
The standard error of the MLEs vectors can thus be obtained easily, in that
the standard error is the square root of the diagonals of the covariance matrix,
where the latter is the inverse of the observed information matrix (OIM).
Louis’s method1
Let Datafull and Dataobs denote the complete (full) and incomplete (ob-
served) data, respectively. The former includes the observed time (T, C)obs,
(which is equivalent to (Y (z), R(z)) in survival analysis, where Y (z) =
min(T (z), C(z)) and R(z) is the censoring indicator), assigned treatment
Z = z, received treatment D(z) and the compliance type U . Thereby
Datafull = ((T, C)
obs, Z = z, D(z), U). As compliance type U is unobserv-
able, we have Dataobs = ((T, C)
obs, Z = z, D(z)). By following equation
(3.3) in Louis (1982), the observed information matrix (OIM), Iobs = I(θˆ),
which can be viewed as the matrix at the MLEs, where matrix I can be ex-
pressed in two parts: the conditional expected full data OIM, Ifull, and the
expected information for the conditional distribution of the complete data
Ifull|obs. This is represented as follows:
Iobs = I(θˆ) = Ifull(θˆ)− Ifull|obs(θˆ). (5.9.17)
1Equation (3.2′) of Louis (1982) is not strictly correct. We believe that the rule of
non-exchangeable vector order in the product was ignored. Details of our correction are
given in Appendix A.
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Under the independent and identically distributed (i.i.d) assumption,
these two matrices Ifull and Ifull|obs can be specified as:
Ifull = Eu{−
n∑
i=1
∂2
∂θ2
logLi(θ, u)|(Ti, Ci)obs, Zi = z, Di(z) = d, Ui = u}
(5.9.18)
Ifull|obs
=
∑
i
Eu
{(
∂
∂θ
loglFi (θ)
)T ( ∂
∂θ
loglFi (θ)
)
|(Ti, Ci)obs, Zi = z, Di(z) = d, Ui = u
}
+
∑
i6=j
 Eu
(
∂
∂θ logl
F
i (θ)|(Ti, Ci)obs, Zi = z, Di(z) = d, Ui = u
)T ×
Eu
(
∂
∂θ logl
F
j (θ)|(Ti, Ci)obs, Zi = z, Di(z) = d, Ui = u
) 
(5.9.19)
where T denotes transpose. Consequently, the observed information matrix
Iobs can be expressed
2, after correcting the classical method of Louis (1982)
as:
Iobs = I(θˆ)
=
n∑
i=1
Eu
{
− ∂
2
∂θ2
(
logli(θ, u)|(Ti, Ci)obs, Zi = z, Di(z) = d
)}
|θ=θˆ
−
∑
i
Eu
{(
∂
∂θ
logli(θ, u)
)T ( ∂
∂θ
logli(θ, u)
)
|(Ti, Ci)obs, Zi = z, Di(z) = d
}
|θ=θˆ
−
∑
i6=j
{
Eu
(
∂
∂θ logli(θ, u)|(Ti, Ci)obs, Zi = z, Di(z) = d
)T ×
Eu
(
∂
∂θ loglj(θ, u)|(Tj , Cj)obs, Zj = z, Dj(z) = d
) }
|θ=θˆ
.
(5.9.20)
Equation (5.9.20) (also see equation (A.4) in Appendix A) guarantees that the
OIM is symmetric. (Details are given on page 115.) As the inverse of Iobs is the
asymptotic variance-covariance matrix of the MLEs, θˆ, this can be denoted as
V(θˆ) = I−1(θˆ). Its diagonal vector is the variance vector associated with each of
the components of βˆ and is denoted by SEθˆ. The standard error of θˆ can then
be calculated directly by taking the square root of σ2
θˆ
, where σ2
θˆ
= {V(θˆ)}ii (i =
1, 2, · · · , p), for p parameters.
2This equation can be regarded as our correction of equation (3.2’) of Louis (1982).
Louis’s subscripts should specify that i 6= j rather than i < j.
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The observed information matrix (OIM)
Note that the first term in equation (5.9.17) is equivalent to the second order
partial derivative of Q-function Q(θ,θk), which can be written as ∂
2Q(θ,θ(k))
∂θ2
and
θ is a interest parameter vector with length p. If we write θ = (θ1, θ2, . . . , θp), the
element at the ith row and the jth column in the matrix ∂
2Q(θ,θ(k))
∂θ2
, the second
order derivative matrix of Q-function Q(θ,θ(k)) with respect to the ith and jth
components of the interest parameter θ, θi and θj , can be written as follows:
∂2Q(θ,θ(k))
∂θ2
=
[
∂2Q(θ,θ(k))
∂θi∂θj
]
ij
for i and j from 1 to p. (5.9.21)
Since in the PPO-survival model, the interest parameter vector θ, given in
equation (5.5.31), consists of the parameters associated with the distributions of
failure and censoring times for three subgroups. This leads to the fact of that
majority of elements in the matrix ∂
2Q(θ,θ(k))
∂θ2
are zeros. For instance, the second
order partial derivative of the Q-function,Q(θ,θ(k)), ∂
2Q(θ,θ(k))
∂θ2
with respect to
two scale parameters θ1 = ρT,c1 and θ2 = ρT,c0 (in Weibull PPO-survival model)
is zero. That is:
∂2Q(θ,θ(k))
∂θi∂θj
=
∂2Q(θ,θ(k))
∂θ1∂θ2
= 0 (5.9.22)
As no an explicit relationship exists between θ1 and θ2, which represent the scale
parameter from two different subgroups here.
Even though in the same subgroup, however, with respect to the parameters
associated with the distributions of failure and censoring times, ∂
2Q(θ,θ(k))
∂θi∂θj
can also
be zero. For example, let i = 1 and j = 5, in Weibull PPO-survival model we have
θ1 = ρT,c1 and θ5 = ρC,c1, where
∂2Q(θ,θ(k))
∂θ1∂θ5
= 0 always holds. This is because there
is not an explicit relationship between these two parameters ρT,c1 and ρC,c1 which
are from two different distributions. Recall that ρT,c1 denotes the scale parameter
of Weibull for failure time in and ρC,c1 denotes the scale parameter of Weibull for
censoring time in subgroup1).
Therefore, in the PPO-survival model (including both Weibull and Log-normal
form), the first term of equation (5.9.20) can be simplified directly without know-
ing the estimated value of parameter θˆ. The simplified form of the matrix is given
in Table 5.5 (page 116) where θi and θj denote any components of parameter
θ, for the specific model, say the NIGN-WW or the NIGN-LL models, θ is de-
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fined in Table 5.4 (on page 104). Note that Table 5.5 shows that in the matrix,
[∂
2Q(θ,θ(k))
∂θi∂θj
]10×10, only few of elements are not zero (denoted by ∗ in the table)
which can be calculated directly through the standard likelihood function. In this
thesis, the standard likelihood function were given as either Weibull or log-normal
form.
Table 5.5: The patten of second order partial derivative matrix of Q(θ,θ(k)).
∂2Q(θ,θ(k))
∂θi∂θj
θ1 θ2 θ3 θ4 θ5 θ6 θ7 θ8 θ9 θ10
θ1 ∗ 0 0 0 ∗ 0 0 0 0 0
θ2 0 ∗ 0 0 ∗ 0 0 0 0 0
θ3 0 0 ∗ 0 ∗ 0 0 0 0 0
θ4 0 0 0 ∗ ∗ 0 0 0 0 0
θ5 ∗ ∗ ∗ ∗ ∗ 0 0 0 0 0
θ6 0 0 0 0 0 ∗ 0 0 0 ∗
θ7 0 0 0 0 0 0 ∗ 0 0 ∗
θ8 0 0 0 0 0 0 0 ∗ 0 ∗
θ9 0 0 0 0 0 0 0 0 ∗ ∗
θ10 0 0 0 0 0 ∗ ∗ ∗ ∗ ∗
All these components of θ are defined in Table 5.4 on page 104.
From Table 5.5, it is easy to see that [∂
2Q(θ,θ(k))
∂θi∂θj
]10×10, the second order partial
derivative matrix of Q-function Q(θ,θ(k)) is a symmetric matrix. In fact, the sec-
ond term in equation (5.9.20) also denotes a symmetric matrix as it is a summation
of a product of a vector and it’s transpose; the third term in the same equation
represents a symmetric too, even though two different vectors were involved in the
product term. This is because that the later summation is taken over on i 6= j
only, which means that those single matrix that satisfied i = j was not included
in the summation. Therefore, the OIM, defined by equation (5.9.20) is really a
symmetric matrix as their three components are all symmetric matrices.
The standard error (SE) of ĈACE(t) and ÂCE(t)
As noted in Chapter 3, estimating CACE(t) and ACE(t) rather than estimat-
ing the model parameters θT,uz may be significantly more valuable and more in-
terpretable. The standard errors corresponding to the estimated ĈACE(t) and
ÂCE(t) have not been derived to date, to the best of the author’s knowledge.
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We now consider the derivation of formulae for calculating the standard errors
of the estimated CACE(t) and ACE(t) via the estimated model parameters θT,uz.
Recall that CACE(t) was defined as the difference in survival values between
compliers in the treated group and the control group (Section 3.3). By following
the notation of the customary survival function (for subgroups), CACE(t) can
thus be re-written as follows:
CACE(t) = Sc1(t;θT,c1)− Sc0(t;θT,c0). (5.9.23)
According to the property of variance of linear combinations (Theorem 4.5.6,
p.171, Casella & Berger (2002)), the variance of CACE(t) can be easily expressed
as:
V ar(CACE(t)) = V ar(Sc1(t;θT,c1)) + V ar(Sc0(t;θT,c0))
− 2Cov(Sc1(t;θT,c1), Sc0(t;θT,c0)),
(5.9.24)
where Scz(t;θT,cz) (for z = 1 or 0) denotes the survival function at time t associated
with the subgroup of individuals who have compliance type Ui = c and who have
been assigned into the group of Zi = z (z = 1 for the treated group and z = 0 for
the control group).
Note that except for the exponential distribution, most common parametric
models for survival outcomes, such as the Weibull, Gamma, log-normal, and the
log-logistic models have two parameters (Klein, 1997; Ibrahim et al., 2001). Let
θT,uz = (θ
(1)
T,uz, θ
(2)
T,uz), and we treat V ar(Suz(t;θT,uz)) as the variance of a function
of two variables (θ(1)T,uz, θ
(2)
T,uz). Then the Cov(Sc1(t;θT,c1), Sc0(t;θT,c0)) has to be
viewed as the covariance function of two variables (θ(1)T,uz, θ
(2)
T,uz). As such, we deal
with the variance and covariance of functions of multiple random variables. The
δ method (Klein, 1997) (see below) can then be used to derive formulae for such
approximations.
The δ method
The δ method, also known as the method of statistical differential (Klein, 1997),
is based on a Taylor series expansion of a continuous function of the MLEs of a
vector of parameters (θ(1)T,uz, θ
(2)
T,uz) for u = c and v = 1 or 0. For convenience, let
f(x, y) denote a function of two variables, e.g. x and y; and suppose that at the
point (x0, y0), the first partial derivative of f(x, y) with respect to x and y exist.
These are denoted by f ′x(x0, y0) and f ′y(x0, y0). Then the first order Taylor series
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expansion at the point (x0, y0) has the form as follows:
f(x, y) = f(x0, y0) + f ′x(x0, y0)(x− x0) + f ′y(x0, y0)(y − y0). (5.9.25)
If x and y are both random variables with mean values, x¯ and y¯, then setting
x0 = x¯ and y0 = y¯, allows equation (5.9.25) to be expressed as:
f(x, y) = f(x¯, y¯) + f ′x(x¯, y¯)(x− x¯) + f ′y(x¯, y¯)(y − y¯). (5.9.26)
Variance of the function of two variables
From equation (5.9.26), it is straightforward to observe that the function of two
random variables, f(x, y), has the mean value f(x¯, y¯), as the last two terms in
equation (5.9.26) are zeros. By following the properties of variance (Theorem
4.5.6, p.171 Casella & Berger (2002)), we have:
V ar(f(x, y)) = f ′x(x¯, y¯)
2V ar(x) + f ′y(x¯, y¯)
2V ar(y)
+ 2f ′x(x¯, y¯)f
′
y(x¯, y¯)Cov(x, y),
(5.9.27)
because variances for constants are zeros, we have V ar(f(x¯, y¯)) = 0, V ar(x¯) = 0
and V ar(y¯) = 0.
By following equation (5.9.27), we can write:
V ar(Suz(t;θT,uz)) = V ar(Suz(t; θ
(1)
T,uz, θ
(2)
T,uz))
=
∂Suz(t; θ(1)T,uz, θ(2)T,uz)
∂θ
(1)
T,uz
2
(θ̂
(1)
T,uz ,θ̂
(2)
T,uz)
var(θ(1)T,uz)
+
∂Suz(t; θ(1)T,uz, θ(2)T,uz)
∂θ
(2)
T,uz
2
(θ̂
(1)
T,uz ,θ̂
(2)
T,uz)
var(θ(2)T,uz) (5.9.28)
+
∂Suz(t; θ(1)T,uz, θ(2)T,uz)
∂θ
(1)
T,uz

(θ̂
(1)
T,uz ,θ̂
(2)
T,uz)
∂Suz(t; θ(1)T,uz, θ(2)T,uz)
∂θ
(2)
T,uz

(θ̂
(1)
T,uz ,θ̂
(2)
T,uz)
cov(θ(1)T,uz, θ
(2)
T,uz).
The approximate formula of V ar(Su(v, t; θ
(1)
T,uz, θ
(2)
T,uz)), the variance of the survival
function, can then be expressed by equation (5.9.28).
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Covariance of functions of two variables
Similarly, if h(u, v) denotes another function of two random variables u and v,
with mean values u¯ and v¯, then the function h(u, v) has a mean value h(u¯, v¯).
By the definition of covariance, the covariance between f(x, y) and h(u, v) is
then the expectation of the product of two factors (f(x, y)− f(x¯, y¯)) and (h(u, v)− h(u¯, v¯));
that is:
Cov(f(x, y), h(u, v)) = E{(f(x, y)− f(x¯, y¯))(h(u, v)− h(u¯, v¯))}. (5.9.29)
By first order Taylor series expansion, equation (5.9.29) can be expressed by
first order partial derivative values at the mean value points, i.e.:
Cov(f(x, y), h(u, v))
= E{f ′x(x¯, y¯)(x− x¯) + f ′y(x¯, y¯)(y − y¯))(h′u(u¯, v¯)(u− u¯) + h′v(u¯, v¯)(v − v¯))}.
(5.9.30)
Furthermore, the covariance between f(x, y) and h(u, v) can be simplified to
Cov(f(x, y), h(u, v)) = f ′x(x¯, y¯)h
′
u(u¯, v¯)Cov(x, u) + f
′
y(x¯, y¯)h
′
u(u¯, v¯)Cov(y, u)
+ f ′x(x¯, y¯)h
′
v(u¯, v¯)Cov(x, v) + f
′
y(x¯, y¯)h
′
v(u¯, v¯)Cov(y, v).
(5.9.31)
By following equation (5.9.31), the covariance between survival functions, say
Sc1(t; θT,c1) and Sc0(t; θT,c0), can then be expressed as follows:
Cov(Sc1(t;θT,c1), Sc0(t;θT,c0)) =∂Sc1(t; θ(1)T,c1, θ(2)T,c1)
∂θ
(1)
T,c1

(θ̂
(1)
T,c1,θ̂
(2)
T,c1)
∂Sc0(t; θ(1)T,c0, θ(2)T,c0)
∂θ
(1)
T,c0

(θ̂
(1)
T,c0,θ̂
(2)
T,c0)
cov(θ(1)T,c1, θ
(1)
T,c0)
+
∂Sc1(t; θ(1)T,c1, θ(2)T,c1)
∂θ
(2)
T,c1

(θ̂
(1)
T,c1,θ̂
(2)
T,c1)
∂Sc0(t; θ(1)T,c0, θ(2)T,c0)
∂θ
(1)
T,c0

(θ̂
(1)
T,c0,θ̂
(2)
T,c0)
cov(θ(2)T,c1, θ
(1)
T,c0)
+
∂Sc1(t; θ(1)T,c1, θ(2)T,c1)
∂θ
(1)
T,c1

(θ̂
(1)
T,c1,θ̂
(2)
T,c1)
∂Sc0(t; θ(1)T,c0, θ(2)T,c0)
∂θ
(2)
T,c0

(θ̂
(1)
T,c0,θ̂
(2)
T,c0)
cov(θ(1)T,c1, θ
(2)
T,c0)
+
∂Sc1(t; θ(1)T,c1, θ(2)T,c1)
∂θ
(2)
T,c1

(θ̂
(1)
T,c1,θ̂
(2)
T,c1)
∂Sc0(t; θ(1)T,c0, θ(2)T,c0)
∂θ
(2)
T,c0

(θ̂
(1)
T,c0,θ̂
(2)
T,c0)
cov(θ(2)T,c1, θ
(2)
T,c0).
(5.9.32)
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Equations (5.9.28) and (5.9.32) both can be simplified via vector operation as
follows:
V ar (Scz(t;θT,cz))
=
∂Scz(t;θT,cz)
∂θ
(1)
T,cz
,
∂Scz(t;θT,cz)
∂θ
(2)
T,cz
Σ1
∂Scz(t; θT,cz)
∂θ
(1)
T,cz
,
∂Scz(t; θT,cz)
∂θ
(2)
T,cz
T , (5.9.33)
and
Cov (Sc1(t; θT,c1), Sc0(t; θT,c0))
=
∂Sc1(t; θT,c1)
∂θ
(1)
T,c1
,
∂Sc1(t; θT,c1)
∂θ
(2)
T,c1
Σ2
∂Sc0(t; θT,c0)
∂θ
(1)
T,c0
,
∂Sc0(t; θT,c0)
∂θ
(2)
T,c0
 ;T (5.9.34)
where Σ1 and Σ2 represent the covariance matrix of all relevant parameters. More
specifically, Σ1 and Σ2 can be written as:
Σ1 =
(
var(θ(1)T,cz) cov(θ
(1)
T,cz, θ
(2)
T,cz)
cov(θ(2)T,cz, θ
(1)
T,cz) var(θ
(2)
T,cz)
)
(5.9.35)
and
Σ2 =
(
cov(θ(1)T,c1, θ
(1)
T,c0) cov(θ
(1)
T,c1, θ
(2)
T,c0)
cov(θ(2)T,c1, θ
(1)
T,c0) cov(θ
(2)
T,c1, θ
(2)
T,c0)
)
. (5.9.36)
Then the standard error of CACE(t) can be calculated by taking the square
root of the variance:
SECACE(t) =
√
V ar(CACE(t)). (5.9.37)
Since we have ACE(t) = picCACE(t), the variance of ACE(t) can then be
calculated by the following equation:
V ar(ACE(t)) = V ar(picCACE(t))
= V ar (picSc1(t; θT,c1)− picSc0(t; θT,c0))
= V ar (picSc1(t; θT,c1)) + V ar (picSc0(t; θT,c0))
− 2cov(picSc1(t; θT,c1), picSc0(t; θT,c0)).
(5.9.38)
Note that as θT,c1 = (θ1T,c1, θ
2
T,c1) and θT,c0 = (θ
1
T,c0, θ
2
T,c0), the two terms in the
last line of equation (5.9.38), namely picSc1(t; θT,c1) and picSc0(t; θT,c0), can both be
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viewed as functions of three variables, which are (pic, θ1T,c1, θ
2
T,c1) (in picSc1(t; θT,c1))
and (pic, θ1T,c0, θ
2
T,c0) in picSc0(t; θT,c0).
By following the logic used to derive the formulations of the variance (equation
(5.9.33)) and covariance (equation (5.9.34)) of the survival function, (Suz(t; θT,uz)
(for z = 1 and 0)), the variance of picSuz(t; θT,uz), denoted by V ar(picSuz(t; θT,uz)),
can then be expressed as follows:
V ar (picScz(t;θT,uz))
=

[
Scz(t; θT,cz), pic
∂Scz(t;θT,cz)
∂θ
(1)
T,cz
, pic
∂Scz(t;θT,cz)
∂θ
(2)
T,cz
]
Σ3[
Scz(t; θT,cz), pic
∂Scz(t|θT,cz)
∂θ
(1)
T,cz
, pic
∂Scz(t;θT,cz)
∂θ
(2)
T,cz
]T
,

(5.9.39)
where Σ3 is given by:
Σ3 =
 var(θ
(1)
T,cz) cov(θ
(1)
T,cz, θ
(2)
T,cz) cov(θ
(1)
T,cz, pic)
cov(θ(2)T,cz, θ
(1)
T,cz) var(θ
(2)
T,cz) cov(θ
(2)
T,cz, pic)
cov(pic, θ
(1)
T,cz) cov(pic, θ
(2)
T,cz) var(pic, pic)
 . (5.9.40)
Thus the covariance matrix of pic and θT,cz and the covariance of these products
cov(picSc1(t), picSc0(t)) can be written as:
Cov (picSc1(t; θT,c1), picSc0(t; θT,c0))
=

[
pic
∂Sc1(t;θT,c1)
∂θ
(1)
T,c1
, pic
∂Sc1(t;θT,c1)
∂θ
(2)
T,c1
, Sc1(t)
]
Σ4[
pic
∂Sc0(t;θT,c0)
∂θ
(1)
T,c0
, pic
∂Sc0(t;θT,c0)
∂θ
(2)
T,c0
, Sc0(t)
]T

(5.9.41)
where Σ4, the covariance matrix of relevant parameters, is given by:
Σ4 =
 cov(θ
(1)
T,c1, θ
(1)
T,c0) cov(θ
(1)
T,c1, θ
(2)
T,c0) cov(θ
(1)
T,c1, pic)
cov(θ(2)T,c1, θ
(1)
T,c0) cov(θ
(2)
T,c1, θ
(2)
T,c0) cov(θ
(2)
T,c1, pic)
cov(pic, θ
(1)
T,c0) cov(pic, θ
(2)
T,c0) var(pic, pic)
 . (5.9.42)
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Therefore, (5.9.38) can be re-written as:
V ar(ACE(t))
=

[
pic
∂Sc1(t;θT,c1)
∂θ
(1)
T,c1
, pic
∂Sc1(t;θT,c1)
∂θ
(2)
T,c1
, Sc1(t; θT,c1)
]
Σ31
[
pic
∂Sc1(t;θT,c1)
∂θ
(1)
T,c1
, pic
∂Sc1(t;θT,c1)
∂θ
(2)
T,c1
, Sc1(t; θT,c1)
]T
+
[
pic
∂Sc0(t;θT,c0)
∂θ
(1)
T,c0
, pic
∂Sc0(t;θT,c0)
∂θ
(2)
T,c0
, Sc0(t; θT,c0)
]
Σ30
[
pic
∂Sc0(t|θT,c0)
∂θ
(1)
T,c0
, pic
∂Sc0(t;θT,c0)
∂θ
(2)
T,c0
, Sc0(t; θT,c0)
]T
−2
[
pic
∂Sc1(t;θT,c1)
∂θ
(1)
T,c1
, pic
∂Sc1(t;θT,c1)
∂θ
(2)
T,c1
, Sc1(t; θT,c1)
]
Σ4
[
pic
∂Sc0(t;θT,c0)
∂θ
(1)
T,c0
, pic
∂Sc0(t;θT,c0)
∂θ
(2)
T,c0
, Sc0(t; θT,c0)
]T

(5.9.43)
where Σ31 and Σ30 are given by equation (5.9.40) with z = 1 and 0, respec-
tively. i.e.:
Σ31 =
 var(θ
(1)
T,c1) cov(θ
(1)
T,c1, θ
(2)
T,c1) cov(θ
(1)
T,c1, pic)
cov(θ
(2)
T,c1, θ
(1)
T,c1) var(θ
(2)
T,c1) cov(θ
(2)
T,c1, pic)
cov(pic, θ
(1)
T,c1) cov(pic, θ
(2)
T,c1) var(pic, pic)
 (5.9.44)
and
Σ30 =
 var(θ
(1)
T,c0) cov(θ
(1)
T,c0, θ
(2)
T,c0) cov(θ
(1)
T,c0, pic)
cov(θ
(2)
T,c1, θ
(1)
T,c0) var(θ
(2)
T,c0) cov(θ
(2)
T,c0, pic)
cov(pic, θ
(1)
T,c0) cov(pic, θ
(2)
T,c0) var(pic, pic)
 . (5.9.45)
Recall that Σ4 is given in (5.9.42). All these covariance matrices are then
available for our PPO-survival models. Consequently, it is straightforward to
obtain the standard error of ACE(t) by taking the square root of its variance
V ar(ACE(t), that is:
SEACE(t) =
√
V ar(ACE(t)). (5.9.46)
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5.10 Ignorable censoring mechanism PPO-survival model (I)
When the censoring mechanism is ignorable, as in the scenario when censor-
ing time and failure time are entirely independent (Section 3.1.4) or when
the non-informative censoring assumption is satisfied (Loeys & Goetghebeur,
2003), the PPO-survival model can then be simplified to the ignorable para-
metric potential-outcome (PPO) survival model, namely the ignorable PPO-
survival model. Note that the assumption of no censoring prior to the end
of the follow-up leads to the fact that no censoring distribution exist, as
censoring times are a constant rather than a random variable (Section 4.3.1).
This implies that under the latter assumption, even though a constant
censoring time does not mean its censoring mechanism is ignorable, we can
still view it as a special case of the ignorable PPO-survival model, because
no censoring distribution is involved.
So we summary the assumptions required for the ignorable PPO-survival
model here:
5.10.1 Assumptions
1. The stable unit treatment value assumption (SUTVA) (Rubin, 1986;
Imbens & Rubin, 1997; Peng et al., 2004): this assumes that the poten-
tial outcomes of each individual are unrelated to the treatment status
of other individuals.
2. Random assignment: this assumes that each individual has been as-
signed randomly to a treatment group.
3. Exclusion restriction: this assumes that the assigned treatment has an
effect on the outcome only through its effect on the received treatment.
4. Monotonicity: the actual received treatment Di(z) is a monotone func-
tion with respect to the potential treatment levels, 1 for being in the
treatment group and 0 for being in the control group.
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5. Non-informative censoring3: the failure times and censoring times are
independent.
5.10.2 The likelihood function for the complete data
Under the assumptions given above, the ignorable PPO-survival model can
be set up by following the logic of deriving the non-ignorable PPO-survival
model. However, after obtaining the non-ignorable PPO-survival model, the
relevant likelihood function can be easily obtained from the formulation of
the likelihood structure of the non-ignorable PPO-survival model. In short
we just need to remove the parts that are associated with censoring time Ci
from equation (5.5.9). We then have:
Li∈{i:Zi=z,Di(z)=d}(β;u)
=
[
f iu(z, t; θT,uz)
]Ri [Siuz(v, t; θT,uz)]1−Ri piu,zd
=liθ(θ, u)l
i
pi(pi, u).
(5.10.1)
Therefore, for the ignorable PPO-survival model, the likelihood formula-
tion with respect to θ for complete data, can then be expressed by equation
(5.10.2) below:
LF (β) = L(β, u) =
∏
i
Li(β, u)
=

∏
i∈{i:Ui=c,Zi=1,Di(1)=1}F ic,11(θT,c1)pic,11∏
i∈{i:Ui=a,Zi=1,Di(1)=1}F ia,11(θT,a1)pia,11∏
i∈{i:Ui=c,Zi=0,D(0)=0}F ic,00(θT,c0)pic,00∏
i∈{i:Ui=n,Zi=0,Di(0)=0}F in,00(θT,n0)pin,00∏
i∈{i:Ui=n,Zi=1,D(0)=0}F in,10(θT,n0)pin,10∏
i∈{i:Ui=a,Zi=0,D(0)=1}F ia,01(θT,a1)pia,01;
(5.10.2)
3For our ignorable PPO-survival model, the non-informative censoring assumption can
be replaced by the assumption of Censored at the end of the follow-up only, or No censoring
prior the end of the follow-up or No loss to follow-up, as under these two assumptions, the
model formulae are same.
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where F iu,zd(θT,uz) is given by the following formulation:
F iu,zd(θT,uz) =
[
f iu(v, t; θT,uz)
]Ri [Siu(v, t; θT,uz)]1−Ri . (5.10.3)
Note that this is dissimilar to equation (5.5.12), which pertains to the more
complex non-ignorable PPO-survival model.
5.10.3 The likelihood function for the incomplete data
As stated in Section 5.5.3, compliance type Ui can be viewed as a variable
with missing data. Thus we use summation, rather than integration in equa-
tion (5.10.2) with respect to compliance type Ui = u, as it is a variable with
up to three categories (u ∈ {c, n, a}). We then have the form of the likelihood
function for the incomplete data for the ignorable PPO-survival model. This
is:
L(β) =
∑
u∈{c,n,a}
L(β, u)
=

∏
i∈A(1,1)
{(F ic,11(θT,c1)pic,11)+ (F ia,11(θT,a1)pia,11)}∏
i∈A(0,0)
{(F ic,00(θT,c0)pic,00)+ (F in,00(θT,n0)pin,00)}∏
i∈A(1,0)
(F in,10(θT,n0)pin,10)∏i∈A(0,1) (F ia,01(θT,a1)pia,01) .
(5.10.4)
5.10.4 The ignorable PPO-survival model parameter specification
Clearly, equations (5.10.2) and (5.10.4) show that θ = θT in the ignorable
PPO model. Similarly to the non-ignorable PPO-survival model, we can
specify θT as follows:
θ = θT = (θT,c1, θT,c0, θT,n, θT,a). (5.10.5)
Since only the failure time distribution is included in the likelihood func-
tion (equation (5.10.1)), we need only to specify one standard survival distri-
bution for the ignorable PPO-survival model. Our convention is as follows:
if the Weibull model is chosen, the ignorable parametric potential-outcome
(PPO) model is called the ignorable PPO-survival Weibull model (called the
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IGN-W model for short). The IGN-W model is thus a parametric potential-
outcome (PPO) survival model for noncompliance with an ignorable censor-
ing mechanism. Similarly, if the specified distribution is the log-normal, our
resultant model is the ignorable PPO-survival log-normal model, called the
IGN-L model. Table 5.6 gives the notation for these ignorable PPO-survival
models.
Table 5.6: Specification of the ignorable PPO-survival models.
Distribution Ignorable survival model
Weibull IGN-W model
log-normal IGN-L model
For these two ignorable PPO-survival models, the pertinent parameters
are only those associated with the failure time distributions, as no censoring
time distribution is involved. We then have the parameters shown in Table
5.7.
Table 5.7: Ignorable PPO-survival model parameter vectors.
Model name model parameters
IGN-W ρT,c1, ρT,c0, ρT,n, ρT,a, αT
IGN-L µT,c1, µT,c0, µT,n, µT,a, σT
5.10.5 The posterior probability of compliance type
Note that in the ignorable PPO-survival model no censoring distribution is
involved. In this case, then the posterior probabilities of the two specific cases
(the case of Zi = 1 and Di(1) = 1, and the case of Zi = 0 and Di(0) = 0)
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can be simplified as follows:
Pr(Ui = u|(Ti(1), Ci(1))obs, Zi = 1, Di = 1; θk)
=

fu(1,t;θT,u1)piu,11
fc(1,t;θT,c1)pic,11+fa(1,t;θT,a1)pia,11
if Ri = 1, Ti(1) = t,
Su(1,t;θT,u1)piu,11
Sc1(t;θT,c1)pic,11+Sa(1,t;θT,a1)pia,11
if Ri = 0,Ci(1) = t;
(5.10.6)
for u ∈ {c, a} and
Pr(Ui = u|(Ti(1, Ci(1))obs, Zi = 0, Di = 0; θ0)
=

fu(0,t;θT,u0)piu,00
fc(0,t;θT,c0)pic,00+fn(0,t;θT,n)pin,00
if Ri = 1, Ti(0) = t,
Su(0,t;θT,u0)piu,00
Sc0(t;θT,c0)pic,00+Sn(0,t;θT,n)pin,00
if Ri = 0,Ci(0) = t;
(5.10.7)
for u ∈ {c, n}.
Therefore, for the ignorable PPO-survival model, P iac, P
i
nc, Q
i
ac, Q
i
nc have
the following equivalences:
P iac =
fc(1, t; θT,c1)pic,11
fc(1, t; θT,c1)pic,11 + fa(1, t; θT,a1)pia,11
for i ∈ C(1, 1, 1), Ti(1) = t ,
P inc =
fc(0, t; θT,c0)pic,00
fc(0, t; θT,c0)pic,00 + fn(0, t; θT,n)pin,00
for i ∈ C(0, 0, 1), Ti(0) = t,
Qiac =
Sc(1, t; θT,c1)pic,11
Sc(1, t; θT,c1)pic,11 + Sa(1, t; θT,a1)pia,11
for i ∈ C(1, 1, 0), Ci(1) = t,
Qinc =
Sc(0, t; θT,c0)pic,00
Sc(0, t; θT,c0)pic,00 + Sn(0, t; θT,n)pin,00
for i ∈ C(0, 0, 0), Ci(0) = t.
(5.10.8)
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5.10.6 The expectation function Q(θ,θk)
For the ignorable PPO-survival model, after substituting equations (5.10.8)
and (5.9.11) into equation (5.9.12), Q(θ,θk) can then be specified as follows:
Q(θ,θk) =
∑
i
Qi(θ,θk) =
∑
i∈C(1,1,1) {log (f ic(1, t; θT,c1)pic,11)P iac + log (f ia(1, t; θT,a)pia,11) (1− P iac)}∑
i∈C(1,1,0) {log (Sic(1, t; θT,c1)pic,11)Qiac + log (Sia(1, t; θT,a)pia,11) (1−Qiac)}∑
i∈C(0,0,1) {log (f ic(0, t; θT,c0)pic,00)P inc + log (f in(0, t; θT,n)pin,00) (1− P inc)}∑
i∈C(0,0,0) {log (Sic(0, t; θT,c0)pic,00)Qinc + log (Sin(0, t; θT,n)pin,00) (1−Qinc)}∑
i∈C(1,0,1) log (f
i
n(1, t; θT,n)pin,10)
∑
i∈C(1,0,0) log (S
i
n(1, t; θT,n)pin,10)∑
i∈C(0,1,1) log (f
i
a(0, t; θT,a)pia,01)
∑
i∈C(0,1,0) log (S
i
a(0, t; θT,a)pia,01) .
(5.10.9)
5.10.7 Computation
Following the same process as stated in Section 5.9, the ignorable PPO-
survival model can be implemented directly. This means that in the special
case (when the censoring mechanism is ignored), we can still use all the
methodologies given in Section 5.9. For example, to maximise the expecta-
tion function for this model Q(θ,θk) (given in equation (5.10.9)), we follow
Section 5.9.3; all formulations given in Section 5.9.4 can also be used to
calculate the standard error with respect to MLEs obtained in the M-step
and formulations with respect to the estimated ĈACE(t) and ÂCE(t) (see
5.9.4).
5.11 Summary
When the noncompliance issue has to be accounted for in likelihood-based
survival models, it is most likely that an underlying non-ignorable censor-
ing mechanism exists. Indeed, as shown in equation (5.5.16), the censor-
ing time distribution must be included in the derivation of the likelihood
function unless censoring is ignorable (Loeys & Goetghebeur, 2003). For
such cases, we formulated a non-ignorable censoring mechanism parametric
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potential-outcome (PPO) survival model, denoted the non-ignorable PPO-
survival model for short. More specifically, when failure and censoring times
are assumed to follow a Weibull or log-normal distribution, we have derived
and coined the NIGN-WW and the NIGN-LL models, respectively. Another
model, the so-called ignorable parametric potential-outcome (PPO) survival
model, (the ignorable PPO-survival model for short), is also given in this
chapter. The ignorable PPO-survival model pertains to the special case
where no censoring occurs prior to the end of follow-up or when the non-
informative censoring assumption holds (Loeys & Goetghebeur, 2003). Sim-
ilarly, the IGN-W and the IGN-L model are ignorable PPO-survival models
for the assumed scenarios where the failure times followWeibull or log-normal
distributions.
Because compliance type is an unobservable variable, we adopt the EM
algorithm to maximise the likelihood function for the complete data, where
the compliance type is considered to be an observable variable with missing
data. We adapt Louis’s method (Louis, 1982) for the PPO-survival mod-
els (including both non-ignorable and ignorable censoring mechanism), to
evaluate the standard error associated with the MLEs, obtained via the EM
algorithm. However, the Bootstrap approach (Efron & Tibshirani, 1993) is
necessary in this scenario to estimate the standard error of parameter pi as
it is not involved in the EM algorithm.
Theorem 1 provides a valuable property of AFT model, which holds for
both Weibull and log-normal distributions. Thereby, the accelerated failure
time (AFT) model guarantees that each subgroup has the same shape pa-
rameter, for the Weibull model, or variance parameter for the logarithm of
failure time (or the logarithm of censoring time) for the log-normal model.
Our approach achieves a reduction in the number of parameters for the
non-ignorable and ignorable survival models, whether we use the NIGN-WW
(or the NIGN-LL) model or the IGN-W (or the IGN-L) model. This leads to
reduced computational costs and time, of particular value to censored RCT
data applications with noncompliance.
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Chapter 6
HIP breast cancer RCT application
The parametric potential-outcome (PPO) survival models, introduced in
Chapter 5, which include both non-ignorable and ignorable censoring mecha-
nisms for noncompliance analysis of survival outcomes, have been established
theoretically. The survival outcome distributions have failure and censoring
times specified by the Weibull or the log-normal distribution. This chapter
demonstrates how these non-ignorable and ignorable survival models perform
on an analysis of the HIP breast cancer data (Shapiro et al., 1988; Baker,
1998). Furthermore, the Frangakis-Rubin (F-R) method (Frangakis & Ru-
bin, 1999) for considering the noncompliance and censoring (non-response)
mechanism jointly from non-parametric perspective (Section 2.3.1), is also
applied to the HIP data. All programmes used in this thesis were run using in-
house code for MATLAB (7.4.0, R2007a) software (Higham & Higham, 2000)
(www.mathworks.com/products/matlab).
The structure of this chapter is as follows: Section 6.1 provides basic
information on the Health Insurance Plan (HIP) of the Greater New York
breast cancer RCT (Shapiro et al., 1988). Sections 6.2 and 6.3 show the
application of our models to the HIP data. The Frangakis-Rubin (F-R)
model is briefly introduced in Section 6.4. The results of our analysis of the
HIP data using the F-R model are also given in Section 6.4. Section 6.5
provides comparisons of the results obtained via the non-parametric (F-R)
model and our parametric potential-outcome (PPO) survival models.
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6.1 The HIP study
6.1.1 HIP breast cancer programme
The breast cancer data used in this chapter were collected from a breast
screening study conducted in the USA by the Health Insurance Plan (HIP) of
Greater New York during the 1960s (Shapiro et al., 1988). Participants were
women who enrolled in the HIP for one year or more when the programme
started in 1963. These women were asymptomatic of breast cancer and aged
between 40 and 64 years old at entry into the HIP trial.
A total of 60,696 eligible women were included in this programme, and
all were randomly assigned into either the screening or the control group.
Women in the screening group were offered free annual breast examinations
four times. These examinations consisted of film mammography (cephalocau-
dal and later views of each breast), a clinical examination of each breast by
a physician (usually a surgeon), and an interview for demographic and other
background information including a health history (Shapiro et al., 1988).
The women in the so-called control group received only their usual health
care (Shapiro et al., 1988). All participants in this study were followed up
in the long-term for up to 18 years from their date of entry. The event of
interest was death from breast cancer, and the outcome of interest was the
observed time (in years), for each individual from entry to death from breast
cancer or to loss to follow-up. Clearly, for those women diagnosed with breast
cancer in the study, there was no loss to follow up. In previous related re-
search (Shapiro et al., 1988; Baker, 1998), the mortality that due to breast
cancer, was the main outcome variable of interest and was used to evaluate
the efficacy of the breast screening programme.
Approximately one-third of the women assigned to the screening group re-
fused the screening examination. Thus the HIP trial satisfies the special case
of noncompliance, known as all-or-none compliance (Baker, 1997), wherein a
switch from the assigned treatment to another treatment occurs immediately
after randomisation. Women who were allocated to the screening group, but
refused to take the examination, are viewed as being switched to the control
group directly at the beginning of the trial. Hence the HIP breast cancer
trial is considered to be a RCT with all-or-none compliance (Baker, 1997).
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In addition, the HIP data satisfies the assumption of no access to treatment
for the control group. This assumption has also been made by Frangakis &
Rubin (1999) and by Loeys & Goetghebeur (2003). This is considered to be
true in the HIP trial, as no women in the control group received the screening
examination.
Previous analyses of the HIP breast cancer data (Shapiro, 1977; Shapiro
et al., 1982, 1988) were mostly based on the intention-to-treat (ITT) princi-
ple, and focused on estimating the cumulative mortality rate of breast cancer
and the survival rate, over particular fixed follow-up durations, rather than
on estimating survival or hazard functions. From a noncompliance perspec-
tive, only Baker (1998) reported the estimated cost-effectiveness of the HIP
intervention.
As was noted in Chapter 1, noncompliance presents a challenge to tradi-
tional statistical methods for the analysis of RCTs. This is because neither an
analysis which ignores non-compliers, nor an analysis which focuses on treat-
ment (actually received), can provide precise and reliable answers (O’Malley
& Normand, 2005; Mealli et al., 2004; Loeys & Goetghebeur, 2003). In this
chapter, we aim to make valid inferences regarding the effect of mammogra-
phy on breast cancer mortality. In the former case, the observed outcomes
of the intervention group are a mixture of outcomes for women receiving
and not receiving the intervention. In the latter case, the two groups are
not necessarily comparable, because of the self-selection of treatment for the
intervention group means that treatment received is not randomized. Conse-
quently, treatment groups may differ on so-called background factors related
to breast cancer and also differ on factors related to breast cancer mortality
risk.
6.1.2 Pre-processing of the HIP breast cancer data
The original HIP data (Shapiro et al., 1988; Baker, 1998) includes 60,696
observations, in which the enrolment date and the last follow-up date for all
individuals had been recorded, as well as their survival status. The latter
indicates whether an individual died of breast cancer during the observation
period or not. Note that in the HIP breast cancer trial, there were two
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examiners independently took the responsibility of determining the course
of each single case of death. For those individuals who died but not due to
breast cancer, they were treated as censored individuals in the trial (Shapiro
et al., 1988).
The observed time (from entry to death or last follow-up) was given in
days in the original HIP data. In this thesis, the survival status of an indi-
vidual is the so-called censoring indicator (denoted by R = 1 for death from
breast cancer, 0 otherwise) and observed times are counted in years, as in
Baker (1998), which was obtained by the following formula:
observed time (in years) =
days for entry to death or last follow-up
365
.
(6.1.1)
We note that 164 individuals in the original HIP data have the same date
for their enrolment and their last follow-up date. This implies that these
individuals did not, in fact, take part in the HIP study and thus should not
be counted as “valid” individuals in the HIP trial. Therefore, in this thesis,
we focus on analyzing the subset of the HIP data (60,696 - 160 = 60,532
women) rather than the original HIP data.
The HIP18 dataset: The first data subset studied follows Shapiro’s report
on the HIP study (Shapiro et al., 1988), wherein the maximum observed time
is fixed at 18 years. This is because Shapiro et al. (1988) purports that in the
HIP study, the maximum follow-up period is 18 years. Thus, women whose
observed times are greater than 18 years (in the original HIP data set) are
all preset at 18. Their censoring indicators are given as 0, as they can be
viewed as censored at year 18 (after entry).
The HIP7 dataset: The second data subset is obtained by following the
arguments of Baker (1998). Baker mentions that: “by seven years, the num-
ber of breast cancers in the control and screen groups have equalized, so
presumably they represent all breast cancers that could have benefitted from
screening.” To reduce the variance of estimators, Baker (1998) focused only
on analyzing those individuals with breast cancer diagnosed in their first
seven years of follow-up. Baker also points out that the choice of seven years
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(for the HIP study) was conservative; other authors have used earlier times
of so-called equalisation (Baker, 1998).
As with Baker (1998), we also chose to analyse the HIP data with seven
years as the maximum follow-up period. The benefit from the screening
examination should therefore be considered “realised” in seven rather than in
eighteen years (Baker, 1998). Note that, as we are interested in investigating
how the screening examination impacts the longevity of women who are in
general good health (rather than breast cancer patients). Hence, unlike Baker
(1998), in this thesis, we focus on analysing all women in the HIP trial rather
than those who had been diagnosed with breast cancer during the observation
period.
After truncating the observed time at 7 years, individuals whose observed
times were greater than seven years have been given 0 as their censored
indicators value, which shows that these individuals had not died at that time
(7 years). Therefore, in this HIP dataset, denoted by HIP7, the maximum
observed time is 7 years; individuals whose observed time are greater than 7
years (in the original HIP data) have Ri = 0. This indicates that individuals
whose observed time has been truncated (in the HIP7 data) did not die from
breast cancer during the the follow-up period (7 years after entry). Summary
statistics for the three HIP datasets (the original HIP, HIP18 and HIP7 )
are given in Table 6.1 (on page 135).
As stated before, we focused on analysing the two aforementioned HIP
data subsets, namely HIP18 and HIP7, with our NIGN-WW and NIGN-
LL survival models. The results are given in Section 6.2. Furthermore, for
the purpose of comparison, these two HIP data subsets are also re-analysed
by the Frangakis-Rubin (F-R) model (Frangakis & Rubin, 1999). To date,
the F-R model has not yet been applied to any time-to-event data in the
literature. The results of the re-analysis of the HIP data subsets are given in
Section 6.4. In addition, a specific IGN-survival model, the so-called IGN-W
model, is applied to the HIP18 and the HIP7 datasets (Section 6.3).
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6.2 HIP data analysis: via the non-ignorable censoring mecha-
nism PPO-survival models
For the HIP trial, it is assumed that whether a participant died from breast
cancer or not would not be related to any other participant’s treatment sta-
tus. We can then suppose Assumption 1 (given in Section 5.2), the SUTVA
assumption is satisfied. Assumption 2 (random assignment) clearly holds
as all participants in the HIP trial were randomly assigned to the screen-
ing or the control group (Shapiro et al., 1988). Some participants assigned
to the screening group refused to take the screening examination (Shapiro
et al., 1988; Baker, 1998). This implies that these individuals did not follow
their allocated randomised assigned treatment (Zi). Assumption 3, namely
that of exclusion restriction, can then be assumed. This means that the as-
signed treatment (Zi) affects the outcome of interest only through the actual
received treatment (Di(Zi)). We also suppose Assumption 4, that of mono-
tonicity, holds in the HIP trial, as it is more acceptable to suppose that no
defiers exist than to have defiers in a RCT (Angrist et al., 1996; Frangakis &
Rubin, 1999; Baker, 1998; Yau & Little, 2001; Peng et al., 2004; O’Malley &
Normand, 2005; Mattei & Mealli, 2007). Finally, we suppose that the latent
ignorability assumption holds in the HIP trial, i.e. that the potential failure
time and censoring time are independent, conditional on the latent compli-
ance type. Hence, all assumptions given in Section 5.2 are assumed satisfied
in the HIP trial. In addition, for all individuals in this trial, there are only
two possible types of compliance behavior, namely compliers or never-takers.
Note that no woman assigned to the control group could receive the screen-
ing examination, which implies that no always-takers exist in the HIP breast
screening trial. In other words, the assumption of no access to treatment for
the control (Loeys & Goetghebeur, 2003; Frangakis & Rubin, 1999) holds in
the HIP breast screening trial. However, it is not a necessary assumption for
our PPO-survival models (derived in Chapter 5).
6.2.1 Model specification for the HIP trial
Since no always-takers exist in the HIP trial, the number of compliance types
in the HIP data has thus been reduced to two, and the number of subgroups of
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interest in the HIP data are thus reduced to three (Subgroup j ; j = 1, 2, 3),
specified as follows:
Subgroup1 : compliers (Ui = c) from the screening group (Zi = 1);
Subgroup2 : compliers (Ui = c) from the control group (Zi = 0);
Subgroup3 : never-takers (Ui = n) from either the screening (Zi = 1) or
the control (Zi = 0) group.
Consequently, for the HIP breast cancer data, the model parameter vector
β, given in equation (5.5.23), is simplified as follows:
β = (θ,pi); where
θ = (θT,c1, θT,c0, θT,n, αT , θC,c1, θC,c0, θC,n, αC), and
pi = (pic,00).
(6.2.1)
Recall that only θ need to be estimated using the EM algorithm, θ is the
interest of model parameter.
Note that the parameters corresponding to the always-takers subgroup in
equation (5.5.23) are thus excluded in equation (6.2.1), because no always-
takers exist in the HIP trial. This can be denoted by pia = 0, which indicates
that the ith individual in the HIP trial, has 0 (zero) probability of being an
always-taker. Therefore, the parameter pic,11, defined by the first equation in
(5.5.27), is fixed as 1 (because pia = 0), i.e. pic,11 ≡ 1. So for the HIP data,
pic,11 is clearly not a parameter that needs to be estimated. Furthermore, the
parameter pic,00, defined by the second equation in (5.5.27) is equivalent to
pic, (pic,00 ≡ pic) because pic + pin ≡ 1 in the case of the HIP study.
Hence, for the NIGN-WW model, which assumes that both failure and
censoring time follow a Weibull distribution, the interest model parameter
vector, θWW , includes eight elements, i.e.:
θWW = (ρT,c1, ρT,c0, ρT,n, αT , ρC,c1, ρC,c0, ρC,n, αC)
T , (6.2.2)
where ρc1, ρc0 and ρn represent the scale parameters of three Weibull distribu-
tions for failure time (Ti) associated with the relevant subgroups (Subgroup1,
137
Subgroup2 and Subgroup3), with αT as the common shape parameter for
these Weibull distributions; and ρC,c1, ρC,c0 and ρC,n represent the scale pa-
rameters of three Weibull distributions for censored time (Ci) associated with
the same three relevant subgroups (Subgroup1, Subgroup2 and Subgroup3)
and with αc as the common shape parameter for these distributions.
When the log-normal is assumed to be the distribution for failure and
censoring time , the interest NIGN-LL model parameter vector, denoted by
θLL, is as follows:
θLL = (µT,c1, µT,c0, µT,n, σT , µC,c1, µC,c0, µC,n, σC), (6.2.3)
where µc1, µc0 and µn denote the mean of the logarithm of failure time,
corresponding to the three extant subgroups (Subgroup1, Subgroup2 and
Subgroup3); σT is their common variance (of the logarithm of failure time);
and µC,c1, µC,c0, µC,n and σC represent the parameters corresponding to the
logarithm of censoring time.
The model parameters corresponding to the specific non-ignorable PPO-
survival models (for the HIP trial) are given in Table 6.2.
Table 6.2: Non-ignorable PPO-survival model parameters for the HIP trial.
Model name model parameter vector
NIGN-WW (ρT,c1, ρT,c0, ρT,n, αT , ρC,c1, ρC,c0, ρC,n, αC)
NIGN-LL (µT,c1, µT,c0, µT,n, σT , µC,c1, µC,c0, µC,n, σC)
The estimated values of the interest model parameter vectors θ, asso-
ciated with the two non-ignorable survival models, namely the NIGN-WW
and NIGN-LL models, are given in Appendix C. Specifically, Tables C-1 and
C-2 (on page 249) give analogous estimates for the HIP18 data; Tables C-3
and C-4 (on page 250), for the HIP7 data. Details on the iteration process
used in the EM algorithm (Dempster et al., 1977) for these two specific non-
ignorable PPO-survival models are detailed in Appendix B, where Tables
C-8 (on page 252) and C-9 (on page 253) give the iteration of convergence
in the EM algorithm for the HIP18 dataset, and Tables C-10 (on page 254)
and C-11 (on page 255), for the HIP7 dataset.
138
6.2.2 Estimation of causal effects: CACE(t) and ACE(t)
Table 6.3: Estimated CACE(t) and associated standard errors per model.
Models NIGN-WW model NIGN-LL model
Data HIP18
Years CACE (SECACE) CACE ( SECACE)
1 0.19E-4 (0.10E-4) 0.15E-4 (0.07E-4)
5 3.56E-4 (1.86E-4) 5.22E-4 (2.19E-4)
10 12.6E-4 (6.57E-4) 17.9E-4 (7.17E-4)
15 26.2E-4 (13.7E-4) 32.1E-4 (13.2E-4)
Data HIP7
Years CACE (SECACE) CACE (SECACE)
1 0.66E-4 (0.24E-4) 0.62E-4 (0.25E-4)
5 14.8E-4 (3.83E-4) 15.7E-4 (4.02E-4)
For causal inference in time-to-event studies, we focus on estimating the
causal effects in terms of CACE(t) and ACE(t). These were previously de-
fined by equations (3.3.7) and (3.3.8) in Chapter 3. Tables 6.3 (on page 139)
and 6.4 (on page 140) give estimated CACE(t) and ACE(t) for the two non-
ignorable PPO survival models (the NIGN-WW and the NIGN-LL model).
Their associated standard errors are also given in Tables 6.3 and 6.4, which
are calculated by following the formulation given in equations (5.9.37) and
(5.9.46).
Since CACE(t) and ACE(t) both are the functions of the MLE and ap-
pealing to large-sample normality of the MLE, the 95% lower and upper
confidence limits (LCL and UCL) of CACE(t) are calculated easily as fol-
lows:
LCLcace(t) = ĈACE(t)− 1.96SEĉace(t)
UCLcace(t) = ĈACE(t) + 1.96SEĉace(t).
(6.2.4)
Similarly, the 95% lower and the upper confidence limits (LCL and UCL)
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Table 6.4: Estimated ACE(t) and associated standard errors per model.
Models NIGN −WW model NIGN − LL model
Data HIP18
Years ACE ( SEACE ) ACE (SEACE)
1 0.13E-4 (0.07E-4) 0.10E-4 (0.05E-4)
5 2.38E-4 (1.25E-4) 3.49E-4 (1.47E-4)
10 8.41E-4 (4.40E-4) 11.6E-4 (4.80E-4)
15 17.5E-4 (9.19E-4) 21.5E-4 (8.81E-4)
Data HIP7
Years ACE (SEACE) ACE (SEACE)
1 0.44E-4 (0.16E-4) 0.41E-4 (0.16E-4)
5 9.90E-4 (2.56E-4) 10.5E-4 (2.69E-4)
of ACE(t) are calculated via the following formulae:
LCLace(t) = ÂCE(t)− 1.96SEâce(t)
UCLace(t) = ÂCE(t) + 1.96SEâce(t).
(6.2.5)
The associated Z values of CACE(t) and ACE(t) are also given for all
analyses. The Z value is calculated by using the following equations:
Z − valuecace(t) = ĈACE(t)− 0
SEĉace(t)
(6.2.6)
and
Z − valueace(t) = ÂCE(t)− 0
SEâce(t)
; (6.2.7)
where 0 is the assumed under the null mean value of CACE(t) or ACE(t).
The p-value derives from 1−Φ(Z − value) (one tail), where Φ() denotes the
standard normal cumulative probability function.
Further details regarding the estimated ACE(t) and CACE(t), obtained
via our non-ignorable PPO-survival models for the HIP18 and HIP7 data
sets are given in Appendix C, where Tables C-13, C-14 give the estimated
ACE(t) for the HIP18 dataset via the NIGN-WW and NIGN-LL model,
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respectively, and Tables C-16 and C-17 give the estimated CACE(t) for the
HIP18 data set via the same two models. Tables C-20, C-21, C-22 and C-23
are analogous for the analysis of the HIP7 data set.
Based on these estimated values of ACE(t) and CACE(t), the curves of
the estimated CACE(t) and ACE(t) against survival time (years survival
post entry) are plotted in the following figures per data subset analysed. For
the the HIP18 data, Figures 6.1 and 6.2 (on page 142) show the estimated
CACE(t) curves obtained using the NIGN-WW and NIGN-LL model, respec-
tively, and their associated ACE(t) curves are given in Figures 6.3 and 6.4
(on page 143); the corresponding curves of estimated CACE(t) and ACE(t)
(with the same names) for the HIP7 data are given in Figures 6.5 and 6.6
(on page 144) and Figures 6.7 and 6.8 (on page 145).
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Figure 6.1: Estimated CACE(t) curve using the NIGN-WW model with
95% confidence interval: HIP18 data. The dash-dot line and the dotted line
indicate the Lower Confidence Limit(LCL) and the Upper Confidence Limit
(UCL).
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Figure 6.2: Estimated CACE(t) curve using the NIGN-LL model with 95%
confidence interval: HIP18 data. The dash-dot line and the dotted line
indicate the Lower Confidence Limit(LCL) and the Upper Confidence Limit
(UCL).
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Figure 6.3: Estimated ACE(t) curve using the NIGN-WW model with 95%
confidence interval: HIP18 data. The dash-dot line and the dotted line
indicate the Lower Confidence Limit(LCL) and the Upper Confidence Limit
(UCL).
2 4 6 8 10 12 14 16 18
−2
−1
0
1
2
3
4
5
6
7
x 10−3
Survival time in years
AC
E(
t)
 
 
ACE
nign−ll for HIP18
LCL of ACE
nign−ll for HIP18
UCL of ACE
nign−ll for HIP18
Figure 6.4: Estimated ACE(t) curve using the NIGN-LL model with 95%
confidence interval: HIP18 data. The dash-dot line and the dotted line
indicate the Lower Confidence Limit(LCL) and the Upper Confidence Limit
(UCL).
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Figure 6.5: Estimated CACE(t) curve with 95% confidence interval: HIP7
data using the NIGN-WW model. The dash-dot line and the dotted line
indicate the Lower Confidence Limit(LCL) and the Upper Confidence Limit
(UCL).
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Figure 6.6: Estimated CACE(t) curve with 95% confidence interval: HIP7
data using the NIGN-LL model. The dash-dot line and the dotted line in-
dicate the Lower Confidence Limit(LCL) and the Upper Confidence Limit
(UCL).
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Figure 6.7: Estimated ACE(t) curve using the NIGN-WW model with 95%
confidence interval: HIP7 data. The dash-dot line and the dotted line in-
dicate the Lower Confidence Limit(LCL) and the Upper Confidence Limit
(UCL).
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Figure 6.8: Estimated ACE(t) curve using the NIGN-LL model with 95%
confidence interval: HIP7 data. The dash-dot line and the dotted line in-
dicate the Lower Confidence Limit(LCL) and the Upper Confidence Limit
(UCL).
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6.2.3 Estimation of relevant survival probabilities
The key point distinguishing our non-ignorable PPO-survival models (the
NIGN-WW and NIGN-LL survival model) from conventional parametric sur-
vival models, is the fact that an individual’s compliance type is allowed for, as
proposed in Chapter 5. Unlike conventional parametric models, the NIGN-
WW and the NIGN-LL models allow us to estimate the survival probability
for three afore-mentioned subgroups in the HIP trial, namely Subgroup 1,
Subgroup 2 and Subgroup 3 as defined in Section 6.2.1.
The estimated survival curves corresponding to these three subgroups
(denoted by Sc1(t), Sc0(t) and Sn(t)) for the NIGN-WW and the NIGN-LL
model application on the HIP18 and the HIP7 subdata are given in Figure
6.9 (on page 148), where the top row gives the estimated survival curves
evaluated using the NIGN-LL model for the HIP18 data (top left) and the
HIP7 data (top right). The figures located in the bottom row of Figure 6.9
represent the corresponding estimated curves for the NIGN-LL model. In
addition, it is not difficult to obtain estimated survival probabilities from an
ITT analytic perspective via our PPO-survival model; Figure 6.10 (on page
149) shows the relevant the ITT estimated survival curves. Equation (6.2.8)
gives the formulations of calculating the ITT survival probabilities S0(t) and
S1(t).
S0(t) = (1− pic)Sn(t) + picSc0(t);
S1(t) = (1− pic)Sn(t) + picSc1(t).
(6.2.8)
All estimated values of the relevant survival probabilities, associated with
Figure 6.9, and Figure 6.10 are detailed in Tables C-28, C-29, C-32 and C-33
in Appendix C for the reader’s perusal.
The survival curves plotted on the two graphs at the right-hand side of
Figure 6.9 (on page 148) correspond to the HIP7 dataset via the NIGN-LL
model (top graph) and the NIGN-WW model (bottom graph), respectively.
They show that Subgroup 1, which consists of compliers, who are assigned
to the screening (treated) group, has the highest survival probability among
the three subgroups; Subgroup 2 has the lowest survival probability, in which
individuals are all compliers and assigned to the control group; while the
estimated survival curve of Subgroup 3, which consists of all never-takers,
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who are assigned to either the screening or the control groups, lies between
the curves of Subgroup 1 and Subgroup 2. These results can be interpreted
thus: Subgroup 3 (never-takers) can be viewed as a healthy group, so it has
a survival probability higher than Subgroup 2. Note that it is reasonable to
make this assumption as presumably individuals in Subgroup 3 do not think
a screening examination is necessary, for they refuse to take the screening
examination (when assigned to the screening group). The estimated survival
curves for the HIP7 dataset also show that the NIGN-LL model and the
NIGN-WW model provide very simliar results.
Unlike the analysis of the HIP7 dataset, for the HIP18 dataset, the sur-
vival curves estimated using the NIGN-LL model and the NIGN-WW model
are slightly different. The NIGN-WW model provides survival curves for
Subgroups 2 and 3 that are closer than does the NIGN-LL model. How-
ever, the estimated survival curve for Subgroup 3 still lies between these two
survival curves for Subgroup 1 and 2 (the left-hand graph in Figure 6.9).
Therefore, the assumption mentioned above, that individuals in Subgroup 3
are all healthy — or at least thought of themselves as healthy at that time
— is still valid. Since this is a scenario of long term follow-up, individuals’
health status, at enrolment, may not affect their survival probability in later
years. It is noteworthy that in the analysis of the HIP18 dataset, the sur-
vival curves of Subgroup 3 are closer to the survival curves of Subgroup 2
than Subgroup 1. This also makes sense in that individuals, either in Sub-
group 2 or Subgroup 3, have not received a screening examination. It is thus
not surprising to see these two subgroups having similar estimated survival
curves. Indeed, the survival probability in later years is minimally related to
the individual’s health status at enrolment.
It is important to note that an ordinary ITT analysis does not provide
these nuances nor this information ( Figure 6.9, on page 148 and Figure 6.10
on page 149).
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6.3 HIP data analysis: via the ignorable censoring mechanism
PPO-survival models
In the IGN-W model, without pre-specifying a censoring distribution, the in-
terest model parameter (θ) has the following form: θW = (ρc1, ρc0, ρn, αT )
T ,
where the first three elements, ρc1, ρc0, ρn, are the scale parameters of the
Weibull distributions for failure time associated with the three subgroups
(Subgroup 1, Subgroup 2 and Subgroup 3 given earlier); αT is the common
shape parameter for the three subgroups, and pic,00 is the conditional prob-
ability of compliance given the assigned treatment (Zi = 0) and the actual
received treatment (Di(0) = 0).
The HIP7 data includes some individuals who were censored before year
7, the pre-set length of the follow-up period. This implies that the HIP7
dataset does not satisfy the assumption of no censoring prior to the end of
the follow-up. Since noncompliance occurred in the HIP trial, the compli-
ance type has to be considered. Hence, we can not treat the HIP data as
independent censoring. In other words, those assumptions required for ig-
norable PPO-survival model are invalid on the HIP7 data. However, for
the purpose of comparison, the IGN-W model is used to analyse the HIP7
data, even though the latter assumption is violated. As in the non-ignorable
PPO-survival model (detailed in Section 6.2), we firstly specify the parameter
vector β for the IGN-W as is relevant to the HIP trial.
6.3.1 Model specification for the HIP trial
In the IGN survival model, the interest model parameter β can then be
further simplified, as by definition no censoring distribution is involved in
this model. That is:
θ = (θT,c1, θT,c0, θT,n, αT , pic), (6.3.1)
The interest model parameter vector, θ, for the IGN survival model with
a Weibull distribution (the IGN-W model) is specified in Table 6.5. This
includes the three scale parameters, ρT,c1, ρT,c0, ρT,n, of the Weibull distribu-
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Table 6.5: Ignorable PPO-survival model parameters for the HIP trial.
Model name model parameter vector
IGN-WW (ρT,c1, ρT,c0, ρT,n, αT )
tions for the three subgroups and one common shape parameter, α, of the
Weibull distributions.
The estimated parameter vector θ of the IGN-W model for the HIP18
and the HIP7 datasets are given in Tables C-6 and C-5 in Appendix C.
6.3.2 Estimation of causal effects: CACE(t) and ACE(t)
In this section, we evaluate the causal effect measured by CACE(t) and
ACE(t) via the IGN-W model. The estimated CACE(t) and ACE(t) for
the HIP7 data (using the IGN-W model) are given in Tables 6.6 and 6.7 (on
page 152). The first column indicates the survival time in years; the second
column shows the estimated values of CACE(t) or ACE(t) at each observed
year. The related standard errors are given in Column 3; the last two columns
represent the lower and upper 95% confidence limits respectively. The re-
lated CACE(t) curves are shown in Figure 6.11 (on page 153, for the HIP18
dataset) and in Figure 6.13 (on page 154, for the HIP7 dataset). Note from
Tables 6.6 and 6.7 that for all years (t = 1, 2, . . . , 7) both the estimated
CACE(t) and estimated ACE(t) derived from the IGN-W model are highly
significant. Interpretation of these estimated CACE(t) and ACE(t) profiles
is given later in Section 6.6.
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Table 6.6: Estimated CACE(t) and its 95% CI using the IGN-W model for
the HIP7 data.
Method: IGN-W Data: HIP7
Year ĈACEIGN−W SEcace LCLcace UCLcace Z − value p− value
1 0.82E−04 0.22E−04 0.40E−04 1.24E−04 3.7857 0.0001
2 3.13E−04 0.70E−04 1.76E−04 4.49E−04 4.4934 0.0000
3 6.85E−04 1.40E−04 4.10E−04 9.59E−04 4.8851 0.0000
4 11.9E−04 2.34E−04 7.35E−04 16.5E−04 5.1043 0.0000
5 18.4E−04 3.52E−04 11.5E−04 25.2E−04 5.2179 0.0000
6 26.1E−04 4.95E−04 16.4E−04 35.8E−04 5.2651 0.0000
7 35.1E−04 6.66E−04 22.0E−04 48.1E−04 5.2701 0.0000
HIP7: HIP data with follow-up of 7 years
Table 6.7: Estimated ACE(t) and its 95% CI using the IGN-W model for
the HIP7 data.
Method: IGN-W Data: HIP7
Year ÂCEIGN−W SEace LCLace UCLace Z − value p− value
1 0.55E−04 0.15E−04 0.27E−04 0.83E−04 3.7852 0.0001
2 2.10E−04 0.47E−04 1.18E−04 3.01E−04 4.4927 0.0000
3 4.59E−04 0.94E−04 2.75E−04 6.43E−04 4.8842 0.0000
4 7.99E−04 1.57E−04 4.92E−04 11.1E−04 5.1032 0.0000
5 12.3E−04 2.36E−04 7.67E−04 16.9E−04 5.2167 0.0000
6 17.5E−04 3.32E−04 11.0E−04 24.0E−04 5.2639 0.0000
7 23.5E−04 4.46E−04 14.8E−04 32.2E−04 5.2688 0.0000
HIP7: HIP data with follow-up of 7 years
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Figure 6.11: Estimated CACE(t) curve with 95% confidence interval: HIP18
data using the IGN-W model. The dash-dot line and the dotted line indicate
the Lower Confidence Limit(LCL) and the Upper Confidence Limit (UCL).
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Figure 6.12: Estimated ACE(t) curve with 95% confidence interval: HIP18
data using the IGN-W model. The dash-dot line and the dotted line indicate
the Lower Confidence Limit(LCL) and the Upper Confidence Limit (UCL).
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Figure 6.13: Estimated CACE(t) curve with 95% confidence interval: HIP7
data using the IGN-W model. The dash-dot line and the dotted line indicate
the Lower Confidence Limit(LCL) and the Upper Confidence Limit (UCL).
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Figure 6.14: Estimated ACE(t) curve with 95% confidence interval: HIP7
data using the IGN-W model. The dash-dot line and the dotted line indicate
the Lower Confidence Limit(LCL) and the Upper Confidence Limit (UCL).
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6.3.3 Estimation of relevant survival probabilities
Figure 6.15 (on page 155) gives the two estimated survival curves obtained
via the IGN-W model. The left hand side indicates the estimated survival
curves for the HIP18 data, and the right hand side shows that for the HIP7
data. The exact numbers of these estimated survival curves ( in Figure 6.15)
are given in Tables C-37 and C-36 in Appendix C. Note that the estimated
survival curves for the two datasets shown in Figure 6.15, correspond to
three subgroups per dataset analysed. The three subgroups are: compliers
from the assigned treatment group (Zi = 1), compliers from the control
group (Zi = 0); and never-takers from either the assigned treatment group
Zi = 1 or the control group Zi = 0. It is noteworthy that Sˆn(t) has a higher
value than the other two subgroups, say Sˆc1(t) and Sˆc0(t). Recall that Sˆn(t)
denotes the survival probability of individuals who are never-takers from
either the assigned treatment group Zi = 1 or the control group Zi = 0.
This information provided by Figure 6.15, Sˆn(t) > Sˆc1(t) > Sˆc0(t), seems
counter-intuitive. It may occur because the HIP data does not satisfy the
assumption required for the IGN-survival model, namely that no censoring
occurs prior to end of the follow-up (Figure 6.15).
Figure 6.16 (on page 156) gives the relevant estimated survival curves for
an ITT analysis using the IGN-W model for the HIP18 data (left) and the
HIP7 data (right); their associated estimated survival values are given in
Tables C-39 and C-38 in Appendix C.
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6.4 HIP data analysis: via the Frangakis-Rubin method
6.4.1 Frangakis-Rubin method
Let Suz(t) denote the survival function for the subgroup with Ui = u and Zi =
z, and let Sz(t) denote the survival function associated with two treatment
levels, z = 1 for the treatment and 0 for the control. According to equation
(5.1) given in Frangakis & Rubin (1999), the survival functions corresponding
to the assigned treatment group Zi = 1 (for i ∈ {i : Zi = 1}) and the control
group Zi = 0 (for i ∈ {i : Zi = 0}) can be re-written as follows:
S0(t) = (1− pic)Sn0(t) + picSc0(t)
S1(t) = (1− pic)Sn1(t) + picSc1(t);
(6.4.1)
where pic is the probability of compliers in the population.
Under the assumption of exclusion restriction, we have Sn0(t) = Sn1(t).
Using Sn(t) to replace Sn0(t) and Sn1(t) in equation (6.4.1), we then have a
form of the Frangakis-Rubin (F-R) model as follows:
S0(t) = (1− pic)Sn(t) + picSc0(t);
S1(t) = (1− pic)Sn(t) + picSc1(t).
(6.4.2)
Note that Sc1(t) and Sn(t) can be estimated with the Kalan-Meier estimator
directly.
Because compliance type Ui = u is unobservable, Sc0(t) the survival func-
tion associated with the subgroup with Ui = c and Zi = 0, cannot be esti-
mated directly with the Kalan-Meier estimator through observation. Fran-
gakis & Rubin (1999) provide a formulation for evaluating this, which is given
below:
Sˆc0(t) = exp
{
−
∫ t
0
dN obs0 (x)/N0 − dNn1(x)/N1
M0(x)/N0 −Mn1(x)/N1
}
; (6.4.3)
where N1 and N0 are the number of individuals randomly assigned to the
treated and the control group respectively, and N obsi (x) and M
obs
i (x) denote
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the stochastic processes (for i = 1, . . . , n) and are defined as follows:
Ni(x) := I(Ti ≤ x,Ri = 1);
Mi(x) := I(Ti ≥ x);
(6.4.4)
and
Nn1(x) =
∑
i
Ni(x)I(Ui = n)I(Zi = 1);
N0(x) =
∑
i
Ni(x)I(Zi = 0);
Mn1(x) =
∑
i
Mi(x)I(Ui = n)I(Zi = 1);
M0(x) =
∑
i
Mi(x)I(Zi = 0).
(6.4.5)
Given equations (6.4.4) and (6.4.5), we note that Nn1(x) and Mn1(x)
indicate the number of event occurrences or the number of survivors at or
prior to the given time t for individuals who are never-takers assigned to
the treatment group; whereas N0(x) and M0(x) denote the number of event
occurrences or the number of survivors at the given time t for individuals
who are assigned to the control group.
The Frangakis-Rubin (F-R) method (Frangakis & Rubin, 1999) can then
be regarded as a non-parametric form of the noncompliance and non-ignorable
survival potential outcomes model. This is true, because even though the F-
R method does not, in fact, conventionally evaluate CACE(t) and ACE(t),
the survival function values, Sc1(t), Sc0(t) and Sn(t), which are required in
the calculation of CACE(t) and ACE(t), can all be obtained by using the
F-R model via the Kaplan-Meier estimator and via equations (6.4.3) and
(6.4.2). More specifically, Sc1(t) and Sn(t)), the survival probabilities corre-
sponding to Subgroup 1 and Subgroup 3, can be estimated directly via the
Kaplan-Meier estimator, and Sc0(t), the survival probability corresponding
to Subgroup 2, can be calculated using equation (6.4.3) as was proposed by
Frangakis & Rubin (1999). Then S1(t) and S0(t), the survival probability
corresponding to the assigned treatment Zi = 1 and the control Zi = 0
group, respectively, can be obtained directly via equation (6.4.2), which was
also proposed by Frangakis & Rubin (1999).
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The two datasets from the HIP trial, (HIP18 and HIP7), are analysed
according to the F-R method, using a programme written in MATLAB
(Higham & Higham, 2000). This code follows equations (6.4.3) and (6.4.5)
as proposed by Frangakis & Rubin (1999).
6.4.2 Estimation of relevant survival probabilities
2 4 6 8 10 12 14 16 18
0.98
0.982
0.984
0.986
0.988
0.99
0.992
0.994
0.996
0.998
1
Survival time in years
Su
rv
iva
l p
ro
ba
bi
lity
S
c1(t) in F−R for HIP18
S
c0(t) in F−R for HIP18
S
n
(t) in F−R for HIP18
1 2 3 4 5 6 7
0.98
0.982
0.984
0.986
0.988
0.99
0.992
0.994
0.996
0.998
1
Survival time in years
Su
rv
iva
l p
ro
ba
bi
lity
S
c1(t) in F−R for HIP7
S
c0(t) in F−R for HIP7
S
n
(t) in F−R for HIP7
Figure 6.17: Estimated survival curves via the F-R for the HIP18 (left) and
for the HIP7 (right) data . The solid line corresponds to the survival curve
for Subgroup 1: compliers assigned to the screening group; the dash-dot
line corresponds to the survival curve for Subgroup 2: compliers assigned
to the control group; the dotted line corresponds to the survival curve for
the Subgroup 3: never-takers assigned to either the control or the screening
group.
Figure 6.17 shows the estimated survival curves obtained via the F-R
method, corresponding to the three subgroups (Sc1(t), Sc0(t) and Sn(t)) for
the two HIP datasets, namely the HIP18 and HIP7 subsets, where the left-
hand graph corresponds to the HIP18 dataset, and the right-hand one to the
HIP7 dataset. Both of the graphs show that Subgroup 1 has a higher sur-
vival probability than the other two subgroups. This is similar to the results
given in Section 6.2, which were obtained via the non-ignorable PPO-survival
model. However, we can also see that in Figure 6.17, the estimated survival
curves for Subgroup 3 are unlike those in Figure 6.9, especially for the HIP18
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Figure 6.18: The ITT estimated survival curves via the F-R for the HIP18
(left) and for the HIP7 (right) data . The solid line corresponds to the
survival curve for the assigned screening group; the dash line corresponds to
the survival curve for the assigned control group.
dataset. Figure 6.17 (left) (on page 160) shows that Subgroup 3 has a higher
value than Subgroup 2 before 12 years, after which time (t = 12) Subgroup
3 has the lowest value among the three subgroups. These results are com-
prehensible, because the F-R model is a non-parametric based method, yet
at the same time they are harder to interpret than results obtained via the
non-ignorable PPO-survival model (Section 6.2.1).
While Figure 6.18 gives the estimated survival curves obtained using the
F-R method in an ITT analysis, S1(t) and S0(t), correspond to the assigned
treated group Zi = 1 (the screen invited group) and the control group Zi = 0,
respectively. All estimated relevant survival values, which are associated
with Figures 6.17 and 6.18, are given in Tables C-30, C-31, C-34 and C-35
in Appendix C.
6.4.3 Estimation of causal effects: CACE(t) and ACE(t)
The estimated values of CACE(t) (obtained by the F-R method) and the as-
sociated 95% confidence intervals (obtained by the bootstrap method (Efron
& Tibshirani, 1993)) are given in Table 6.8 ( for the HIP7 dataset) and Ta-
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ble 6.9 ( for the HIP18 dataset) on page 163. Estimated ACE(t) values are
given in Tables 6.10 and 6.11 (on page 164). Note that no parameters are
estimated using the F-R model, as this is a non-parametric model. The for-
mulae given at the end of Section 6.2.2, including equations (6.2.4), (6.2.6),
(6.2.5) and (6.2.7), are also used to obtain Tables 6.8, 6.9, 6.10, 6.11, which
provide estimated CACE(t) and ACE(t) values for the F-R method.
Related CACE(t) curves for the HIP7 and the HIP18 data, estimated by
the F-R method, are given in Figures 6.19 and 6.20 (on page 166).
In Tables 6.9 and 6.11, it is noteworthy that CACE(t) and ACE(t) for
years 4 to 13 (inclusive), are significant in the F-R analyses of the HIP18.
This result is similar to that obtained for the HIP7 data, where CACE(t)
and ACE(t) for years 4 to 7 are highly significant (Tables 6.8 and 6.10).
Note that the estimated CACE(t) at the first seven years for the HIP7
and the HIP18 datasets (Table 6.9 and Table 6.8) are slight different. This
is because of that these two datasets are not same even though we only
consider the first seven years: 1) the censoring indicators for individuals
whose observed time are seven years in these two HIP datasets are different.
2) the datasets re-sampled for Bootstrap are high likely not same. Recall
that for the F-R method, the Bootstrap approach is employed for obtaining
the standard errors of the estimated CACE(t) and ACE(t).
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Table 6.8: Estimated CACE(t) (95% CI) using the F-R method for the HIP7
data.
Method: F-R Data: HIP7
Year ĈACEFR SEcace LCLcace UCLcace Zvalue p− value
1 0.57E−04 1.39E−04 −2.14E−04 3.29E−04 0.4127 0.3399
2 3.03E−04 2.43E−04 −1.74E−04 7.80E−04 1.2464 0.1063
3 5.35E−04 3.31E−04 −1.14E−04 11.8E−04 1.6159 0.0531
4 11.0E−04 4.44E−04 2.32E−04 19.7E−04 2.4836 0.0065
5 18.1E−04 5.85E−04 6.58E−04 29.5E−04 3.0846 0.0010
6 28.0E−04 7.08E−04 14.1E−04 41.9E−04 3.9505 0.0000
7 28.0E−04 7.08E−04 14.1E−04 41.9E−04 3.9505 0.0000
HIP7: HIP data with follow-up of 7 years
Table 6.9: Estimated CACE(t) (95% CI) using the F-R method for theHIP18
data.
Method: F-R Data: HIP18
Year ĈACEFR SEcace LCLcace UCLcace Zvalue p− value
1 0.57E−04 1.39E−04 −2.14E−04 3.29E−04 0.4127 0.3399
2 3.03E−04 2.43E−04 −1.74E−04 7.80E−04 1.2464 0.1063
3 5.35E−04 3.31E−04 −1.14E−04 11.8E−04 1.6159 0.0531
4 11.0E−04 4.44E−04 2.32E−04 19.7E−04 2.4836 0.0065
5 18.1E−04 5.85E−04 6.58E−04 29.5E−04 3.0846 0.0010
6 27.7E−04 7.13E−04 1.38E−03 41.7E−04 3.8930 0.0000
7 25.6E−04 7.91E−04 1.01E−03 41.1E−04 3.2321 0.0006
8 21.1E−04 8.68E−04 4.05E−04 38.1E−04 2.4272 0.0076
9 25.8E−04 9.69E−04 6.80E−04 44.8E−04 2.6616 0.0039
10 21.7E−04 10.5E−04 1.23E−04 42.3E−04 2.0772 0.0189
11 25.9E−04 11.3E−04 3.68E−04 48.0E−04 2.2849 0.0112
12 22.2E−04 12.2E−04 −1.64E−04 46.1E−04 1.8252 0.0340
13 22.1E−04 13.0E−04 −3.26E−04 47.5E−04 1.7082 0.0438
14 15.6E−04 13.8E−04 −11.3E−04 42.6E−04 1.1349 0.1282
15 16.5E−04 15.1E−04 −13.0E−04 46.1E−04 1.0962 0.1365
16 15.8E−04 16.3E−04 −16.1E−04 47.6E−04 0.9682 0.1665
17 17.7E−04 17.1E−04 −15.8E−04 51.1E−04 1.0353 0.1502
18 31.8E−04 18.2E−04 −3.96E−04 67.5E−04 1.7427 0.0407
HIP18: HIP data with follow-up 18 years
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Table 6.10: Estimated ACE(t) (95% CI) using the F-R method for the HIP7
data.
Method: F-R Data: HIP7
Year ÂCEFR SEace LCLace UCLace Zvalue p− value
1 0.38E−04 0.93E−04 −1.44E−04 2.20E−04 0.4126 0.3399
2 2.03E−04 1.63E−04 −1.16E−04 5.23E−04 1.2464 0.1063
3 3.58E−04 2.22E−04 −0.76E−04 7.93E−04 1.6160 0.0530
4 7.38E−04 2.97E−04 1.56E−04 13.2E−04 2.4843 0.0065
5 12.1E−04 3.92E−04 4.41E−04 19.8E−04 3.0855 0.0010
6 18.7E−04 4.74E−04 9.44E−04 28.0E−04 3.9507 0.0000
7 18.7E−04 4.74E−04 9.44E−04 28.0E−04 3.9507 0.0000
HIP7: HIP data with follow-up of 7 years
Table 6.11: Estimated ACE(t)(95% CI) using the F-R method for the HIP18
data.
Method: F-R Data: HIP18
Year ÂCEFR SEace LCLace UCLace Zvalue p− value
1 0.38E−04 0.93E−04 −1.44E−04 2.20E−04 0.4126 0.3399
2 2.03E−04 1.63E−04 −1.16E−04 5.23E−04 1.2464 0.1063
3 3.58E−04 2.22E−04 −0.76E−04 7.93E−04 1.6160 0.0530
4 7.38E−04 2.97E−04 1.56E−04 1.32E−03 2.4843 0.0065
5 12.1E−04 3.92E−04 4.41E−04 1.98E−03 3.0855 0.0010
6 18.6E−04 4.77E−04 9.23E−04 2.79E−03 3.8932 0.0000
7 17.1E−04 5.30E−04 6.74E−04 2.75E−03 3.2317 0.0006
8 14.1E−04 5.81E−04 2.71E−04 2.55E−03 2.4268 0.0076
9 17.3E−04 6.49E−04 4.55E−04 3.00E−03 2.6614 0.0039
10 14.6E−04 7.01E−04 0.82E−04 2.83E−03 2.0769 0.0189
11 17.3E−04 7.58E−04 2.46E−04 3.22E−03 2.2844 0.0112
12 14.9E−04 8.15E−04 −1.10E−04 3.08E−03 1.8249 0.0340
13 14.8E−04 8.68E−04 −2.19E−04 3.18E−03 1.7081 0.0438
14 10.5E−04 9.21E−04 −7.60E−04 2.85E−03 1.1350 0.1282
15 11.1E−04 10.1E−04 −8.72E−04 3.09E−03 1.0963 0.1365
16 10.5E−04 10.9E−04 −10.8E−04 3.19E−03 0.9683 0.1665
17 11.8E−04 11.4E−04 −10.6E−04 3.42E−03 1.0354 0.1502
18 21.3E−04 12.2E−04 −2.66E−04 4.52E−03 1.7426 0.0407
HIP18: HIP data with follow-up of 18 years
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6.5 Model comparisons
In Sections 6.2, 6.3 and 6.4, we analysed the HIP data using three models,
namely the NIGN-WW model, the IGN-W model and the F-R method. In
this section, we focus on comparing these three models using the results of
analysis of both the HIP18 and HIP7 datasets.
We first compare the non-ignorable PPO-survival model and the F-R
method (Section 6.5.1). Secondly, we compare the ignorable PPO-survival
model and the non-ignorable PPO-survival model (Section 6.5.2).
6.5.1 Non-ignorable PPO-survival model vs the F-R method
Since the non-ignorable PPO-survival model is developed under the same
assumptions as those for the F-R method, it is reasonable to expect that
the results from these two approaches would be comparable. However, it
also would not be surprising to see some differences between these results on
the HIP data; as indeed, these two approaches derive from different method-
ologies. Recall that the non-ignorable PPO-survival model is derived from
a parametric perspective through the maximum likelihood method, whilst
the F-R method is a nonparametric approach which uses the Kaplan-Meier
estimator (p.84, Klein (1997)).
The results from the NIGN-WW and the NIGN-LL model are comparable
to those obtained by the Frangakis-Rubin (F-R) method, as applied to the
HIP7 data (Figure 6.21, on page 167). This was also observed after an
analogous analysis of the HIP18 data (Figure 6.23, on page 169).
Since the F-R method derives from a nonparametric perspective, it would
not be surprising to see, however, some fluctuation in the F-R specific plot of
CACE(t) (shown on the left hand side of Figure 6.23 for the HIP18 dataset).
Note, however, from the left hand side plots (Figure 6.21), that little fluctu-
ation is evident in the F-R specific CACE(t) plot for the HIP7 dataset. This
is because indeed the period of follow-up is shortened from 18 to 7 years.
In addition to the results mentioned above, we have shown that the non-
ignorable PPO-survival models provide more precise estimators than those
obtained by the F-R method (Figures 6.21, and 6.23), evident by the dis-
crepancy in width of the associated confidence intervals.
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Figure 6.19: Estimated CACE(t) using the F-R method (with 95% confidence
interval): HIP7 data. The dash-dot line and the dotted line indicate the
Lower Confidence Limit(LCL) and the Upper Confidence Limit (UCL).
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Figure 6.20: Estimated CACE(t) using the F-R method (with 95% confidence
interval): HIP18 data. The dash-dot line and the dotted line indicate the
Lower Confidence Limit (LCL) and the Upper Confidence Limit (UCL).
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6.5.2 The NIGN-WW model vs the IGN-W model
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Figure 6.25: Comparisons of estimated CACE(t) curves using three models
for the HIP7 data. The dash-dot line shows the IGN-W model, the dotted
line shows the NIGN-LL model and the solid line shows the NIGN-WW
mdoel.
Figure 6.25 gives three model-specific curves of ̂CACE(t) for the HIP7
data, including the ̂CACE(t) curve that estimated by the IGN-W model. It
shows that the ̂CACE(t) curve corresponding to the IGN-W model is farther
from the two curves associated with the NIGN-WW model and the NIGN-
LL model. This implies that the IGN-W model may overestimate CACE(t)
on the HIP7 data. Hence, in the HIP7 data, we need to assume latent
ignorability; in which case, HIP7 should be regarded as the special case of
a non-ignorable censoring mechanism. Furthermore, Figure 6.25 shows that
the two specific models from the non-ignorable PPO-survival model provide
very similar values for ̂CACE(t) at each given time (in years). This provides
strong evidence that the non-ignorable-survival model is a robust model, in
that it is not sensitive to the assumed distribution. Column 2 of Table 6.12
gives the estimated CACE (for the HIP7 data) with respect to failure time
171
Table 6.12: Comparisons between CACE and CACE(t) in two models: HIP7
Model CACET¯ CACE(1) CACE(5) AIC = −2ln(L(θ)) + 2m
NIGN-WW 52.64 0.66E-04 14.8E-04 2.0949E+05
NIGN-LL 1312.8 0.62E-04 15.7E-04 2.8393E+05
T (in the general definition, page 26), which can be expressed as
CACE = E(Ti(1)|Zi = 1, Ui = c)− E(Ti(0)|Zi = 0, Ui = c).
The values of CACE obtained by using the NIGN-WWmodel and the NIGN-
LL model were 52.64 vs 1312.8. They are clearly showing that the estimator
CACE strongly relies on the assumed distribution; while Column 3 and 4
of Table 6.12 give the estimated CACE(t) (in the specific definition, page
52) for t = 1 and t = 5 on the HIP7 dataset via the two aforementioned
models, namely 0.66E − 045 vs 0.62E − 04 (for t = 1) and 14.8E − 04 vs
15.7E−04 (for t = 5). These results provide evidence that inferences for the
specific complier average causal effect CACE(t) (for time-to-event data), are
not as sensitive to distributional assumptions as inference for CACE. Indeed,
by comparing their AIC (Akaike Information criterion 1) for the HIP7 data,
the Weibull distribution (AICnign−ww = 2.0948E + 5) fits better than the
log-normal (AICnign−ll = 2.8392E + 5) distribution for the non-ignorable
PPO-survival model. But both models give similar results (Figures 6.5 and
6.6 on page 144).
On the other hand, estimated survival values for the HIP18 and HIP7
data, using the IGN-W model (given on the right-hand graphs in Figure
6.26 on page 174 and Figure 6.28 on page 176), also show that the IGN-W
model does not provide as reasonable results as the non-ignorable PPO-
survival models, (the NIGN-WW and the NIGN-LL model). According to
the estimated survival values for the three subgroups using the IGN-Wmodel,
Subgroup 3 is the highest among the three subgroups, which is not consistent
1A measure of the goodness fit of an estimated statistical model, AIC = −2ln(L(θ))+
2m where m is the number of parameters and ln(L(θ)) is the maximum nature logarithm
likelihood function for the estimated model. The one with lowest AIC is the best model.
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with the results provided via the F-R method and the non-ignorable PPO-
survival models. This is hard to interpret reasonably.
In fact, both the NIGN-WW and the NIGN-LL models perform much
better than the IGN-W model (Figure 6.28 on page 176) and Figure 6.26 on
page 174).
Figures 6.26 (on page 174) and 6.28 (on page 176) provide strong evi-
dence to support our argument, that in the case of both the HIP18 and HIP7
datasets, the NIGN-WW model provides more precise results than does the
IGN-W model. With respect to the F-R and the NIGN-WW models, Sub-
group 1 (individuals who took the screening examination) has a higher sur-
vival probability than subgroups where individuals did not take the screening
examination. This shows a clear and significant treatment benefit of breast
screening.
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6.6 Results of the analysis of the HIP data via the non-ignorable
PPO-survival model
Table 6.3 (on page 139) shows the estimated complier average causal effect
ĈACE(t) and Table 6.4 (on page 140) shows the estimated average causal
effect ÂCE(t) obtained via the NIGN-WW and the NIGN-LL models. (Fur-
ther details are given in Tables C-22, C-23, C-16 and C-17 in Appendix C).
From these tables, we can see that ĈACE(t) and ÂCE(t) are completely
positive at each given observed year. This implies that a woman undertak-
ing screening would have a higher probability of surviving breast cancer than
she would without having been screened.
6.6.1 Estimated CACE(t) for the HIP7 data
More specifically, from the NIGN-WWmodel on theHIP7 data, ĈACE(5) =
14.8E− 04 and SEcace(5) = 3.83E− 04 (Table 6.3 on page 139 or Table C-22
on page 264). This indicates that after five years, a woman has about 0.148%
more probability (with 0.0383% standard error) of survival than otherwise.
This can also be interpreted as follows: out of 10,000, women about 14.8
(±3.83) women would be saved from breast cancer-related death five years
after screening.
The result from the NIGN-LL model is similar, in that ĈACE(5) =
15.7E−04 (SEcace(5) = 4.02E−04) (Table 6.3 on page 139 or Table C-23 on
page 264). This is equivalent to about 15.7 (±4.02) women in 10,000 being
saved from breast cancer-related death five years after screening.
6.6.2 Estimated CACE(t) for the HIP18 data
For the HIP18 data, the results show that in 10,000 women, about 3.56
(±1.86) women would be saved from breast cancer-related death five years
after screening, as the complier average causal effect (CACE(t)) with its asso-
ciated standard error estimated (via the NIGN-WW model) is ĈACE(5) =
3.56E − 04 (SEcace(5) = 1.86E − 04) (Table 6.3 on page 139 or Table C-16
on page 260). On the other hand, the ĈACE(t) obtained via the NIGN-LL
model is ĈACE(5) = 5.22E−04 (SEcace(5) = 2.19E−04) (Table 6.3 on page
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139 or Table C-17 on page 261), which is equivalent to stating that about
5.22 (±2.19) women in 10,000 are being saved from breast cancer-related
death five years after screening.
Even though the estimated values of ̂CACE(5) from these two specific
non-ignorable PPO-survival models are different, they all tend to support
the conclusion that women (over 40 years), who are screened would have a
significantly reduced risk of breast cancer-related death.
By comparing the estimated complier average causal effects at the first
year ( ̂CACE(1)) in the HIP trial, it is easy to see that ̂CACE(1) < ̂CACE(5)
(Table 6.3 on page 139) for the two specific non-ignorable PPO-survival
models. More details are given in Tables C-22 , C-23, C-16 and C-17 in
Appendix C. These results indicate that out of 10,000 women, the number
of women saved from breast cancer related-death at the first year is signifi-
cantly less than at the fifth year after screening. For the HIP7 dataset, the
number of women saved from breast cancer related-death at the first year is
0.66(±0.24) vs 14.8(±3.83) the number of women being saved at the fifth year
(using the NIGN-WW model); with the NIGN-LL model, it is 0.62(±0.25)
vs 15.7(±4.02).
This provides strong evidence to support, what is nowadays, accepted
as common sense: the earlier breast cancer is detected, (and the earlier
it is treated), the greater a woman’s chance of survival. This conclusion
is consistent with that reported by Shapiro et al. (1988). Mammography
screening is now commonplace in the US (www.radiologyinfo.org), Australia
(www.health.gov.au) and New Zealand (www.nzbcf.org.nz).
However, the results for the HIP18 and HIP7 datasets (Table 6.3 on page
139) obtained using the NIGN-WW and the NIGN-LL models are different.
One needs to make a decision as to which model is closer to the truth. As
we stated in section 6.2.3, in a scenario of long-term follow-up, individuals’s
health status at beginning may not affect their survival probability in later
years. Especially, Figure 6.17 (on page 160) shows that around 12 years it
appears a crossing of the survival curves corresponding to Subgroup 2 Sc0(t)
and Subgroup 3 Sn(t). This implies that for the HIP trial, the non-ignorable
PPO-Survival models, (e.g. the NIGN-WW and the NIGN-LL models) would
perform better in analysing a short term follow-up data (the HIP7) than a
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long-term follow-up data (the HIP18).
Furthermore, by comparison with the F-R method, which gives ĈACE(5) =
18.1E − 04 (SEcace(5) = 5.85E − 04) for both the HIP18 and HIP7 datasets
(Table 6.3 on page 139), we believe that the non-ignorable PPO-survival
model is optimal for the HIP7 data than the HIP18 data, because the re-
sults of the HIP7 data obtained by the non-ignorable PPO-survival model,
ĈACE(5) = 14.8E− 04 (SEcace(5) = 3.83E− 04) (in the NIGN-WW model)
and ĈACE(5) = 15.7E − 04 (SEcace(5) = 4.02E − 04) (in the NIGN-LL
model), are much more closer to those obtained via the F-R method than
the results of the HIP18 data, which are ĈACE(5) = 3.56E−04 (SEcace(5) =
1.86E−04) (in the NIGN-WWmodel) and ĈACE(5) = 5.22E−04 (SEcace(5) =
2.19E − 04) (in the NIGN-LL model).
Theoretically, the non-ignorable PPO-survival model and the F-R method
are comparable, as they are both derived under the same assumptions. The
difference between them is only that the former is a parametric survival
model, while the latter is a non-parametric survival model. Table 6.13 (on
page 180) shows the results of the HIP7 data from the non-ignorable and F-R
models. Clearly, the non-ignorable PPO-survival models provide significantly
smaller standard errors for ĈACE(t) compared to the F-R method.
Table 6.13: Results of the analysis of the HIP7 data via the non-ignorable
PPO survival model. Numbers indicate the number of increased survivals
due to screening per 10,000 (on HIP7 data). The associated standard error
is given in brackets.
Survival year NIGN-WW model NIGN-LL model F-R method
1 0.66(±0.24) 0.62(±0.24) 0.57 (±1.39)
5 14.8(±3.83) 15.7(±4.02) 18.1 (±5.85)
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6.7 Summary
Briefly, the non-ignorable PPO-survival model variants do work well on the
re-analysis of the HIP data, especially on the HIP7 dataset using our two
specific models, the NIGN-WW and the NIGN-LL model. This can be seen
from the following: first, the results of CACE(t) and ACE(t) from these two
models are comparable as shown by Tables C-22, C-23 (for CACE(t)) and by
Tables C-20, C-21 (for ACE(t)). That is the NIGN-WW and the NIGN-LL
specific CACE(t) and ACE(t) are very close in the analysis of the HIP7 data
(Figures 6.5 and 6.6 on page 144 for CACE(t) and Figures 6.7 and 6.8 on
page 145 for ACE(t)). Secondly, these results are also comparable with the
results obtained via the F-R method (Table 6.13 on page 180). Note, however,
that the latter yields larger standard errors for its estimated CACE(t). In
addition, inferences for ACE(t) and CACE(t) via the non-ignorable PPO-
survival model are not sensitive to distributional assumptions for failure time
and censoring time (Figure 6.25 on page 171 and Table 6.12 on page 172).
On the other hand, for RCTs with all-or-none compliance, the non-
ignorable PPO-survival model provides more precise results of the analysis of
the HIP7 data than the ignorable PPO-survival model, because of the occur-
rence of noncompliance. Indeed, the ignorable PPO-survival model provides
an overestimated treatment benefit (Figure 6.25 on page 171, Figure 6.15 on
page 155, Table 6.6 and Table 6.7 on page 152). However, the ignorable PPO-
survival model is worth consideration, as it can be applied to the scenario
when the non-informative censoring assumption holds (Section 3.1.4).
The non-ignorable and ignorable PPO-survival models, proposed in this
thesis, provide a significant contribution by dealing with the important issue
of making causal inferences on survival outcomes from RCTs with all-or-none
compliance. These models are derived by a likelihood-based method, which
is different from the potential-outcome models proposed earlier by Robins
and his colleagues (Robins & Tsiatis, 1991, 1992). Since our non-ignorable
(and ignorable) PPO-survival models aim to analyse survival outcomes, we
require different distributions rather than the conventional normal distribu-
tion. Thus our work differs from the approach of O’Malley & Normand
(2005), which does not consider time-to-event data.
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Our non-ignorable and ignorable PPO-survival models provide a new
point of view in survival analysis, which combines the potential outcomes
framework (Greenland, 2004; Pearl, 2001, 2000; Graham, 2000) with the
traditional parametric survival approach (Klein, 1997; Cox & Oakes, 1984;
Kalbfleisch & Prentice, 2002) and also adopts the EM algorithm (Dempster
et al., 1977; Louis, 1982) to deal with unobservable variables. This is origi-
nal work, not done to date. In Chapter 7, we extend the non-ignorable and
ignorable PPO-survival models to the scenario when pre-treatment covari-
ates are involved. Further discussion about the non-ignorable and ignorable
PPO-survival models and their covariate extension are given in Chapter 8.
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Chapter 7
Parametric potential-outcome survival models with
pre-treatment covariates
7.1 Motivation
In Chapter 5, two parametric potential-outcome (PPO) survival models,
namely the non-ignorable and ignorable censoring mechanism survival mod-
els, were formulated. They pertain, however, only to cases where no pre-
treatment covariates (excluding assigned treatment Zi) are included. In med-
ical research, pre-treatment covariates, such as an individual’s age, gender,
smoking history, blood pressure, preliminary disease or health status etc.,
may play an important role in mediating the effect of treatment. For many
RCTs, it is often of interest to investigate the causal effect of treatment, as
the treatment effect may vary with pre-treatment covariate levels when these
are involved (Peng et al., 2004; Mealli et al., 2004).
In this chapter, we extend the parametric potential-outcome (PPO) sur-
vival model(s) of Chapter 5 to incorporate time independent pre-treatment
covariates, denoted by X. Unlike Peng’s approach (Peng et al., 2004),
we model the compliance type variable (Ui) conditionally on related pre-
treatment covariates (X). This seems more natural than Peng’s approach
(Peng et al., 2004) which modelled the covariates, X, conditionally on com-
pliance type (Peng et al., 2004). However, the two different model specifica-
tions are, of course, related by Bayes’ theorem. Note that to date, only Peng’s
work (Peng et al., 2004) has focused on estimating CACE and ACE in the
presence of covariates, but Peng’s approach is not applicable to time-to-event
studies (Peng et al., 2004).
In this chapter, the assumptions specified in Chapter 5 are extended
specifically to the case of time independent covariates, X. Recall that, in
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brief, these assumptions are: 1) the stable unit treatment value assumption
(SUTVA), 2) random assignment, 3) exclusion restriction, 4) monotonicity,
and 5) latent ignorablity. In addition, we assume that all pre-treatment co-
variates involved in a RCT may impact individual’s compliance type. For
convenience, we call the PPO-survival models derived in Chapter 5 the PPO-
survival models (I), while the extensions derived in this chapter are called
the PPO-survival model (II).
This chapter follows this outline: first we structure the joint distribution
of all potential observable variables, including the pre-treatment covariates,
in Section 7.2. The likelihood function of the PPO-survival model (II) is
given in Section 7.3. Section 7.4 addresses the AFT model, and they are
specified to Weibull and log-normal distributions for failure and censoring
time in Section 7.5. The issues surrounding the model computation are
given in Section 7.6. The special case of the extended PPO-survival model
with pre-treatment covariates, the so-called ignorable PPO-survival model
(II), is disccused in Section 7.7. Section 7.8 illustrates the implementation of
the EM algorithm involved in the non-ignorable PPO-survival model (II) by
using the HIP7 data. Section 7.9 provides the summary of this chapter.
7.2 Structure of joint distribution with pre-treatment covariates
7.2.1 Joint distribution of T, C, D, Z and X
In the scenario of additional pre-treatement covariates (Xi), for each in-
dividual, the potentially observable entities are given by T, C, D, Z and
X. As before, these variables are all assumed to be independent and iden-
tically distributed (i.i.d.), where the bold symbol with underline represent
potential-outcome vectors for all individuals, such as T, C and D. The joint
distribution of the potentially observable entries can then be written as:
Pr(T,C,D, Z,X;ΨX) =
N∏
i=1
Pr(Ti,Ci,Di, Zi, Xi;ΨX), (7.2.1)
where ΨX represents this new model’s parameters, and Pr() denotes the
probability of variables given in brackets. By following the rule of conditional
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probability, the joint distribution of all potential variables, say for the ith
individual, can be written as below:
Pr(Ti,Ci,Di, Zi, Xi;ΨX)
= Pr(Ti,Ci|Zi,Di, Xi;θX)Pr(Di|Zi, Xi; εX)Pr(Zi; ν)Pr(Xi;ω).
(7.2.2)
Note that ΨX is now broken down as (θX , εX , ν, ω) in equation (7.2.2),
where θX denotes the parameter associated with the joint distribution of
failure and censoring times that is conditioal on pre-treatment Xi ; εX rep-
resents the parameter associated with the conditional distribution of actual
received treatment Di (given the assigned treatment Zi = z and the pre-
treatment covariates Xi = x); and the parameters ν and ω are associated
with the assigned treatment (Zi) distribution and the pre-treatment covari-
ates (Xi) distribution respectively.
Similar to the PPO-survival model (I) formulated in Chapter 5, the distri-
bution ofDi = (D
obs
i , D
mis
i ), given the observed variables: assigned treatment
Zi and covariates Xi, can be re-written as follows:
Pr(Di|Zi,Xi; εX) = Pr(Dobsi , Dmisi |Zi, Xi; εX)
= Pr(Dmisi |Dobsi , Zi, Xi; εzdx)Pr(Dobsi |Zi, Xi; εzx),
(7.2.3)
where the parameter εX has been partitioned as (εzdx, εzx), for which the
partitioned components denote the parameters corresponding to the condi-
tional distributions of Dmisi and D
obs
i separately. By the definition of actual
received treatment Dobsi , Pr(D
obs
i |Zi, Xi; εzx) can be further split as follows:
Pr(Dobsi |Zi, Xi; εzx) = Pr(Dobsi |Zi, εz)Pr(Zi; ν)Pr(Xi;ω). (7.2.4)
The parameter εzx has then been broken down as εzx = (εz, ν, ω). As stated
in Section 5.3, for this extended model, we can re-write equation (5.3.2) to
accommodate pre-treatment covariates as follows:
Pr(Ui|Dobsi , Zi, Xi;piX)⇐d⇒ Pr(Dmisi |Dobsi , Zi, Xi; εzdx); (7.2.5)
where ⇐d⇒ is used to denote distributional equivalence, as in equation
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(5.3.2). Therefore, the joint distribution of all variables, including the potential-
outcome vectors Ti, Ci, Di and the observed variable Zi and Xi, denoted by
Pr(Ti, Ci, Di, Zi, Xi;ΨX), is equivalent to the following product:
Pr(Ti,Ci,Di, Zi, Xi;ΨX)
⇐d⇒

Pr(Ti,Ci|Zi, Ui, Xi;θX)
Pr(Ui|Dobsi , Zi, Xi;piX)
Pr(Dobsi |Zi; εz)Pr(Zi; ν)Pr(Xi;ω).

(7.2.6)
7.2.2 Joint distribution of the observable variables
The joint distribution of all observable variables, T obsi , C
obs
i , D
obs
i , Zi and Xi,
which is denoted by Pr(T obsi , C
obs
i , D
obs
i , Zi, Xi;ΨX), can then be expressed
as follows:
Pr(T obsi , C
obs
i , D
obs
i , Zi, Xi;ΨX)
=
∫ ∫ ∫
Pr(Ti,Ci,Di, Zi, Xi;ΨX)dD
mis
i dC
mis
i dT
mis
i .
(7.2.7)
By substituting equation (7.2.6) into equation (7.2.7), the latter is equiv-
alent to:
Pr(T obsi , C
obs
i , D
obs
i , Zi, Xi;ΨX)
⇐d⇒
∫ ∫ ∫ 
Pr(Ti,Ci|Zi, Ui, Xi;θX)
×Pr(Ui|Dobsi , Zi, Xi; piX)
×Pr(Dobsi |Zi; εz)Pr(Zi; ν)Pr(Xi;ω)
 dUidCmisi dTmisi
(7.2.8)
Note that T obsi and C
obs
i can never be fully observed together. So strictly,
Pr(T obsi , C
obs
i , D
obs
i , Zi, Xi;ΨX) cannot be considered to be the joint distri-
bution of the observed variables. As in Section 5.4.2, we call it the joint
distribution of the observable variable.
Furthermore, because the assumption of latent ignorablility, we have:
Pr(Ti,Ci|Zi, Ui, Xi;θX) = Pr(Ti|Zi, Ui, Xi;θTX)Pr(Ci|Zi, Ui, Xi;θCX).
(7.2.9)
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Equation (7.2.8) can then be re-written as follows:
Pr(T obsi , C
obs
i , D
obs
i , Zi, Xi;ΨX)
⇐d⇒
∫ ∫ ∫

Pr(Ti|Zi, Ui, Xi;θTX)
×Pr(Ci|Zi, Ui, Xi;θCX)
×Pr(Ui|Dobsi , Zi, Xi; piX)
×Pr(Dobsi |Zi; εz)Pr(Zi; ν)Pr(Xi;ω)
 dUidC
mis
i dT
mis
i
(7.2.10)
Since compliance type Ui is a discreate variable with three catergories,
equation (7.2.10) can be expressed as the similar form as equation (5.4.18),
that is:
Pr(T obsi , C
obs
i , D
obs
i , Zi, Xi;ΨX)
⇐d⇒
∫ ∫ ∫ 
Pr(Ti,Ci|Zi, Ui, Xi;θX)
×Pr(Ui|Dobsi , Zi, Xi;piX)
×Pr(Dobsi |Zi; εz)Pr(Zi; ν)Pr(Xi;ω)
 dUidCmisi dTmisi
=

Pr(Dobsi |Zi; εz)
×Pr(Zi; ν)
×Pr(Xi;ω)

∑
u∈{a,c,n}

∫
Pr(Ti|Zi, Ui, Xi;θTX)dTmisi
× ∫ Pr(Ci|Zi, Ui, Xi;θCX)dCmisi
×Pr(Ui|Dobsi , Zi, Xi;piX)

=Pr(Dobsi , Zi;λ)Pr(Xi;ω)
∑
u∈{a,c,n}

Pr(T obsi |Zi, Ui, Xi;θTX)
×Pr(Cobsi |Zi, Ui, Xi;θCX)
×Pr(Ui|Dobsi , Zi, Xi; piX)

(7.2.11)
7.3 The likelihood function
7.3.1 The idealised likelihood function
According to the formulation of the joint distribution of the observed vari-
ables, Pr(T obsi , C
obs
i , D
obs
i , Zi, Xi;ΨX), given in equation (7.2.11), the ide-
alised likelihood function for the PPO-survival model (II), denoted by IDL
(E)
i (ΨX),
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can then be expressed as the following sums of products (in brackets):
IDLEi (ΨX)
=Pr(Dobsi , Zi, λ)Pr(Xi;ω)
∑
Ui∈{c,n,a}

Pr(T obsi |Ui, Zi, Xi;θTX)
Pr(Cobsi |Ui, Zi, Xi;θCX)
Pr(Ui|Dobsi , Zi, Xi;piX),

(7.3.1)
where θTX and θCX denote the parameters associated with the failure and the
censoring time distributions given the pre-treatment covariates Xi; Pr(Xi;ω)
denotes the distribution of pre-treatment covariatesXi which is only included
in the idealised likelihood function IDLEi (ΨX) (equation (7.3.1)) rather than
the idealised likelihood function IDLi(Ψ) (equation (5.5.2)); Pr(D
obs
i , Zi, λ)
is same as in equation (5.5.2).
Note that except for Pr(Dobsi , Zi, λ)), the remains of distributions involved
in the idealised likelihood function IDLEi (ΨX) (equation (7.3.1)), all are
conditional on the given pre-treatment covariates Xi.
As in the PPO-survival model (I) (Chapter 5), we are interested in in-
vestigating the parameters associated with the failure time. We write the
relevant parametrisation as (θTX) for this chapter’s extension to covariate-
adjusted PPO-survival models. However, from equation (7.3.1), it is clear
that θTX cannot be estimated independently from θCX and pi, because these
three paramters are all involved in the summation over compliance type and,
therefore, the likelihood for these paramters does not separate into distinct
components which can be maximised separately. We thus use the following
notation β = (θTX , θCX ,piX), to allow for all parametric inter-relationships.
We focus now on deriving the idealised likelihood function with respect to β
rather than with respect to ΨX , denoted by L
E
i (β). We then write IDL
E
i (β)
as follows:
IDLEi (β)
=
∑
Ui∈{c,n,a}

Pr(T obsi |Ui, Zi, Xi;θTX)
×Pr(Cobsi |Ui, Zi, Xi;θCX)
×Pr(Ui|Dobsi , Zi, Xi;piX).

(7.3.2)
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7.3.2 The conditional probability of compliance
Clearly, the term Pr(Ui|Dobsi , Zi, Xi;piX) in equation (7.3.2), denotes the
conditional probability of compliance type Ui, given Zi = z, Di(z) = d and
Xi = x. Here, the parameter piX can be specified as piu,zdx = Pr(Ui = u|Zi =
z,Di(z) = d,Xi = x) for u = (a, c, n), z, d = 0or 1, andXi = x.
Recall from Table 5.1 that knowledge of the values of Zi = z and Di = d,
allows the ith individual’s compliance type to be determined for up to two
types. We can thus assume that the conditional probability of compliance
type, Ui = u, given Zi = z, Di = d, and Xi = x, piu,zdx, follows a logistic
model (see Mealli et al. (2004) and, more recently, Mattei & Mealli (2007)).
This can be expressed as follows:
logit(pic,zdx) = log(
pic,zdx
1− pic,zdx ) = ηzd0 + ηzd1Xi, (7.3.3)
or equivalently:
pic,zdx =
exp(ηzd0 + ηzd1Xi)
1 + exp(ηzd0 + ηzd1Xi)
. (7.3.4)
where ηzd0 and ηzd1 denote the regression coefficients associated with the
intercept term and the pre-treatment covariates Xi, respectively.
7.3.3 The likelihood function for complete data
Suppose that each individual’s compliance type, Ui = u, is known. Then the
idealised likelihood function, with respect to β, for the complete data is as
follows:
IDLEi(β, u) =

Pr(T obsi |Ui = u, Zi = z,Xi = x;θTX)
×Pr(Cobsi |Ui = u, Zi = z,Xi = x;θCX)
×Pr(Ui = u|Dobsi = d, Zi = z,Xi = x;piu,zdx).

(7.3.5)
For the specified assigned treatment Zi = z and the pre-treatment covari-
atesXi = x (with known Ui = u), and given the indicator of censoring Ri, the
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likelihood function of β, denoted by LEi (β;u), has the following formulation:
LEi(β;u) =
Pr(Ti(z) = t|Ui = u, Zi = z,Xi = x;θT,uzx)Ri
×Pr(Ci(z) > t|Ui = u, , Zi = z,Xi = x;θC,uzx)Ri
×Pr(Ti(z) > t|Ui = u, Zi = z,Xi = x;θT,uz)1−Ri
×Pr(Ci(z) = t|Ui = u, , Zi = z,Xi = x;θC,uzx)1−Ri
×Pr(Ui = u|Di(z) = d, Zi = z,Xi = x;piu,zdx).

(7.3.6)
Note that in equation (7.3.6), all relevant parameters have the pre-treatment
covariates x included in their subscript. As in equation (5.5.6), Ri is the indi-
cator of censoring, 1 indicates the event of interest, and 0 indicates censoring.
From equation (7.3.6), the ith individual with the pre-treatment Xi = x
(x ∈ X ) who is randomised to treatment Z = 1, and who dies or is censored
at (observed) time t, contributes to the complete data likelihood for β as
follows:
LEi∈{i:Zi=1}(β;u)
=

Pr(Ti(1) = t|Ui = u, Zi = 1, Xi = x;θT,u1x)Ri
×Pr(Ci(1) > t|Ui = u, Zi = 1, Xi = x;θC,u1x)Ri
×Pr(Ti(1) > t|Ui = u, Zi = 1, Xi = x;θT,u1x)1−Ri
×Pr(Ci(1) = t|Ui = u, Zi = 1, Xi = x;θC,u1x)1−Ri
×Pr(Ui = u|Di(1) = d, Zi = 1, Xi = x,piu,1dx);

(7.3.7)
for d = 0 or 1, u ∈ {c, a, n} and x ∈ X .
Similarly, the ith individual with the pre-treatment Xi = x (x ∈ X ), who
is randomised to the control Z = 0, and who dies or is censored at (observed)
time t, contributes to the complete data likelihood for β as follows:
LEi∈{i:Zi=0}(β;u)
=

Pr(Ti(0) = t|Ui = u, Zi = 0, Xi = x;θT,u0x)Ri
×Pr(Ci(0) > t|Ui = u, Zi = 0, Xi = x;θC,u0x)Ri
×Pr(Ti(0) > t|Ui = u, Zi = 0, Xi = x;θT,u0x)1−Ri
×Pr(Ci(0) = t|Ui = u, Zi = 0, Xi = x;θC,u0x)1−Ri
×Pr(Ui = u|Di(0) = d, Zi = 0, Xi = x;piu,0dx);

(7.3.8)
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for d = 0 or 1, ,u ∈ {c, a, n} and x ∈ X .
Hence, given the values of z and d, equations (7.3.7) and (7.3.8) can then
be expressed as one overall equation with the following formulation:
LEi∈{i:Zi=z,Di(z)=d}(β; u)
=

Pr(Ti(z) = t|Ui = u, Zi = z,Xi = x;θT,uzx)Ri
×Pr(Ci(z) > t|Ui = u, Zi = z,Xi = x;θC,uzx)Ri
×Pr(Ti(z) > t|Ui = u, Zi = z,Xi = x;θT,uzx)1−Ri
×Pr(Ci(z) = t|Ui = u, Zi = z,Xi = x;θC,uzx)1−Ri
×Pr(Ui = u|Di(z) = d,Xi = x, piu,zdx);

(7.3.9)
for z, d = 0 or 1, u ∈ {c, a, n} and x ∈ X .
As before, for notational convenience, we introduce the following conven-
tions in this chapter:
f iux(v, t; θT,uvx) = pr(Ti(v) = t|Ui = u,Xi; θT,uvx), for v = 0, 1,
eiux(v, t; θC,uvx) = pr(Ci(v) = t|Ui = u,Xi; θC,uvx), for v = 0, 1,
Siux(v, t; θT,uvx) = Pr(Ti(v) > t|Ui = u,Xi; θT,uvx), for v = 0, 1,
Giux(v, t; θC,uvx) = Pr(Ci(v) > t|Ui = u,Xi; θC,uvx), for v = 0, 1,
where Pr() and pr() represent the probability density distribution and the
probability distriution, respectively, and v dentoes potential treatment levels.
Using this notation in equation (7.3.9), we obtain the form of the likeli-
hood function for the ith individual with respect to β for the non-ignorable
PPO-survival model (II), which is given in equation (7.3.10) below. This cor-
responds to the case where the pre-treatment covariates Xi and compliance
type Ui are assumed to be known. We write this as:
LEi∈{i:Zi=z,Di(z)=d}(β;u)
=
{
[f iux(z, t; θT,uzx)G
i
uzx(z, t; θC,uzx)]
Ri
[Siux(z, t; θT,uzx)e
i
ux(v, t; θC,uzx)]
1−Ri piu,zdx.
}
(7.3.10)
Equation (7.3.10) thus gives the likelihood function (corresponding to the
ith individual) for complete data, in the so-called non-ignorable PPO-survival
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model (II), where the model parameter β accommodates the inclusion of
covariates X, which has a form as the following:
β = (θT,uzx,θC,uzx,piu,zdx); (7.3.11)
where θT,uzx denotes the parameter associated with the failure time distribu-
tion, it can be further partitioned when considering the specific subgroups,
that is
θT,uzx = (θT,c1x,θT,c0x,θT,nx,θT,ax). (7.3.12)
Similarly, the parameter associated with the censoring time distributioin
θC,uzx can be expressed as follows:
θC,uzx = (θC,c1x,θC,c0x,θC,nx,θC,ax). (7.3.13)
Note that, unlike in the non-ignorable PPO-survival model (I), the parameter
associated with the conditional distribution of compliance type is denoted by
piu,zdx rather than piu,zd because in this case the pretreatment covariates X
are involved. This implies that more parameters have to be included in the
model paremeter β. In fact, equation (7.3.4) gives the formula of calculating
pic,zdx, where ηzd0 and ηzd1 (for both z and d with 1 and 0) refer to the
regression coefficients in the logistic model.
7.4 AFT model including pre-treatment covariates
For time-to-event studies, the accelerated failure time model (AFT) (p.64
Cox & Oakes (1984) or p.46, Klein (1997)) is a powerful tool to link survival
outcomes with related covariates. Recall that in Section 5.7, we derived an
AFT model for a RCT with noncompliance without covariates (see equations
(5.7.16) or (7.4.17)). In this section, we extend the AFT model, given in
equation (5.7.16), to incorporate pre-treatment covariates Xi = x. We do
likewise for the censoring time component (Section 7.4.2).
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7.4.1 The AFT model for failure time
Given equation (5.7.16), derived in Section 5.7, it is relatively straightforward
to introduce pre-treatment covariates into the AFT model structure. The full
range of possibilities for modelling covariate effects, including interactions
between covariates, compliance type and non-linear covariate effects, can be
considered for both the causal and selection parts of the model. The simplest
model would assume no interaction between compliance type and covariates
on the effect of assigned treatment, and assume that the effect of covariates
on failure time, if not assigned to treatment, is the same for all compliance
types. Thus the simplest model could be written as:
Ti(1) = Ti(0) exp(ζ + ζ
(c)U
(c)
i + ζ
(a)U
(a)
i + ζxXi);
Ti(0) = T0i exp(φ
(c)U
(c)
i + φ
(a)U
(a)
i + φxXi).
T0i ∼ D(θ(1), θ(2)).
(7.4.1)
Let us consider another scenario. If it is necessary to explore the possi-
bility that the effect of treatment, in particular for compliance types Ui = u,
depends on the covariate levels Xi = x (e.g., the effect of treatment for com-
pliers could depend on age, with the effectiveness of the treatment declining
effects with increased age) then interaction terms need to be introduced into
the casual model to relate to potential outcomes. Thus a model allowing the
causal effect of treatment (i.e. assigned treatment) for particular compliance
types, to vary with covariate levels can be specified as follows:
Ti(1) = Ti(0) exp(ζ + ζ
(c)U
(c)
i + ζ
(a)U
(a)
i + ζxXi + ζ
(c)
x XiU
(c)
i + ζ
(a)
x XiU
(a)
i ).
(7.4.2)
Given compliance type Ui = u, for u{c, a, n}, the failure time Ti(1)
corresponding to potential treatment level v = 1, can be expressed as follows:
Ti(1) =

Ti(0) exp(ζ + ζ
(c) + (ζx + ζ
(c)
x )Xi) for Ui = c,
Ti(0) exp(ζ + ζ
(a) + (ζx + ζ
(a)
x )Xi) for Ui = a,
Ti(0) exp(ζ + ζxXi) for Ui = n.
(7.4.3)
Under the assumption of exclusion restriction, Ti(1) = Ti(0) (for Ui = a
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or n) holds. This implies the following:
exp(ζ + ζ(a) + (ζx + ζ
(a)
x )Xi) = 1 for all Xi,
exp(ζ + ζxXi) = 1 for all Xi,
(7.4.4)
which are equivalent to
ζ + ζxXi = 0 for all Xi,
ζ(a) + ζ(a)x Xi = 0 for all Xi.
(7.4.5)
Equation (7.4.3) can then be simplified as follows:
Ti(1) =

Ti(0) exp(ζ
(c) + ζ
(c)
x Xi) for Ui = c,
Ti(0) for Ui = a,
Ti(0) for Ui = n.
(7.4.6)
Equation (7.4.2) is then easily reduced to
Ti(1) = Ti(0) exp(ζ
(c)U
(c)
i + ζ
(c)
x XiU
(c)
i ). (7.4.7)
Similarly, interaction terms can be introduced into the model for failure
time, in the absence of treatment (i.e. if not assigned to the treatment group),
if the differences between compliance types Ui are likely to vary depending
on covariate level. We then have the following formulation:
Ti(0) = T0i exp(φ
(c)U
(c)
i + φ
(a)U
(a)
i + φxXi + φ
(c)
x XiU
(c)
i + φ
(a)
x XiU
(a)
i ),
(7.4.8)
which is equivalent to:
Ti(0) =

T0i exp(φ
(c) + φxXi + φ
(c)
x Xi) for Ui = c,
T0i exp(φ
(a) + φxXi + φ
(a)
x Xi) for Ui = a,
T0i exp(φxXi) for Ui = n.
(7.4.9)
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Combining equations (7.4.7) and (7.4.8), we have:
Ti(1)
=
{
T0i exp(φ
(c)U
(c)
i + φ
(a)U
(a)
i + φxXi + φ
(c)
x XiU
(c)
i + φ
(a)
x XiU
(a)
i )
exp(ζ(c)U
(c)
i + ζ
(c)
x XiU
(c)
i )
}
,
=T0i exp((φ
(c) + ζ(c))U
(c)
i + φ
(a)U
(a)
i + φxXi + (φ
(c)
x + ζ
(c)
x )XiU
(c)
i + φ
(a)
x XiU
(a)
i ).
(7.4.10)
Given compliance type Ui = u, (for u ∈ {c, a, n}), equation (7.4.10) can
then be specified as the following relationships:
Ti(1) =

T0i exp(ζ
(c) + φ(c) + (φx + φ
(c)
x )Xi) for Ui = c,
T0i exp(φ
(a) + (φx + φ
(a)
x )Xi) for Ui = a,
T0i exp(φxXi) for Ui = n.
(7.4.11)
Similarly, equation (7.4.8), is specified as follows:
Ti(0) =

T0i exp(φ
(c) + (φx + φ
(c)
x )Xi) for Ui = c,
T0i exp(φ
(a) + (φx + φ
(a)
x )Xi) for Ui = a,
T0i exp(φxXi) for Ui = n.
(7.4.12)
Suppose that in a RCT, P covariates are involved . In this case, Xi
denotes a column vector of length P,
Xi = (X
(1)
i , X
(2)
i , . . . , X
(P )
i ).
T
Hence its associated regression coefficients, φx can be viewed as a row vector
with length P, i.e:
φx = (φ
(1)
x , φ
(2)
x , . . . , φ
(P )
x ).
This implies that φxXi can be expanded as
P∑
p=1
φ(p)x X
(p)
i , (7.4.13)
if these P covariates involved in the RCT are continuous or categorical (with
only two levels) variables. When the categorical covariates have more than
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two levels, then more dummy variables are required1.
Similarly, the coefficients associated with the interaction term of covari-
ates Xi and compliance type Ui, which we denote by φ
(c)
x , φ
(a)
x , ζ
(c)
x and ζ
(c)
x ,
can all be written as row vectors with length P. These can be expressed as:
φ(c)x = (φ
(c1)
x , φ
(c2)
x , . . . , φ
(cp)
x );
φ(a)x = (φ
(a1)
x , φ
(a2)
x , . . . , φ
(ap)
x );
ζ(c)x = (ζ
(c1)
x , ζ
(c2)
x , . . . , ζ
(cp)
x ).
(7.4.15)
The term φ
(u)
x Xi (for u = c or a) can also be written as
P∑
p=1
φ(cp)x X
(p)
i = φ
(c1)
x X
(1)
i + φ
(c2)
x X
(2)
i + . . .+ φ
(cP )
x X
(P )
i ;
P∑
p=1
φ(ap)x X
(p)
i = φ
(a1)
x X
(1)
i + φ
(a2)
x X
(2)
i + . . .+ φ
(aP )
x X
(P )
i ;
P∑
p=1
ζ(cp)x X
(p)
i = ζ
(c1)
x X
(1)
i + φ
(c2)
x X
(2)
i + . . .+ ζ
(cP )
x X
(P )
i .
(7.4.16)
Note that the forumulae given in equations (7.4.13) and (7.4.16) are only
for the cases when the covariates involved are continuous variables or cat-
egorical variables with only two levels. When categorical covariates have
more than two levels, more dummy variables are required. Consequently, the
number of regression coefficients will increase. For notational convenience,
we continue to use φxXi to denote the regression terms in the AFT model
rather than using their expansions as given in equation (7.4.13). However,
1More generally, when the pth pre-treatment covariate variable involved in the RCT,
X
(p)
i , has more than two levels, lp> 2, we can then use lp-1 dummy variables
X
(p1)
i , X
(p2)
i , . . . , X
(p(1p−1))
i
to replace X(p)i . Hence the term φ
(p)
x X
(p)
i can then be replaced by:
lp−1∑
l=1
φ(pl)x X
(pl)
i = φ
(p1)
x X
(p1)
i + ζ
(p2)
x X
(p2)
i + . . .+ φ
(p(lp−1))
x X
(p(lp−1))
i . (7.4.14)
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we need to keep in mind that φxXi can be replaced by
∑
p=1
∑lp−1
l=1 φ
(pl)
x X
(pl)
i
where lp denotes the pth covariate’s categorical level and lp−1 is the number
of dummy variables involved in the expansion for the pth covariate.
7.4.2 The AFT model for censoring time
Similarly, for censoring time, its AFT model extension which incorporates
pretreatment covariates Xi, can be formulated as follows:
Ci(1)
=
{
C0i exp(ϕ
(c)U
(c)
i + ϕ
(a)U
(a)
i + ϕxXi + ϕ
(c)
x XiU
(c)
i + ϕ
(a)
x XiU
(a)
i )
exp(ξ(c)U
(c)
i + ξ
(c)
x XiU
(c)
i );
}
=C0i exp((ϕ
(c) + ξ(c))U
(c)
i + ϕ
(a)U
(a)
i + ϕxXi + (ϕ
(c)
x + ξ
(c)
x )XiU
(c)
i + ϕ
(a)
x XiU
(a)
i );
(7.4.17)
This is because under the assumption of exclusion restriction (Angrist et al.,
1996; Frangakis & Rubin, 1999), we have:
ξ + ξxXi = 0 for all Xi,
ξ(a) + ξ(a)x Xi = 0 for all Xi.
(7.4.18)
(See Section 7.4.1).
According to equation (7.4.17), the AFT model for censoring time, allow-
ing pre-treatment covariates Xi = x, can be expressed as:
Ci(1) =

C0i exp(ξ
(c) + ϕ(c) + (ϕx + ϕ
(c)
x )Xi) for Ui = c,
C0i exp(ϕ
(a) + (ϕx + ϕ
(a)
x )Xi) for Ui = a,
C0i exp(ϕxXi) for Ui = n,
Ci(0) =

C0i exp(ϕ
(c) + (ϕx + ϕ
(c)
x )Xi) for Ui = c,
C0i exp(ϕ
(a) + (ϕx + ϕ
(a)
x )Xi) for Ui = a,
C0i exp(ϕxXi) for Ui = n.
(7.4.19)
7.5 Model specifications
Recall that when the failure and censoring times, corresponding to the base-
line, T0i and C0i, are assumed to follow a Weibull or a log-normal distribution,
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the failure time Ti(1) and censoring time Ci(1), which correspond to com-
pliance type Ui = u (for u ∈ {c, a, n}) and covariate values Xi = x, also
follow a Weibull or a log-normal distribution. So do Ti(0) and Ci(0) (Chapter
5). Their relevant parametrisation can be specified as in Section 7.5.1 and
Section 7.5.2.
7.5.1 Weibull specific model parameters
When the failure time, corresponding to the baseline T0i, is assumed to fol-
low a Weibull distribution with ρ0T and α
0
T , we then have the NIGN-WW(II),
in which the components of θT,uzx in equation (7.3.12) can be further parti-
tioned into two scalars. Thus the NIGN-WW(II) model involves the following
parameters:
θT,c1x = (ρT,c1x, αT,c1x),
θT,c0x = (ρT,c0x, αT,c0x),
θT,nx = (ρT,nx, αT,nx),
θT,ax = (ρT,ax, αT,ax),
(7.5.1)
where ρ∗ and α∗ denote the scale and shape parameter of the Weibull distri-
bution (∗ indicates the subscript of the parameters).
Given the AFT model for failure time (equation (7.4.1)) and following
Theorem 1, we have the following relationships between the scale parameter
ρ∗ of the Weibull distribution and the regression coefficients ζ∗ and φ∗ in the
AFT model (∗ indicates the subscript of the parameters). These relationships
are specified below:
ρT,c1x = ρ
0
T exp(ζ
(c) + φ(c) + (φx + ζ
(c)
x + φ
(c)
x )Xi),
ρT,c0x = ρ
0
T exp(φ
(c) + (φx + φ
(c)
x )Xi),
ρT,nx = ρ
0
T exp(φxXi),
ρT,ax = ρ
0
T exp(φ
(a) + (φx + φ
(a)
x )Xi),
(7.5.2)
and
αT,c1x = αT,c0x = αT,nx = αT,ax = α
0
T . (7.5.3)
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Note that equation (7.5.2) is equivalent to the following:
ρT,c1x = ρ
0
T exp(ζ
(c) + φ(c)) exp((φx + ζ
(c)
x + φ
(c)
x )Xi),
ρT,c0x = ρ
0
T exp(φ
(c)) exp((φx + φ
(c)
x Xi),
ρT,nx = ρ
0
T exp(φxXi),
ρT,ax = ρ
0
T exp(φ
(a)) exp((φx + φ
(a)
x )Xi).
(7.5.4)
According to the relationships given in equation (5.8.1), we can then re-
write equation (7.5.2) as follows:
ρT,c1x = ρT,c1 exp((φx + ζ
(c)
x + φ
(c)
x )Xi),
ρT,c0x = ρT,c0 exp((φx + φ
(c)
x )Xi),
ρT,nx = ρT,n exp(φxXi),
ρT,ax = ρT,a exp((φx + φ
(a)
x )Xi).
(7.5.5)
Similarly, the parameters associated with the censoring time distribution,
θC,uzx = (θC,c1, θC,c0,θC,n θC,a), can also be specified as follows:
θC,c1x = (ρC,c1x, αC,c1x),
θC,c0x = (ρC,c0x, αC,c0x),
θC,nx = (ρC,nx, αC,nx),
θC,ax = (ρC,ax, αC,ax),
(7.5.6)
where ρC,∗ and αC,∗ denote the scale and shape parameter of the Weibull
distribution (C, ∗ represents the subscript of ρ and α associated with the
distribution of censoring time).
Furthermore, according to Theorem 1 and equation (7.4.17), these scale
parameters satisfy the following relationships:
ρC,c1x = ρ
0
C exp(ξ
(c) + ϕ(c) + (ξ(c)x + ϕx + ϕ
(c)
x )Xi),
ρC,c0x = ρ
0
C exp(ϕ
(c) + (ϕ(c)x + ϕx)Xi),
ρC,nx = ρ
0
C exp(ϕxXi);
ρC,ax = ρ
0
C exp(ϕ
(a) + (ϕx + ϕ
(a)
x )Xi),
(7.5.7)
199
and
αC,c1x = αC,c0x = αC,nx = αC,ax = α
0
C . (7.5.8)
The components of equation (7.5.7) are thus equivalent to:
ρC,c1x = ρ
0
C exp(ξ
(c) + ϕ(c)) exp((ξ(c)x + ϕx + ϕ
(c)
x )Xi),
ρC,c0x = ρ
0
C exp(ϕ
(c)) exp((ϕ(c)x + ϕx)Xi),
ρC,nx = ρ
0
C exp(ϕxXi),
ρC,ax = ρ
0
C exp(ϕ
(a)) exp((ϕx + ϕ
(a)
x )Xi).
(7.5.9)
Note that ρ0C and α
0
C denote the scale and shape parameter of the Weibull
distribution for censoring time C0i for the baseline.
After substituting the relationships given in equation (5.8.2) into equation
(7.5.9), the latter can be re-written as follows:
ρC,c1x = ρC,c1 exp((ξ
(c)
x + ϕx + ϕ
(c)
x )Xi),
ρC,c0x = ρC,c0 exp((ϕ
(c)
x + ϕx)Xi),
ρC,nx = ρC,n exp(ϕxXi),
ρC,ax = ρC,a exp((ϕx + ϕ
(a)
x )Xi).
(7.5.10)
We have now linked the two scale parameters ρT,uz, ρC,uz (for the NIGN-
WW model) and ρT,uzx, ρC,uzx (for the NIGN-WW(II)). In other words,
equations (7.5.5), (7.5.3), (7.5.10) and (7.5.8) show that we have successfully
extended the NIGN-WW model to accommodate pretreatment covariates.
Table 7.1 gives the relevant parameters for the extended NIGN-WW model,
namely the NIGN-WW(II) model.
Table 7.1: Non-ignorable PPO Weibull survival model (II) parameters.
Parameters in NIGN-WW (II) model
failure time (ρT,c1, ρT,c0, ρT,n, ρT,a, αT )
censoring time (ρC,c1, ρC,c0, ρC,n, ρC,a, αC)
AFT model (ζ
(c)
x , φx, φ
(c)
x , φ
(a)
x , ξ
(c)
x , ϕx, ϕ
(c)
x , ϕ
(a)
x )
Logistic model (ηc,110, ηc,111, ηc,000, ηc,001)
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7.5.2 Log-normal specific model parameters
Similarly, when the failure time corresponding to the baseline is assumed
to follow a log-normal distribution, we then have the NIGN-LL(II) model,
which involves the following parameters:
θT,c1x = (µT,c1x, σT,c1x);
θT,c0x = (µT,c0x, σT,c0x);
θT,nx = (µT,nx, σT,nx);
θT,ax = (µT,ax, σT,ax);
(7.5.11)
where µT,∗ and σT,∗ denote the mean and variance parameter of the logarithm
of failure time, respectively. (T, ∗ represents the related subscript of the
parameters associated with faliure time distribution).
Given equation (7.4.10) and following Theorem 1, these parameters satisfy
the following equalities:
µT,c1x = µ
0
T + ζ
(c) + φ(c) + (φx + ζ
(c)
x + φ
(c)
x )Xi;
µT,c0x = µ
0
T + φ
(c) + (φx + φ
(c)
x )Xi;
µT,nx = µ
0
T + φxXi;
µT,ax = µ
0
T + φ
(a) + (φx + φ
(a)
x )Xi;
(7.5.12)
and
σT,c1x = σT,c0x = σT,nx = σT,ax = σ
0
T . (7.5.13)
Given the relationship between µT,uz and ζ and φ in equation (5.8.5),
equation (7.5.12) can then be rewritten as follows:
µT,c1x = µT,c1 + (φx + ζ
(c)
x + φ
(c)
x )Xi;
µT,c0x = µT,c0 + (φx + φ
(c)
x )Xi;
µT,nx = µT,n + (φx)Xi;
µT,ax = µT,a + (φx + φ
(a)
x )Xi.
(7.5.14)
Similarly, for the censoring time, the following parameters can also per-
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tain:
µC,c1x = µC,c1 + (ϕx + ξ
(c)
x + ϕ
(c)
x )Xi;
µC,c0x = µC,c0 + (ϕx + ϕ
(c)
x )Xi;
µC,nx = µC,n + (ϕx)Xi;
µC,ax = µC,a + (ϕx + ϕ
(a)
x )Xi;
(7.5.15)
and
σC,c1x = σC,c0x = σC,nx = σC,ax = σ
0
C . (7.5.16)
Consequently, the parameters of the log-normal PPO-survival model(s)(II)
for the NIGN-LL(II) survival model, are as given in Table 7.2.
Table 7.2: Non-ignorable PPO log-normal survival model (II) parameters.
Parameters in NIGN-LL (II) model
failure time (µT,c1, µT,c0, µT,n, µT,a, σT )
censoring time (µC,c1, µC,c0, µC,n, µC,a, σC)
AFT model (ζ
(c)
x , φx, φ
(c)
x , φ
(a)
x , ξ
(c)
x , ϕx, ϕ
(c)
x , ϕ
(a)
x )
Logistic model (ηc,110, ηc,111, ηc,000, ηc,001)
7.6 Computational issues
The extended model, including covariates, can again be fitted using the EM
algorithm, alternating between maximising the expected log-likelihood and
computing the posterior compliance type probabilities.
7.6.1 Posterior probability of compliance type Ui
Let P iacx, P
i
ncx, P
i
nx, P
i
ax and Q
i
acx, Q
i
ncx, Q
i
nx, Q
i
ax denote the posterior prob-
abilities for non-censored (Ri = 1) and censored (Ri = 0) individuals, respec-
tively, for the following cases: (1) Zi = 1, Di(1) = 1 and Xi = x; (2) Zi = 0,
Di(0) = 0 and Xi = x; (3) Zi = 1, Di(1) = 0 and Xi = x; and (4) Zi = 0,
Di(0) = 1 and Xi = x.
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These posterior probabilities can then be expressed as follows:
P iacx = Pr(Ui = c | (Ti(1), Ci(1))obs, Zi = 1, Di(1) = 1, Xi = x; βk) for Ri = 1,
P incx = Pr(Ui = c | (Ti(0), Ci(0))obs, Zi = 0, Di(0) = 0, Xi = x; βk) for Ri = 1,
P inx = Pr(Ui = n | (Ti(1), Ci(1))obs, Zi = 1, Di(1) = 0, Xi = x; ; βk) for Ri = 1,
P iax = Pr(Ui = a | (Ti(0), Ci(0))obs, Zi = 0, Di(0) = 1, Xi = x; βk) for Ri = 1,
Qiacx = Pr(Ui = c | (Ti(1), Ci(1))obs, Zi = 1, Di(1) = 1, Xi = x; βk) for Ri = 0,
Qincx = Pr(Ui = c | (Ti(0), Ci(0))obs, Zi = 0, Di(0) = 0, Xi = x; βk) for Ri = 0,
Qinx = Pr(Ui = n | (Ti(1), Ci(1))obs, Zi = 1, Di(1) = 0, Xi = x; βk) for Ri = 0,
Qiax = Pr(Ui = a | (Ti(0), Ci(0))obs, Zi = 0, Di(0) = 1, Xi = x; βk) for Ri = 0.
(7.6.1)
where (Ti, Ci)
obs is as given in equation (5.5.32), which indicates the ob-
servable part of the survival outcomes (Ti, Ci). (Ti, Ci)
obs is equivalent to
T obsi = Ti(z) and C
obs
i > Ti(z) given Zi = z, when Ri = 1; and (Ti, Ci)
obs is
equivalent to Cobsi = Ci(z) and T
obs
i > Ci(z) given Zi = z, for Ri = 0.
Because of the assumption of monotonicity, which ensures that no defiers
exist (Angrist et al. (1996); Frangakis & Rubin (1999) and see Section 5.2),
an individual with Zi = 1 and Di(1) = 0, has his/her compliance type Ui
fixed at that of a never-taker, Ui = n, i.e.:
Pr(Ui = n | (Ti, Ci)obs, Zi = 1, Di(1) = 0; Xi;βk) = 1. (7.6.2)
Other individuals with Zi = 0 and Di(0) = 1 have compliance type Ui which
must be that of an always-taker, Ui = a. We then have:
Pr(Ui = a | (Ti, Ci)obs, Zi = 0, Di(0) = 1; Xi;βk) = 1. (7.6.3)
According to equations (7.6.2) and (7.6.3), we have the following equiva-
lences:
P inx = 1 for i ∈ C(1, 0, 1,x),
Qinx = 1 for i ∈ C(1, 0, 0,x),
P iax = 1 for i ∈ C(0, 1, 1,x),
Qiax = 1 for i ∈ C(0, 1, 0,x),
(7.6.4)
where C(z, d, r,x) denotes the subset of individuals, which is defined by the
following: C(z, d, r,x) = {i : Zi = z, Di = d, Ri = r, x} for all z, d, r ∈
{1, 0} and x ∈ X .
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Equation (7.6.4) then provides the required posterior probabilities for the
last two cases, i.e. Zi = 1, Di(1) = 0 and Xi = x, and Zi = 0, Di(0) = 1 and
Xi = x.
In the formulation of the posterior probabilities associated with the re-
maining two cases: (Zi = 1, Di(1) = 1 and Xi = x, and Zi = 0, Di(0) = 0
andXi = x), we need to follow Bayes’ theorem, with additional pre-treatment
covariatesXi included. The posterior probabilities for the non-ignorable PPO
survival model can thus be expressed as follows:
Pr(Ui = u | (Ti, Ci)obs, Zi = 1, Di(1) = 1, Xi = x;βk)
=

fux(1,t;θT,u1x)Gux(1,t;θC,u1x)piu,11x
fcx(1,t;θT,c1x)Gcx(1,t;θC,c1x)pic,11x+fax(1,t;θT,a1x)Gax(1,t;θC,a1x)pia,11x
, if Ri = 1, Ti(1) = t,
Sux(1,t;θT,u1x)eux(1,t;θT,u1x)piu,11x
Scx(1,t;θT,c1x)ec1x(1,t;θC,c1x)pic,11x+Sax(1,t;θT,a1x)eax(1,t;θC,a1x)pia,11x
, if Ri = 0, Ci(1) = t,
(7.6.5)
for u ∈ {c, a} and x ∈ X ; and:
Pr(Ui = u | (Ti, Ci)obs, Zi = 0, Di(0) = 0; Xi = x; βk)
=

fux(0,t;θT,u0x)Gux(1,t;θC,u0x)piu,00x
fcx(0,t;θT,c0x)Gcx(0,t;θC,c0x)pic,00x+fnx(0,t;θT,n0x)Gnx(0,t;θC,n0x)pin,00x
if Ri = 1, Ti(0) = t,
Sux(0,t;θT,u0x)eux(0,t;θC,u0x)piu,00x
Scx(0,t;θT,c0x)ecx(0,t;θC,c0x)pic,00x+Snx(0,t;θT,n0x)enx(0,t;θC,n0x)pin,00x
if Ri = 0, Ci(0) = t,
(7.6.6)
where u ∈ {c, n} and x ∈ X .
Therefore, P iacx, P
i
ncx, Q
i
acx, Q
i
ncx can then be formulated as in equation
(7.6.7) given overleaf.
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As in Chapter 5 (Section 5.9.2), we use Wi(u,β
k) to denote the posterior
probability of compliance type Pr(Ui = u|(Ti, Ci)obs, Zi = z,Di(z) = d,Xi =
x;βk) given the observed data and parameter values for the extended non-
ignorable PPO-survival model. That is:
Wi(u,β
k) = Pr(Ui = u|(Ti, Ci)obs, Zi = z, Di(z) = d, Xi = x; βk), (7.6.8)
The posterior probability Wi(u,β
k) of the ith individual can then be
written as:
Wi(u,β
k) =

(P iacx)
I{u=c}(1− P iacx)I{u=a} for i ∈ C(1, 1, 1,x),
(P incx)
I{u=c}(1− P incx)I{u=n} for i ∈ C(0, 0, 1,x),
(Qiacx)
I{u=c}(1−Qiacx)I{u=a} for i ∈ C(1, 1, 0,x),
(Qincx)
I{u=c}(1−Qincx)I{u=n} for i ∈ C(0, 0, 0,x),
P inx = 1 for i ∈ C(1, 0, 1,x),
Qinx = 1 for i ∈ C(1, 0, 0,x),
P iax = 1 for i ∈ C(0, 1, 1,x),
Qiax = 1 for i ∈ C(0, 1, 0,x),
(7.6.9)
where I{} is an indicator function, and P iacx, P incx, Qiacx, Qincx denote the
posterior probabilities for the cases, given by equation (7.6.7) for the non-
ignorable PPO-survival model, and given by equation (7.7.4) for the ignorable
PPO-survival model.
7.6.2 Structures of the expectation function Q(β,βk)
Because covariates are included in the PPO-survival model(s) (II), the pa-
rameters, pic11x and pic00x, associated with the conditional probability of com-
pliance given Zi = z, Di(z) = d and Xi = x cannot be estimated directly by
following the earlier formulations (equation (5.5.27) in Chapter 5). Equation
(7.3.4) has thus linked the parameters pic11x and pic00x with the pre-treatment
covariates Xi = x. Unlike the scenario of the PPO-survival model(s)(I),
pic11x and pic00x need to be involved in the likelihood function. Therefore, in
the PPO-survival model(s) (II), the expectation function, is still denoted by
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Q(β,βk). However, we need to keep in mind that the model paramter β here
involves more conponents than it had in the PPO-survival model(s)(I).
Table 7.1 (on page 200) and Table 7.2 (on page 202) give all parameters of
β for the NIGN-WW and the NIGN-LL model, repectively. Note that the pa-
rameters associated with the distributions (without pretreatment covariates)
of failure time (θT,uz), and of the censoring time (θC,uz) (for u ∈ {c, a, n}
and z = 1 or 0) are included in, β, the parameter vector of the non-ignorable
PPO-survival model. Recall that θT,uz and θC,uz (for u ∈ {c, a, n} and z = 1
or 0) are determined by the assumed distributions (Section 5.7). Details
are given by equations (5.8.1) and (5.8.2) for the Weibull model, and by
equations (5.8.5) and (5.8.6) for the log-normal model.
The expectation function Q(β,βk) can thus be expressed as follows:
Qi(β,βk) =∑
u∈{c,n,a}
{
Pr(Ui = u|(Ti, Ci)obs, Zi = z, Di(z), Xi;βk)
log{LE(β;u)}
}
,
(7.6.10)
where LE(β;u) is specified by equation (7.3.10) for the non-ignorable PPO-
survival model.
Using the notation in equation (7.6.9), equation (7.6.10) can be further
simplified as follows:
Qi(β,βk)
=
∑
u∈{c,n,a}
Wi(u,β
k) log{LEi (β; u)}. (7.6.11)
Substituting equation (7.3.10) into equation (7.6.11), Qi(β,βk), the ex-
pectation function for the non-ignorable PPO-survival model (for the ith
individual), then has the following form:
Qi(β,βk)
=
∑
u∈{c,n,a}
W (u,βk) log
{
[f iux(z, t; θT,uzx)G
i
ux(z, t; θC,uzx)]
Ri
[Siux(z, t; θT,uzx)e
i
uxz, t; θC,uzx)]
1−Ri piu,zdx
}
.
(7.6.12)
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Recall that piu,zdx is given in equation (7.3.4) and denotes the conditional
probability of compliance type, Ui = u, given Zi = z, Di = d, and Xi = x.
The structure of the expectation function, the so-called Q-functionQi(β,βk),
is maximised for some initial2 values for all relevant parameters β0. We
then replace β0 in Qi(β,β0) with the new updated estimate β1, leading to
Qi(β,β1). This process is repeated untill convergence.
When the parameters included in the relevant model have been estimated,
the survival function corresponding to the subgroups of interest can be cal-
culated from the assumed distributional form (such as Weibull), and ACE(t)
and CACE(t) can then be obtained directly (Section 3.3.2). Methods for cal-
culating the standard error (addressed in Section 5.9.4) are still applicable
for our PPO-survival model(s) (II). We omit details here.
7.7 Ignorable censoring mechanism PPO-survival model (II)
7.7.1 The likelihood function
When the censoring mechanism is ignorable, the likelihood function for the
ith individual, given in equation (7.3.10), can then be simplified as follows:
LEi∈{i:Zi=z,Di(z)=d}(β;u)
=
{
[f iux(z, t; θT,uzx))]
Ri
[Siux(z, t; θT,uzx))]
1−Ri piu,zdx.
}
.
(7.7.1)
Equation (7.7.1) thus provides a tractable likelihood function for complete
data for the ignorable PPO-survival model (II) where
β = (θT,uzx, ζx(v) , φx(v) , ξx(v) , ϕx(v) ,η).
7.7.2 Model specification
Similar to the non-ignorable PPO-survival model (I), we take the ignorable
PPO-survival model (II) to be the IGN-W(II) model and the IGN-L(II)
2The initial value of the missing Ui, can be generated from a Bernoulli distribution
with a given value of pˆic.
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model, given by a Weibull or a log-normal distribution, respectively. Ta-
ble 7.3 gives all relevant components for β, for both models.
Table 7.3: Specific ignorable PPO-survival model (II) parameters.
Model Parameters Parameters
for failure time for covariates
IGN-W(II) (ρT,c1, ρT,c0, ρT,n, ρT,a, α) (ζx, ζ
(c)
x , φx, φ
(c)
x , φ
(a)
x , ξx, ξ
(c)
x , ϕx, ϕ
(c)
x , ϕ
(a)
x , η110, η111, η000, η001)
IGN-L(II) (µT,c1, µT,c0, µT,n, µT,a, σ) (ζx, ζ
(c)
x , φx, φ
(c)
x , φ
(a)
x , ξx, ξ
(c)
x , ϕx, ϕ
(c)
x , ϕ
(a)
x , η110, η111, η000, η001)
7.7.3 Posterior probability of compliance type
Because no censoring time distribution is included in the likelihood function
of the ignorable PPO survial model, the posterior distribution of compliance
type can be formulated from equations (7.6.5) and (7.6.6). We then have
Pr(Ui = u|(Ti, Ci)obs, Zi = 1, Di = 1, Xi = x;βk)
=

fux(1,t;θT,u1x)piu,11x
fcx(1,t;θT,c1x)pic,11x+fax(1,t;θT,a1x)pia,11x
if Ri = 1, Ti(1) = t,
Sux(1,t;θT,u1x)piu,11x
Scx(1,t;θT,c1x)pic,11x+Sax(1,t;θT,a1x)pia,11x
if Ri = 0, Ci(1) = t,
(7.7.2)
for u ∈ {c, a} and x ∈ X , and
Pr(Ui = u|(Ti, Ci)obs, Zi = 0, Di = 0; Xi = x;βk)
=

fux(0,t;θT,u0x)piu,00x
fcx(0,t;θT,c0x)pic,00x+fnx(0,t;θT,n0x)pin,00x
if Ri = 1, Ti(0) = t,
Sux(0,t;θT,u0x)piu,00x
Scx(0,t;θT,c0x)pic,00x+Snx(0,t;θT,n0x)pin,00x
if Ri = 0, Ci(0) = t,
(7.7.3)
where for u ∈ {c, n} and x ∈ X .
Therefore, for the ignorable PPO-survival model, the posterior probabil-
ities P iacx, P
i
ncx, Q
i
acx, Q
i
ncx can then be written as follows:
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P iacx =
fcx(1,t;θT,c1x)pic,11x
fcx(1,t;θT,c1x)pic,11x+fax(1,t;θT,a1)pia,11x
for i ∈ C(1, 1, 1,x), Ti(1) = t,
P incx =
fcx(0,t;θT,c0x)pic,00x
fcx(0,t;θT,c0x)pic,00x+fnx(0,t;θT,n0x)pin,00x
for i ∈ C(0, 0, 1,x), Ti(0) = t,
Qiacx =
Scx(1,t;θT,c1x)pic,11x
Scx(1,t;θT,c1x)pic,11+Sax(1,t;θT,a1x)pia,11x
for i ∈ C(1, 1, 0,x), Ci(1) = t,
Qincx =
Scx(0,t;θT,c0x)pic,00x
Scx(0,t;θT,c0x)pic,00x+Snx(0,t;θT,n0x)pin,00x
for i ∈ C(0, 0, 0,x), Ci(0) = t.
(7.7.4)
7.7.4 Expectation function Q(β,βk)
By following equation (7.7.1), the expectation function, th so-called Q-function
Qi(β,βk), for the ignorable PPO-survival model has the following form:
Qi(β,βk)
= Pr(Ui = u|(Ti, Ci)obs, Zi = z, Di(z), Xi = x;βk) log
{
LEi (β;u|βk)
}
= W (u,βk) log
{
f iux(z, t; θT,uzx)
RiSiux(z, t; θT,uzx)
1−Ripiu,zdx
}
,
(7.7.5)
where β = (θT,uzx,piu,zdx) is given in Table 7.3.
7.7.5 Computation
Similar to the derivation of the PPO-survival model (I), the ignorable PPO-
survival model (II) can be implemented directly by following the methods
given in Section 7.6.
7.8 Illustration of the implementation an EM algorithm for the
non-ignorable PPO-survival model (II)
The parameter vector in the non-ignorable PPO-survival model (II) has more
components than that one in the non-ignorable PPO-survival model (I) for
the inclusion of pre-treatment covariates. For instance, in the NIGN-WW
(I), only the parameter θ, a vector with 8 components in the HIP trial,
need to be estimated via the EM algorithm; whereas in the NIGN-WW (II),
the parameter involved into the EM alogrithm is β rather than θ, and it
has 16 components in the HIP trial. This is because in this case, one single
covariate, the age at entry is in the model, hence the regression coefficients for
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both the AFT model (equations (7.4.10) and (7.4.17)) and the logistic model
(equations (7.3.3) or (7.3.4)) must be included in the model. Consequently,
the process of implementing the new model developed in this chapter is much
more complicated than the PPO-survival model (I) derived in Chapter 5. In
this section, we demonstrate how the EM algorithm is applied to the NIGN-
WW (II) via the HIP7 data.
7.8.1 Model modification of Q(β,βk)
Recall that in the HIP data, only two compliance types and three subgroups
are involved because of the assumption that there are no always-takers (no
access to screening in the control group). So we can use Ui = 1 to indicate
complier, and Ui = 0 to indicate never-taker. Equations (7.5.5) and (7.5.10),
which give the relationships between the scale parameter and regression co-
efficients in the AFT and the logistic model for failure time and censoring
time, can then be simplified as follows:
ρT,c1x = ρT,c1 exp((φx + ζ
(c)
x + φ
(c)
x )Xi),
ρT,c0x = ρT,c0 exp((φx + φ
(c)
x )Xi),
ρT,nx = ρT,n exp(φxXi),
(7.8.1)
and
ρC,c1x = ρC,c1 exp((ξ
(c)
x + ϕx + ϕ
(c)
x )Xi),
ρC,c0x = ρC,c0 exp((ϕ
(c)
x + ϕx)Xi),
ρC,nx = ρC,n exp(ϕxXi),
(7.8.2)
respectively.
For the same reason, the relationships between shape parameters associ-
ated with each subgroup are also simplified as follows:
αT,c1x = αT,c0x = αT,nx = α
0
T . (7.8.3)
αC,c1x = αC,c0x = αC,nx = α
0
C . (7.8.4)
Therefore, Table 7.1 given in Section 7.5.1, which lists the model param-
eters in the NIGN-WW (II), is simplified in the analysis of the HIP7 data.
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It is given in Table 7.4, where the parameters associated with Subgroup 4,
individuals who are always-takers, are excluded, as well as (ηc,110, ηc,111), the
regression coefficients in the logistic model for pic,11x. This is because when
no always-takers exist in the HIP trial, pic,11x has a constant value 1 for all
given x.
Table 7.4: Non-ignorable PPO Weibull survival model (II) parameters for
the HIP7 data.
Parameters in NIGN-WW (II) model
failure time (ρT,c1, ρT,c0, ρT,n, αT )
censoring time (ρC,c1, ρC,c0, ρC,n, αC)
AFT model (ζ
(c)
x , φx, φ
(c)
x , ξ
(c)
x , ϕx, ϕ
(c)
x )
Logistic model (ηc,000, ηc,001)
Based on the formulation of the expectation function Q(θ,θk) associated
with the NIGN-WW (I), given in equation (5.9.12), the expectation function
associated with the NIGN-WW (II), denoted by Q(β,βk) and given in equa-
tion (7.6.11), can be modified by adding in equations (7.8.1), (7.8.2), (7.8.3)
and (7.8.4). Note that the first formula in equations (7.8.1) and (7.8.2) in-
clude two regression coefficients which both correspond to the interactive
term of compliance type and age covariates X×U in the AFT model. Recall
that for compliers, we have Ui = 1, which is why compliance type U did not
appear in these related regression AFT models.
7.8.2 Preparation of computation
Normalisation of covariate
To avoid extreme values of the scale parameter, the covariate X is normalised
by the given formula:
X = (X −mean(X))/std(X) (7.8.5)
where mean() and std() denote the functions of average and standard devi-
ation in MATLAB.
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Imputation of missing compliance type for initial values
The compliance type covariate can be treated as a variable with missing
data since those individuals who are assigned to the control group, have
unobservable compliance types. In order to initiate the EM algorithm, we
impute compliance types by generating them, from a Bernoulli distribution
given parameter pˆic. This is because individuals in the HIP data have only
two types of compliance behaviours: compliers and never-takers. The value
of pˆic is given as 0.6698, which was obtained in Chapter 6. Note that these
generated values of compliance type are only used in calculating the initial
parameter values.
Initial values
The NIGM-WW(II) for the HIP7 data involves 16 parameters in total (Table
7.4). Eight of them are scale and shape parameters corresponding to the
PPO-survival Weibull model (I); these eight parameters initial values are
given directly as those obtained via the NIGN-WW(I) given in (Table C-1
in Appendix C). The remainding parameters are the regression coefficients
that are associated with the AFT model and logistic model.
For the AFT model, six regression coefficients are involved in the analysis
of the HIP data, denoted by ζc, φc, φx (for failure time) and ξc, ϕc, ϕx
(for censoring time). They correspond to the interactive term X × U with
U = 1, and term X (age at the year of enrollment in the HIP data), also used
in equations (7.8.1) and (7.8.2) for calculating the scale parameter in the
Weibull distribution of failure time and censoring time for each subgroup.
We use the glmfit command in MATLAB to estimate the regression
coefficients in the AFT model, which are only used as the initial values in our
extended non-ignorable PPO-Survival model; where the required distribution
of input data and link function were given as normal and log. The related
outputs for the HIP7 data in the AFT model are given in Table 7.5.
Note that the intercept in the AFT model is not included in either equa-
tion (7.8.1) or (7.8.2), so the intercept in Table 7.5 needs to be excluded from
intitial values. In addition, the coefficient for the interactive term X × U is
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Table 7.5: Regression coefficients in the AFT model for the HIP7 data.
Model AFT Data HIP7
Coefficient Intercept X X × Ua
failure time 1.5864 -0.0187 0.0315
censoring time 1.8804 -0.0070 -0.0029
aU value is given by imputation in Bernoulli distribution
related to two parameters ζc, φc (in the AFT model for failure time) and ξc,
ϕc (in the AFT censoring time model). Hence we give half of the estimated
coefficent value of the interactive term X × U as the as the initial value of
relevent parameter. Note that according to the AFT model given on p.46 of
Klein (1997), equations (7.8.1) and (7.8.2) should take the negative values of
parameters obtained by regression formula. Therefore, the initial values for
the parameters associated with the AFT model are given in Table 7.6.
Table 7.6: Initial values for the parameters corresponding to the regression
coefficients in the AFT model for the HIP7 data.
Model AFT Data HIP7
a
Failure time Censoring time
parameter ζc φc φx ξc ϕc ϕx
initial value -0.01575 -0.01575 0.0187 0.00145 0.00145 0.007
aU value is given by imputation in Bernoulli distribution
For the logistic model, we also use the glmfit command in MATLAB
to find the initial values of the logistic regression coefficients by setting the
distribution to binomial and using the imputed compliance types as the out-
come variables. Table 7.7 lists the regression coefficients in the logistic model.
By now, the initial values for analysing the HIP7 data with the NIGN-WW
(II) model are all obtained, they are given in Table 7.8.
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Table 7.7: Regression coefficients in the logistic model (pic,00x) for the HIP7
data.
Model logistic Data: HIP7
a
coefficient η000 η001
model fitted 0.6944 0.0020
aU value is given by imputation in Bernoulli distribution
Table 7.8: Initial values of model parameter β0 in the NIGN-WW(II) model
for the HIP7 data.
Weibull model failure time ρT,c1 ρT,c0 ρT,n α
0
T
169.49 108.7 144.93 1.9362
censoring time ρC,c1 ρC,c0 ρC,n α
0
C
6.9541 6.9156 6.8871 10.378
AFT model failure time ζ
(c)
x φ
(c)
x φx
-0.01575 -0.01575 0.0187
censoring time ξ
(c)
x ϕ
(c)
x ϕx
0.00145 0.00145 0.007
Logistic model ηc,000 ηc,001
0.6944 0.002
7.8.3 Implementation of EM alogrithm
The first maximisation
As in the NIGM-WW(I), the fminsearch command in MATLAB is used to
minimise the negative Q-function −Q(β,βk), which is equivalent to max-
imising the Q-function Q(β,βk).
We first obtain the initial values of model parameter β as shown in Table
7.8(Section 7.8.2):
β0 = [169.49, 108.7, 144.93, 1.9362, 6.9541, 6.9156, 6.8871, 10.378,
− 0.01575, −0.01575, 0.0187, 0.00145, 0.00145, 0.007, 0.6944, 0.002].
Then the estimated values of model parameter β1 are obtained by running
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the NIGM-WW(II) for the HIP7 data, where the value of the posterior
probabilities of compliance type are given based on the value of β0.
β1 = [86.7594, 59.1747, 81.5242, 2.3221, 6.9525, 6.9614, 6.8703, 10.3718,
− 0.0279, −0.0213, 0.0033, 0.0018, 0.0017, 0.0083, 0.4053, 0.0030];
Note that for the purposes of illustrating the computations, we reduced
the computing time by setting the termination criteria in the maximisation
both for β and Q(β,βk) at 0.1 level. According to the output messages of
running fminsearch in MATLAB, it has taken 150 iterations to reach the
maximazation of Q(β,βk) in this first M-step.
The iterations in the EM alogrithm
Using β1 as a new initial value for the model parameter in the NIGN-WW
(II) corresponding to the HIP7 data and after running the NIGN-WW (II),
the estimated values of model parameter β2 are obtained, where the value of
the posterior probabilities of compliance type are given based on the value
of β1. After k iterations, the initial parameter is βk, and the new esti-
mated model parameter is βk+1, which maximises the expectation function
Q(β,βk). These iterations are continued until convergence is achieved.
Table 7.9 shows the following six iterations (for k = 2 to 7) in the EM
alogrithm for the HIP7 data, where β
1 is applied as a new inital value. From
the table, we can read that ∆ = 0.0243 when k = 7. Clearly, the iteration
would need to be continued in order to meet more stringent convergence cri-
teria. However, we stop the computation here as it is enough to demonstrate
how the EM algorithm is applied in the NIGN-WW (II) model.
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7.8.4 Conclusion
The computing process in the NIGN-WW(II) model is much more compli-
cated than the NIGN-WW(I) as the dimension of the model parameter vector
increases considerably when covariates are included in the model. As men-
tioned before in the HIP7 data, only one pre-treatment covariate (the age
at the year of enrollment) was added in, the dimension of model parameter
in the NIGN-WW(II) is doubled as the one in the NIGN-WW(I),(16 vs 8).
It is therefore not surprising that the computing time required to implement
the NIGN-WW(II) for the HIP7 data is considerably greater than for the no
covariate model. This is why, as an illustration of the computations, we set
the termination criteria for the M-step at 0.1, and stopped the EM algorithm
after six iterations.
Even though the HIP7 data have not been analysed properly with the
NIGN-WW(II) model at this stage, we have reached the aim of this section,
which is to demonstrate the application of the EM algorithm in the NIGN-
WW(II) model. We can conclude that both the theory and program related
to the NIGN-WW(II) do work well.
7.9 Summary
In this chapter, the PPO-survival model(s) formulated in Chapter 5, have
thus been extended to PPO-survival model(s) (II) by adding in time inde-
pendent pre-treatment covariates Xi. The accelerated failure time (AFT)
(p.64, Cox & Oakes (1984) or p.46, Klein (1997)) has played an important
role in the development. Because pre-treatment covariates Xi are involved,
besides the assigned treatment Zi = z and the actual received treatment
Di(z) = d, in this case, the conditional probability of compliance type must
be conditional on the pre-treatment covariates Xi. This leads to a much
more complicated formulation than that discussed in Chapter 5.
Importantly, we assume that the conditional probability of compliance
type, given Zi = z, Di(z) = d and Xi = x, which is denoted by pic,zdx, follows
a logistic model as in Mealli et al. (2004). This is justisfied because given
Zi = z, Di(z) = d, compliance type has up to two categories, and pic,11x and
pic,00x both satisfy a logistic model.
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Our PPO-survival model(s) (II) assume a Weibull and a log-normal dis-
tribution for the failure T0i and the censoring time C0i (corresponding to the
baseline), and also assume T0i and C0i to satisfy the accerlerated failure time
(AFT) model. By following Theorem 1 (Section 5.7.1) and the conclusion
given in Chapter 5, which states that when T0i and C0i follow a Weibull (or a
log-normal) distribution, the failure and censoring time corresponding to the
observed subgroups all follow a Weibull (or a log-normal) distribution, we
can therefore conclude that the failure and censoring time corresponding to
the observed subgroups with pre-treatment covariatesXi also follow the same
distribution types. These results allow us to formally create the link between
the PPO-survival model with covariates and those without covariates (the
PPO-survival model(s) (I)). These equivalences facilitate specification of the
likelihood. Our initial exploration of the application of the EM algorithm to
the extended model suggests that the EM algorithm is a feasible approach
to model-fitting, although computation times will clearly be greater than in
the no-covariate case.
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Chapter 8
Discussion and Conclusions
8.1 Overview and Summary
This thesis has used the framework of potential outcomes to develop para-
metric survival models for modelling treatment effects in RCTs with time-to-
event outcomes which allow for noncompliance and non-ignorable censoring.
As in most of the literature on the analysis of RCTs (Mealli et al., 2004;
Peng et al., 2004; Barnard et al., 2003; Loeys & Goetghebeur, 2003; Yau
& Little, 2001), the modelling approach developed in this thesis deals only
with all-or-none compliance. Extensions to handle partial compliance are left
for future work. While challenging, these extensions should follow the gen-
eral framework outlined here with the concept of compliance type (Section
1.7.2) being extended to accommodate the quantitative notion of “degree of
compliance.”
The fundamental idea underpinning this thesis and previous work on
causal inference, under noncompliance and subsequent missing outcomes
(Frangakis & Rubin, 1999; Barnard et al., 2003; O’Malley & Normand, 2005),
is that adjustment for bias related to post-randomisation self-selection of
treatment, can be achieved by the introduction of a compliance type co-
variate, which characterises treatment received, under all possible treatment
assignments. Censoring is assumed to be ignorable conditional on compliance
type latent ignorability, but because this covariate is only partially observed,
the assumed censoring mechanism is, in general, not ignorable given the ob-
servable data. This leads to a more complex likelihood construction than
in standard time-to-event analyses because the model for the censoring time
does not leave out of the likelihood. As a consequence, the censoring distri-
bution needs to be explicitly modelled (Section 5.5). While the assumption
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of latent ignorability cannot be verified from observed data, we agree with
Frangakis & Rubin (1999) that because compliance type may be associated
with loss to follow-up, the ignorability of the censoring mechanism condi-
tional on compliance type will generally be a more plausible assumption
than unconditional ignorability. We note, however, that in some randomised
time-to-event studies with noncompliance, it will be reasonable to ignore the
censoring mechanism. For example, in some studies, particularly those with
short follow-up time, it is possible that censoring is caused solely by the con-
clusion of the study, in which case the censoring time is effectively a known
constant for each individual (end of study date minus entry date). Therefore
in this scenario, censoring time does not enter the analysis (Cox & Oakes,
1984; Klein, 1997) (Section 4.3.1).
Since the compliance type covariate is partially missing, this compli-
cates model-fitting. Computational methods from the missing data litera-
ture (Mattei & Mealli, 2007; O’Malley & Normand, 2005; Mealli et al., 2004;
Frangakis & Rubin, 2002, 1999) are then required to fit the model. In Chap-
ter 5, we outlined an EM algorithm (Dempster et al., 1977) for fitting the
model to the data with missingness. However, because of a drawback in the
EM algorithm, which is that it does not produce estimates of the variances
for model parameters, Louis’s method (Louis, 1982) need to be adapted for
our approach. We estimated the variances for the interest part of model pa-
rameters θ through the observed information matrix (OIM). Therefore the
standard error corresponding to these estimated parameters are obtained
straightforwardly after having their variances values. The standard error for
the rest part of model parameters such as pic need an alternative method
because pic is not involved in the EM algorithm. In this thesis we adopted
the Bootstrap approach to figure out the standard error of parameter pic.
The modelling approach developed in Chapter 5 and applied to the HIP
study (in Chapter 6) is extended to deal with covariates in Chapter 7. This is
an important extension as it allows for the analysis of variation in treatment
effects by covariate level. Our extension to accommodate covariates takes
advantage of an Accelerated Failure Time (AFT) (p.64, Cox & Oakes (1984)
or p.46, Klein (1997)) representation of the basic model developed in Chapter
5. Under this representation of the model, extension to include covariates is
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quite natural and parallels the approach outlined by Peng et al. (2004) for
normally distributed outcomes.
In addition to developing a new modelling approach for randomised time
to event studies with noncompliance, a further contribution of this thesis is
to re-formulate the definition of causal effects in a time-dependent manner
appropriate for time -to-event studies (Chapter 3). In the potential outcomes
literature, causal effects are conventionally defined as contrasts between av-
erage responses (Rubin, 2005; Imbens & Rubin, 1997; Holland, 1986). How-
ever, in time-to-event studies, interest often centres on other aspects of out-
come distributions, such as the survival or hazard function. Accordingly, we
defined the Average Causal Effect at time t, ACE(t), to be the difference
between the probability of surviving to time t, if assigned to the experi-
mental treatment and the probability of surviving to time t, if assigned to
the control treatment (Section 3.3.3). The Complier Average Causal Effect
at time t, CACE(t), is then defined as the same contrast but restricted to
the subgroup of compliers, (the subgroup of individuals who would always
comply with their assigned treatment) (Section 3.3.4). Because assigned and
received treatments are identical for compliers, it will often be reasonable to
attribute non-zero values of CACE(t) to the causal effect of treatment on the
probability of surviving to time t. By contrast, the ACE(t) reflects only the
effect of assigned treatment, rather than the effect of actually receiving the
treatment. For the subgroups who would always receive the new treatment
(always-takers) or the control treatment (never-takers), regardless of their
assigned treatment, it is plausible to assume that assigned treatment has no
impact on outcome because, for these groups, the treatment actually received
is not modified by assigned treatment. This assumption is formalised as the
exclusion restriction assumption (equation (5.5.18) or equation (5.5.17) in
Chapter 5). When this assumption is true and there are no individuals
who would always receive the opposite of their assigned treatment (defiers),
ACE(t) then mixes the causal effect of treatment for compliers, (with the ab-
sence of effect of assignment) for never-takers and always-takers, and hence
clearly ACE(t) does not represent the causal effect of treatment.
The analytical approach developed in this thesis is fully parametric and
consequently inferences are potentially sensitive to distributional assump-
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tions for both the failure time and censoring-time distributions. However, in
the analysis of the HIP study presented in Chapter 6, inferences for ACE(t)
and CACE(t) were not sensitive to distributional assumptions. Whereas
inferences for the conventional causal effect measures contrasting expected
failure times were sensitive to these assumptions. This can be seen from
Table 6.12 (page 172). Similar conclusions can be made by comparing the
results of estimated ACE and ACE(t) for the HIP7 via these two specific
non-ignorable PPO survival models (Section 6.2.2).
In general, sensitivity to distributional assumptions can be explored by
fitting the model under different distributional assumptions and comparing
the usual sorts of likelihood-based model selection criteria, such as AIC and
BIC. Table 6.12 shows that the AIC for the non-ignorable PPO-survival
Weibull model (NIGN-WWmodel) is less than the AIC for the non-ignorable
PPO-survival log-normal model (NIGN-LL model), i.e. 2.0949E + 05 <
2.8393E + 05. This implies that the non-ignorable PPO-survival Weibull
model (NIGN-WW model) performed slightly better than the non-ignorable
PPO-survival log-normal model (NIGN-LL model) on the analysis of the
HIP7 data.
It is noteworthy that the PPO-survival models analysis of the HIP breast
cancer data (Shapiro et al., 1988; Baker, 1998) in this thesis (see Chapter
6) are more informative than those from previous analyses of the HIP data
(Shapiro et al., 1988, 1982; Shapiro, 1977). Indeed, we have shown that
Subgroup 1, (individuals who took the screening examination), has a higher
survival probability than the subgroups where individuals did not take the
screening examination. This shows a clear treatment benefit. More specially,
according to the results of the analysis of the HIP7 dataset, we can conclude
that in 10,000 women, about 14.8 (±3.83) women would be saved from breast
cancer-related death, five years after screening. The result from the NIGN-
LL model is similar, in that ĈACE(5) = 15.7E−04 (SEcace(5) = 4.02E−04)
(Table 6.3 on page 139 or Table C-23 on page 264). This is equivalent to
about 15.7 (±4.02) women in 10,000 being saved from breast cancer-related
death five years after screening.
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8.2 Limitations
Only a single application was considered in this thesis and this means that
it is not possible to draw general conclusions concerning sensitivity to distri-
butional assumptions, the performance of the EM algorithm or frequentist
performance of the likelihood-based estimators. Regarding the latter point,
likelihood theory guarantees consistency of point estimates, as is also the case
for the moment estimates of Frangakis-Rubin (Frangakis & Rubin, 1999). In
the context of normally distributed outcomes, the recent simulation study of
O’Malley & Normand (2005) suggested likelihood-based methods had prac-
tical, finite sample advantages compared to moment-based methods in terms
of efficiency, mean-squared error and confidence interval coverage. Encour-
agingly for likelihood-based methods, these advantages persisted even when
the distributional assumptions of the likelihood construction were incorrect
(O’Malley & Normand, 2005). However, it is not known whether this model-
robustness carries over to time-to-event data. In the analysis reported in
Chapter 6, standard errors for causal effect estimates were markedly reduced
under the parametric models, compared to the non-parametric Frangakis-
Rubin estimates; whereas point estimates were similar, at least up to seven
years of follow-up (Table 6.3). Thus it seems reasonable to conjecture that
the parametric approach leads to a genuine efficiency over the non-parametric
Frangakis-Rubin method (Frangakis & Rubin, 1999).
A limitation of the models proposed in this thesis is that the comparison
with the nonparametric Frangakis-Rubin (F-R) method (Frangakis & Rubin,
1999) suggests that the standard parametric forms used in the HIP analysis
are insufficiently flexible to model long-term follow-up data (Figure 6.21 (on
page 167) and Figure 6.23 (on page 169)). It appears that the parametric and
non-parametric approaches give similar results when follow-up is restricted
to seven years, but results diverge when follow-up is extended to 18 years
(Figures 6.21 and 6.23). The non-parametric analysis suggests the beneficial
effect of mammographic screening levels off after 6 to 7 years. For both
for the Weibull and log-normal models developed here, our results indicate
that the effect of screening keeps increasing long after screening. The latter
result is possibly less plausible than a levelling off in the so-called screening
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effect (Baker, 1998) and reflects the parametric formulation of the survival
functions used in the analysis. While this suggests the need for more flexible
models, it does not invalidate the modelling approach, in general, as it relates
only to specific distributional choices.
8.3 Extensions and directions for further work
8.3.1 Improvement in computation
The EM algorithm (outlined in Chapter 5) was generally slow to converge.
The EM algorithm was implemented in the MATLAB computer software
(www.mathworks.com/products/matlab). Computational performance could
be improved by implementing the algorithm in a lower-level language such
as C++.
Another plausible way of improving computation, would be to replace the
EM algorithm with its extensions, such as the Supplemented EM (SEM) algo-
rithm (Meng & Rubin, 1991; McLachlan & Krishnan, 1997) or the Expectation-
Conditional Maximum (ECM) algorithm (Meng & Rubin, 1993; McLachlan
& Krishnan, 1997). These algorithms can speed up convergence and thus
would be very helpful when more components are involved in the model
parameter vector. This is in the case of the parametric potential-outcome
PPO-survival model (II).
8.3.2 Time-dependent covariates
The parametric potential-outcome (PPO) survival model with covariates de-
veloped in Chapter 7 was defined only for time-independent pre-treatment
covariates. However, given that the model can be represented using the AFT
model framework and that this framework extends to accommodate time-
varying covariates (Cox & Oakes, 1984; Korhonen, 2000), it may be possible
to further exploit the AFT model structure in dealing with more complicated
RCTs, involving longitudinal designs and time-dependent covariates.
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8.3.3 More flexible model forms
As noted above, standard choices of parametric failure time distributions
seem insufficiently flexible for modelling longer-term effects of treatment.
This suggests the need to develop more flexible parametric models. Alterna-
tively, it may be advantageous to exploit the connection with AFT models
discussed in Chapters 5 and 7, and to develop semi-parametric approaches
by developing non-parametric approaches to estimating the baseline survival
distribution (Robins & Tsiatis, 1991). It is also likely that Cox type mod-
els could be applied to modelling both the failure time and censoring time
distributions, thereby leading to an alternative semi-parametric approach.
However, a drawback to moving to Cox models is that these models are most
easily interpreted in terms of hazard functions and computation of effect
measures, such as ACE(t) and CACE(t), which are based on survival prob-
abilities, may therefore be less convenient under Cox models. However, it
would also be possible to develop causal effect definitions based on hazard
ratios (Loeys & Goetghebeur, 2003).
8.3.4 Bayesian inference
Because of the rapid development of computer techniques during the last
two decades, Bayesian approaches (Gelman et al., 2004) have shown proved
advantageous, particularly to missing data problems (Imbens & Rubin, 1997;
Gelman et al., 2004; Ibrahim et al., 2001; Graham, 2000; Gong et al., 2005).
The Bayesian model treats the model parameters as random variables via a
prior distribution, which follows from previous inference and is updated by
the data. The prior distribution is selected to reflect the investigator’s prior
belief in the values of the parameters. In general, the prior distribution is
expressed as a multivariate distribution on the parameters. Bayesian models
thus allow incorporation of prior information in a natural way. This is well
known as: “Today’s posterior is tomorrow’s prior” (Gelman et al., 2004).
The likelihood formulations given in Chapters 5 and 7 provide the basis for
moving to a Bayesian perspective by combining the likelihood with a prior
distribution over the model parameters. Posterior simulation could proceed
using a Gibbs sampling framework (Gelman et al., 2004; Arjas & Gasbarra,
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1994), alternating between imputation of unobserved compliance types, and
sampling parameters from the conditional posterior distribution, given the
imputed compliance states. Both AFT and Cox type models could well
be fitted within a Bayesian framework (Ibrahim et al., 2001) and therefore
both fully parametric and semi-parametric Bayesian modelling should prove
feasible using the general likelihood construction presented in Chapters 5 and
7. See a recent Bayesian adaptation by Gong et al. (2005).
8.3.5 Noncompliance and “Truncation-by-death”
Many randomised studies involving humans require treatment comparisons,
not only to accommodate noncompliance (with the randomly assigned treat-
ment), but treatment comparisons need to be adjusted for “truncation-by-
death”, which indicates the case where the input data missing due to death
(Mattei & Mealli, 2007; Frangakis et al., 2007; Zhang & Rubin, 2003).
Whilst our work considered the outcome of interest as death (from breast
cancer in the HIP trial), our model could just as well focus on patient states
apart from death, and the truncation by death issue could possibly be ac-
commodated for, whether by an application of principal stratification (Fran-
gakis & Rubin, 2002) with a Bayesian parametric approach as in Mattei &
Mealli (2007) to the time-to-event scenario (where death is not the outcome
of interest) or by an extension of the work of Imai (Imai, 2008a) who re-
cently generalised the results of Zhang & Rubin (2003) and Imai (2008) to
randomised experiments with noncompliance by deriving the bounds on the
average and quartile treatment effects for compliers. Mattei & Mealli (2007)
have an approach which is an alternative to Imai’s approach (Imai, 2008a),
in that they consider point identification of treatment effects via (Bayesian)
parametric modelling. None of the above work pertains to time-to-event sce-
narios (where death is not the outcome of interest). See also Imai (2007) and
Imai (2008).
It is noteworthy that the approach proposed by Mattei & Mealli (2007)
applied to the Faenza randomised experiment on Breast Self-Examination
(Ferro et al. (1996) and Mealli et al. (2004)) did not include covariates,
and their structural and functional assumptions (stable unit treatment value
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assumption (SUTVA) formalised with potential outcomes by Rubin (1978))
alone do not allow for full identification of the underlying parameters of
interest.
Recently, Frangakis et al. (2007) proposed a framework for addressing the
issue of missingness caused by death. Their approach is to obtain and use
data and explicit assumptions bout a treatment mechanism that could cause
missing values to different levels of the treatment had been assigned. We
could address our PPO-survival models to account for so-called non-death
events (earlier heath states) but allow for “truncation-by-death”, noncom-
pliance and so accommodate missingness within a so-called potential out-
comes framework.
8.4 Conclusions
In brief, by exploiting the potential outcomes framework and carefully con-
sidering the likelihood construction for RCTs with noncompliance in time-
to-event studies, we have developed a parametric, likelihood-based approach,
namely the parametric potential-outcome (PPO) survival model, for the anal-
ysis of such studies. Because censoring is common in time-to-event studies
and censoring gives rise to a type of missing outcome data, the additional
complications of missing outcomes cannot be ignored in RCTs with failure
time outcomes. In the modelling framework developed in Chapter 5, the
possibility of non-ignorable censoring is accommodated by the assumption of
latent ignorability (Frangakis & Rubin, 1999). This model structure is more
general than standard approaches for analysing time-to-event data which
assume ignorable censoring (Loeys & Goetghebeur, 2003).
Noncompliance is common in RCTs and proper analysis of such studies
is crucial to obtaining valid estimates of treatment effects. The models and
methods developed in this thesis therefore contribute to the literature on an
important and commonly occurring problem in the analysis of RCTs. The
approach developed in Chapter 5 of this thesis can be viewed as a para-
metric alternative to the moment-estimation method proposed by Frangakis
& Rubin (1999) and extends the likelihood-based approach of O’Malley &
Normand (2005) to the case of failure time data. The extended model with
228
pre-treatment covariates derived in Chapter 7 of this thesis can be viewed as
an approach which was developed from the combination of Peng et al. (2004)
and O’Malley & Normand (2005) to time-to-event studies.
Although the issue of treatment noncompliance shifts the analysis of ran-
domised studies towards the analysis of observational studies, the randomisa-
tion of assigned treatment gives randomised studies a distinct advantage over
observational studies; because it ensures that the distribution of compliance
type can be assumed to be the same in each treatment arm. Together with
plausible assumptions, such as the exclusion restriction assumption (Angrist
et al., 1996; Frangakis & Rubin, 1999), this ensures that the observed study
data are informative about the distribution of compliance type (equation
(5.5.18)).
The observational study counterpart to noncompliance in randomised
studies is the problem of confounding by unobserved covariates, and be-
cause the observed study data are uninformative about unobserved covari-
ates, causal inference in the observational study setting can be highly sen-
sitive to prior assumptions about the adequacy of control for confounding
variables (Greenland et al., 1999; Greenland, 2004). Therefore, while non-
compliance complicates the analysis of RCTs, the RCTs with noncompliance
are still likely to yield stronger inferences concerning treatment effects than
observational studies.
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APPENDICES
Appendix A
A Correction of equation (3.2’) in Louis (1982)
The likelihood function can be expressed as the product of each individual’s
likelihood function LF (β) =
∏n
i=1 L
F
i (β). After taking the logarithm of the
complete data likelihood LF (β), the observed information matrix (OIM), Iobs,
(given in equation (5.9.17) in Section 5.9.4) can be re-written as below:
Iobs = I(βˆ) = I1 − I2
where
I1 = E
{(
−
n∑
i=1
∂2
∂β2
logLFi (β)
)
|u ∈ {c, a, n}, βk
}
,
I2 = E

(
n∑
i=1
∂
∂β
logLFi (β)
)T  n∑
j=1
∂
∂β
logLFj (β)
 |u ∈ {c, a, n}, βk
 .
(A.1)
Note that the descriptive index with respect to the summation in the second
term in equation ( A.1) above are not the same, (denoted by i and j) here.
By dividing the so-called index set, 1) i = j; 2) i 6= j, we can re-write the
term, I2 = E1 + E2, which is equivalent to:
E

(
n∑
i=1
∂
∂β
logLFi (β)
)T  n∑
j=1
∂
∂β
logLFj (β)
 |u ∈ {a, c, n}, βk

= E1 +E2
where
E1 =
∑
i
E
{(
∂
∂β
logLFi (β)
)T ( ∂
∂β
logLFi (β)
)
|u ∈ {a, c, n}, βk
}
E2 =
∑
i 6=j
{
E
(
∂
∂β
logLFi (β)
)T
|u ∈ {a, c, n}, βk
}{
E
(
∂
∂β
logLFj (β)
)
|u ∈ {a, c, n}, βk
}
.
(A.2)
Note that in the first term in equation (A.2), the summation is overall obser-
vations (for i = 1 to n); whereas in the second term, it is only a summation
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for i 6= j.
Suppose that the parameter β is a vector with p dimensions. Then
∂
∂β
logLi(β) denotes a row vector with p components, for different individ-
uals, say the ith and jth, in general, ∂
∂β
logLFi (β) 6= ∂∂β logLFj (β). Therefore,
their corresponding expected vectors are not the same, that is:
E
{
∂
∂β
logLFi (β)|u ∈ {c, n, a}, βk
}
6= E
{
∂
∂β
logLFj (β)|u ∈ {c, n, a}, βk
}
.
Consequently, it is easy to produce:
E
{(
∂
∂β
logLFi (β)
)T
|u ∈ {c, n, a}, βk
}
E
{(
∂
∂β
logLFj (β)
)
|u ∈ {c, n, a}, βk
}
6= E
{(
∂
∂β
logLFj (β)
)T
|u ∈ {c, n, a}, βk
}
E
{(
∂
∂β
logLFi (β)
)
|u ∈ {c, n, a}, βk
}
,
(A.3)
which implies that the product of E
{(
∂
∂β
logLFi (β)
)T
|u ∈ {c, n, a}, βk
}
and E
{(
∂
∂β
logLFj (β)
)
|u ∈ {c, n, a}, βk
}
are not exchangeable.
Hence, we give the corrected form of equation (3.2’) in Louis (1982) as
follows:
Iobs = I(βˆ) = I1 −E1 −E2
where
I1 =
n∑
i=1
E
{
−
(
∂2
∂β2
logLi(β)
)
|u ∈ {c, n, a}, βk
}
E1 =
∑
i
E
{(
∂
∂β
logLFi (β)
)T ( ∂
∂β
logLFi (β)
)
|u ∈ {c, n, a}, βk
}
E2 =
∑
i6=j
{
E
(
∂
∂β
logLFi (β)
)T
|u ∈ {c, n, a}, βk
}{
E
(
∂
∂β
logLFj (β)
)
|u ∈ {c, n, a}, βk
}
.
(A.4)
Note that equation (A.4) guarantees that the OIM, Iobs, is a p×p symmetric,
but Louis’s equation (3.2’) in Louis (1982) cannot yield a symmetric matrix
even though the author had thought Iobs should be symmetric (Louis, 1982).
The distinction between these two equations, namely Louis’s equation (3.2’)
in Louis (1982) and its corrected form equation (A.4) given above, are that
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the last term in the former, given as:
2
∑
i<j
{
E
(
∂
∂β
logLFi (β)
)T
|u ∈ {c, n, a}, βk
}{
E
(
∂
∂β
logLFj (β)
)
|u ∈ {c, n, a}, βk
}
,
is not symmetric as the summation is only for i < j rather than overall
observations as in equation (A.4), where the last term is a symmetric matrix.
This is because that after taking summation with respect to all observations
both for i and j but excluding i = j,
∑
i 6=j
{
E
(
∂
∂β
logLFi (β)
)T
|u ∈ {c, n, a}, βk
}{
E
(
∂
∂β
logLFj (β)
)
|u ∈ {c, n, a}, βk
}
is a symmetric matrix, even though matrixEβ
{
∂
∂β [logL
F
i (β)]
}T
Eβ
{
∂
∂β [logL
F
j (β)]
}
is not symmetric for i 6= j.
In other words, as Eβ
{
∂
∂β
[logLFi (β)]
}
is not a scalar, we cannot follow
the rule of ab + ba = 2ab. This is the key error in equation (3.2’) of Louis
(1982).
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Appendix B
B Iterations of the EM algorithm for the NIGN-WW and NIGN-
LL models
Iteration details for the NIGN-WWmodel and the NIGN-LL model are given
in Tables C-8 and C-9 of Appendix C. The tolerance of convergence is
set at 0.005. From Tables C-8 and C-9 we see that, after 14 iterations ∆
reached 0.0044 (< 0.005) for the NIGN-WW model, and one iteration leads
to ∆ reaching 0.0008 (< 0.005) for the NIGN-LL model. Thereby we know
convergence has been achieved.
Note that the formula used to obtain Table C-8 follows the formula-
tion of the Weibull distribution provided by the MATLAB (7.4.0, R2007a)
(www.mathworks.com/products/matlab) software. This is slightly different
to the form we used in equations (5.6.1), (5.6.3) and (5.6.2). MATLAB (see
the MATLAB help documentation) gives the following form for the proba-
bility density function of a Weibull distribution:
fw(t) =
B
A
(
t
A
)(B−1)exp[−( t
A
)B]. (B.1)
Consequently, the survival function and hazards rate function are expressed
as:
Sw(t) = exp[−( t
A
)B], (B.2)
hw(t) =
B
A
(
t
A
)(B−1). (B.3)
where A and B indicate the scale and shape parameters, respectively, of a
Weibull distribution. The scale parameter in the two forms of the Weibull dis-
tribution, denoted by ρ (for the formulation given in Cox & Oakes (1984) used
in this thesis) and A (for the form given in the MATLAB (7.4.0, R2007a))
have the following relationship, that is A = 1/ρ. Therefore the estimated
parameters θ
(1)
T,c1, θ
(1)
T,c0, θ
(1)
T,n (given in Table C-8) are equivalent to the recip-
rocal values of ρT,c1, ρT,c0, ρT,n (given in Table C-1). Similarly, the estimated
parameters associated with the censoring time distribution, θ
(1)
C,c1, θ
(1)
C,c0, θ
(1)
C,n
(given in Table C-8) are equivalent to the reciprocal values of γC,c1, γC,c0, γC,n
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(given in Table C-1).
The iteration details of the EM algorithm are given in Table C-10 for the
NIGN-WW model and given in Table C-11 for the NIGN-LL model. The ∆
values given in the last column of Tables C-10 and C-11 show the maximum
component of the difference between the two estimated parameters. The
tolerance of convergence is preset at 0.005. While Mflag = 1 indicates that
the MLEs have been achieved at each iteration.
Because of the difference of the formulation of the Weibull distribution
functions provided in MATLAB, the estimated parameters shown in Table
C-3 are the reciprocal of the parameters given in the last row of Table C-10.
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Appendix C
C Tables
Table C-1: Estimated model parameter θˆ in the NIGN-WW model for the
HIP18 data.
Method: NIGN-WW Data: HIP18
θˆ Estimates SE LCL UCL
ρT,c1 0.0057 0.0005 0.0047 0.0067
ρT,c0 0.0064 0.0006 0.0052 0.0076
ρT,n 0.0064 0.0006 0.0053 0.0075
αT 1.8254 0.0613 1.7053 1.9456
ρC,c1 0.0622 0.0001 0.0620 0.0625
ρC,c0 0.0639 0.0002 0.0636 0.0642
ρC,n 0.0663 0.0003 0.0657 0.0669
αC 3.1928 0.0006 3.1916 3.1940
HIP18: HIP data with follow-up of 18 years.
Table C-2: Estimated model parameter θˆ in the NIGN-LL model for the
HIP18 data.
Method: NIGN-LL Data: HIP18
θˆ Estimates SE LCL UCL
µT,c1 6.2597 0.1157 6.0331 6.4864
µT,c0 6.1094 0.1134 5.8871 6.3317
µT,n 6.1481 0.1233 5.9065 6.3898
σT 1.5595 0.0479 1.4657 1.6533
µC,c1 2.6173 0.0040 2.6094 2.6252
µC,c0 2.6217 0.0041 2.6136 2.6298
µC,n 2.3269 0.0055 2.3162 2.3376
σC 0.5674 0.0000 0.5673 0.5674
HIP18: HIP data with follow-up of 18 years.
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Table C-3: Estimated model parameter θˆ in the NIGN-WW model for the
HIP7 data.
Method: NIGN-WW Data: HIP7
θˆ Estimates SE LCL UCL
ρT,c1 0.0059 0.0014 0.0031 0.0087
ρT,c0 0.0092 0.0020 0.0053 0.0131
ρT,n 0.0069 0.0016 0.0037 0.0101
αT 1.9362 0.1389 1.6640 2.2084
ρC,c1 0.1438 0.0001 0.1436 0.1440
ρC,c0 0.1446 0.0001 0.1444 0.1448
ρC,n 0.1452 0.0001 0.1450 0.1454
αC 10.3780 0.0004 10.3770 10.3790
HIP7: HIP data with follow-up of 7 years.
Table C-4: Estimated model parameter θˆ in the NIGN-LL model for the
HIP7 data.
Method: NIGN-LL Data: HIP7
θˆ Estimates SE LCL UCL
µT,c1 6.7587 0.3394 6.0935 7.4239
µT,c0 6.2969 0.3073 5.6947 6.8992
µT,n 6.6068 0.3393 5.9419 7.2718
σT 1.6828 0.1134 1.4605 1.9052
µC,c1 1.8900 0.0020 1.8861 1.8939
µC,c0 1.8808 0.0017 1.8775 1.8840
µC,n 1.7764 0.0034 1.7697 1.7831
σC 0.2831 0.0000 0.2830 0.2832
HIP7: HIP data with follow-up of 7 years.
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Table C-5: Estimated model parameter θˆ in the IGN-W model for the HIP7
data.
Method: NIGN-W Data: HIP7
θˆ Estimates SE LCL UCL
ρT,c1 0.0059 0.0011 0.0038 0.0080
ρT,c0 0.0098 0.0014 0.0070 0.0126
ρT,n 0.0039 0.0007 0.0025 0.0053
αT 1.9326 0.0974 1.7418 2.1234
HIP7: HIP data with follow-up of 7 years.
Table C-6: Estimated model parameter θˆ in the IGN-W model for the HIP18
data.
Method: NIGN-W Data: HIP18
θˆ Estimates SE LCL UCL
ρT,c1 0.0057 0.0004 0.0049 0.0065
ρT,c0 0.0073 0.0005 0.0064 0.0082
ρT,n 0.0043 0.0003 0.0037 0.0049
αT 1.8186 0.0491 1.7224 1.9148
HIP18: HIP data with follow-up of 18 years.
Table C-7: Estimated parameters pˆic for the HIP data
pic Estimates SE LCL UCL
HIP18 0.6686 0.0005 0.6677 0.6696
HIP7 0.6698 0.0000 0.6697 0.6698
HIP18: HIP data with following-up 18 years.
HIP7: HIP data with follow-up of 7 years
The SE given in the table is obtained by bootstrap.
251
T
ab
le
C
-8
:
It
er
at
io
n
s
of
th
e
E
M
al
go
ri
th
m
u
si
n
g
th
e
N
IG
N
-W
W
m
o
d
el
fo
r
th
e
H
I
P
1
8
d
at
a.
M
o
d
el
:
N
IG
N
-W
W
D
at
a:
H
I
P
1
8
It
er
k
θ(
1
)
T
,c
1
θ(
1
)
T
,c
0
θ(
1
)
T
,n
0
α
T
θ(
1
)
C
,c
1
θ(
1
)
C
,c
0
θ(
1
)
C
,n
0
α
C
M
fl
ag
a
∆
b
1
17
4.
74
15
6.
41
15
5.
26
1.
83
16
.0
7
15
.6
4
15
.0
9
3.
19
1
11
3.
93
00
2
17
4.
75
15
6.
20
15
5.
52
1.
83
16
.0
7
15
.6
4
15
.0
9
3.
19
1
0.
25
20
3
17
4.
77
15
6.
06
15
5.
70
1.
83
16
.0
7
15
.6
5
15
.0
8
3.
19
1
0.
18
70
4
17
4.
77
15
5.
96
15
5.
82
1.
83
16
.0
7
15
.6
5
15
.0
8
3.
19
1
0.
11
72
5
17
4.
78
15
5.
89
15
5.
91
1.
83
16
.0
7
15
.6
5
15
.0
8
3.
19
1
0.
08
87
6
17
4.
78
15
5.
85
15
5.
96
1.
83
16
.0
7
15
.6
5
15
.0
8
3.
19
1
0.
05
69
7
17
4.
78
15
5.
81
15
6.
00
1.
83
16
.0
7
15
.6
5
15
.0
8
3.
19
1
0.
03
90
8
17
4.
78
15
5.
79
15
6.
03
1.
83
16
.0
7
15
.6
5
15
.0
8
3.
19
1
0.
02
72
9
17
4.
79
15
5.
78
15
6.
05
1.
83
16
.0
7
15
.6
5
15
.0
8
3.
19
1
0.
01
73
10
17
4.
78
15
5.
77
15
6.
06
1.
83
16
.0
7
15
.6
5
15
.0
8
3.
19
1
0.
01
30
11
17
4.
78
15
5.
76
15
6.
07
1.
83
16
.0
7
15
.6
5
15
.0
8
3.
19
1
0.
00
94
12
17
4.
78
15
5.
76
15
6.
07
1.
83
16
.0
7
15
.6
5
15
.0
8
3.
19
1
0.
00
55
13
17
4.
78
15
5.
75
15
6.
07
1.
83
16
.0
7
15
.6
5
15
.0
8
3.
19
1
0.
00
52
14
17
4.
78
15
5.
75
15
6.
08
1.
83
16
.0
7
15
.6
5
15
.0
8
3.
19
1
0.
00
44
H
I
P
1
8
:
H
IP
d
at
a
w
it
h
fo
ll
ow
-u
p
of
18
ye
ar
s.
a
M
f
la
g
=
1
in
di
ca
te
s
th
e
m
ax
im
um
of
Q
(β
,β
(k
)
is
re
ac
he
d
in
th
e
k
th
it
er
at
io
n.
b
∆
re
pr
es
en
ts
th
e
m
ax
im
um
co
m
po
ne
nt
of
|β
(k
+
1
)
−
β
(k
)
|,
th
e
ab
so
lu
te
ve
ct
or
of
di
f-
fe
re
nc
e.
252
T
ab
le
C
-9
:
It
er
at
io
n
s
of
E
M
al
go
ri
th
m
fo
r
th
e
N
IG
N
-L
L
m
o
d
el
on
th
e
H
I
P
1
8
d
at
a
M
o
d
el
:
N
IG
N
-L
L
D
at
a:
H
I
P
1
8
It
er
k
θ(
1
)
T
,c
1
θ(
1
)
T
,c
0
θ(
1
)
T
,n
0
σ
θ(
1
)
C
,c
1
θ(
1
)
C
,c
0
θ(
1
)
C
,n
0
σ
c
M
fl
ag
a
∆
b
1
6.
25
97
6.
10
94
6.
14
81
1.
55
95
2.
61
73
2.
62
17
2.
32
69
0.
56
74
1
0.
00
08
H
I
P
1
8
:
th
e
H
IP
d
at
a
w
it
h
fo
ll
ow
in
g-
u
p
in
18
ye
ar
s.
a
M
f
la
g
=
1
in
di
ca
te
s
th
e
m
ax
im
um
of
Q
(β
,β
(k
)
is
re
ac
he
d
in
th
e
k
th
it
er
at
io
n.
b
∆
re
pr
es
en
ts
th
e
m
ax
im
um
co
m
po
ne
nt
of
|β
(k
+
1
)
−
β
(k
)
|,
th
e
ab
so
lu
te
ve
ct
or
of
di
f-
fe
re
nc
e.
253
T
ab
le
C
-1
0:
It
er
at
io
n
s
of
th
e
E
M
al
go
ri
th
m
fo
r
th
e
N
IG
N
-W
W
m
o
d
el
on
th
e
H
I
P
7
d
at
a
M
o
d
el
:
N
IG
N
-W
W
D
at
a:
H
I
P
7
It
er
θ(
1
)
T
,c
1
θ(
1
)
T
,c
0
θ(
1
)
T
,n
0
α
θ(
1
)
C
,c
1
θ(
1
)
C
,c
0
θ(
1
)
C
,n
0
α
c
M
fl
ag
a
∆
b
1
16
9.
16
10
9.
66
14
2.
30
1.
94
6.
95
6.
91
6.
89
10
.3
8
1
59
84
.8
00
0
2
16
9.
18
10
9.
32
14
3.
14
1.
94
6.
95
6.
91
6.
89
10
.3
8
1
0.
83
89
3
16
9.
19
10
9.
10
14
3.
67
1.
94
6.
95
6.
91
6.
89
10
.3
8
1
0.
52
88
4
16
9.
20
10
8.
96
14
4.
00
1.
94
6.
95
6.
91
6.
89
10
.3
8
1
0.
33
67
5
16
9.
21
10
8.
88
14
4.
23
1.
94
6.
95
6.
91
6.
89
10
.3
8
1
0.
22
29
6
16
9.
22
10
8.
83
14
4.
36
1.
94
6.
95
6.
91
6.
89
10
.3
8
1
0.
13
29
7
16
9.
22
10
8.
80
14
4.
45
1.
94
6.
95
6.
91
6.
89
10
.3
8
1
0.
08
87
8
16
9.
21
10
8.
77
14
4.
49
1.
94
6.
95
6.
91
6.
89
10
.3
8
1
0.
04
05
9
16
9.
22
10
8.
76
14
4.
53
1.
94
6.
95
6.
91
6.
89
10
.3
8
1
0.
03
88
10
16
9.
21
10
8.
75
14
4.
54
1.
94
6.
95
6.
91
6.
89
10
.3
8
1
0.
01
66
11
16
9.
22
10
8.
75
14
4.
56
1.
94
6.
95
6.
91
6.
89
10
.3
8
1
0.
01
90
12
16
9.
23
10
8.
75
14
4.
58
1.
94
6.
95
6.
91
6.
89
10
.3
8
1
0.
01
62
13
16
9.
22
10
8.
74
14
4.
58
1.
94
6.
95
6.
91
6.
89
10
.3
8
1
0.
01
02
14
16
9.
22
10
8.
74
14
4.
58
1.
94
6.
95
6.
91
6.
89
10
.3
8
1
0.
00
45
H
I
P
7
:
H
IP
d
at
a
w
it
h
fo
ll
ow
-u
p
of
7
ye
ar
s.
a
M
f
la
g
=
1
in
di
ca
te
s
th
e
m
ax
im
um
of
Q
(β
,β
(k
)
is
re
ac
he
d
in
th
e
k
th
it
er
at
io
n.
b
∆
re
pr
es
en
ts
th
e
m
ax
im
um
co
m
po
ne
nt
of
|β
(k
+
1
)
−
β
(k
)
|,
th
e
ab
so
lu
te
ve
ct
or
of
di
f-
fe
re
nc
e.
254
T
ab
le
C
-1
1:
It
er
at
io
n
s
of
th
e
E
M
al
go
ri
th
m
fo
r
th
e
N
IG
N
-L
L
m
o
d
el
on
th
e
H
I
P
7
d
at
a
M
o
d
el
:
N
IG
N
-L
L
D
at
a:
H
I
P
7
It
er
k
θ(
1
)
T
,c
1
θ(
1
)
T
,c
0
θ(
1
)
T
,n
0
σ
θ(
1
)
C
,c
1
θ(
1
)
C
,c
0
θ(
1
)
C
,n
0
σ
c
M
fl
ag
a
∆
b
1
8.
22
7.
56
8.
02
2.
18
1.
89
1.
88
1.
80
0.
28
1
1.
96
02
2
6.
76
6.
29
6.
62
1.
68
1.
89
1.
87
1.
78
0.
28
1
1.
46
41
3
6.
76
6.
29
6.
61
1.
68
1.
89
1.
88
1.
78
0.
28
1
0.
00
68
4
6.
76
6.
30
6.
61
1.
68
1.
89
1.
88
1.
78
0.
28
1
0.
00
41
H
I
P
7
:
H
IP
d
at
a
w
it
h
fo
ll
ow
-u
p
of
7
ye
ar
s.
a
M
f
la
g
=
1
in
di
ca
te
s
th
e
m
ax
im
um
of
Q
(β
,β
(k
)
is
re
ac
he
d
in
th
e
k
th
it
er
at
io
n.
b
∆
re
pr
es
en
ts
th
e
m
ax
im
um
co
m
po
ne
nt
of
|β
(k
+
1
)
−
β
(k
)
|,
th
e
ab
so
lu
te
ve
ct
or
of
di
f-
fe
re
nc
e.
255
Table C-12: Estimated ACE(t)(95% CI) using the F-R method for the HIP18
data.
Method: F-R Data: HIP18
Year ÂCEFR SEace LCLace UCLace Zvalue p− value
1 0.38E−04 0.93E−04 −1.44E−04 2.20E−04 0.4126 0.3399
2 2.03E−04 1.63E−04 −1.16E−04 5.23E−04 1.2464 0.1063
3 3.58E−04 2.22E−04 −0.76E−04 7.93E−04 1.6160 0.0530
4 7.38E−04 2.97E−04 1.56E−04 1.32E−03 2.4843 0.0065
5 12.1E−04 3.92E−04 4.41E−04 1.98E−03 3.0855 0.0010
6 18.6E−04 4.77E−04 9.23E−04 2.79E−03 3.8932 0.0000
7 17.1E−04 5.30E−04 6.74E−04 2.75E−03 3.2317 0.0006
8 14.1E−04 5.81E−04 2.71E−04 2.55E−03 2.4268 0.0076
9 17.3E−04 6.49E−04 4.55E−04 3.00E−03 2.6614 0.0039
10 14.6E−04 7.01E−04 0.82E−04 2.83E−03 2.0769 0.0189
11 17.3E−04 7.58E−04 2.46E−04 3.22E−03 2.2844 0.0112
12 14.9E−04 8.15E−04 −1.10E−04 3.08E−03 1.8249 0.0340
13 14.8E−04 8.68E−04 −2.19E−04 3.18E−03 1.7081 0.0438
14 10.5E−04 9.21E−04 −7.60E−04 2.85E−03 1.1350 0.1282
15 11.1E−04 10.1E−04 −8.72E−04 3.09E−03 1.0963 0.1365
16 10.5E−04 10.9E−04 −10.8E−04 3.19E−03 0.9683 0.1665
17 11.8E−04 11.4E−04 −10.6E−04 3.42E−03 1.0354 0.1502
18 21.3E−04 12.2E−04 −2.66E−04 4.52E−03 1.7426 0.0407
HIP18: HIP data with follow-up of 18 years
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Table C-13: Estimated ACE(t) (95% CI) using the NIGN-WW model for
the HIP18 data.
Method: NIGN-WW Data: HIP18
Year ÂCEnign−ww SEace LCLace UCLace Zvalue p− value
1 0.13E−04 0.07E−04 −0.01E−04 0.26E−04 1.8643 0.0311
2 0.45E−04 0.24E−04 −0.02E−04 0.91E−04 1.8920 0.0292
3 0.94E−04 0.49E−04 −0.03E−04 1.91E−04 1.9030 0.0285
4 1.59E−04 0.83E−04 −0.04E−04 3.22E−04 1.9084 0.0282
5 2.38E−04 1.25E−04 −0.06E−04 4.83E−04 1.9111 0.0280
6 3.32E−04 1.74E−04 −0.08E−04 6.73E−04 1.9123 0.0279
7 4.40E−04 2.30E−04 −0.11E−04 8.91E−04 1.9127 0.0279
8 5.61E−04 2.93E−04 −0.14E−04 11.4E−04 1.9126 0.0279
9 6.95E−04 3.63E−04 −0.17E−04 14.1E−04 1.9121 0.0279
10 8.41E−04 4.40E−04 −0.21E−04 17.0E−04 1.9113 0.0280
11 10.0E−04 5.23E−04 −0.26E−04 20.3E−04 1.9104 0.0280
12 11.7E−04 6.13E−04 −0.31E−04 23.7E−04 1.9094 0.0281
13 13.5E−04 7.09E−04 −0.376E−04 27.4E−04 1.9083 0.0282
14 15.5E−04 8.11E−04 −0.43E−04 31.4E−04 1.9072 0.0282
15 17.5E−04 9.19E−04 −0.50E−04 35.5E−04 1.9061 0.0283
16 19.7E−04 10.3E−04 −0.57E−04 39.9E−04 1.9049 0.0284
17 21.9E−04 11.5E−04 −0.65E−04 44.5E−04 1.9037 0.0285
18 24.3E−04 12.8E−04 −0.73E−04 49.4E−04 1.9026 0.0285
HIP18: HIP data with follow-up of 18 years
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Table C-14: Estimated ACE(t) (95% CI) using the NIGN-LL model for the
HIP18 data.
Method: NIGN-LL Data: HIP18
Year ÂCEnign−ll SEace LCLace UCLace Zvalue p− value
1 0.10E−04 0.05E−04 0.01E−04 0.19E−04 2.1060 0.0176
2 0.53E−04 0.23E−04 0.07E−04 0.98E−04 2.2561 0.0120
3 1.27E−04 0.55E−04 0.20E−04 2.34E−04 2.3214 0.0101
4 2.27E−04 0.96E−04 0.38E−04 4.16E−04 2.3576 0.0092
5 3.49E−04 1.47E−04 0.62E−04 6.37E−04 2.3804 0.0086
6 4.89E−04 2.04E−04 0.89E−04 8.89E−04 2.3958 0.0083
7 6.42E−04 2.67E−04 1.19E−04 11.7E−04 2.4068 0.0080
8 8.08E−04 3.34E−04 1.52E−04 14.6E−04 2.4150 0.0079
9 9.82E−04 4.06E−04 1.87E−04 17.8E−04 2.4213 0.0077
10 11.6E−04 4.80E−04 2.24E−04 21.1E−04 2.4262 0.0076
11 13.5E−04 5.57E−04 2.62E−04 24.5E−04 2.4302 0.0075
12 15.5E−04 6.36E−04 3.01E−04 27.9E−04 2.4334 0.0075
13 17.5E−04 7.16E−04 3.41E−04 31.5E−04 2.4361 0.0074
14 19.5E−04 7.98E−04 3.82E−04 35.1E−04 2.4384 0.0074
15 21.5E−04 8.81E−04 4.23E−04 38.8E−04 2.4404 0.0073
16 23.6E−04 9.65E−04 4.65E−04 42.5E−04 2.4421 0.0073
17 25.6E−04 10.5E−04 5.07E−04 46.2E−04 2.4435 0.0073
18 27.7E−04 11.3E−04 5.49E−04 49.9E−04 2.4448 0.0072
HIP18: HIP data with follow-up of 18 years.
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Table C-15: Estimated CACE(t) (95% CI) using the F-R method for the
HIP18 data.
Method: F-R Data: HIP18
Year ĈACEFR SEcace LCLcace UCLcace Zvalue p− value
1 0.57E−04 1.39E−04 −2.14E−04 3.29E−04 0.4127 0.3399
2 3.03E−04 2.43E−04 −1.74E−04 7.80E−04 1.2464 0.1063
3 5.35E−04 3.31E−04 −1.14E−04 11.8E−04 1.6159 0.0531
4 11.0E−04 4.44E−04 2.32E−04 19.7E−04 2.4836 0.0065
5 18.1E−04 5.85E−04 6.58E−04 29.5E−04 3.0846 0.0010
6 27.7E−04 7.13E−04 1.38E−03 41.7E−04 3.8930 0.0000
7 25.6E−04 7.91E−04 1.01E−03 41.1E−04 3.2321 0.0006
8 21.1E−04 8.68E−04 4.05E−04 38.1E−04 2.4272 0.0076
9 25.8E−04 9.69E−04 6.80E−04 44.8E−04 2.6616 0.0039
10 21.7E−04 10.5E−04 1.23E−04 42.3E−04 2.0772 0.0189
11 25.9E−04 11.3E−04 3.68E−04 48.0E−04 2.2849 0.0112
12 22.2E−04 12.2E−04 −1.64E−04 46.1E−04 1.8252 0.0340
13 22.1E−04 13.0E−04 −3.26E−04 47.5E−04 1.7082 0.0438
14 15.6E−04 13.8E−04 −11.3E−04 42.6E−04 1.1349 0.1282
15 16.5E−04 15.1E−04 −13.0E−04 46.1E−04 1.0962 0.1365
16 15.8E−04 16.3E−04 −16.1E−04 47.6E−04 0.9682 0.1665
17 17.7E−04 17.1E−04 −15.8E−04 51.1E−04 1.0353 0.1502
18 31.8E−04 18.2E−04 −3.96E−04 67.5E−04 1.7427 0.0407
HIP18: HIP data with follow-up 18 years
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Table C-16: Estimated CACE(t) (95% CI) using the NIGN-WW model for
the HIP18 data.
Method: NIGN-WW Data: HIP18
Year ĈACEnign−ww SEcace LCLcace UCLcace Zvalue p− value
1 0.19E−04 0.10E−04 −0.01E−04 0.39E−04 1.8643 0.0311
2 0.67E−04 0.35E−04 −0.02E−04 1.36E−04 1.8921 0.0292
3 1.40E−04 0.74E−04 −0.04E−04 2.85E−04 1.9031 0.0285
4 2.37E−04 1.24E−04 −0.06E−04 4.80E−04 1.9084 0.0282
5 3.56E−04 1.86E−04 −0.09E−04 7.21E−04 1.9111 0.0280
6 4.96E−04 2.59E−04 −0.12E−04 10.0E−04 1.9124 0.0279
7 6.57E−04 3.43E−04 −0.16E−04 13.3E−04 1.9128 0.0279
8 8.37E−04 4.38E−04 −0.21E−04 17.0E−04 1.9126 0.0279
9 10.4E−04 5.42E−04 −0.26E−04 21.0E−04 1.9121 0.0279
10 12.6E−04 6.57E−04 −0.32E−04 25.4E−04 1.9114 0.0280
11 14.9E−04 7.81E−04 −0.39E−04 30.2E−04 1.9105 0.0280
12 17.5E−04 9.15E−04 −0.46E−04 35.4E−04 1.9095 0.0281
13 20.2E−04 10.6E−04 −0.55E−04 40.9E−04 1.9084 0.0282
14 23.1E−04 12.1E−04 −0.64E−04 46.8E−04 1.9073 0.0282
15 26.2E−04 13.7E−04 −0.74E−04 53.0E−04 1.9061 0.0283
16 29.4E−04 15.4E−04 −0.85E−04 59.6E−04 1.9049 0.0284
17 32.8E−04 17.2E−04 −0.97E−04 66.5E−04 1.9038 0.0285
18 36.3E−04 19.1E−04 −1.09E−04 73.7E−04 1.9026 0.0285
HIP18: HIP data with follow-up of 18 years.
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Table C-17: Estimated CACE(t) (95% CI) using the NIGN-LL models for
the HIP18 data.
Method: NIGN-LL Data: HIP18
Year ĈACEnign−ll SEcace LCLcace UCLcace Zvalue p− value
1 0.15E−04 0.07E−04 0.01E−04 0.29E−04 2.1061 0.0176
2 0.78E−04 0.35E−04 0.10E−04 1.47E−04 2.2562 0.0120
3 1.89E−04 0.82E−04 0.30E−04 3.49E−04 2.3215 0.0101
4 3.39E−04 1.44E−04 0.57E−04 6.21E−04 2.3577 0.0092
5 5.22E−04 2.19E−04 0.92E−04 9.51E−04 2.3805 0.0086
6 7.30E−04 3.05E−04 1.33E−04 13.3E−04 2.3959 0.0083
7 9.59E−04 3.98E−04 1.78E−04 17.4E−04 2.4069 0.0080
8 12.1E−04 4.99E−04 2.27E−04 21.8E−04 2.4151 0.0079
9 14.7E−04 6.06E−04 2.79E−04 26.5E−04 2.4214 0.0077
10 17.4E−04 7.17E−04 3.34E−04 31.4E−04 2.4263 0.0076
11 20.2E−04 8.31E−04 3.91E−04 36.5E−04 2.4303 0.0075
12 23.1E−04 9.49E−04 4.50E−04 41.7E−04 2.4336 0.0075
13 26.1E−04 10.7E−04 5.09E−04 47.0E−04 2.4363 0.0074
14 29.1E−04 11.9E−04 5.70E−04 52.4E−04 2.4386 0.0074
15 32.1E−04 13.2E−04 6.32E−04 57.9E−04 2.4405 0.0073
16 35.2E−04 14.4E−04 6.94E−04 63.4E−04 2.4422 0.0073
17 38.3E−04 15.7E−04 7.57E−04 68.9E−04 2.4437 0.0073
18 41.4E−04 16.9E−04 8.20E−04 74.5E−04 2.4449 0.0072
HIP18: HIP data with follow-up of 18 years.
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Table C-18: Estimated ACE(t) (95% CI) using the F-R method for the HIP7
data.
Method: F-R Data: HIP7
Year ÂCEFR SEace LCLace UCLace Zvalue p− value
1 0.38E−04 0.93E−04 −1.44E−04 2.20E−04 0.4126 0.3399
2 2.03E−04 1.63E−04 −1.16E−04 5.23E−04 1.2464 0.1063
3 3.58E−04 2.22E−04 −0.76E−04 7.93E−04 1.6160 0.0530
4 7.38E−04 2.97E−04 1.56E−04 13.2E−04 2.4843 0.0065
5 12.1E−04 3.92E−04 4.41E−04 19.8E−04 3.0855 0.0010
6 18.7E−04 4.74E−04 9.44E−04 28.0E−04 3.9507 0.0000
7 18.7E−04 4.74E−04 9.44E−04 28.0E−04 3.9507 0.0000
HIP7: HIP data with follow-up of 7 years
Table C-19: Estimated CACE(t) (95% CI) using the F-R method for the
HIP7 data.
Method: F-R Data: HIP7
Year ĈACEFR SEcace LCLcace UCLcace Zvalue p− value
1 0.57E−04 1.39E−04 −2.14E−04 3.29E−04 0.4127 0.3399
2 3.03E−04 2.43E−04 −1.74E−04 7.80E−04 1.2464 0.1063
3 5.35E−04 3.31E−04 −1.14E−04 11.8E−04 1.6159 0.0531
4 11.0E−04 4.44E−04 2.32E−04 19.7E−04 2.4836 0.0065
5 18.1E−04 5.85E−04 6.58E−04 29.5E−04 3.0846 0.0010
6 28.0E−04 7.08E−04 14.1E−04 41.9E−04 3.9505 0.0000
7 28.0E−04 7.08E−04 14.1E−04 41.9E−04 3.9505 0.0000
HIP7: HIP data with follow-up of 7 years
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Table C-20: Estimated ACE(t) (95% CI) using the NIGN-WW model for
the HIP7 data.
Method: NIGN-WW Data: HIP7
Year ÂCEnign−ww SEace LCLace UCLace Zvalue p− value
1 0.44E−05 0.16E−04 0.13E−04 0.75E−05 2.7777 0.0027
2 1.68E−04 0.51E−04 0.69E−04 2.67E−04 3.3248 0.0004
3 3.69E−04 1.02E−04 1.69E−04 5.68E−04 3.6237 0.0001
4 6.43E−04 1.70E−04 3.10E−04 9.76E−04 3.7839 0.0001
5 9.90E−04 2.56E−04 4.87E−04 14.9E−04 3.8593 0.0001
6 14.1E−04 3.63E−04 6.97E−04 21.2E−04 3.8822 0.0001
7 19.0E−04 4.89E−04 9.36E−04 28.5E−04 3.8729 0.0001
HIP7: HIP data with follow-up of 7 years.
Table C-21: Estimated ACE(t) (95% CI) using the NIGN-WW model for
the HIP7 data.
Method: NIGN-LL Data: HIP7
Year ÂCEnign−ll SEace LCLace UCLace Zvalue p− value
1 0.41E−04 0.16E−04 0.09E−04 0.74E−04 2.5238 0.0058
2 1.86E−04 0.58E−04 0.73E−04 2.99E−04 3.2280 0.0006
3 4.15E−04 1.15E−04 1.89E−04 6.41E−04 3.5969 0.0002
4 7.07E−04 1.86E−04 3.42E−04 10.7E−04 3.7917 0.0001
5 10.5E−04 2.69E−04 5.20E−04 15.8E−04 3.8924 0.0000
6 14.3E−04 3.62E−04 7.18E−04 21.4E−04 3.9413 0.0000
7 18.4E−04 4.64E−04 9.28E−04 27.5E−04 3.9612 0.0000
HIP7: HIP data with follow-up of 7 years
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Table C-22: Estimated CACE(t) (95% CI) using the NIGN-WW model for
the HIP7 data.
Method: NIGN-WW Data: HIP7
Year ĈACEnign−ww SEcace LCLcace UCLcace Zvalue p− value
1 0.66E−04 0.24E−04 0.19E−04 1.12E−04 2.7779 0.0027
2 2.51E−04 0.76E−04 1.03E−04 3.99E−04 3.3251 0.0004
3 5.50E−04 1.52E−04 2.53E−04 8.48E−04 3.6241 0.0001
4 9.60E−04 2.54E−04 4.63E−04 14.6E−04 3.7843 0.0001
5 14.8E−04 3.83E−04 7.27E−04 22.3E−04 3.8597 0.0001
6 21.0E−04 5.41E−04 10.4E−04 31.6E−04 3.8827 0.0001
7 28.3E−04 7.31E−04 14.0E−04 42.6E−04 3.8734 0.0001
HIP7: HIP data with follow-up of 7 years
Table C-23: Estimated CACE(t) (95% CI) using the the NIGN-LL model
for the HIP7 data.
Method: NIGN-LL Data: HIP7
Year ĈACEnign−ll SEcace LCLcace UCLcace Zvalue p− value
1 0.62E−04 0.25E−04 0.14E−04 1.10E−04 2.5240 0.0058
2 2.78E−04 0.86E−04 1.09E−04 4.47E−04 3.2283 0.0006
3 6.19E−04 1.72E−04 2.82E−04 9.57E−04 3.5972 0.0002
4 10.6E−04 2.78E−04 5.10E−04 16.0E−04 3.7921 0.0001
5 15.7E−04 4.02E−04 7.77E−04 23.5E−04 3.8929 0.0000
6 21.3E−04 5.41E−04 10.7E−04 31.9E−04 3.9418 0.0000
7 27.4E−04 6.92E−04 13.9E−04 41.0E−04 3.9617 0.0000
HIP7: HIP data with follow-up of 7 years
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Table C-24: Estimated CACE(t) (95% CI) using the IGN-W model for the
HIP7 data.
Method: IGN-W Data: HIP7
Year ĈACEign−w SEcace LCLcace UCLcace Zvalue p− value
1 0.82E−04 0.22E−04 0.40E−04 1.24E−04 3.7857 0.0001
2 3.13E−04 0.70E−04 1.76E−04 4.49E−04 4.4934 0.0000
3 6.85E−04 1.40E−04 4.10E−04 9.59E−04 4.8851 0.0000
4 11.9E−04 2.34E−04 7.35E−04 16.5E−04 5.1043 0.0000
5 18.4E−04 3.52E−04 11.5E−04 25.2E−04 5.2179 0.0000
6 26.1E−04 4.95E−04 16.4E−04 35.8E−04 5.2651 0.0000
7 35.1E−04 6.66E−04 22.0E−04 48.1E−04 5.2701 0.0000
HIP7: HIP data with follow-up of 7 years.
Table C-25: Estimated CACE(t) (95% CI) using the IGN-W model for the
HIP18 data.
Method: IGN-W Data: HIP18
Year ĈACEign−w SEcace LCLcace UCLcace Zvalue p− value
1 0.47E−04 0.11E−04 0.26E−04 0.68E−04 4.2754 0.0000
2 1.66E−04 0.36E−04 0.97E−04 2.36E−04 4.6724 0.0000
3 3.47E−04 0.71E−04 2.08E−04 4.86E−04 4.8988 0.0000
4 5.86E−04 1.16E−04 3.58E−04 8.13E−04 5.0498 0.0000
5 8.78E−04 1.70E−04 5.45E−04 12.1E−04 5.1582 0.0000
6 12.2E−04 2.33E−04 7.65E−04 16.8E−04 5.2392 0.0000
7 16.2E−04 3.05E−04 10.2E−04 22.1E−04 5.3014 0.0000
8 20.6E−04 3.85E−04 13.0E−04 28.1E−04 5.3501 0.0000
9 25.5E−04 4.73E−04 16.2E−04 34.7E−04 5.3885 0.0000
10 30.8E−04 5.69E−04 19.7E−04 42.0E−04 5.4191 0.0000
11 36.6E−04 6.73E−04 23.4E−04 49.8E−04 5.4436 0.0000
12 42.8E−04 7.84E−04 27.5E−04 58.2E−04 5.4631 0.0000
13 49.5E−04 9.03E−04 31.8E−04 67.2E−04 5.4786 0.0000
14 56.5E−04 10.3E−04 36.3E−04 76.7E−04 5.4909 0.0000
15 63.9E−04 11.6E−04 41.2E−04 86.7E−04 5.5004 0.0000
16 71.8E−04 13.0E−04 46.2E−04 97.3E−04 5.5078 0.0000
17 80.0E−04 14.5E−04 51.6E−04 108.0E−04 5.5132 0.0000
18 88.6E−04 16.1E−04 57.1E−04 120.0E−04 5.5171 0.0000
HIP18: HIP data with follow-up of 18 years.
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Table C-26: Estimated ACE(t) (95% CI) using the IGN-W model for the
HIP7 data.
Method: IGN-W Data: HIP7
Year ÂCEign−w SEcace LCLcace UCLcace Zvalue p− value
1 0.55E−04 0.15E−04 0.27E−04 0.83E−04 3.7852 0.0001
2 2.10E−04 0.47E−04 1.18E−04 3.01E−04 4.4927 0.0000
3 4.59E−04 0.94E−04 2.75E−04 6.43E−04 4.8842 0.0000
4 7.99E−04 1.57E−04 4.92E−04 11.1E−04 5.1032 0.0000
5 12.3E−04 2.36E−04 7.67E−04 16.9E−04 5.2167 0.0000
6 17.5E−04 3.32E−04 11.0E−04 24.0E−04 5.2639 0.0000
7 23.5E−04 4.46E−04 14.8E−04 32.2E−04 5.2688 0.0000
HIP7: HIP data with follow-up of 7 years.
Table C-27: Estimated ACE(t) (95% CI) using the IGN-W model for the
HIP18 data.
Method: IGN-W Data: HIP18
Year ÂCEign−w SEcace LCLcace UCLcace Zvalue p− value
1 0.32E−04 0.07E−04 0.17E−04 4.60E−05 4.2747 0.0000
2 1.11E−04 0.24E−04 0.65E−04 1.58E−04 4.6716 0.0000
3 2.33E−04 0.48E−04 1.40E−04 3.26E−04 4.8979 0.0000
4 3.92E−04 0.78E−04 2.40E−04 5.45E−04 5.0488 0.0000
5 5.88E−04 1.14E−04 3.65E−04 8.12E−04 5.1570 0.0000
6 8.19E−04 1.56E−04 5.12E−04 11.3E−04 5.2380 0.0000
7 10.8E−04 2.04E−04 6.82E−04 14.8E−04 5.3002 0.0000
8 13.8E−04 2.58E−04 8.74E−04 18.8E−04 5.3488 0.0000
9 17.1E−04 3.17E−04 10.9E−04 23.3E−04 5.3872 0.0000
10 20.6E−04 3.81E−04 13.2E−04 28.1E−04 5.4178 0.0000
11 24.5E−04 4.51E−04 15.7E−04 33.4E−04 5.4422 0.0000
12 28.7E−04 5.25E−04 18.4E−04 39.0E−04 5.4617 0.0000
13 33.1E−04 6.05E−04 21.3E−04 45.0E−04 5.4773 0.0000
14 37.8E−04 6.89E−04 24.3E−04 51.4E−04 5.4895 0.0000
15 42.8E−04 7.79E−04 27.6E−04 58.1E−04 5.4991 0.0000
16 48.1E−04 8.73E−04 31.0E−04 65.2E−04 5.5064 0.0000
17 53.6E−04 9.72E−04 34.5E−04 72.6E−04 5.5118 0.0000
18 59.3E−04 10.8E−04 38.2E−04 80.4E−04 5.5157 0.0000
HIP18: HIP data with follow-up of 18 years.
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Table C-28: Estimated survival values using the non-ignorable PPO survival
models for the HIP18 data.
Data: HIP18
Model: NIGN-WW NIGN-LL
Years Sc1(t) Sc0(t) Sn(t) Sc1(t) Sc0(t) Sn(t)
1 0.9999 0.9999 0.9999 1.0000 1.0000 1.0000
2 0.9997 0.9997 0.9997 0.9998 0.9997 0.9998
3 0.9994 0.9993 0.9993 0.9995 0.9993 0.9994
4 0.9990 0.9988 0.9988 0.9991 0.9988 0.9989
5 0.9985 0.9981 0.9981 0.9986 0.9980 0.9982
6 0.9979 0.9974 0.9974 0.9979 0.9972 0.9974
7 0.9972 0.9965 0.9966 0.9972 0.9962 0.9965
8 0.9964 0.9956 0.9956 0.9963 0.9951 0.9955
9 0.9956 0.9945 0.9945 0.9954 0.9939 0.9943
10 0.9946 0.9934 0.9934 0.9944 0.9927 0.9932
11 0.9936 0.9921 0.9921 0.9934 0.9913 0.9919
12 0.9925 0.9908 0.9908 0.9922 0.9899 0.9906
13 0.9913 0.9893 0.9893 0.9911 0.9885 0.9892
14 0.9901 0.9878 0.9878 0.9899 0.9870 0.9878
15 0.9888 0.9861 0.9862 0.9886 0.9854 0.9863
16 0.9874 0.9844 0.9845 0.9873 0.9838 0.9848
17 0.9859 0.9826 0.9827 0.9860 0.9822 0.9832
18 0.9843 0.9807 0.9808 0.9846 0.9805 0.9817
Table C-29: Estimated survival values using the non-ignorable PPO survival
models for the HIP7 data.
Data: HIP7
Model: NIGN-WW NIGN-LL
Years Sc1(t) Sc0(t) Sn(t) Sc1(t) Sc0(t) Sn(t)
1 1.0000 0.9999 0.9999 1.0000 0.9999 1.0000
2 0.9998 0.9996 0.9998 0.9998 0.9996 0.9998
3 0.9996 0.9990 0.9994 0.9996 0.9990 0.9995
4 0.9993 0.9983 0.9990 0.9993 0.9982 0.9990
5 0.9989 0.9974 0.9985 0.9989 0.9973 0.9985
6 0.9984 0.9963 0.9979 0.9984 0.9963 0.9979
7 0.9979 0.9951 0.9972 0.9979 0.9951 0.9972
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Table C-30: Estimated survival values using the F-R method for the HIP18
data.
Data: HIP18
Model: F-R
Years Sc1(t) Sc0(t) Sn(t)
1 0.9999 0.9998 0.9998
2 0.9997 0.9993 0.9996
3 0.9994 0.9989 0.9992
4 0.9991 0.9980 0.9985
5 0.9985 0.9967 0.9977
6 0.9979 0.9951 0.9969
7 0.9971 0.9945 0.9959
8 0.9960 0.9939 0.9949
9 0.9950 0.9924 0.9941
10 0.9940 0.9918 0.9930
11 0.9932 0.9907 0.9916
12 0.9922 0.9900 0.9896
13 0.9910 0.9888 0.9879
14 0.9898 0.9883 0.9860
15 0.9887 0.9870 0.9841
16 0.9872 0.9857 0.9825
17 0.9857 0.9840 0.9816
18 0.9845 0.9813 0.9809
Table C-31: Estimated survival values using the F-R method for the HIP7
data.
Data: HIP18
Model: F-R
Years Sc1(t) Sc0(t) Sn(t)
1 0.9999 0.9998 0.9998
2 0.9997 0.9993 0.9996
3 0.9994 0.9989 0.9992
4 0.9991 0.9980 0.9985
5 0.9985 0.9967 0.9977
6 0.9979 0.9951 0.9972
7 0.9979 0.9951 0.9972
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Table C-32: The ITT estimated survival values using the non-ignorable PPO
survival models for the HIP18 data.
Data: HIP18
Model: NIGN-WW NIGN-LL
Years S1(t) S0(t) S1(t) S0(t)
1 0.9999 0.9999 1.0000 1.0000
2 0.9997 0.9997 0.9998 0.9998
3 0.9994 0.9993 0.9995 0.9994
4 0.9989 0.9988 0.9990 0.9988
5 0.9984 0.9981 0.9984 0.9981
6 0.9977 0.9974 0.9977 0.9972
7 0.9970 0.9965 0.9969 0.9963
8 0.9961 0.9956 0.9960 0.9952
9 0.9952 0.9945 0.9951 0.9941
10 0.9942 0.9934 0.9940 0.9928
11 0.9931 0.9921 0.9929 0.9915
12 0.9919 0.9908 0.9917 0.9902
13 0.9907 0.9893 0.9905 0.9887
14 0.9893 0.9878 0.9892 0.9872
15 0.9879 0.9862 0.9879 0.9857
16 0.9864 0.9844 0.9865 0.9841
17 0.9848 0.9826 0.9851 0.9825
18 0.9832 0.9808 0.9837 0.9809
Table C-33: The ITT estimated survival values using the non-ignorable PPO
survival models for the HIP7 data.
Data: HIP7
Model: NIGN-WW NIGN-LL
Years S1(t) S0(t) S1(t) S0(t)
1 1.0000 0.9999 1.0000 0.9999
2 0.9998 0.9996 0.9998 0.9996
3 0.9996 0.9992 0.9996 0.9991
4 0.9992 0.9986 0.9992 0.9985
5 0.9988 0.9978 0.9988 0.9977
6 0.9983 0.9969 0.9982 0.9968
7 0.9977 0.9958 0.9977 0.9958
269
Table C-34: The ITT estimated survival values using the F-R method for
the HIP18 data.
Data: HIP18 Model: F-R
Years S1(t) S0(t)
1 0.9999 0.9998
2 0.9996 0.9994
3 0.9994 0.9990
4 0.9989 0.9982
5 0.9983 0.9970
6 0.9976 0.9957
7 0.9967 0.9950
8 0.9956 0.9942
9 0.9947 0.9930
10 0.9937 0.9922
11 0.9927 0.9910
12 0.9914 0.9899
13 0.9900 0.9885
14 0.9886 0.9875
15 0.9872 0.9861
16 0.9857 0.9846
17 0.9843 0.9832
18 0.9833 0.9812
Table C-35: The ITT estimated survival values using the F-R method for
the HIP7 data.
Data: HIP7 Model: F-R
Years S1(t) S0(t)
1 0.9999 0.9998
2 0.9996 0.9994
3 0.9994 0.9990
4 0.9989 0.9982
5 0.9983 0.9971
6 0.9977 0.9958
7 0.9977 0.9958
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Table C-36: Estimated survival values using the IGN-W model for the HIP18
data.
Model: IGN-W Data: HIP18
Years Sc1(t) Sc0(t) Sn(t)
1 0.9999 0.9999 1.0000
2 0.9997 0.9995 0.9998
3 0.9994 0.9990 0.9996
4 0.9990 0.9984 0.9994
5 0.9985 0.9976 0.9991
6 0.9979 0.9966 0.9987
7 0.9972 0.9955 0.9983
8 0.9964 0.9943 0.9979
9 0.9955 0.9929 0.9973
10 0.9946 0.9914 0.9968
11 0.9936 0.9898 0.9962
12 0.9925 0.9881 0.9955
13 0.9913 0.9862 0.9948
14 0.9901 0.9843 0.9941
15 0.9888 0.9822 0.9933
16 0.9874 0.9800 0.9924
17 0.9859 0.9777 0.9916
18 0.9844 0.9753 0.9907
Table C-37: Estimated survival values using the IGN-W model for the HIP7
data.
Model: IGN-W Data: HIP7
Years Sc1(t) Sc0(t) Sn(t)
1 1.0000 0.9999 1.0000
2 0.9998 0.9995 0.9999
3 0.9996 0.9989 0.9998
4 0.9993 0.9981 0.9997
5 0.9989 0.9970 0.9995
6 0.9984 0.9958 0.9993
7 0.9979 0.9943 0.9991
271
Table C-38: ITT estimated survival values using the IGN-W model for the
HIP18 data.
Data: HIP18 Model: IGN-W
Years S1(t) S0(t)
1 0.9999 0.9999
2 0.9998 0.9996
3 0.9995 0.9992
4 0.9991 0.9987
5 0.9987 0.9981
6 0.9981 0.9973
7 0.9976 0.9964
8 0.9969 0.9955
9 0.9961 0.9944
10 0.9953 0.9932
11 0.9944 0.9919
12 0.9935 0.9905
13 0.9925 0.9891
14 0.9914 0.9875
15 0.9902 0.9859
16 0.9890 0.9841
17 0.9878 0.9823
18 0.9864 0.9804
Table C-39: ITT estimated survival values via the IGN-W model for the
HIP7 data.
Data: HIP7 Model: IGN-W
Years S1(t) S0(t)
1 1.0000 0.9999
2 0.9999 0.9996
3 0.9997 0.9992
4 0.9994 0.9986
5 0.9991 0.9979
6 0.9987 0.9970
7 0.9983 0.9959
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